Systematic review on the health outcomes associated to fortified complementary foods

– Final report (R2) –

(18/10/2021)

prepared by: Ildikó Csölle^{1,2}, Regina Felső¹, Éva Szabó³, Maria-Inti Metzendorf⁴, Lukas Schwingshackl⁵, Tamás Ferenci^{6,7}, and Szimonetta Lohner^{8,9*}

¹Department of Paediatrics, Clinical Centre of the University of Pécs, Medical School, University of Pécs, Pécs, Hungary

²Szentágothai Research Centre. University of Pécs, Pécs, Hungary

³Department of Biochemistry and Medical Chemistry, Medical School, University of Pécs, Pécs, Hungary

⁴Cochrane Metabolic and Endocrine Disorders Group, Medical Faculty of the Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany

⁵Institute for Evidence in Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany

⁶Physiological Controls Research Center, Obuda University, Budapest, Hungary

⁷Department of Statistics, Corvinus University of Budapest, Budapest, Hungary

⁸Cochrane Hungary, Clinical Centre of the University of Pécs, Medical School, University of Pécs, Pécs, Hungary

⁹Department of Public Health Medicine, Medical School, University of Pécs, Pécs, Hungary

*Corresponding author. E-mail: londer.szimonetta@pte.hu

Contribution of authors:

Search strategy development: MIM, SL; Systematic searches: MIM; Title/abstract screening: IC, RF, ES, SL; Full text screening: IC, RF, ES, SL; Data extraction: IC, RF; Risk of bias assessment: ES, SL; Statistical analyses: TF, SL; GRADE assessment: LS, SL; Manuscript first draft: IC, RF, ES, SL; Approval of final manuscript: IC, RF, ES, MIM, LS, TF, SL; Coordination of tasks: SL.

ABSTRACT

Background

Fortified complementary foods are centrally processed foods enriched with essential micronutrients with the aim of preventing or correcting deficiency of one or more micronutrients in the critical period of complementary feeding. They provide an alternative to home or point-of-use fortification with micronutrient powders or crushable or soluble micronutrient tablets.

Objectives

To assess the health effects and safety of fortified complementary foods on health, nutrition and developmental outcomes of apparently healthy infants and children six to 23 months of age.

This review did not assess the effects of food fortificants and supplements added to the complementary food at point-of-use, typically in the homes of children. In this review only those studies were included, where effects of the fortified complementary food were compared to those of an unfortified version of the same complementary food.

Search methods

On 9 March 2021, we searched Cochrane CENTRAL, Ovid MEDLINE, Embase, CINAHL, Global Index Medicus, Web of Science and two trials registers (ClinicalTrials.gov, WHO ICTRP) for relevant studies. We also checked the reference lists of included studies and systematic reviews.

Selection criteria

We included both randomised controlled trials (RCTs) and non-randomised studies of interventions (NRSI) with individual randomisation or cluster-randomisation. Participants were infants and young children aged 6 to 23 months at the start of intervention, with no identified specific health problems. The intervention consisted of consumption of centrally fortified food with one micronutrient or a combination of vitamins and/or minerals. As an eligible comparator studies had to contain a group, which received the same complementary food, but without micronutrient fortification.

Data collection and analysis

Two review authors independently screened studies for eligibility and, for those studies included in the review, extracted data, assessed risk of bias and rated the certainty of the evidence. We carried out statistical analysis using RevMan software. We used a random-effects meta-analysis for combining data as the interventions differed significantly. We reported dichotomous outcomes as risk ratios

(RRs), with 95% confidence intervals (CIs), and continuous outcomes as mean differences (MDs) with 95% CIs. We used the GRADE approach to assess the certainty of evidence.

Main results

This review includes 16 studies with a total of 5089 participants (range of mean baseline hemoglobin values: 91 to 133 g/L; 13 out of the 16 studies performed in malaria-endemic areas). There was only one trial with an overall low risk of bias, we judged all other trials to have unclear or high risk of bias in one or more 'Risk of bias' domains. Overall, 12 studies were included in the quantitative syntheses.

Moderate-certainty evidence show that providing fortified complementary food to children aged 6 to 23 months at the start of the intervention reduced anaemia by 43%, and those who received fortified complementary food compared to those who did not had significantly higher haemoglobin concentrations (MD 3.44 g/L, 95% Cl 1.33 to 5.55; moderate certainty evidence) and significantly higher ferritin concentrations (log ferritin: MD 0.43 μ g/L, 95% Cl 0.14 to 0.72; low certainty evidence).

Available evidence showed no difference in weight-for-age z scores (MD -0.01, 95% CI -0.07 to 0.06; moderate-certainty evidence), weight for height/length Z-scores (MD -0.05, 95% CI -0.19 to 0.10; moderate-certainty evidence), and height/length for age Z-scores (-0.01, 95% CI -0.21 to 0.20; low-certainty evidence) between groups.

The intervention led to no effects on serum zinc (MD -0.13 g/dL, 95% CI -0.82 to 0.56; low-certainty evidence), and serum vitamin A (MD 0.03 μ mol/L, 95% CI -0.02 to 0.08; moderate-certainty evidence).

Children consuming the fortified as compared to those consuming the unfortified complementary food had significantly better mental skill development scores (MD 0.80, 95% CI 0.12 to 1.48; moderate-certainty evidence), and total psychomotor development scores (MD 1.13, 95% CI 0.35 to 1.91; low-certainty evidence), but no significant differences were seen when fine and gross motor scores were assessed separately (low-certainty evidence).

Low-certainty evidence showed no difference in the acceptability of fortified as compared to unfortified complementary food products.

Author's conclusions

Centrally fortified complementary foods probably reduce anaemia in infants and young children aged 6 months to two years, in malaria-endemic regions and can probably lead to better mental and psychomotor achievement. Consumption of fortified complementary foods in this age group may improve iron status, but make little or no difference to the levels of other micronutrients, including zinc and vitamin A. Several aspects of providing fortified foods to children in the complementary

feeding period should be further investigated, including the fortification dose which can lead to adequate nutrient intakes, and potential adverse effects.

INTRODUCTION

Description of the condition

Exclusive breastfeeding is recommended for the first 6 months of age by several committees, like the World Health Organisation (WHO) (1), the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) (2) and the American Academy of Pediatrics (AAP) (3). This should be followed by appropriate complementary feeding and continued breastfeeding for 1 year or more as desired for mother and infant (2, 3) or up to 24 months of age or even longer (1). Complementary feeding is the transition from exclusive breastfeeding to family foods, typically the period from 6-23 months of age (4). In this period infants and young children need to have a great dietary diversity to ensure their nutrient needs are met (5). This is a critical period not only for physical, but also for cognitive and motor development.

Infants' diet at the age of 6 to 23 months often doesn't provide sufficient quantity of micronutrients. This may be due to a number of factors, including the low mineral content of breast milk (iron, zinc), the relatively small amount of complementary food consumed and its inadequate nutrient density as well as the relatively high requirement of these nutrients. Therefore, complementary food should have a high nutrient density and locally available foods are preferred. Plant-based complementary foods are insufficient in some micronutrients, like iron, zinc or calcium, so meat, fish and eggs should also be offered as often as possible. Besides breastfeeding calcium-rich dairy products (preferably cheese, yogurt and dried milk, mixed with other foods) should also be given(6).

Vitamin and mineral (micronutrient) deficiencies are common in low and middle-income countries affecting more than two billion people worldwide. Children living in South Asia (7) and Africa (8, 9) are in particular at risk for developing it. In the background several causes can stand, like the low dietary intake of micronutrients (8), the low nutrient density of complementary foods (10, 11) as well as low consumption of haem-iron containing meat (6, 11). The highest nutrient gaps in the complementary feeding period are for iron, vitamin A, vitamin B_{12} , zinc and calcium (7, 9).

Anaemia is still a worldwide health problem in preschool-age children affecting about 273 million children worldwide. The highest percentage of affected children can be found in Africa (62.3%), South-East-Asia (53.8%), and the Eastern Mediterranean Region (48.6%) (12). Approximately half of anaemia cases is caused by iron deficiency (ID), but other micronutrient deficiencies (folate, vitamin B₁₂, zinc), infection (malaria, HIV) and disturbed haemoglobin synthesis might also stand in the background (12).

Iron is important not only for haemoglobin synthesis, but it also plays a key role in neurodevelopment, so 6-23 months-old infants with iron deficiency are at increased risk for poorer cognitive, motor and

neurodevelopmental outcomes (13). The prevalence of iron deficiency in children under 5 years of age is higher (18% in Ethiopia – 35% in Kenya) than in the 5-19 age group (4% in Kenya – 18% in South Africa) (8). In these countries a big number of children also have inadequate intake of iron (13% - 62%) (8).

Vitamin A is required for vision, epithelial integrity and both innate and adaptive immunity (14). Vitamin A deficiency (VAD) is the main cause of preventable blindness (15), but children with VAD also have an increased risk of morbidity and mortality (16). It affects about 190 million preschool-age children worldwide, mainly in Africa and South-East Asia (2). The prevalence of VAD is also high in Africa in children <5 years ranging between 15% (in Kenya) and 35% (in South Africa) that greatly correlate with inadequate intake in this age group ranging between 1 - 100% (8).

Zinc is essential for normal physical and mental development and as part of zinc-finger proteins for both DNA and RNA synthesis as well as in several enzymatic functions (17, 18). Many children <5 years have zinc deficiency with prevalence from 35% (in Ethiopia) to 63% (in Nigeria) that correspond to the inadequate intake in 51 - 99% of these children (8). This can lead to increased risk of childhood infections and death from infectious diseases (18).

Description of the intervention

In the first two years of life the need for nutrients is high due to rapid growth that should be covered by complementary feeding providing a wide variety of foods to ensure proper nutrient content after the age of 6 months in addition to breastfeeding (6) or milk products for non-breastfed children (19). However, unfortified complementary foods as well as plant-based foods may provide insufficient amounts of some nutritionally important minerals like iron, zinc or calcium. In these populations the use of fortified complementary food or vitamin-mineral supplementation of the infant can be beneficial.

Food fortification means the addition of micronutrients to processed food with the aim to increase the intake of these micronutrients and thereby correcting or preventing deficiency. Fortification differs from supplementation, which means the provision of relatively large doses of micronutrients in the form of pills, capsules, or syrups. (20). Food fortification can mean the addition of micronutrients at the time of food production (including mass, targeted, and market-driven fortification), at point of use (home fortification), or the breeding and genetic modification of plants so as to improve their micronutrient content (biofortification).

Food fortification can improve the micronutrient status of a population quite rapidly and can be a very cost-effective intervention in public health. However, fortified food must be consumed in adequate amounts to achieve proper effect and fortificant should be well absorbed and shouldn't affect the smell and taste of enriched foods (20).

Fortification of complementary foods might be done either by the industry or at point of use. In the present systematic review, we discuss the potential health effects of adding micronutrients (minerals, vitamins) to industrially processed and widely consumed complementary food products (i.e. fortified ready-to-eat or ready-to-cook products).

The first complementary food for an infant is usually a porridge, gruel or infant cereal, so fortified cereals can be beneficial in meeting the infants' micronutrient requirements. There are several ready-to-eat porridges, grains, blended foods (e.g. corn-soy blend or wheat-soy blend) and ready-to-cook products (e.g. made from rice, wheat, corn, millet, grains, legumes, soy, peanuts, sugar and oil) and instant infant flours. In the first months of complementary feeding infants also consume fruits and vegetables in form of different purees and sauces or baby jars that also can be fortified with one or more micronutrients. When the child is old enough to consume lumpy food, different finger foods, snacks, pastas, noodles, bakery products (e.g. rusk, biscuit, cake) can be given. Besides breastmilk other drinks and beverages, like fruit juices can be offered to the infant. All of these complementary food types can be industrially fortified with one or more micronutrients.

How the intervention might work

In infants, the small amount of complementary food consumed and their increased demand due to rapid growth and development may result in micronutrient deficiencies. Most of the complementary foods are fortified with iron to meet this increased need. Studies conducted in 6-12 months old infants indicated that iron containing rice porridge (22), or with highly bioavailable iron containing maize and soy-flour based complementary food can significantly reduce the prevalence of ID (23). Cereal fortified with ferrous fumarate, ferric pyrophosphate or ferrous sulphate was described to have similar effects on maintaining haemoglobin concentrations and preventing ID in Bangladeshi children (24). In US infants, both electrolytic iron and ferrous fumarate containing cereal had the same effectiveness on iron status (25). In a malaria-endemic region iron-fortified complementary food can effectively reduce the risk of ID and IDA in developing countries when its dose and chemical form is appropriate (11).

The same beneficial effects were indicated, when fortification was done with multiple micronutrients. Micronutrient fortification in form of fortified rusk was described to efficiently maintain haemoglobin concentration (27), while multi-fortified instant flour was reported to decrease the prevalence of ID, IDA and anaemia (28). Results of other studies indicated that multi-fortified rice-based infant cereal was not only an effective way to decrease the prevalence of ID and IDA in infants, but might have beneficial effects on language and mental developmental scores on Bayley-III scale (29) and motor development in infants living in poor areas (30). However, effects of micronutrient fortification on mental and motor development are conflicting (31, 32).

Some studies suggested that there might be differences based on the type of complementary food fortified: different effects in reducing anaemia were described for fortified wheat flour, (33), maize flour (34) and rice (35). Furthermore, intervention was indicated to be effective in reducing risk of anaemia to a different level in different age groups (36).

Some researchers reported that locally produced ready-to-use foods as well as fortified blended complementary foods may reduce linear growth deceleration and decrease the prevalence of stunting (37). Micronutrient-fortified complementary food might have not only short-term (during experimental period), but even longer term (6 months after the intervention) beneficial effect on length and ponderal growth (38).

In zinc-deficient areas zinc supplementation for children over 6 months of age can be beneficial in reducing the duration of diarrhoea (39) and mortality as well as morbidity due to diarrhoea (40). Adding zinc to food during infancy and early childhood can improve child growth (41), but results are conflicting (42).

In South-Africa, provitamin A-biofortified maize as well as provitamin A and iron rich orange-fleshed sweet potato is available (43), and their acceptance suggested that these biofortified foods can replace the unfortified ones in traditional dishes (44). Micronutrient fortified complementary food might prevent the decline in serum retinol concentration over a 6-month intervention period (32, 45).

Why it is important to do this review

Micronutrient deficiencies are common in low- and several middle-income countries (mainly in South-Asia and Africa), where staple foods do not provide enough nutrients to cover the daily demand. The most vulnerable groups are pregnant and lactating women and children as well. Therefore, most studies are investigating the possible positive health effects of supplementing the diet in these groups at increased risk. Large scale food fortification for example had a positive impact on goitre, neural tube defect and anaemia and reduced both ID and VAD in children and in women of reproductive age (46).

IDA is one of the major health problems worldwide with a high prevalence in 6-24-month-old children. In several developing countries, like South-Asian and African countries complementary foods don't provide sufficient amount of iron, so iron supplementation or fortification might be beneficial in preventing IDA. Complementary food containing substantial amount of iron in form of meat or ironfortified cereal help to prevent ID during the first year of life in infants who are at risk of insufficient iron stores (47).

Several Cochrane Reviews evaluated the possible effects of different micronutrient powder or lipidbased nutrient supplements containing vitamins or minerals in children. De-Regil et al found that pointof-use fortification of foods with iron-containing micronutrient powder (MNP) reduces anaemia and ID in both preschool- and school-age children (48). Similarly, home (point-of-use) fortification of foods with MNP (containing at least iron, zinc and vitamin A) reduced anaemia and ID in 6-23 months old infants (49). Multiple micronutrient fortification may reduce anaemia by 32%, the prevalence of IDA by 72%, ID by 56% and VAD by 58% compared to placebo (50). Lipid-based nutrient supplements with complementary feeding were also effective in improving growth in this age group in low- and middleincome countries reducing the prevalence of moderate stunting by 7% and moderate wasting by 18% (51).

Several trials exist also on the potential beneficial and harmful effects of complementary feeding with fortified foods (22-27, 31, 32, 37, 38, 45, 52, 53), although, there is currently no up-to-date systematic review summarising these results.

OBJECTIVES

To assess the effects of the consumption of fortified complementary food (excluding milk) as compared to unfortified version of the same complementary food on beneficial or harmful dietary and health outcomes in infants and young children 6-23 months of age.

METHODS

Criteria for considering studies for this review

Types of studies

We included randomised controlled trials (RCTs) with both individual randomisation and cluster randomisation. We also included controlled clinical trials (CCTs), if concurrently controlled (i.e. with the intervention group and control group chosen from the same population and treated concurrently). Studies with external (historical) control groups, or with matched cross-sectional control groups were excluded.

Types of participants

We included infants and young children aged six to 23 months at the start of the intervention. We did not include infants under six months, as exclusive breastfeeding is the recommendation for infants from birth to six months of age. We intended to include apparently healthy children from the general population, although some may be at risk of having highly prevalent diseases (e.g. malaria, HIV, diarrhoea, undernutrition).

We included studies targeted to broader age groups and attempted to extract data for children six to 23 months from these studies, if possible.

For populations in malaria-endemic areas, we planned to report on malaria incidence and malaria severity. Because this was not reported by trial authors, we investigated, whether authors mentioned the region to be malaria endemic, whether children with malaria were included or excluded. As malaria prevalence was not reported in most of the cases, we defined an area as malaria endemic based on the WHO classification (54).

Types of interventions

Consumption of fortified complementary products (excluding milk and milk-based formula). Products might have been fortified with one micronutrient or a combination of vitamins and/or minerals.

The following fortified complementary food products were eligible to be included:

- ready-to-eat porridges
- infant cereal, grains/ ready-to-cook products (e.g. made from rice, wheat, corn, millet, grains, legumes; soy, peanuts, sugar; and oil)/ blended foods (e.g. corn-soy blend, wheat-soy blend)
- ready-to-cook/instant infant flour

- pastas, noodles
- bread and other bakery products (including rusks, biscuits, cakes)
- baby food
- purees, sauces
- finger food, snacks
- beverages (drinks, juices)

There was no restriction based on the dose of fortification, nor based on the frequency and duration of the fortified complementary food consumption. All fortification strategies were eligible, if food products were fortified processed centrally.

We excluded food supplements (e.g. lipid-based nutrient supplements) and micronutrient powders, or any other ways of home (point-of-use) fortification.

Comparator was consumption of an unfortified version of the same complementary product. Studies comparing two or more different fortified products to eachother, without comparing them to an unfortified version of the same complementary food product were excluded.

Types of outcome measures

Main outcomes

- Growth, measured by the following growth indicators:
 - Weight for age Z-scores (reported continuously; WAZ)
 - Weight for height/length Z-scores (reported continuously; WHZ)
 - Height/length for age Z-scores (reported continuously; HAZ)
 - Other growth measures (e.g. head circumference or arm circumference for age; as measured by trialists)
- Stunting (reported as a categorical outcome; defined as HAZ more than 2 SDs below the reference WHO standard; [1])
- Wasting (reported as a categorical outcome; defined as WHZ more than 2 SDs below the reference WHO standard; [1])
- Nutrient adequacy (evaluated relative to estimated average requirements or adequate intakes; as defined by trialists) for iron, zinc, vitamin A, or any other micronutrient investigated by trialists

- Nutrient excess (intakes above the tolerable upper intake level (UL), as defined by trialists) for iron, zinc, vitamin A, or any other micronutrient investigated by trialists
- Anaemia (as defined by trialists)
- Haemoglobin concentration (measured as g/L)
- Iron status (as defined by trialists)
- Serum zinc concentration (g/dL)
- Serum retinol concentration (µmol/L)

Additional outcomes

- All-cause mortality
- Adverse effects (any)
- Mental and motor skill development (as defined by trialists; might include: Bayley Mental Development Index (MDI), Bayley Psychomotor Development Index (PDI), Stanford-Binet Test, DENVER II Developmental Screening Test)
- Morbidity (Including: incidence of diarrhoea, acute respiratory tract diseases, fever diseases)
- Ferritin level (µg/L)
- Serum/urine concentration of other vitamins or minerals (including vitamin D, vitamin B₁₂, folate, iodine, selenium)
- Gut microbiota composition (measured as relative abundance of specific Bacterium spp.)
- Taste preference
- Displacement of other foods

We included outcomes that are measured for as long as follow-up is carried out at any given time point.

Search methods for identification of studies

Electronic searches

We searched the following electronic databases and trial registers from the inception of each database up to March 2021, without restrictions on the language of publication:

- Ovid MEDLINE
- Cochrane Central Register of Controlled Trials (CENTRAL)

- CINAHL Cumulative Index to Nursing and Allied Health Literature
- Global Index Medicus, comprising
 - African Index Medicus (AIM)
 - Index Medicus for the Eastern Mediterranean Region (IMEMR)
 - Index Medicus for the South-East Asia Region (IMSEAR)
 - Latin America and the Caribbean Literature on Health Science (LILACS)
 - Western Pacific Region Index Medicus (WPRO)
- Embase.com
- Web of Science, comprising:
 - Science Citation Index
 - Emerging Citation Index
- Trials registers
 - ClinicalTrials.gov (clinicaltrials.gov)
 - WHO ICTRP (International Clinical Trials Registry Platform) (apps.who.int/trialsearch)

Details for all search strategies are available in Appendix 1.

Searching other resources

We tried to identify other potentially eligible trials or ancillary publications by searching the reference lists of included trials and related systematic reviews, meta-analyses, and health technology assessment reports.

We searched for grey literature, which we defined as searching the Global Index Medicus, as well as the trials registers.

Data collection and analysis

Selection of studies

Pairs of review authors (IC, RF, ES, SL) independently screened the abstract, title, or both, of every record retrieved by the literature searches to determine which trials should be assessed further. We performed the screening using Covidence software (55). We obtained the full texts of all potentially relevant records and screened these for eligibility. Any disagreements were resolved through consensus or by recourse to a third review author. We have presented a PRISMA flow diagram to

describe the process of trial selection (56). All articles excluded after full-text assessment and the reasons for their exclusion are described in *Characteristics of excluded studies* tables (**Appendix 5**).

Data extraction and management

From full-text publications, we extracted data on study methods, participants, intervention, control, reported outcomes, source of funding and potential conflict of interest statements from all included studies. If studies reported outcomes at multiple time points, we extracted data for each time point. Data extraction was performed by one reviewer and checked for completeness, accuracy and consistency by a second independent reviewer (IC, RF).

We attempted to extract data on food consumption for children six to 23 months from those studies targeted to broader age groups. Long-term outcomes were extracted as long as participants were followed up.

We did not use abstracts or conference proceedings for data extraction, because this information source does not fulfil the CONSORT requirements, which consist of "an evidence-based, minimum set of recommendations for reporting randomised trials) (57, 58). Key data of included abstracts are listed in **Appendix 4**.

If data from included trials were available as study results in clinical trial registries such as ClinicalTrials.gov or similar sources, we made full use of this information and extracted the data. If there was also a full publication of the trial, we collated and critically appraised all available data. If no results were available (in the registries, as publication, or both), we added this trial to the 'Characteristics of studies awaiting classification' table (**Appendix 4**).

Assessment of risk of bias in included studies

Two review authors (ES, SL) independently assessed the risk of bias of each included trial. Any disagreements were resolved by consensus. Risk of bias was evaluated with version 2 of the Cochrane risk-of-bias tool for randomised trials (RoB 2) (59). The following domains were considered: bias arising from the randomization process; bias due to deviations from intended interventions; bias due to missing outcome data; bias in measurement of the outcome; and bias in selection of the reported result. For cluster-randomised trials we additionally assessed the risk of bias arising from the timing of identification or recruitment of participants in cluster-randomised trials, and for cross-over trials bias

due to potential period and carryover effects. Overall risk of bias was defined for each trial as the least favourable assessment across the domains of bias.

Measures of treatment effect

For *dichotomous data, we* presented results as risk ratios (RRs) or odds ratios (ORs) with 95% confidence intervals (CIs). For *continuous data,* we used mean differences (MDs) with 95% CIs for studies measuring outcomes in the same way, and standardized mean differences (SMDs) with 95% CIs for studies measuring outcomes in a variety of ways.

Unit of analysis issues

We combined results from cluster-randomised and individually randomised studies. We labelled all cluster-randomised studies with '(C)'. Where trial authors had adjusted their results for the effect of clustering, we aimed to extract the cluster adjusted RR and standard error and enter the natural log of these into Review Manager (RevMan) using the generic inverse variance method as recommended by Higgins 2011 (60). Where trial authors had not adjusted their results for the effect of clustering, we extracted the simple summary data for all relevant outcomes and calculated crude RR and 95% Cl using Review Manager (RevMan). We adjusted for the effects of clustering using the approximate analysis method (as described in Section 23. 1. 5 of the Cochrane Handbook). This involves inflating the standard error of the RR using an estimate of the design effect, and entering the natural logs of the adjusted RR and corresponding Standard Errors (SE) into Review Manager (RevMan) using the generic inverse variance method. Intracluster correlation coefficient (ICC) was unfortunately not reported in any of the trials, so the value of 0.03 was used as suggested by Leyrat et al (61) referring to the data collected by Campbell et al (62). Sensitivity analysis with respect to ICC was not undertaken.

We examined the potential effects of clustering using sensitivity analyses.

For outcomes with skewed data (ferritin, retinol) a part of the included studies presented their results as geometric means, or medians with interquartile ranges. In such cases we calculated log-transformed data for all studies and performed a meta-analysis on the scale of the log-transformed data.

Studies with more than two treatment groups

For studies with more than two intervention groups (multi-arm studies), we reported all arms in the Characteristics of included studies tables (**Appendix 2**) and included the directly relevant arm only, including each group in the analysis only once (63). If we came across a study that compared two possible fortified products with one unfortified comparator, we combined groups to create a single pair-wise comparison (as described in Section 6.5.2.10 of the Cochrane Handbook).

Assessment of heterogeneity

We assessed methodological heterogeneity by examining risk of bias, and clinical heterogeneity by examining similarities and differences between studies regarding types of participants, interventions, and outcomes. We considered the size and direction of effect and used a standard χ^2 test with a significance level of $\alpha = 0.1$ (64) and l² statistic — which quantifies inconsistency across trials — to assess the impact of heterogeneity on the meta-analysis (65, 66). We explored heterogeneity by conducting pre-specified subgroup analyses (See Section 'Subgroup analysis and investigation of heterogeneity' below).

Assessment of reporting biases

We used funnel plots to assess reporting bias (such as publication bias) and to investigate the relationship between effect size and standard error when 10 or more studies were included in a metaanalysis. Degree of funnel plot asymmetry was quantified using Egger's test (67). Visualisation of risk of bias was done with Robvis Tool (https://mcguinlu.shinyapps.io/robvis/).

Data synthesis

We carried out statistical analysis using RevMan 5 (version 5.4.1). As we expected differences between studies in both the population and the intervention, we decided to combine the data using a random effects model, when it was clinically meaningful to do so, to provide an average treatment effect across studies. We used Mantel-Haenszel weighting for dichotomous outcomes and inverse variance for continuous outcomes. In case both individually randomised and cluster-randomised trials were included in a meta-analysis, we used the inverse variance method, as described in the "Unit of analysis issues" section.

Subgroup analysis and investigation of heterogeneity

We expected the following characteristics to introduce clinical heterogeneity, and we planned to carry out subgroup analyses for these, for all outcomes, where enough trials were available:

- Age groups (6-8 months; 9-11 months; 12-23 months)
- Different types of nutrients added through fortification
- Different types of products fortified
- By duration of intervention: less than six months versus six months or more
- The country income classification (HIC vs. LMIC)
- By anaemic status at start of intervention (anaemia defined according to trialists): anaemic, non-anaemic or unknown anaemic status
- Sponsor: industry vs. academy (investigator)

Sensitivity analysis

When possible, we conducted sensitivity analyses to examine the potential effects of clustering on the CIs of summary estimates.

Grading of recommendations assessment, development, and evaluation (certainty of the evidence)

We followed the GRADE approach to rate the certainty of evidence. Each outcome was evaluated with the following GRADE criteria: risk of bias, indirectness, inconsistency, imprecision, and dissemination bias. GRADE specifies four levels of certainty of evidence: high, moderate, low, and very low (68, 69).

RESULTS

Description of studies

Results of the search

The search was run on 09.03.2021. We retrieved 15496 unique records through database searching. After removing duplicates 8313 records were screened based on their titles and abstracts. Most of the references clearly did not meet the inclusion criteria based on title and abstract review and were excluded (*Figure 1.*). We evaluated 494 full texts or records to determine their eligibility for inclusion in the review (8 further records will be assessed after their full texts could be retrieved). 21 studies met our inclusion criteria (16 studies with full-text publications and further 5 studies where results are not yet published).

Included studies

For a detailed description of included trials, see Characteristics of included studies (Appendix 2).

Study design

We included 16 studies with 5089 participants. Eight studies were RCTs randomised at the individual level (Bovell-Benjamin 1999; Faber 2005; Gannon 2019; Lartey 2000; Nesamvuni 2005; Palmer 2021; Quintero 2011; Schumann 2005), one was a non-randomised controlled trial (Huey 2018) and seven were cluster-RCTs (Arcanjo 2012, Arcanjo 2013, Bagni 2009, Ekoe 2020, Gershoff 1977, Liu 1993, Ma 2016,).

Setting

Only one study was conducted in a high income country (USA: Bovell-Benjamin 1999); ten studies were conducted in upper middle income countries including China (Ma 2016; Liu 1993), Brazil (Arcanjo 2012; Arcanjo 2013; Bagni, 2009), Thailand (Gershoff 1977); Mexico (Quintero 2011); South Africa (Faber 2005, Nesamvuni 2005); Guatemala (Schumann 2005); while five studies were conducted in lower middle income countries including Zambia (Palmer 2021), Cameroon (Ekoe 2020), India (Huey 2018; Gannon 2019), and Ghana (Lartey, 2000), and no study was conducted in a low income country.

Figure 1. Trial flow diagram



Screening

Eligibility

Included

According to the WHO classification (54), 13 out of the 16 studies were performed in malaria-endemic areas (see **Appendix 7**). Three studies, conducted in the USA and China, were classified as non-malaria-endemic (Bovell-Benjamin 1999; Ma 2016, Liu 1993).

Participants

Participant age ranged from 6 to 60 months. All studies included children of both sexes. Sample sizes ranged from 40 in Bovell-Benjamin 1999 to 1465 in Ma 2016. However, the analyses include only participants allocated to the study arms relevant for this systematic review in case of studies with more than two arms and the estimated effective sample size calculated for cluster-randomised trials in order to adjust study data to account for the clustering effect.

Out of the 16 studies included in the systematic review nine studies reported anaemia prevalence at baseline. In two studies participants were reported to be anaemic (Ekoe 2020) or moderately anaemic (Schümann 2005). Seven trials included both anaemic and non-anaemic children (Palmer 2021; Ma 2016; Arcanjo 2013; Arcanjo 2012; Faber 2005; Lartey 2000; Liu 1993). In the remaining seven trials baseline anaemia status was not reported.

Interventions

There were three acute studies with an intervention duration of three subsequent feeding sessions (Bovell-Benjamin 1999) to three consecutive days (Gannon 2019, Huey 2018). Among studies investigating longer-term effect of fortified complementary food consumption, intervention duration lasted between 10 weeks (Schumann 2005) and 18 months (Arcanjo 2012, Arcanjo 2013). Study duration was variable in one study (Gershoff 1977).

Products fortified were cereals in most of the cases, including 2 studies with fortified wheat-based products (Liu 1993; Ekoe 2020); five with fortified maize/corn-based products (Bovell-Benjamin 1999; Quintero 2011; Faber 2005; Palmer 2021; Nesamvuni 2005); five with fortified rice or rice cereal (Ma 2016; Gershoff 1977; Bagni 2009; Arcanjo 2012; Arcanjo 2013) and one with fortified pearl millet (Huey 2018). In two studies the fortified complementary food product was a cereal-legume blend (Lartey 2000; Gannon 2019), while in one study legume (beans) were fortified (Schümann 2005).

Vitamin and mineral composition

Macro-and micronutrient composition of the fortified products and the micronutrients added to these products as fortificants are shown in *Appendix 3*. In six studies complementary food products were fortified with iron only (Ekoe 2020; Arcanjo 2012; Arcanjo 2013; Bagni 2009; Schumann 2005; Bovell-Benjamin 1999). In the remaining studies fortification was done with a combination of two or more micronutrients: iron and zinc in one study (Huey 2017); iron, zinc and vitamin B₁₂ in one study (Ma 2016); iron, vitamin A acetate and thiamine in one study (Gershoff 1977), iron, zinc, vitamin A, niacin and folic acid in one study (Quintero 2011); vitamin A palmitate (or biofortification) in one study (Palmer 2021); vitamin A, thiamine, riboflavine and pyridoxine in one study (Nesamvuni 2005). There were three studies where a combination of ten or more vitamins and minerals was used (Faber 2005, Lartey 2000; Liu 1993). Biofortification was done in two studies (Gannon 2019; Palmer 2021).

Outcomes

Out of the primary outcomes of this systematic review the following were measured in the included studies: growth measured by weight for age Z-scores (WAZ) in 5 studies, by weight for height/length Z-scores (WHZ) in 4 studies, by height/length for age Z-scores (HAZ) in 4 studies; nutrient adequacy for zinc and vitamin A in one study; anaemia in 6 studies; haemoglobin concentrations in 13 studies (but results reported only in 11 studies); iron status measured by ferritin concentrations in 6 studies, by body iron in one study and by free erythrocyte porphyrin in one study; serum retinol concentrations in 5 studies; serum zinc concentration in 2 studies. Stunting, wasting, and nutrient excess (intakes above the tolerable upper intake level) were reported in none of the included studies.

Out of the secondary outcomes of this systematic review the following were measured: mental skill development in 2 studies, motor skill development in 3 studies; morbidity (including diarrhoea, acute respiratory tract diseases, fever diseases) in two studies (but appropriately reported only in one study); plasma vitamin E concentration in one study; acceptability of fortified as compared to non-fortified complementary food products in 3 studies. Adverse effects were mentioned in one study. All-cause mortality, gut microbiota composition and displacement of other foods were reported in none of the included studies.

Funding sources

Funding sources of included studies are described in the "Publication details" of each Characteristics of included studies table (see **Appendix 2**). A total of 8 studies were funded by government programmes or by other non-commercial organisations (Gannon 2019; Huey 2017; Ma 2016; Arcanjo

2012; Arcanjo 2013; Bagni 2009; Liu 1993; Gershoff 1977), while there were 6 partly or fully commercially funded studies (Palmer 2021; Ekoe 2020; Quintero 2011; Nesamvuni 2005; Lartey 2000; Faber 2005). Two studies did not report any funding source (Schümann 2005; Benjamin-Bovell 1999).

Ongoing studies

We identified a total of 5 trials, potentially eligible to be included in the systematic review, but not yet published as a full-text publication. For further details of these trials, see **Appendix 4**.

Excluded studies

For a detailed description studies excluded in the full text screening phase, see **Appendix 5**. *Characteristics of excluded studies*. A total of 42 studies were excluded, because they were not primary studies with participants allocated to two or more intervention groups. In 70 studies participants were not children aged 6-23 monts: in 9 studies children were younger at the start of the intervention, while 61 studies included older children or women. We excluded 191 studies because the intervention was not a complementary food fortified with vitamins and/or minerals. In 157 studies there was no eligible comparator (i.e. none of the participants received the same complementary food as in the intervention group, just without fortification); at this stage also studies comparing two different dosages of fortification were excluded. Further 13 studies were identified as duplicates of already included/excluded studies and were excluded as duplicates.

Risk of bias in included studies

For an overview of review authors' judgements about each 'Risk of bias' item for individual trials and across all trials, see *Figure 2* and *Figure 3*.

The randomisation process was appropriately described in only two studies (Palmer 2021; Gannon 2019), while in 13 studies there were some concerns due to lack of infomation about the randomisation process (Ma 2016; Quintero 2011; Nesamvuni 2005; Schümann 2005; Benjamin-Bovell 1999; Gershoff 1977) or the allocation sequence concealement (Ekoe 2020; Ma 2016; Arcanjo 2012; Arcanjo 2013; Quintero 2011; Bagni 2009; Nesamvuni 2005; Faber 2005; Schümann 2005; Lartey 2000; Benjamin-Bovell 1999; Liu 1993; Gershoff 1977). In one study the allocation sequence was clearly non-random, as all the participants received the non-fortified products first (Huey 2017).

Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials.



Deviations from intended intervention were rated with high risk of bias in five cases (Bagni 2009; Nesamvuni 2005; Faber 2005; Schümann 2005; Gershoff 1977); because there was a potential for a substantial impact on the result of the failure to analyse participants in the group to which they were randomised. In five cases there were some concerns about potential deviations from the interventions (Ekoe 2020; Ma 2016; Quintero 2011; Lartey 2000; Liu 1993), while in the remaining six cases this risk of bias domain was evaluated with low risk of bias.

Missing outcome data lead to high risk of bias in six studies (Nesamvuni 2005; Faber 2005; Schümann 2005; Benjamin-Bovell 1999; Liu 1993; Gershoff 1977), while in the remaining ten studies this domain was evaluated to be of low risk of bias.

Measurement of the outcome and selection of the reported results raised concerns in only one case each (Ma 2016 and Gershoff 1977, respectively).

There were seven cluster-randomised trials, where we additionally assessed the timing of identification or recruitment of participants; in one case this domain was judged to be of low risk of bias (Ekoe 2020) and in four cases we had some concerns (Ma 2016; Arcanjo 2012; Arcanjo 2013; Bagni 2009; Liu1993; Gershoff 1977).

There were three cross-over trials, where we additionally assessed the presence or absence of period and carryover effects. In one case this domain was judged to be of high risk of bias, because the number of participants allocated to each of the two sequences was clearly not equal (Huey 2017), while in two

cases we had some concerns due to lack of information about allocation to sequences and whether period effects were accounted for in the analysis (Gannon 2019; Benjamin-Bovell 1999).

		Risk of bias							
		D1	D2	D3	D4	D5	D6	D7	Overall
Study	Palmer 2021	+			+	+	+	+	+
	Ekoe 2020	-	+		-	+	+	+	-
	Gannon 2019	+		-	+	+	+	+	-
	Huey 2017	×		X	+	+	+	+	X
	Ma 2016	-	-		-	+	-	+	-
	Arcanjo 2012	-	-		+	+	+	+	-
	Arcanjo 2013	-	-		+	+	+	+	-
	Quintero 2011	-			-	+	+	+	-
	Bagni 2009	-	-		X	+	+	+	X
	Nesamvuni 2005	-			×	X	+	+	X
	Faber 2005	-			×	X	+	+	X
	Schümann 2005	-			×	X	+	+	X
	Lartey 2000	-			-	+	+	+	-
	Benjamin-Bovell 1999	-		-	+	X	+	+	X
	Liu 1993	-	-		-	X	+	+	X
	Gershoff 1977	-	-		×	X	+	-	×
	D1: Randomization process D2: Timing of identification or recruitment of participants (cluster) D3: Period and carryover effects (cross-over) D4: Deviations from intended interventions D5: Missing outcome data D6: Measurement of the outcome D7: Selection of the reported result							Judgement High Some concerns Low Not applicable	

Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included trial

Overall, 8 studies (50%) were rated with high risk of bias, due to the randomization process and carryover-effects (Huey 2017), deviations from the intended interventions (Bagni 2009; Nesamvuni

2005; Faber 2005; Schümann 2005; Gershoff 1977) or missing outcome data (Nesamvuni 2005; Faber 2005; Schümann 2005; Benjamin-Bovell 1999; Liu 1993; Gershoff 1977).

Effects of intervention

This review includes 16 studies with 5089 children. In trials with more than two treatment arms some of the children were allocated to interventions, which were not relevant to our systematic review and therefore not included in our analyses. Most of the included studies focused on anaemia and haematological indices; few reported on growth measures and developmental outcomes. There were three acute studies measuring acceptability of the products; their results were summarised narratively. There was one further trial (Gershoff 1997) not providing any quantitative data separately for the intervention groups. A total of 12 studies provided data for the quantitative analyses.

For detailed results on primary and secondary outcomes see the **Main outcomes** section below, and **Data and analyses** in **Appendix 6**.

Main outcomes

Growth

Growth was measured by weight for age Z-scores (WAZ) in five studies (Ekoe 2020; Faber 2005; Lartey 2000; Ma 2016; Quintero 2011), by weight for height/length Z-scores (WHZ) in four studies (Ekoe 2020; Faber 2005; Ma 2016; Quintero 2011), by height/length for age Z-scores (HAZ) in four studies (Ekoe 2020; Faber 2005; Lartey 2000; Ma 2016). All these studies had an intervention duration longer than 6 months (Analysis 1.21; Analysis 1.29; Analysis 1.37).

Available evidence showed no difference in weight-for-age z scores (MD -0.01, 95% CI -0.07 to 0.06; P = 0.88; 5 trials; 1206 participants; moderate-certainty evidence; **Analysis 1.17**), weight for height/length Z-scores (-0.05, 95% CI -0.19 to 0.10; P = 0.54; 4 trials; 1109 participants; moderate-certainty evidence; **Analysis 1.25**), and height/length for age Z-scores (-0.01, 95% CI -0.21 to 0.20; P = 0.93; 4 trials; 811 participants; low-certainty evidence; **Analysis 1.33**) between groups.

Subgroup analyses for weight-for-age z scores are shown in **Analyses 1.18 – 1.26**; those for weight for height/length Z-scores in **Analyses 1.26 – 1.31** and for height/length for age Z-scores in **Analyses 1.34 – 1.40**); in none of the subgroups a significant difference between children consuming fortified as compared to unfortified complementary food was detected.

We investigated the effect of clustering by removing cluster-randomised trials from the meta-analyses as part of sensitivity analyses and saw no changes in the direction of the pooled estimate either for weight-for-age Z-scores (MD -0.02, 95% CI -0.07 to 0.03; P = 0.57; 3 trials; 658 participants), for weight for height/length Z-scores (-0.01, 95% CI -0.28 to 0.26; P = 0.94; 2 trials; 683 participants), or for height/length for age Z-scores (-0.03, 95% CI -0.24 to 0.18; P = 0.93; 2 trials; 385 participants).

Stunting and wasting

No studies reported data on stunting and wasting.

Nutrient adequacy

We intended to evaluate nutrient adequacy relative to estimated average requirements or adequate intakes; as defined by trialists for iron, zinc, vitamin A, or any other micronutrient investigated by trialists. Only one study reported on nutritient adequacy (Lartey 1999), although for the three non-fortified groups of this study (cereal legume blend, cereal legume blend plus fish powder, fermented maize dough plus fish powder) only summary results were reported for the entire study population: the total zinc intake from all complementary foods in this three groups combined was 81% of the recommended amount (2.8 mg/d; reference: (70)), whereas the fortified cereal-legume blend group consumed an average of 281% of the recommended intake. In the same study total vitamin A intake (from breast milk and other foods) between 6 and 10 mo of age by infants in the three non-fortified groups combined was 50–70% of the recommended 350 mg/d (reference: (71)). By contrast, children in the fortified cereal-legume blend group consumed 2–3 times the recommended intake as a result of fortification.

Nutrient excess

Nutrient intakes above the tolerable upper intake level (UL), as defined by trialists were described in none of the included studies.

Anaemia (as defined by trialists)

Six studies (1205 children) evaluated this outcome (Arcanjo 2012; Arcanjo 2013; Bagni 2009; Ekoe 2020; Lartey 2000; Ma 2016). Children receiving fortified complementary food products were significantly less likely to have anaemia at follow-up than children receiving a non-fortified version of the same complementary food product (risk ratio (RR) 0.57, 95% confidence interval (CI) 0.39 to 0.82; P = 0.003; 6 trials; 1209 participants; moderate-certainty evidence; **Analysis 1.1**). This favourable effect on anaemia prevalence was seen in the subgroup of children aged 12 to 23

months (risk ratio (RR) 0.43, 95% confidence interval (CI) 0.19 to 0.99; P = 0.05; 2 trials; 330 participants

Analysis 1.2), but no statistically significant difference was present between groups in children aged 6 to 11 months (RR 0.65, 95% CI 0.32 to 1.35; P = 0.11; 2 trials; 368 participants) and in the group of children with mean age >23 months (RR 0.48, 95% CI 0.19 to 1.18; P = 0.13; 2 trials; 507 participants). Children receiving wheat and rice-based complementary food products fortified with iron or a combination of iron, zinc and vitamin B_{12} were less likely to have anaemia, while this favourable effect on anaemia prevalence was not seen in one small study (with 95 participants) where cereal-legume blend was fortified with multivitamins and minerals (**Analysis 1.3-1.4**).

The favourable effects on post-intervention anaemia prevalence did not vary among subgroups by duration of the intervention (**Analysis 1.5**), and were seen independently from anaemia status at the start of the intervention (**Analysis 1.6**) and from the income classification of the country where the study was performed (**Analysis 1.7**). The effect was seen in the noncommercially, but not in the commercially funded studies (**Analysis 1.8**).

Iron deficiency (as defined by trialsists, not prespecified outcome)

Three studies with 571 participating children assessed iron deficiency at follow-up after an intervention with iron-containing fortified food (Ekoe 2020; Lartey 2000; Ma 2016). All of these studies defined iron deficiency as ferritin concentrations less than 12 ug/L. These studies found that children consuming iron-fortified complementary food were significantly less likely to have iron deficiency at follow-up than children consuming an unfortified version of the same complementary food (RR 0.39, 95% CI 0.21 to 0.75; P = 0.004; moderate-certainty evidence; **Analysis 1.56**).

Haemoglobin concentration (measured as g/L)

Eleven studies evaluated this outcome (Arcanjo 2012; Arcanjo 2013; Bagni 2009; Ekoe 2020; Faber 2005; Lartey 2000; Liu 1993; Ma 2016; Nesamvuni 2005; Quintero 2011; Schumann 2005). Compared to children receiving a non-fortified complementary food product, children consuming fortified complementary food had higher haemoglobin concentration at follow-up (MD 3.44 g/L, 95% Cl 1.33 to 5.55; P = 0.001; 11 trials; 2175 participants; moderate-certainty evidence; Analysis 1.9).

The intervention was effective in children aged 6 to 11 months (MD 4.37 g/L, 95% CI 0.39 to 8.35; P = 0.03; 4 trials; 816 participants; **Analysis 1.10**), but no significant difference in haemoglobin concentrations were seen at follow-up in the age group of 12 to 23 months' children (MD 1.48 g/L, 95% CI -0.34 to 3.29; P = 0.11; 5 trials; 852 participants), neither in studies including children both younger and older than two years of age (MD 2.60 g/L, 95% CI -1.51 to 6.71; P = 0.22; 2 trials; 307 participants). We saw significant improvement in haemoglobin concentration when complementary foods were fortified with iron only (MD 2.89 g/L, 95% CI 0.01 to 5.77; P = 0.05; 5 trials; 928 participants). There was no significant variation in the mean effects when studies with different types of products

fortified (Analysis 1.12) were compared. Effect on haemoglobin concentration was independent from intervention duration (Analysis 1.13). In two studies including slightly anaemic children no effect on haemoglobin concentrations was seen (MD 2.69 g/L, 95% CI -1.69 to 7.07; P = 0.23; 2 trials; 244 participants; Analysis 1.14). The intervention was shown to be effective in studies conducted in upper middle-income countries, while in lower middle-income countries haemoglobin concentrations tended to be higher, without a statistically significant difference between groups (Analysis 1.15). The intervention was shown to be effective in studies 1.15). The intervention was shown to be effective in studies 1.15).

The beneficial effect of fortified complementary food on haemoglobin concentration was not significant any more, when removing all the cluster-randomised trials from the meta-analysis as part of a sensitivity analysis (MD 4.48 g/L, 95% CI -0.10 to 9.05; P = 0.06; 5 trials; 903 participants)

As 11 trials were included in the meta-analysis, we investigated the relationship between effect size and standard error by drawing a funnel plot (Figure 4), and we found no evidence of reporting bias (Egger's test p = 0.3663).





Iron status (as defined by trialists)

Seven studies (1047 children) provided information on ferritin concentration (Ekoe 2000; Faber 2005; Lartey 2000; Liu 1993; Ma 2016; Palmer 2021; Schumann 2005). In six of these studies the fortified product contained iron; these studies were included in the meta-analyses on ferritin. Daily dose of iron added to the complementary food products via fortification varied among studies, with a daily amount of 0.36 mg (Ma 2016), 2.5 mg (Ekoe 2020), 3.66 mg (Faber 2005), 4.6 mg (Schümann 2005) 4.93 mg (Liu 1993) of elemental iron consumed, or with >10.9 mg/day or <21.9 mg/day (Lartey 2000).

Children receiving fortified complementary foods had on average higher ferritin concentrations at follow-up than children consuming non-fortified complementary food (MD 0.43 μ g/L on log scale, 95% CI 0.14 to 0.72; P = 0.003; 6 trials; 903 participants; low-certainty evidence; **Analysis 1.42**).

Subgroup analyses indicated that the intervention appeared to be effective in children aged 6 to 11 months, while there was only one study conducted in children aged 12 to 23 months, with a total number of 153 participants, which showed no significant difference between groups (Analysis 1.42). Intervention was shown to be effective, when fortification was done with iron alone (Analysis 1.43). Subgroup analysis based on types of products fortified indicated effects for maize/corn-based complementary food products, but not for wheat-, or rice-based food products, for fortified cereal-legume blends or fortified legumes (Analysis 1.44). Consumption of fortified complementary food appeared to be effective in increasing ferritin concentrations in populations with different anaemia status at baseline (Analysis 1.46), independently from the duration of the intervention being more or less than 6 months (Analysis 1.45), in both upper and lower middle-income countries (Analysis 1.47), and independently from the fact whether the study was commercially or noncommercially funded (Analysis 1.48).

The significant beneficial effects were still seen, when removing the three cluster-randomised trials from the meta-analysis as part of a sensitivity analysis (MD 0.64 μ g/L on log scale, 95% Cl 0.23 to 1.05; P = 0.002; 3 trials; 423 participants).

There was one study where complementary food was supplemented with retinyl palmitate (Palmer 2021); this intervention did not increase ferritin levels (MD -0.13 μ g/L on log scale, 95% CI -0.45 to 0.15; 1 trial; 144 participants).

One study investigated body iron (Ma 2016) and descibed iron, zinc and vitamin B_{12} -fortified rice cereal to be effective in increasing body iron in 6-month-old children (MD 1.47 µg/L on log scale, 95% Cl 0.63 to 2.31; 1 trial; 201 participants; low-certainty evidence; **Analysis 1.49**).

One further study investigated iron status as free erythrocyte porphyrin (Liu 1993) and found no effects of an iron, zinc, and calcium-containing rusk on free erythrocyte porphyrin levels (MD 30.0 μ g/L, 95% CI -26.06 to 86.06; 1 trial; 147 participants; very-low-certainty evidence; **Analysis 1.50**).

Serum zinc concentration (g/dL)

Two studies with a total of 333 children reported on serum zinc concentration after consuming a complementary food fortified with zinc and other micronutrients (Lartey 2000; Faber 2005). Studies provided <10.26 mg/day and 6 mg/day daily doses of zinc, respectively. The percent of children with low serum zinc values (cut-off values defined as serum zinc <10.7 μ mol/L in Lartey 2000 and <9.9 μ mol/L in Faber 2005) at baseline was 3.6% and 43-48%, respectively. These studies found no effect of the provision of a zinc-fortified complementary food on children's serum zinc concentrations (MD - 0.13 g/dL, 95% CI -0.82 to 0.56; 2 trials; 333 participants; low-certainty evidence; **Analysis 1.52**).

Zinc deficiency (as dichotomous outcome, not prespecified)

One study investigated the number of children with values of serum zinc below a given cutoff at followup, in 61 children (Lartey 2000). In this study, zinc values <10.7 μ mol/L were defined as low. Prevalence of children with low zinc values decreased from 6.5 to 3.2% in the unfortified, and increased from 3.3 to 10.0% in the fortified groups (**Analysis 1.58**).

).

Serum retinol concentration (µmol/L)

Five trials with 475 children reported on serum retinol concentrations (Faber 2005; Lartey 2000; Liu 1993; Nesamvuni 2005; Palmer 2021). The percentage of children with serum retinol concentrations less than 0.7 µmol/L at baseline were 17-19% (Faber 2005), 21.6-34.5% (Lartey 2000), 0-7% (Nesamvuni 2005), 19.6-34.5% (Palmer 2021), and not reported for one study (Liu 1993). Overall, the provision of fortified complementary food as compared to non-fortified complementary food products had no effects on serum retinol concentrations (MD 0.03 µmol/L, 95% CI -0.02 to 0.08; 5 trials; 475 participants; moderate-certainty evidence; **Analysis 1.51**).

Vitamin A deficiency (as dichotomous outcome, not prespecified)

Three trials reported on vitamin A deficiency at follow-up. All these trials defined vitamin A deficiency as serum retinol concentrations less than 0.70 μ mol/L. The percentage of children with marginal vitamin A deficiency (defined as serum retinol 0.35 – 0.7 μ mol/L by trialists) remained unchanged in both groups in one study providing vitamin A fortified maize meal to children for 12 months (Nesamvuni 2005). In another study providing daily >560 RE or <1100 RE vitamin A for 6 months to children, the prevalence of low plasma retinol concentrations decreased from 34.5 to 10.4% in the fortified group, but increased from 21.6 to 27.0% in the unfortified group (Lartey 1999). The third study compared fortification with retinyl palmitate, biofortification and unfortified maize; the prevalence of children with low plasma retinol increased in all three groups (from 21.2 to 26.9% in the retinyl palmitate-fortified, from 19.6 to 29.4% in the biofortified, and from 31.0 to 34.5% in the unfortified maize group) (Palmer 2021). Overall, these studies found no differences in the likelihood of children consuming iron-fortified complementary as compared to those consuming an unfortified version of the same complementary food to have vitamin A deficiency at follow-up (RR 0.97, 95% CI 0.24 to 3.90; P = 0.97; very low certainty evidence; **Analysis 1.57**).

Additional Outcomes

All-cause mortality

No studies reported data on all-cause mortality.

Adverse effects (any)

In one study authors reported, that fortified complementary foods "were well tolerated and no side effects were reported in either group" (Ekoe 2020).

Mental and motor skill development

Mental skill development was assessed in two studies, the one measuring it on the first version (Quintero 2011), the other on the third version (Ma 2016) of the Bayley child development scale (BSID). Overall, children consuming fortified complementary food had higher scores than children consuming the unfortified version of the same complementary food (MD 0.80, 95% Cl 0.12 to 1.48; 2 trials; 308 participants; moderate-certainty evidence; **Analysis 1.54**).

Motor skill development was reported as fine motor and gross motor score (measured on BSID III) in one study (Ma 2016), as psychomotor score (measure on BSID I) in one study (Quintero 2011) and 25item motor development score (Bayley II) in one study (Faber 2005). Psychomotor development was improved in children consuming fortified complementary food (MD 1.13, 95% CI 0.35 to 1.91; 2 trials; 661 participants; low-certainty evidence; **Analysis 1.55**). This effect was not seen in the one study investigating fine and gross motor scales separately (**Analysis 1.55**).

Morbidity

One trial with 97 children reported on morbidity (Lartey 2000), as number of new episodes/ 100 days at risk. Number of diarrhoeas, acute respiratory tract disease, and fever disease episodes did not differ

between children consuming fortified and unfortified complementary food (very-low-certainty evidence; **Analysis 1.53**).

Gut microbiota composition

No studies reported data on gut microbiota composition.

Taste preference

Acceptability of fortified as compared to unfortified complementary food was measured in three acute studies (Bovell-Benjamin 1999; Gannon 2019; Huey 2018) with a total of 215 children. All studies evaluated acceptance on a 9-point hedonic scale (answers of toddler interpreted by mothers), a higher score representing better acceptance. Degree of liking did not differ signifcantly in any of these studies between fortified and unfortified groups.

Displacement of other foods

No studies reported data on this outcome.

DISCUSSION

Summary of main results

This review includes 16 studies with a total of 5089 participants, comparing the consumption of fortified complementary food with the consumption of an unfortified version of the same comlementary product. There was only one trial with an overall low risk of bias, we judged all other trials to have unclear or high risk of bias in one or more 'Risk of bias' domains. Overall, 12 studies contribute data to the quantitative syntheses.

Results show that providing fortified complementary food to children aged 6 to 23 months at the start of the intervention reduced anaemia by 43%, and those who received fortified complementary food compared to those who did not had significantly higher haemoglobin concentrations and significantly higher ferritin concentrations. The intervention led to no effects on zinc status, and vitamin A status. Children consuming the fortified as compared to those consuming the unfortified complementary food had significantly better mental skill development scores, and total psychomotor development scores, but no significant differences were seen when fine and gross motor scores were assessed separately.

Overall completeness and applicability of evidence

This review summarises findings from 16 studies. The studies were published between the years 1977 and 2020. Most of the studies were conducted in upper- or lower middle-income countries, and in malaria-endemic regions. Both the foods fortified and the micronutrients used for fortification were diverse; most of the studies providing iron either alone or in combination with other micronutrients. Most studies used low-dose iron for fortification, though, a low number of studies used high-dose (>12.5 mg). Foods fortified included mainly cereals (wheat-, maize/corn-, rice, and millet-based complementary food products), there were only two studies with cereal-legume blends and one study with fortified legumes.

There were five studies where fortification was done in 6 to 11-month-old children. Further seven studies included children aged 12-23 months and one in 6 to 23-month-old children. In three studies the age range was broader and children aged 6 to 60 months were included.

The findings of this review are generalisable to apparently healthy and non-hospitalised children in LMIC settings in Asia and Africa, although some children may be at risk of having highly prevalent diseases such as malaria, diarrhoea or even malnutrition. Although complementary food fortification might have implications also for children in developed countries, studies investigating the effects of

this intervention in high-income countries are lacking. Use of fortified complementary food in the studies included in this review is limited for preventive purposes, and hence this review does not evaluate their effectiveness in treating any form of malnutrition.

Certainty of the evidence

After evaluating available evidence using GRADE, we judged the evidence to be of moderate-certainty for the outcomes anaemia, haemoglobin concentration, weight-for-age (z scores), weight-for-lenght (z scores), serum retinol, mental skill development, and motor skill development measured on Baley scale. We judged the outcomes length-for-age (z scores), ferritin concentrations, body iron, serum zinc, fine motor scores and gross motor scores to be of low certainty, and the outcomes free erythrocyte porphyrin, diarrhoea, acute respiratory tract diseases, and fever diseases of very low certainty.

The evidence was downgraded due to design limitations (risk of bias) with at least one level in case of all outcomes, for inconsistency in case of the outcomes lengt-for-age (z scores) and ferritin levels, for imprecision with at least one level in case of the outcomes body iron, free erythrocythe pophyrin, serum zinc, morbidity, fine motor score and gross motor score.

Potential biases in the review process

The search for trials in this area was performed using a broad search strategy, by searching in both electronic databases and trials registries, without applying restrictions, such as based on language. It is unlikely that trials that have been conducted and published have been missed; however, unpublished trials, or ongoing trials not registered in clinical trials registries could be missing.

We aimed to reduce bias wherever possible by having at least two review authors work independently on trial selection, data extraction, and 'Risk of bias' and GRADE assessments.

We were able to explore the potential for publication bias using funnel plots only for the outcome haemoglobin concentration, as other outcomes were investigated in less than 10 trials.

Agreement and disagreements with other studies or reviews

To our knowledge this is the first systematic review summarising evidence on the consumption of fortified complementary food as compared to the unfortified version of the same complementary food in 6 to 23-months-old children.

Health effect of centrally-processed micronutrient-fortified food products were already assessed in children aged 6 month to 5 years (72) and in 5 to 15 years (73) by Eichler et al; these systematic reviews included both fortified dairy products and fortified cereals. In our systematic review milk, formula, and fortified milk-based products were excluded.

A broadly focused systematic review assessed the effects of all types of interventions, which might have an effect on the development of children aged 6 months to 2 years, including also micronutrientfortified complementary foods (both central and home fortification was eligible to be included) (21). Health effects of fortification of foods with muliple micronutrient powders at home (at point-of-use) was assessed in a recent systematic review, where, similar to our review, the authors included children aged 6 to 23 (49).

The above-mentioned systematic reviews all concluded, that fortification of food products with micronutrients is an effective tool to reduce anaemia in children in the complementary feeding period in developing countries. However, the literature is sparse to draw firm conclusions for functional health outcomes. These conclusions are is line with our findings.

CONCLUSIONS

Implications for practice

Use of centrally fortified complementary foods is probably an effective intervention to reduce anaemia in infants and young children aged 6 months to two years in malaria-endemic regions, therefore this intervention can be integrated into strategies to prevent anaemia in this age group. The currently available evidence showed, based on results from two studies, that consumption of fortified complementary foods likely results in a slight increase of mental and motor scores. Most of the available studies contained a daily dose of iron less than 12.5 mg. Effects of food fortification on nutrition adequacy or nutrition excess for iron was assessed in none of the studies.

Fortification with the applied micronutrient composition and doses probably makes little or no difference to growth outcomes. There seems to be no significant difference in the acceptability of fortified and unfortified food products among children aged 6 to 23 months.

Currently available evidence does not show the intervention to be effective in improving zinc and vitamin A status; while there is no available evidence on further vitamins and minerals.

Implications for research

It has to be further explored, whether consumption of fortified complementary foods

- 1. has an effect on all-cause mortality
- 2. has any adverse effects
- 3. can lead to adequate or excess nutrient intakes (and at what level of fortification)
- 4. have an effect on stunting or wasting
- 5. can influence vitamin and mineral status (other than iron)
- 6. and under what circumstances can influence mental and motor skill development
- 7. can influence microbiota composition
- 8. has an effect on taste preference
- 9. can lead to displacement of other foods.

Studies with both higher and lower nutrient content has to be conducted, so that dose-response effects can be determined. Effects of complementary food fortification should be further investigated in developing countries, but should be also assessed in high-income countries, and in regions were malaria is not endemic. Planned randomised controlled trials should be conducted with rigorous methodology and with large sample sizes.
APPENDICES

Appendix 1. Search strategies

Medline (Ovid)

- 1. Food, Fortified/
- 2. ((complement* or supplement* or fortif* or enrich*) adj3 (food* or feed* or nutri*)).tw.
- 3. ((fortif* or enrich*) adj3 (cereal* or porridg* or maize or grain* or rice or wheat or corn or millet or cowpea* or soy or peanut* or pasta* or noodle* or bread* or bakery or rusk* or biscuit* or cake* or puree* or sauce* or snack* or drink* or juice*)).tw.
- 4. ((fortif* or enrich*) adj3 (vitamin* or multivitamin* or mineral* or micronutrient* or multimicronutrient* or nutri*)).tw.
- 5. or/1-4
- 6. exp Infant/
- 7. (baby or babies or infant* or toddler* or child or children* or kid or kids).tw.
- 8. or/6-7
- 9. 5 and 8
- 10. randomized controlled trial.pt.
- 11. controlled clinical trial.pt.
- 12. randomized.ab.
- 13. placebo.ab.
- 14. clinical trials as topic.sh.
- 15. randomly.ab.
- 16. trial.ti.
- 17. or/10-16
- 18. exp animals/ not humans.sh.
- 19. 17 not 18
- 20. 9 and 19
- 21. remove dupliates from 20

Cochrane Central Register of Controlled Trials (Cochrane Register of Studies Online)

- 1. MESH DESCRIPTOR Food, Fortified
- 2. ((complement* or supplement* or fortif* or enrich*) ADJ4 (food* or feed* or nutri*)):TI,AB,KY

- 3. ((fortif* or enrich*) ADJ4 (cereal* or porridg* or maize or grain* or rice or wheat or corn or millet or cowpea* or soy or peanut* or pasta* or noodle* or bread* or bakery or rusk* or biscuit* or cake* or puree* or sauce* or snack* or drink* or juice*)):TI,AB,KY
- 4. ((fortif* or enrich*) ADJ4 (vitamin* or multivitamin* or mineral* or micronutrient* or multimicronutrient* or nutri*)):TI,AB,KY
- 5. #1 OR #2 OR #3 OR #4
- 6. MESH DESCRIPTOR Infant EXPLODE ALL TREES
- 7. (baby or babies or infant* or toddler* or child or children* or kid or kids):TI,AB,KY
- 8. #6 OR #7
- 9. #5 AND #8

CINAHL (EbscoHost)

- 1. MH "Food, Fortified"
- TI ((complement* or supplement* or fortif* or enrich*) N3 (food* or feed* or nutri*)) OR AB ((complement* or supplement* or fortif* or enrich*) N3 (food* or feed* or nutri*))
- 3. TI ((fortif* or enrich*) N4 (cereal* or porrdig* or maize or grain* or rice or wheat or corn or millet or cowpea* or soy or peanut* or pasta* or noodle* or bread* or bakery or rusk* or biscuit* or cake* or puree* or sauce* or snack* or drink* or juice*)) OR AB ((fortif* or enrich*) N4 (cereal* or porrdig* or maize or grain* or rice or wheat or corn or millet or cowpea* or soy or peanut* or pasta* or noodle* or bread* or soy or peanut* or pasta* or noodle* or bread* or soy or peanut* or pasta* or noodle* or bread* or bakery or rusk* or biscuit* or cake* or puree* or sauce* or snack* or drink* or juice*))
- 4. TI ((fortif* or enrich*) N4 (vitamin* or multivitamin* or mineral* or micronutrient* or multimicronutrient* or nutri*)) OR AB ((fortif* or enrich*) N4 (vitamin* or multivitamin* or mineral* or micronutrient* or multimicronutrient* or nutri*))
- 5. S1 OR S2 OR S3 OR S4
- 6. MH "Infant+"
- 7. TI (baby or babies or infant* or toddler* or child or children* or kid or kids) OR AB (baby or babies or infant* or toddler* or child or children* or kid or kids)
- 8. S6 OR S7
- 9. S5 AND S8
- 10. MH "treatment outcomes+" OR MH "experimental studies+" or random*
- 11. S9 AND S10

Web of Science (Science Citation Index Expanded and Emerging Sources Citation Index)

 TI=((complement* or supplement* or fortif* or enrich*) NEAR/3 (food* or feed* or nutri*)) OR AB=((complement* or supplement* or fortif* or enrich*) NEAR/3 (food* or feed* or nutri*))

- 2. TI=((fortif* or enrich*) NEAR/4 (cereal* or porridg* or maize or grain* or rice or wheat or corn or millet or cowpea* or soy or peanut* or pasta* or noodle* or bread* or bakery or rusk* or biscuit* or cake* or puree* or sauce* or snack* or drink* or juice*)) OR AB=((fortif* or enrich*) NEAR/4 (cereal* or porridg* or maize or grain* or rice or wheat or corn or millet or cowpea* or soy or peanut* or pasta* or noodle* or bread* or soy or peanut* or pasta* or noodle* or bread* or soy or peanut* or pasta* or noodle* or bread* or bakery or rusk* or biscuit* or cake* or puree* or sauce* or soy or peanut* or pasta* or noodle* or bread* or bakery or rusk* or biscuit* or cake* or puree* or sauce* or snack* or drink* or juice*))
- TI=((fortif* or enrich*) NEAR/3 (vitamin* or multivitamin* or mineral* or micronutrient* or multimicronutrient* or nutri*)) OR AB=((fortif* or enrich*) NEAR/3 (vitamin* or multivitamin* or mineral* or micronutrient* or multimicronutrient* or nutri*))
- 4. #1 OR #2 OR #3
- 5. TI=(baby or babies or infant* or toddler* or child or children* or kid or kids) OR AB=(baby or babies or infant* or toddler* or child or children* or kid or kids)
- 6. #4 AND #5
- 7. TI=(random* OR placebo OR trial OR groups) OR AB=(random* OR placebo OR trial OR groups)
- 8. #6 AND #7, Indexes=SCI-EXPANDED, ESCI Timespan=All years

Embase

#1. 'fortified food'/exp

- #2. ((complement* OR supplement* OR fortif* OR enrich*) NEAR/3 (food* OR feed* OR nutri*)):ti,ab
- #3. ((fortif* OR enrich*) NEAR/3 (cereal* OR porridg* OR maize OR grain* OR rice OR wheat OR corn OR millet
- OR cowpea* OR soy OR peanut* OR pasta* OR noodle* OR bread* OR bakery OR rusk* OR biscuit* OR cake*

OR puree* OR sauce* OR snack* OR drink* OR juice*)):ti,ab

#4. ((fortif* OR enrich*) NEAR/3 (vitamin* OR multivitamin* OR mineral* OR micronutrient* OR multimicronutrient* OR nutri*)):ti,ab

- #5. #1 OR #2 OR #3 OR #4
- #6. 'infant'/exp

#7. baby:ti,ab OR babies:ti,ab OR infant*:ti,ab OR toddler*:ti,ab OR child:ti,ab OR children*:ti,ab OR kid:ti,abOR kids:ti,ab

- #8. #6 OR #7
- #9. #5 AND #8
- #10. 'randomized controlled trial'/exp
- #11. 'double blind procedure'/exp
- #12. 'crossover procedure'/exp
- #13. 'parallel design'/exp
- #14. 'single blind procedure'/exp
- #15. random*:ti,ab
- #16. doubl* NEAR/1 blind*
- #17. singl* NEAR/1 blind*

#18. assign*:ti,ab
#19. allocat*:ti,ab
#20. volunteer*:ti,ab
#21. placebo*:ti,ab
#22. factorial*:ti,ab
#23. crossover*:ti,ab
#24. 'cross over':ti,ab
#25. #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23
OR #24
#26. #9 AND #25

Global Index Medicus (WHO)

(((complement* OR supplement* OR fortif* OR enrich*) AND (food* OR feed* OR nutri*)) OR ((fortif* or enrich*) AND (cereal* OR porridg* OR maize OR grain* OR rice OR wheat OR corn OR millet OR cowpea* OR soy OR peanut* OR pasta* OR noodle* OR bread* OR bakery OR rusk* OR biscuit* OR cake* OR puree* OR sauce* OR snack* OR drink* OR juice*)) OR ((fortif* or enrich*) AND (vitamin* OR multivitamin* OR mineral* OR micronutrient* OR multimicronutrient* OR nutri*))) AND (baby OR babies OR infant* OR toddler* OR child OR children* OR kid OR kids) AND (random* OR placebo OR trial OR groups)

ICTRP (Standard search) fortif* AND infant* OR fortif* AND child* OR fortif* AND bab* OR food* AND complement* AND infant* OR food* AND complement* AND child* OR food* AND complement* AND bab* OR food* AND enrich* AND infant* OR food* AND enrich* AND child* OR food* AND enrich* AND bab* OR feed* AND complement* AND infant* OR feed* AND complement* AND child* OR feed* AND complement* AND bab* OR feed* AND enrich* AND infant* OR feed* AND enrich* AND child* OR feed* AND enrich* AND bab*

ClinicalTrials.gov (Expert search)

(((fortified OR fortification OR fortificant OR enriched) AND (food OR foods OR feeding OR cereal OR cereals OR porridge OR porridges OR maize OR corn OR wheat OR rusk OR drink OR vitamin OR vitamins OR multivitamin OR multivitamins OR mineral OR micronutrient OR micronutrients OR nutrient OR nutrients OR nutrition)) OR "complementary food" OR "complementary foods" OR "food complement" OR "complementary feeding" OR "micronutrient fortified" OR "vitamin fortified" OR "supplemented food" OR "supplemented foods") AND (baby OR babies OR infant OR infants OR toddler OR toddlers OR child OR children OR kid OR kids)

Appendix 2. Characteristics of included studies

Study	Palmer 2021
identifier)	(#4720) (74, 75)
	Study design: parallel randomized control trial Unit of randomisation: individual
Methods	Blinding: blinding (colour-coded containers) not mentioned single-blind or
	double blind
	Location/Setting: Mkushi District in the Central Province of Zambia
	Country where trial was performed: Zambia
	Sample size: 255
	Dropouts/withdrawals: Lost to follow up: 18 (refused), 7 (moved), and incomplete biospecimen: 60 infants
	Sex: both male and female
	Inclusion criteria:
	Infants:
	healthy
	singleton infants
	• hemoglobin concentration $\geq 7.0 \text{ g/dL}$
	• received a vitamin A capsule (105 µmor) at 6mo or age
	Mothers:
	• age 18-45 years
	 Hemoglobin concentration ≥8.0 g/dL
	 free from chronic health conditions (i.e., any issue requiring regular modical visits)
	 brestfeeding and planning to continue through >12 mo postpartum
Participants	 not currently pregnant
	not planning to relocate
	Exclusion criteria:
	Infant(s):
	 not receiving the 105 μmol dose of vitamin A at ~6 months
	or intent to move from the study area
	mother(s):
	 pregnancy not currently breastfeeding or planning to cease breastfeeding prior to
	the infant's first birthday
	Both (Mother/infants pairs):
	 chronic health condition in the mother or infant
	• severe anemia in the mother (Hb < 8.0 g/dL) or infant (Hb < 7.0 g/dL)
	Health status: healthy infants
	Anaemic status: mixed (Defined as hemoglobin <12 g/dL for women and <10
	g/dL for infants)
	Age range at start of intervention: 9-12 months

	Mean age: no data
	Intervention(s):
	 retinyl palmitate–fortified white maize (FM) (n=85); serving size (287 g dry weight/d for women; 50 g dry weight for infants; 2 meals/day, for 6d/wk for 90 d biofortified orange maize (BM) (n=85); serving size (287 g dry weight/d for women; 50 g dry weight for infants; 2 meals/day, for 6d/wk for 90 d)
	Comparator(s):
Interventions	 conventional low-carotenoid white maize (CM) (n=85); serving size (287 g dry weight/d for women; 50 g dry weight for infants; 2 meals/day, for 6d/wk for 90 d)
	 white maizes (for the WM and FM) purchased from the same harvest season
	Duration of intervention: 90-d
	Duration of follow-up: 90 days
	Run-in period: –
	Number of study centres: 1
	Reported outcomes in full text of publication: plasma retinol, total body stores (TBS), liver retinol concentration, weight for age Z-scores (WAZ), Height (length for age Z-scores (HAZ)). Stunting Anaemia, Haemoglobia
	concentration
	Primary outcomes:
	Secondary outcomes:
Outcomes	Secondary outcomes: Breast milk ratinal concentrations of woman measured by high performance
	liquid chromatography
	Ilquiu chi officiography Diasma ratinal concentrations of women measured by high performance liquid
	chromatography
	Pupillary responsiveness of women measured by portable field dark
	adantometer
	Timing of outcome assessment: baseline and endline
	Trial identifier: NCT02804490
Identification	Trial terminated early: no
	Language of nublication: English
	Eunding: HarvestPlus (www.HarvestPlus.org) In-kind support was provided by
Publication	DSM Nutritional Products Inc. (fortificant) and Rioanalyt GmbH (iCheck Fluoro
	and consumables) Additional funding was provided by the Sight and Life
	Global Nutrition Research Institute at Johns Honkins University, with support
	from the Christian Blind Mission.
	Conflict of interest: "The authors report no conflicts of interest"
	Publication status: full article in peer-reviewed journal
	Quote: " To determine whether biofortified or industrially fortified maize
Stated aim for	consumption by Zambian women and their breastfeeding infants could
study	improve milk retinol concentration and infant TBS."
	Study start date: March 2016
Note	Study end date: June, 2017

Study	
(Covidence	Ekoe 2020 (76, 77)
identifier)	(# 5741)
Methods	Study design: cluster randomised trial
	Unit of randomisation: cluster (30 villages)
	Blinding: double-blind
	Number of study arms: 2 arms
	Location/Setting: Salapoumbé
	Country where trial was performed: (East) Cameroon
	Sample size: 205
	Dropouts/withdrawals: 52 (14 moved away, 13 absent, 25 refused blood
	collection)
	Sex: both male and female children included
	Inclusion criteria:
	 Apparent good health
	• 18 to 59 months
	 Haemoglobin rate ranging 7 to 11 g/dl
	Exclusion criteria:
	 iron supplementation in progress
	Clinical presentation of severe malnutrition (e.g., bilateral pitting
Participants	oedema
	 Diagnosis of any chronic infection (tuberculosis, HIV);
	• Severe acute infection (e.g., severe malaria, pneumonia, meningitis):
	 Blood transfusion < 3 months prior to enrollment:
	 Allergy/intelerance to the cow's milk and/or to the gluton
	Health status: apparent good health"
	Organing treatment: no data
	Anaomic status: anaomic (anomic (homoglohin 7, 11 g/dl) but otherwise
	healthy children")
	Age range at start of intervention: 18 to 50 months
	Mean age:
	Near $(months)$ from fortified (C group (N = 106): 22.1 + 10.0:
	Age (months) from for the divergence $(N = 100)$, 32.1 ± 10.5 ,
	Age (months) control c group ($N = 33$). So.1 \pm 10.8
	Intervention(s).
	• If off for the difficult cerear (ic).
	two 50 g servings/day ic with 7.5 mg of ferrous fulfialate
	providing 3.75 mg iron/serving; (n = 106)
	Comparator(s):
Interventions	Control IC: Infant cereal
	two 50 g servings/day IC
	Control IC group (N = 99)
	Duration of intervention: 6 months
	Duration of follow-up: 6 months
	Run-in period: no
	Number of study centres: 1
Outcomes	Reported outcomes in full text of publication:

	Haemoglobin rate/level, Se ferritin, Se iron, CRP, transferrin, frequencies of
	anaemia, nutrititon status, iron deficiency, iron deficiency anaemia, weight,
	height, weight-for-age z-scores, height-for-age, weight-for-height z-score
	Primary outcomes: seven parameters:
	hemoglobin, serum ferritin adjusted to CRP, serum iron, transferrin saturation,
	prevalence of anemia, iron deficiency, iron deficiency anemia.
	Secondary outcomes: changes in weight, height, and other anthropometric z-
	scores
	Timing of outcome assessment: baseline, 3 months, 6 months
	Trial identifier: PACTR201802003069111
Identification	Trial terminated early: no
	Language of publication: English
	Funding: Nestlé Nutrition Institute of Africa; Helen Keller Foundation for
Publication	Research and Education; Cameroon Ministry of Public Health; UNICEF; National
dotails	Statistics Institute
details	Conflict of interest: "NPH is employed by Société des Produits Nestlé SA. No
	other author has any conflict of interest to report"
	Publication status: full article in peer-reviewed journal
Stated aim for study	Quote: "To evaluate the efficacy of iron fortified wheat flour for the correction
	and the prevention of iron deficiency anaemia among 18-59 months old
	children in Salapoumbé in Cameroon."
Nota	Study start date: February 2017
NOLE	Study end date: August 2017

Study	Gannon 2019 (78)
(Covidence	(#6180)
identifier)	
	Study design: cross-over randomised controlled trial
	Unit of randomisation: individual (mother infant pairs)
Methods	Blinding: no data
	Number of study arms: 2 arms
	Location/Setting: "near Madanapalle, Andrhra Pradesh"
	Country where trial was performed: India
	Sample size: 52 children-mother pairs
	Dropouts/withdrawals: "Twelve participant pairs attended for less than 6 days.
	Of the remaining, median (Q1, Q3) daily attendance compliance was 62.8%
	(44.1%, 83.5%)."
	Sex: both male and female children included
Participants	Inclusion criteria: age: 6- to 24-months old
	Exclusion criteria:
	 dietary allergies
	 currently diagnosed with malaria or dengue
	 ever diagnosed with HIV or tuberculosis, or severe malnutrition (ie,
	weight-for-length Z-score [WLZ] < 3) determined using World Health
	Organization (WHO) field tables
	Health status: no data

	Ongoing treatment: no data
	Anaemic status: no data
	Age range at start of intervention: 6-24 months
	Mean age: 14.3 (5.6) months
	Intervention(s):
	 Multiple biofortified food crops, three times per day, six days per week,
	median daily intake was 75 g, (n = 52)
	Comparator(s):
Interventions	 Commercially available non-fortified food crops, three times per day,
interventions	six days per week, median daily intake was 75 g, (n = 52)
	Duration of intervention: 3 days
	Duration of follow-up: 3 days
	Run-in period: –
	Number of study centres: 2 feeding centers
	Reported outcomes in full text of publication: weight, stunting, wasting,
	acceptability
Outcomes	Primary outcomes: not defined
	Secondary outcomes: –
	Timing of outcome assessment: after each feeding
Identification	Trial identifier: NCT02648893; IRB #: 1508005782
Identification	Trial terminated early: no
	Language of publication: English
	Funding: non-commercial (HarvestPlus, grant number #2015H8336 awarded to
	Cornell University)
Dublication	Conflict of interest: "The author(s) declared the following potential conflicts of
Publication	interest with respect to the research, authorship, and/ or publication of this
detalls	article: S.M. is an unpaid board member for a diagnostic startup focused on
	developing point-of-care assays for nutritional status informed by his research
	as a faculty member at Cornell University."
	Publication status: full article in peer-reviewed journal
Stated aims fair	Quote: "To determine whether biofortified or industrially fortified maize
Stated aim for	consumption by Zambian women and their breastfeeding infants could improve
study	milk retinol concentration and infant TBS."
Note	this paper reports short-term results of a longer, ongoing study
	Study start date: December 2017
	Study end date: April 2018

Study (Covidence identifier)	Huey 2018 (79) (#3636/1)
Methods	Study design: cross-over, controlled clinical trial Unit of allocation: individual Blinding: no data Number of study arms: 2 arms
Participants	Location/Setting : a feeding center within a large slum known locally as Nehru Nagar, in Vile Parle, a suburb in Mumbai

Country where trial was performed: India
Sample size: 125
Dropouts/withdrawals: no information
Sex: both male and female children included
Inclusion criteria: –
Exclusion criteria: –
Age at the start of the intervention: 12-24 month
Country where trial was performed: India
Intervention(s):
 FeZnPM (iron- and zinc-biofortified pearl millet); 18 types of different recipies (n = 125)
Comparator(s):
 CtrlPM (conventional pearl millet) (n = 125)
Duration of intervention: 3 days
Duration of follow-up: 3 days
Run-in period: yes, 3 days
Number of study centres: 1 feeding center
Reported outcomes in full text of publication:
acceptability
Trial identifier: –
Trial terminated early: no
Language of publication: English
Funding: non-commercial (HarvestPlus; 2014H8302)
Conflict of interest: "SM is an unpaid board member for a diagnostic start up
focused on developing point-of-care assays for nutritional status informed by
his research as a faculty member at Cornell University. All other authors declare
that the research was conducted in the absence of any commercial or financial
relationships that could be construed as a potential conflict of interest
Publication status: full article in peer-reviewed journal
Quote: "The main objective of this study was to formulate and test the
acceptability (in terms of volume consumed and sensory characteristics) of new
pearl millet-based palatable complementary food products for wearing infants.
The food products with highest acceptability would be ideal candidates for a
improving iron status in infonts and young shildron"
This is an acute study. Pased on the results a longer term study is alanged
(Mebta 2017)
Study start date: January 2015
Study and date: December 2015

Study	Ma 2016 (Sheng 2019; Krebs 2013) (80-83)
(Covidence	(#3906)
identifier)	
	Study design: cluster randomized, non-masked, controlled efficacy intervention
Methods	trial ("this study was a cross-sectional sub-sample nested within a larger
	intervention")

	Unit of randomisation: cluster (60 villages clustered, 9 districts in Xichou
	County)
	Blinding: nonmasked
	Number of study arms: 3 arms
	Location/Setting: Xichou county in Yunnan province
	Country where trial was performed: China
	Sample size: 1465 (954 allocated to the arms relevant to this systematic review)
	Dropouts/withdrawals:149 (123 moved away, 22 refused to participate, 2 died,
	2 were visited out of the range of the scheduled age)
	Sex: both male and female children included
	Inclusion criteria:
	 healthy singleton infants between 3–5 months of age
	 born between 37 to 42 weeks gestational age
Participants	 born with birth weight >2 000 g
	 with no metabolic or physical problems
	lack of acute or chronic illness
	 being exclusively breastfed
	Exclusion criteria: –
	Health status: healthy infants
	Ongoing treatment: no data
	Anaemic status: mixed
	Age range at start of intervention: 6 months
	Mean age: –
	Intervention(s):
	 fortified infant rice cereal (commercial infant rice cereals (Nestie), fortified with inergeing and vitemin B12): 202 (day (a=410)
	fortified with iron, zinc and vitamin B12); 20g/day (n=419)
	• red meat (Sug/day) (n=461)
Intorvontions	Comparator(s):
interventions	 local (83)Infant file cereal (from a mixture of glutinous file flour, while grapulated sugar and henou) 20g/day/(n= 426)
	Buration of intervention: 12 months
	Duration of follow-up: 12 months
	Bun-in period: 1-3 months after enrolment (no intervention)
	Number of study centres: 1
	Reported outcomes in full text of publication:
	WA7 LA7 WL7 serum B12 Hb iron status ferritin B12 concentration MCV
	MCH. MCHC. cognitive score, fine motor score, gross motor score
	Primary outcomes: based on clinicaltrial.com:
	Linear Growth [Time Frame: 6-18 mos of age]
•	Secondary outcomes: based on clinicaltrial.com:
Outcomes	Morbidity [Time Frame: 6-18 mos of age]
	Cognitive development [Time Frame: 0-18 mo of age]
	Zn absorption [Time Frame: 9 and 18 mos of age]
	Timing of outcome assessment: 6, 12 and 18 months were measured
	antropometric data, venous blood samples and cognitive scale and the fine
	motor and gross motor subtests were collected at the end of intervention.
Identification	Trial identifier: NCT0072610
	Trial terminated early: no
Publication	Language of publication: English
details	Funding: non-commercial (National Natural Science Foundation of China and
	Thrasher Foundation)

	Conflict of interest: "The authors declare that they have no conflicts of
	interest"
	Publication status: full article in peer-reviewed journal
Stated aim for study	Quote: "Our objective was to compare iron status at 18 months and growth
	from 6 to 18 months in rural poor toddlers fed 3 different complementary
	foods."
Note	Study start date: March 2009
	Study end date: December 2011

Study	Arcanjo, 2012 (84)
(Covidence	(#2936)
identifier)	
	Study design: cluster-randomised trial
Mathada	Unit of randomisation: cluster (2 day-care centers)
wiethods	Blinding: double-blind, pacebo-controlled
	Number of study arms: 2 arms
	Location/Setting: City of Morrinhos—Ceara
	Country where trial was performed: Brazil
	Sample size: 216
	Dropouts/withdrawals: 10 (3 left center, 5 absentee, 2 non-compliant)
	Sex: both male and female children included
	Center A: 60:40 (male:female)
	Center B: 54:44 (male:female)
	Inclusion criteria:
	• age: 10-23 months
Participants	Exclusion criteria:
•	 infants already taking iron supplements
	Health status: no data
	Ongoing treatment: no data
	Anaemic status: mixed (Anemia prevalence in the study population was
	estimated at 40%)
	Age range at start of intervention: 10-23 months
	Mean age:
	• Center A: 16.4 (4.77)
	Center B: 15.8 (4.27)
	Intervention(s):
	• fortified rice (Ultrarice), containing 56.4 mg elemental iron (micronized
	ferric pyrophosphate/ 50 g portion (n=100)
	Comparator(s):
Interventions	 standard rice (n=98)
	Duration of intervention: 18 weeks
	Duration of follow-up: 18 weeks
	Run-in period: no
	Number of study centres: 1
	Reported outcomes in full text of publication: Hb concentration, anaemia
	prevalence
	Primary outcomes: hemoglobin values (before and after intervention), anemia
Guicomes	(Hb < 110 g/L)
	Secondary outcomes: –
	Timing of outcome assessment: before and after trail

Identification	Trial identifier: –
	Trial terminated early: no
Publication details	Language of publication: English
	Funding: non-commercial (Santa Casa de Misericórdia de Sobral Hospital-
	Research Initiative Grant)
	Conflict of interest: no data
	Publication status: full article in peer-reviewed journal
Stated aim for	Quote: ",,to evaluate the impact of iron-fortified rice (Ultrarice) weekly on
study	hemoglobin and anemia levels compared with standard rice (control)"
Note	Study start date: August 2010
	Study end date: December 2010

Study	Arcanjo 2013 (85)
(Covidence	(#2937)
identifier)	
	Study design: cluster-randomised, controlled trial
Mathada	Unit of randomisation: cluster (two day-care center)
wiethous	Blinding: no data
	Number of study arms: 2 arms
	Location/Setting: City of Sobral
	Country where trial was performed: Brazil
	Sample size: 171
	Dropouts/withdrawals: 7 (1 left center, 5 absentee, 1 non-compliant)
	Sex:
	both male and female children included
	Center A: 39:35 (male:female)
	• Center B: 34:41 (male:female)
	Inclusion criteria:
	• 10 to 23 months
Participants	written parental consent
•	Exclusion criteria:
	 Infants' parents who refused to participate
	 infants already using iron supplementation
	Health status: no data
	Ongoing treatment: no data
	Anaemic status: mixed
	Age range at start of intervention: 10-23 months
	Mean age:
	• Center A: 17.8 (2.85)
	Center B (18.0 (2.97)
	Intervention(s):
	Center A : fortified rice (Ultrarice), containing 56.4 mg elemental iron
	(micronized ferric pyrophosphate/ 50 g portion ($n = 74$ at baseline)
	once weekly
	Comparator(s):
Interventions	 Center B: standard (household) rice (n =75 at baseline)
	Duration of intervention: 18 weeks
	Duration of follow-up: 18 weeks
	Run-in period: no
	Number of study centres: 1

	Reported outcomes in full text of publication: hemoglobin values, anaemia
	prevalance (Hb < 110 g/L)
Outcomes	Primary outcomes: hemoglobin values, anaemia prevalance (Hb < 110 g/L)
	Secondary outcomes: –
	Timing of outcome assessment: baseline and endpoint
Identification	Trial identifier: –
Identification	Trial terminated early: no
	Language of publication: English
Dublication	Funding: non-commercial (Federal University of Ceara - Research Initiative
Publication	Grant)
detalls	Conflict of interest: no data
	Publication status: full article in peer-reviewed journal
Stated aim for	Quote: "to evaluate the impact of iron-fortified rice (Ultrarice) weekly on
study	hemoglobin and anemia levels compared with standard rice (control)"
Noto	Study start date: August 2010
NOLE	Study end date: December 2010

Study	Quintero 2011 (86)
(Covidence	(# 2309)
identifier)	
	Study design: parallel, randomised controlled trial
	Unit of randomisation: individual
wiethous	Blinding: double-blind
	Number of study arms: 2
	Location/Setting: the State of Mexico
	Country where trial was performed: Mexico
	Sample size: 395 infants and pre-schoolers
	Dropouts/withdrawals: 5 cases at the end of the study
	Sex: both male and female children included
	Inclusion criteria:
	• 7 to 24 months
	 no neurological diseases
Douticinente	written informed consent
Participants	municipality of residence
	condition of indigenismo
	Exclusion criteria: –
	Health status: "it was necessary that families resided in municipalities before
	mentioned, who did not have neurological diseases"
	Ongoing treatment: no data
	Anaemic status: no data
	Age range at start of intervention: 7-24 monts
	Mean age: 16 months
	Intervention(s):
Interventions	enriched maize flour:
	(100 grams: 1.5 g of soybean meal (3%), 42.4 mg of iron, 33.3 mg of
	zinc, 120 mcg of vitamin A, 6,5 mg of niacin, 548 mcg of folic acid (n =
	195)
	Comparator(s):
	 Control group: corn flour without fortification (n =200)
	Duration of intervention: 10 months

	Duration of follow-up: 10 months
	Run-in period: no
	Number of study centres: 14
	Reported outcomes in full text of publication: weight, height, nutritional
	status, weight for age z-score, weight for height z-score, mental and
Outcomos	psychomotor development, blood haemoglobin levels
Outcomes	Primary outcomes: not defined
	Secondary outcomes: not defined
	Timing of outcome assessment: before and after trail
Identification	Trial identifier: –
Identification	Trial terminated early: no
	Language of publication: Spanish
	Funding: commercial (DICONSA; "formerly CONASUPO, which is a majority
Publication	state-owned company belonging to the Secretariat of Social Development of
details	Mexico")
	Conflict of interest: no data
	Publication status: full article in peer-reviewed journal
Stated aim for study	Quote: "To evaluate the effect of the consumption of a corn flour enriched
	with 3% soy, vitamins and minerals, on the growth and development of infants
	and preschool children."
Noto	Study start date: no data
Note	Study end date: no data

Study (Covidence	Bagni, 2009 (87, 88) (#5201)
identifier)	
	Study design: cluster-randomised trial
Methods	Dinding double blind
	Binding: double-blind
	Number of study arms: 2
	Location/Setting: Rio de Janeiro
	Country where trial was performed: Brazil
	Sample size: 354
	Dropouts/withdrawals: intervention group: loss of 57 children (22.4%), loss
	of 8.6%, control group: loss of 65 children (25.5%), loss of 8.4%,
	Sex: both male and female children included
	Inclusion criteria:
	• all preschoolers in the established age group attending day care centres
Participants	at baseline
-	 had written consent from those responsible
	Exclusion criteria: sickle cell anaemia, purpura
	Health status: no data
	Ongoing treatment: no data
	Anaemic status: mixed ("Anemia was defined as hemoglobin <11.0g / dL"; "In
	the IG, the frequency of anemia was 39.1%, and in the CG, it was 44.7%")
	Age range at start of intervention: 12-60 months
	Mean age: no data

Interventions	 Intervention(s): white rice fortified with Iron Bisglycine Chelate, rice was held once a week at lunchtime (90g) (n= 180) Comparator(s): rice with placebo once a week (n = 174) Duration of intervention: 16 weeks Duration of follow-up: 16 weeks Run-in period: no Number of study centres: -
Outcomes	Reported outcomes in full text of publication: frequency of anaemia, haemoglobin Primary outcomes: frequency of anaemia, haemoglobin Secondary outcomes: – Timing of outcome assessment: before and after trail
Identification	Trial identifier: NCT00727545 Trial terminated early: no
Publication details	Language of publication: Portuguese Funding: non-commercial (Universidade Federal do Rio de Janeiro) Conflict of interest: no data Publication status: full article in peer-reviewed journal
Stated aim for study Note	Quote: "to evaluate the effect of weekly rice fortification with iron on the frequency of anaemia and haemoglobin concentration in children from public daycare centres in the city of Rio de Janeiro" Study start date: March 2006

Study	Nesamvuni 2005 (89)
(Covidence	(#3052)
identifier)	
	Study design: randomised, parallel, intervention trail
Mathada	Unit of randomisation: children and their household or families
wiethous	Blinding: single-blind
	Number of study arms: 2
	Location/Setting: Oukasie, Brits, in the North West Province
	Country where trial was performed: South Africa
	Sample size: 44 of children randomly assigned
	Dropouts/withdrawals: 8 lost to follow-up
	Sex: both male and female children included
	Inclusion criteria:
Participants	 1 –3-year-old children at the crèches and the well-baby clinic
	 who had weight-for-age or height-for-age below the 5th percentile of
	the National Centre for Health Statistics (NCHS) reference
	(undernourished)
	Exclusion criteria:
	 any physical or mental disability (not on disability grant),
	 severe forms of undernutrition (marasmus and kwashiorkor),

	 children of mothers who recently relocated to the area
	Health status: undernourished (had weight-for-age or height-for-age helow the
	5th nercentile)
	Ongoing treatment: no data
	Anaomic status: no data
	Age range at start of intervention: 1.2 years old
	Mean age, no data
	wean age: no data
	Intervention(s):
	• to 150 g of raw maize meal, 1700 IU vitamin A, 0.61 mg thiamine, 0.62
	mg riboflavin and 0.56 mg pyridoxine were added (25 and 50 kg
	(depending on usual monthly consumption) of maize meal flour was
	provided to the families per month to replace all maize meal consumed
	by these households) ($n = 16$)
Interventions	Comparator(s):
	 unfortified maize (n =20)
	Duration of intervention: 12 months
	Duration of follow-up: 12 months
	Bun-in period: no
	Number of study centres: -
	Reported outcomes in full text of publication: weight, height, haemoglobin,
	haematocrit, serum retinol and serum retinol-binding protein
_	Primary outcomes: haemoglobin, haematocrit, serum retinal and serum
Outcomes	retinol-binding protein
	Secondary outcomes: weight, height
	Timing of outcome assessment: before and after trail
	Trial identifier: –
Identification	Trial terminated early: no
	Language of publication: English
	Funding: non-commercial (grants from the National Research Foundation,
Dublication	Potchefstroom University for Christian Higher Education) and commercial
Publication	(Hoffman La Roche (Switzerland), Roche Vitamin and Fine Chemicals and a gift
detalls	of maize from Maizecor)
	Conflict of interest: no data
	Publication status: full article in peer-reviewed journal
Stated aim for	Quote: "To evaluate the effectiveness of a vitamin-fortified maize meal to
study	improve the nutritional status of 1–3-year-old malnourished African children"
Noto	Study start date: no data
INOTE	Study end date: no data

Study	Faber 2005 (30)
(Covidence	(#6626)
identifier)	
Methods	Study design: parallel randomized controlled trial
	Unit of randomisation: individual
	Blinding: double-blind
	Number of study arms: 2

Participants	Location/Setting: The Valley of a Thousand Hills in Kwa2ulu-Natal province Country where trial was performed: South Africa Sample size: 361 infants Dropouts/withdrawals: 72 lost to follow-up Sex: both male and female children included Inclusion criteria: • aged 6 – 12 mo Exclusion criteria: • their parent or legal guardian did not sign the consent form, • birth weight <2500 g • a baseline blood sample was not obtained, • haemoglobin concentration <80 g/L Health status: not defined Ongoing treatment: no data Anaemic status: mixed Age range at start of intervention: 6-12 months Mean age: 8.9 months
Interventions	 Intervention(s): milled maize meal was fortified to supply 3 mg β-carotene, 11 mg iron (ferrous fumarate), and 3 mg zinc (zinc sulfate) per 40 g dry product; ascorbic acid (sodium ascorbate) was added (56mg/40 g dry product); 110 µg copper, 10 µg selenium, 0.4 mg riboflavin, 0.15 mg vitamin B-6, 0.25 µg vitamin B-12, and 2.5 mg vitamin E per 40 g dry product; 2 sachets/d was recommended, consumed as either 1 or 2 meals (n =144) Comparator(s): same porridge, but without the added micronutrients; 2 sachets/d was recommended, consumed as either 1 or 2 meals (n = 145) Duration of intervention: 6 months Duration of follow-up: 6 months Run-in period: no Number of study centres: 1
Outcomes	Reported outcomes in full text of publication: motor development, weight, length, length-for-age, weight-for-age, and weight-for length—which were expressed as z scores, Hb concentration, serum ferritin, serum retinol, serum zinc, CRP, stunting Primary outcomes: Hemoglobin concentration, serum ferritin concentration, serum retinol concentration, serum zinc concentration, motor development Secondary outcomes: weight, length, length-for-age, weight-for-age, and weight-for length—which were expressed as z scores, stunting Timing of outcome assessment: before and after trial
Identification	Trial identifier: – Trial terminated early: no
Publication details	 Language of publication: English Funding: non-commercial (Thrasher Research Fund and the Community-based Health Programme of The Valley Trust and commercial (Tiger Food Brands Limited donated the fortified-porridge product) Conflict of interest: None of the authors had any personal or financial conflict of interest. Publication status: full article in peer-reviewed journal

Stated aim for	Quote: "We assessed whether the fortified porridge could reduce anaemia and
study	improve the micronutrient status and motor development of infants."
Note	Study start date: February 2002
	Study end date: March 2003

Study	Schumann 2005 (90)					
(Covidence	(#1790)					
identifier)						
	Study design: parallel, randomised, controlled trial					
Mathods	Unit of randomisation: individual					
Wethous	Blinding: double-masked					
	Number of study arms: 3					
	Location/Setting: Ciudad Peronia					
	Country where trial was performed: Guatemala					
	Sample size: 110 number of children randomly assigned					
	Dropouts/withdrawals: 13 lost to follow-up					
	Sex: both male and female children included					
	Inclusion criteria:					
	 12 to 36 months age 					
	 a high susceptibility to anaemia (Hb value was in the range of 100 to 					
	IIS g (')					
	• give informed consent					
	 abide by the dietary instructions involved in the 5-day-per-week bean administration 					
	Exclusion criteria:					
	recent use of vitamin or mineral preparations containing iron					
Participants	recent surgery					
	 diagnosed chronic gastric or intestinal diseases. or chronic infections 					
	 used supplements during the intervention 					
	• at any point the parents made the decision to withdraw them from the					
	study					
	moved from the house of residence and re-localisation was not possible					
	 child with Hb concentration of <115 g/l 					
	Health status: an age group with high susceptibility to anaemia)					
	Ongoing treatment: no data					
	Anaemic status: anaemic ("moderately anaemic"; "high susceptibility toa					
	naemia"; [Hb value was in the range of 100 to 115 g/l])					
	Age range at start of intervention: 12 to 36 months age					
	Mean age: 20,9 months					
	Intervention(s):					
	• FeSO ₄ (inorganic salt) fortified black bean paste; 156-g cans for 5 days					
	of a week with 31.2 mg of fortification iron (n=37)					
Interventions	• Haem-fortified (from bovine blood) black bean paste; 35.0 mg Fe/can					
	for 5 days of a week (n=36)					
	Comparator(s):					
	 basic black bean paste for 5 days of a week (n =37) 					

	Duration of intervention: 10 weeks					
	Duration of follow-up: 10 weeks					
	Run-in period: no					
	Number of study centres: 1					
	Reported outcomes in full text of publication: Hb concentration, Ferritin					
	concentration					
Outcomes	Primary outcomes: Hb, Ferritin					
	Secondary outcomes: –					
	Timing of outcome assessment: baseline, 5 and 10 weeks					
Identification	Trial identifier: –					
Identification	Trial terminated early: no					
	Language of publication: English					
Publication	Funding: no data					
details	Conflict of interest: no data					
Publication status: full article in peer-reviewed journal						
	Quote: "Haem iron as a fortificant was compared with FeSO4 and a placebo					
Stated aim for	treatment for the restoration of Hb and the incrementing of circulating ferritin					
study	as an index of iron stores" "The goal was to produce the same iron fortification					
study	that, with the intrinsic iron content, would total approximately 35.0 mg Fe per					
	can in haem iron-fortified as well as in inorganic iron-fortified beans."					
Note	Study start date: no data					
NOLE	Study end date: no data					

Study	Lartey, 2000 (91, 92)				
(Covidence	(#4145)				
identifier)					
	Study design: randomized, controlled trial				
	Unit of randomisation: individual				
Methods	Blinding: no data				
	Number of study arms: 4				
	Location/Satting: Techiman (district capital is located about 400 km porth of				
	Accra)				
	Country where trial was performed: Ghana				
	Sample size: 216 infants				
	Dropouts/withdrawals: 18 during the intervention (7 because child's mother				
	left the area, 1 because the father refused participation, 4 because the infant				
	rejected the project food (2 for WM, 1 for WF, and 1 for KF), 4 because the				
Participants	mother did not feed the project food (2 for WF and 2 for KF), and the death of				
Farticipants	infant (n = 1).				
	Sex: both male and female children included				
	Inclusion criteria:				
	 breast-fed 				
	no health complication				
	 birth weight ≥2.5 kg 				
	 no congenital abnormalities 				
	 assigned a Maternal and Child Health card 				

	• the child's mother was not planning to travel or move out of study area					
	during the study period					
	Exclusion criteria: –					
	Health status: healthy					
	Ongoing treatment: no data					
	Anaemic status: mixed					
	Age range at start of intervention: 6 months					
	Mean age: 6 months					
	Intervention(s):					
	• Weanimix plus vitamins and minerals (Iron, zinc, calcium, vitamin A,					
	riboflavin) (WM), (High and low refer to 2 formulations of Weanimix					
	with vitamins and minerals added: "high" for infants consuming ≤60 g/d					
	and "low" for infants consuming > 60 g/d of the food.) (n=47)					
	 Weanimix plus fish (smoked anchovy) powder (WF), (n=48) 					
Interventions	 koko (fermented maize dough) plus fish powder (KF) (n= 45) 					
	Comparator(s):					
	• Weanimix (75% maize (corn), 15% soybeans, and 10% groundnuts					
	(peanuts) (n = 50)					
	Duration of intervention: 6 months					
	Duration of follow-up: 6 months					
	Run-In period: no					
	Number of study centres: 1 Reported outcomes in full toxt of publication:					
	nlasma zing plasma ratingly arythrogyta riboflavin haamaglohin haamatogrit					
	plasma ferritin saturation, plasma ferritin, plasma transferrin saturation, plasma					
	transferrin breastfeeding iron intake zinc intake Vitamin A intake riboflavin					
	intake, weight-for-age z-score length-for-age z score, weight gain length gain					
	midupper arm circumference, head circumference, tricens skinfold thickness.					
	subscapular skinfold thickness, midupper arm fat area, midupper arm muscle					
Outcomes	area, haemoglobin, haematocrit, plasma ferritin saturation, plasma ferritin,					
	diarrhea, fever, respiratory illness, C-reactive protein , dietary intake (weighed					
	food and beverages, energy intake, nutrient intake)					
	Primary outcomes: not defined					
	Secondary outcomes: not defined					
	Timing of outcome assessment: monthly anthropometric and morbidity data;					
	baseline and after treatment blood draw					
Identification	Trial identifier: –					
Trial terminated early: no						
	Language of publication: English					
	Funding: commercial (Roche Vitamins and Fine Chemicals) and non-commercial					
Publication	(Nestle Foundation, a Rockefeller Foundation African Dissertation Internship					
details	Award, a Fulbright Scholarship)					
	Conflicts of Interest: no data					
	Publication status: full afficie in peer-reviewed journal					
	vitamin A) status of Ghanajan infants $6-12$ mo of age fed Weanimix (W) or 1 of					
Stated aim for	3 other improved complementary foods". "This study describes the factors					
study	associated with hemoglohin and plasma ferriting zinc and retinol concentrations					
study	and erythrocyte riboflavin status among 208 Ghanaian infants who narticinated					
	in a complementary feeding intervention trial from 6 to 12 mo of age "					
Note	Study start date: November 1994					

C1 1				
Study	Boven-Benjamin 1999 (93)			
(Covidence	(#/084)			
identifier)				
	Study design: cross-over randomized controlled trial			
	Unit of randomisation: individual (mother-toddler pairs)			
Methods	Blinding: double-blind			
	Number of study arms: 3			
	Location/Setting: -			
	Country where trial was performed: USA			
	Sample size: 40 mothers-toddlers pairs			
	Dropouts/withdrawals: 2 mothers-toddlers pairs (because they did not test all			
	three porridges at one of the three test sessions)			
	Sex: both male and female toddlers included with their mothers			
	Inclusion criteria:			
	eating infant cereals			
-	able to eat from a spoon			
Participants	not allergic to milk or maize			
	Exclusion criteria:			
	not sample the norridge			
	Health status: no data			
	Organing treatment , no data			
	Anaomic status: no data			
	Andernic status: no uata			
	Age range at start of intervention: 6-24 months			
	Wean age: 13,5 ± 4,8 months			
	Intervention(s):			
	 whole maize fortified with ferrous bisglycinate (30 mg iron/kg) in their 			
	home, at the toddlers' regular mealtime and largest meal of the day.			
	They recieved in 65 ml cup, but mothers were free to feed toddlers			
	additional porridge (n = 38)			
	 maize fortified with ferrous bisglycinate and containing the antioxidant 			
	butylated hydroxyanisole (50 ppm) in their home, at the toddlers'			
	regular mealtime and largest meal of the day. They received in 65 ml			
	cup, but mothers were free to feed toddlers additional porridge (n=			
Interventions	38)			
	Comparator(s):			
	• unfortified whole maize in their home, at the toddlers' regular			
	mealtime and largest meal of the day. They received in 65 ml cun, but			
	meanine and largest mean of the day. They received in 05 million particular mothers were free to feed toddlers additional particular $(n - 38)$			
	Duration of intervention: 3 subsequent sessions			
	Duration of follow-un: 3 subsequent sessions			
	Run-in neriod: no			
	Number of study centres: 1			

	Reported outcomes in full text of publication: DOL (degree of liking) among			
	porridges			
Outcomos	Primary outcomes: not defined			
Outcomes	Secondary outcomes: –			
	Timing of outcome assessment: After each sample was tested, mothers			
	indicated the toddlers' degree of liking of the sample			
Identification	Trial identifier: –			
identification	Trial terminated early: no			
	Language of publication: English			
Publication Funding: Albion Laboratories, Clearfield, CT				
details	Conflict of interest: no data			
	Publication status: full article in peer-reviewed journal			
Stated aim for	Quote: "Our ultimate goal is to use BIS as an iron fortificant in infants' and			
Stated and for	children's cereals in developing countries to reduce the high prevalence of ID			
study	and IDA."			
Noto	Study start date: no data			
NOLE	Study end date: no data			

Study	Liu 1993 (27)					
(Covidence	(#4438)					
identifier)						
	Study design: cluster randomized trial					
Mathada	Unit of randomisation: cluster					
Wethous	Blinding: N/A					
	Number of study arms: 2					
	Location/Setting: Mi-yun rural area near Beijing					
	Country where trial was performed: China					
	Sample size: 164					
	Dropouts/withdrawals: N/A no data					
	Sex: both male and female children included					
	Inclusion criteria:					
	healthy full-term infants.					
	born without complication					
	 born with birth weights > 2.5 kg. 					
	 aged 6-13 mo 					
Participants	 enrolled from 33 villages of the Mi-yun rural area near Beijing 					
Farticipants	Exclusion criteria:					
	 not consumed all the rusks 					
	 hemoglobin concentrations <100 g/L 					
	Health status: No clinical deficiency signs attributable to micronutrient					
	deficiencies were observed in any of the children.					
	Ongoing treatment: no data					
	Anaemic status: mixed ("Of the children in the present study, only 15% were					
	anemic at the outset (hemoglobin < $1 10 \text{ g/L}$)")					
	Age range at start of intervention: 6-13 mo					
	Mean age: T: 9,63 mo; C: 9,86 mo					

	Intervention(s):		
Interventions	 Calcium (300 mg/day), ferric ammonium citrate (5 mg/day), zinc (3 mg/day), vitamin A (224ug/day), cholecalciferol (4 ug/day), thiamine (0.15 ug/day), riboflavin (0.2 mg/day), niacin (2.5 mg/day), cyanocobalamin (0.3 ug/day), folic acid (25 ug/day) fortified rusk (17 g) daily supply (n =77) Comparator(s): 		
	Duration of intervention: 3 months		
	Duration of follow-up: 3 months		
	Run-in period: no		
	Number of study centres: 1		
	Reported outcomes in full text of publication: Weight, length, free erythrocyte		
	porphyrin in red cells, plasma ferritin, eryihrocyte glutathione reductase		
	activation coefficient, plasma vitamin E and plasma retinol, hemoglobin		
Outcomes	concentration		
	Primary outcomes: not defined		
	Secondary outcomes: not defined		
	Timing of outcome assessment: before trail, after trail		
Identification	Trial identifier: -		
	Trial terminated early: no		
	Language of publication: English		
Publication	Funding: Supported in part by a grant from the United Kingdom Department of		
details	Trade and Industry.		
	Conflict of interest: no data		
	Publication status: full article in peer-reviewed journal		
Stated aim for	Quote: "A micronutrient-fortified rusk for weanling children was tested in a		
study	rural area near Beijing." "The purpose of the study was to investigate the		
	efficacy of the micronutrients addition not of the rusk per se."		
Note	Study start date: February 1990		
	Study end date: June 1990		

Study (Covidence	Gershoff 1977 (Gershoff 1975) (94, 95)				
identifier)	(#0115)				
	Study design: parallel cluster randomized trial				
Mathada	Unit of randomisation: cluster				
wiethous	Blinding: no data				
	Number of study arms: 5				
	Location/Setting: province of Chiang Mai				
	Country where trial was performed: Thailand				
	Sample size: 1265 children at the start; 2250 at the end (<2 years: 357)				
	Dropouts/withdrawals: no data				
Participants	Sex: both male and female children included				
	Inclusion criteria: -				
	Exclusion criteria: "villages not selected where there is iodine deficiency area"				
	Health status: no data				
	Ongoing treatment: no data				

	Anaemic status: no data					
	Age range at the start of intervention: 6 months to 5 years					
	Mean age: no data					
	Intervention(s): daily received					
	BEG1: rice fortification grain 1 contains 0.0873% thiamine nanbthalene					
	disulfonate (equivalent to 0.05% thiamine nitrate) 0.0.1% retinol					
	(added starting in August of 1972) 0.0915% of rotinol acotate, and					
	(added starting in Adgust of 1972), 0.0015% of retinor acetate, and					
	0.8% FePO ₄ 4H ₂ O (0.2% iron), iysine HCI and 10% L-threonine. (n= no					
	Udld)					
	RFG2: rice fortification grain 1 contains 0.0873% thiamine haphthalene					
Interventions	disulfonate (equivalent to 0.05% thiamine nitrate), 0.0.4% retinol					
	(added starting in August of 1972), 0.0815% of retinol acetate, and					
	0.8% FePO ₄ 4H ₂ O (0.2% iron), no amino acids (n= no data)					
	Comparator(s):					
	 RFG3: Rice fortification grains (daily received) (n= no data) 					
	Duration of intervention: 4 years					
	Duration of follow-up: 4 years					
	Run-in period: no					
	Number of study centres: 29					
	Reported outcomes in full text of publication:					
	• data from anthropometric measurements (length, weight, bone age,					
	head circumference, chest circumference, arm circumference, triceps					
	skinfold, subscapular skinfold)					
	haemoglobin, haematocrit					
	morbidity data					
Outcomes	 handwrist x-ray 					
	Primary outcomes: not defined					
	Secondary outcomes: not defined					
	• Timing of outcome assessment : Two physical examinations and					
	haemoglobin and haematocrit values were conducted every year					
	Morhidity data were collected on each child every 15 days for up to 3					
	vears					
	Trial identifier: _					
Identification	Trial terminated early: no					
	Language of nublication: English					
	Funding: Supported in part by Contract AID/CSD-3291 from the United States					
Publication	Agency for International Development and the Fund for Research and Teaching					
details	Agency for international Development and the rund for Research and Tedching, Department of Nutrition, Harvard School of Public Health					
uctans	Publication status: full article in peer-reviewed journal					
	Conflict of interest: no data					
	Ouote: "a large-scale field study in villages of northern Thailand designed to					
Stated aim for	measure the health benefits to be derived from the fortification of rice with					
study	lysine threenine thiamine riboflavin vitamin A and iron"					
	Study start date: January 1071					
Note	Study and data: Juliud 19/1					
	Study end date: July 19/5					

Appendix 3. Composition of fortified complementary foods

		Composition of the non-fortified complementary food			
Study number #	Type of comple- mentary food	Total Energy	Macronutrients (Protein, Fat Carbohydrate)	Micronutrients	Micronutrient(s) added to the fortified products
Palmer 2021 (74, 75)	Maize meal	Not specified	Not specified	Not specified	Retinyl palmitate ~55 μg RE/d OR provitamin A carotenoid-biofortified
Gannon 2019 (78)	Crops	Not specified	Not specified	Not specified	Biofortified crops (not further specified)
Ma 2016 (Sheng 2019; Krebs 2013) (80-83)	Rice cereal	80 kcal/day (20 g/ day)	Not specified	Iron (0.04 mg/20g)	Iron (ferrous fumarate; 1.10 mg/20 g); zinc (zinc sulfate; amount not specified); vitamin B12 (amount not specified)
Ekoe 2020 (76, 77)	Cereal	420 kcal/100g of cereal/day	Protein 14.5g; Fat 10 g; Carbo-hydrate 68 g/ 100g	Sodium 135 mg, Calcium 450 mg, Zinc 5 mg, Vitamin A 1,300 IU, Vitamin D 180 IU, Vitamin C 50 mg, Vitamin B ₁ (thiamin) 0.6 mg /100g	Iron (ferrus fumarate; 7.5 mg/100g)
Arcanjo 2013	Rice	Not specified (~50g/day)	Not specified	Not specified	56.4 mg ferric pyrophosphate/ 50 g portion

(14)					
Arcanjo 2012 (13)	Rice	Not specified	Not specified	Not specified	56.4 mg ferric pyrophosphate/ 50 g portion
Huey 2018 (79, 96)	Pearl millet	Not specified	Not specified	Iron (21.24 ppm); zinc (19.34 ppm)	Iron (additional 61.5 ppm); Zinc (additional 14.83 ppm)
Quintero 2011 (15) (# 2309)	Corn flour	Not specified (20 kg flour/family/ month)	Not specified	Iron 3.90 mg; zinc 2.00 mg; retinol 0.50 mcg; niacin 1.30mg/100 g flour	1.5 g of soybean meal, iron 42.4mg, zink 33.3 mg, retinol 120 mcg, niacin 6.5 mg, 548mcg folic acid/ 100 g flour
Bagni, 2009 (17, 18) (#5201)	Rice	Not specified (80 g rice /once a week)	Not specified	Not specified	Iron (3.78 mg/once a week)
Nesamvu ni 2005 (19) (#3052)	Maize meal	Not specified	Not specified	Not specified	1700 IU vitamin A, 0.61 mg thiamine, 0.62 mg riboflavin, 0.56 mg pyridoxine/150g raw maize meal
Faber 2005 (20) (#6626)	Porridge	Dry product: 617 KJ/ day (40 g /day)	Not specified	Not specified	3mg β-carotene; 11 mg iron (ferrous fumarate); 3 mg zinc (zinc sulfate); 56 mg ascorbic acid (sodium ascorbate); 110 μg copper; 10 μg selenium; 0.4 mg riboflavin; 0.15 mg vitamin B6; 0.25 μg vitamin B12; 2.5 mg vitaminE /40 g dry product
Schüman n 2005 (21) (#1790)	Beans	Not specified (5 cans/week)	Not specified	Iron (3.1 mg/can)	Iron (FeSO₄) 32.5 mg/can (20 mg/ 100 g beans) OR haem iron (from bovin blood) 34.0 mg/can (1.33 g haem powder/ 100 g beans)

Lartey,	Cereal-	4350 kcal/	Protein 150 g (14E%);	Calcium 530 mg, Iron 56 mg, Zinc mg	for infants consuming ≤60 g/d (content/1000 g dry
2000	legume	1000 g dry	Fat 114 g	28, Copper 4 mg, Magnesium 1400	weight): Calcium 17360 mg, Iron 366 mg, Zinc mg 171,
(22, 23)	blend	weight	(24E%)/1000 g	mg, Potassium 5660 mg, Sodium 30	Copper 25 mg, Magnesium 1400 mg, Potassium
				mg, Phosphorus 2920 mg, Ascorbic	18960 mg, Sodium 30 mg, Phosphorus 17900 mg,
				acid 1 mg, Niacin 39 mg, Pyridoxine	Ascorbic acid 781 mg, Niacin 259 mg, Pyridoxine 31.3
				3.5 mg, Riboflavin 0.4 mg, Thiamine	mg, Riboflavin 19.5 mg, Thiamine 22.1 mg, Vitamin
				4.8 mg, Vitamin B12 0 μg, Folic acid	B12 70 μg Folic acid 5470 μg, Vitamin A 18360 RE
				670 μg, Vitamin A 360 RE	for infants consuming >60 g/d of the food (content/
					1000 g dry weight: Calcium 8950 mg, Iron 183 mg,
					Zinc mg 86, Copper 13 mg, Magnesium 1400 mg,
					Potassium 12310 mg, Sodium 30 mg, Phosphorus
					9400 mg, Ascorbic acid 391 mg, Niacin 149 mg,
					Pyridoxine 17.4 mg, Riboflavin 9.8 mg, Thiamine 13.5
					mg, Vitamin B12 35 μg, Folic acid 3070 μg, Vitamin A
					9360 RE
Bovell-	whole	Not specified	Not specified	Not specified	Ferrous bisglycinate 30 mg/kg maize meal
Benjamin	maize				
1999	meal				
(24)					
Liu 1993	Rusk	9.20 KJ/g	Protein: 0.06 g, Fat:	Not specified	Per gram: Calcium 17.60 mg, Iron 0.29 mg, zinc 0.18
(26)		rusk	0.08 g, Carbohydrate		mg, vitamin A 13.20 μg (RE (provided as retinyl
			(sugar): 0.31 g/		acetate), cholecalciferol 0.22 μ g, thiamin 0.009 μ g,
		155 KJ/17 g	1 g		riboflavin 0.012 mg, niacin 0.147 mg, cyanocobalamin
		(1 portion			0.018 μg, folic acid 1.47 μg
		rusk)	Protein 1.0 g, Fat 1.4		
			g, Carbohydrate		Per rusk: Calcium 300 mg, Iron 5.0 mg, zinc 3 mg,
			(sugar) 5.2 g/ portion		vitamin A 224 μ g (RE (provided as retinyl acetate),
			(17 g)		cholecalciferol 4 μg, thiamin 0.15 μg, riboflavin 0.2
					mg, niacin 2.5 mg, cyanocobalamin 0.3 µg, folic acid
					25.0 μg
Gershoff	Rice	Not specified	Not specified	Not specified	Artifical rice grain conatained 0.0873% thiamin
1977					naphthalene disulfonate (equivalent to 0.05%

(Gershoff			thiamin nitrate), 0.04% riboflavin, 0.0815% retinol
1975)			acetate, 0.8% FePO ₄ *4H ₂ O (0.2% iron), no amino acid
(27, 28)			(RFG2)

Appendix 4. Characteristics of studies awaiting classification

a) registered trials without publication

Study identifier	NCT03573570 (97)
(Covidence ID)	(#1741)
Study title:	Reducing anaemia through food fortification at scale
	Acronym: –
Official title:	Reducing Anemia Through Food Fortification at Scale
Methods:	Type of trial: interventional
	Allocation: randomised
	Intervention model: parallel assignment
	Masking: none
	Primary purpose: treatment
Participants:	Age: 6 months to 5 years
	Enrollment: 0
	Inclusion criteria: 6 months to 5 years
	Exclusion criteria: none
Interventions	Intervention(s): Rice will be fortified using Fortified Rice Kernels
	(FRKs) containing iron, zinc, vitamin A and vitamins B1, B3, B6, B9 and
	B12
	Comparator(s): regular rice
Starting date	Trial start date: –
	Trial completion date: –
	Status: Withdrawn (The Government of Tamil Nadu decided not to
	proceed with implementation of fortified rice through the Public
	Distribution (per the original study protocol))
Contact information	Responsible party/principal investigator: Norman G Miller, Stanford
	University
Stated purpose of study	Quote: "This trial proposes to address anemia and other
	micronutrient deficiencies by providing micronutrient fortified rice
	through the Public Distribution System (PDS) of Tamil Nadu in a
	manner that requires no change in behaviour by end-user households
	and that can feasibly be conducted on a large scale "
Note	Recruitment Status: Withdrawn (The Government of Tamil Nadu
	decided not to proceed with implementation of fortified rice
	through the Public Distribution (per the original study protocol))
	First Posted: June 29, 2018
	Last Update Posted: March 18, 2021

Study identifier	NCT02532816 (98)		
(Covidence ID)	(#5389)		
Study title:	Nutrient-dense complementary foods on catch-up growth and		
	nutritional status of stunting children		
	Acronym: –		
Official title:	The Effect of Higher Nutrient-Dense Complementary Foods on Ca		
	up Growth and Nutritional Status of Stunting Children in Dompu		
	District, Indonesia		
Methods:	Type of trial: interventional		
	Allocation: randomised		
	Intervention model: not clear		
	Masking: Quadruple (Participant, Care Provider, Investigator,		
	Outcomes Assessor)		
	Primary purpose: treatment		
Participants:	Age: 12-23 months		
	Enrollment: actual 217		
	Inclusion criteria:		
	• identified as stunting (having HAZ \leq -2SD of the WHO Growth		
	Standard 2006)		
	• no clinical evidence of any acute infectious disease or other		
	diseases or morbidity condition that could interfere with the		
	intake of study diets		
	 parents and children residence in the study area. 		
	 parental concent obtained 		
	Exclusion criteria:		
	presence of oedema, severe illness warranting hospitalization on		
	the enrolment day such as persistent diarrhea and other disease		
	which may influence feeding practices and nutrient absorption		
	 conncurrent participation in another clinical trial 		
	• severe anemia with hemoglobine concentration $< 7.0 \text{ g/dI}$		
Interventions	Intervention(s):		
	Ontimized Complementary Feeding Recommendation (CER) +		
	fortified biscuit L (ferrous fumarate 83.5 mg. zinc oxide 50.95		
	mg Calcium carbonate 3104.05 mg Thiamine		
	Mononitrate1.85 mg. Nicotinic Acid 30.45 mg. Pyridoxine		
	Hydrocloride 2.90 mg. Pterovl monoglutamic acid 764.90		
	mcg. Cvanocobalamin 0.95 mcg. Retinol Palmitate (drv)		
	742.50 mcgRE)		
	CFR + fortified biscuit II (ferrous fumarate 32.6 mg. zinc oxide		
	3.78 mg. Calcium carbonate 874.12 mg. Thiamine		
	Mononitrate1.25 mg. Nicotinic Acid 17.95 mg. Pvridoxine		
	Hydrocloride 1.10 mg, Pterovl monoglutamic acid 329.90		
	mcg, Cvanocobalamin 0.55 mcg)		
	Comparator(s):		
	CFR + non-fortified biscuit		
Starting date	Trial start date: April 2016		
	Trial completion date: July 2016		

Contact information	Responsible party/principal investigator: Duma O Fransisca and Umi		
	Fahmida, SEAMEO Regional Centre for Food and Nutrition		
Stated purpose of study	Quote: "to determine and compare the effect of higher nutrient-		
	dense complementary foods and standard nutrient dense		
	complementary foods on the catch-up growth and nutritional status		
	of stunting children aged 12-23 months old in Indonesia"		
Note	Recruitment Status: Unknown		
	Verified August 2015 by Duma Octavia Fransisca, MSc, SEAMEO		
	Regional Centre for Food and Nutrition.		
	Recruitment status was: Active, not recruiting		
	First Posted: August 26, 2015		
	Last Update Posted: August 26, 2015		

Study	Mehta 2017 (96)		
(Covidence	(#3636/2)		
identifier)			
Methods	Study design: randomised controlled trial		
Participants	Inclusion criteria:		
	 12–18 months old Hemoglobin ≥9 g/dL living in urban slums of Mumbai Exclusion criteria: Age <12 months, 0 days or >18 months Hemoglobin < 9 g/dL and/or hemoglobinopathy severe malnutrition (marasmus, marasmic kwashiorkor, kwashiorkor, weight-for-height z-score < -3) Diagnosis: Prior: HIV/AIDS or Tuberculosis, or Current: HIV/AIDS, malaria, Dengue fever, Tuberculosis >1-day hospitalization Children without caretaker no migrating from the slum for 4 weeks Prior/current consumption: iron/zinc supplements in the past 1 year no dietary allergies Age at the start of the intervention: 12-18 month Country where trial was performed: India 		
Interventions	 Intervention(s): FeZnPM (iron- and zinc-biofortified pearl millet) 		
	Comparator(s):		
	 CtrlPM (conventional pearl millet) 		
	Duration of intervention: 9 months		
	Duration of follow-up: 9 months		
	Run-in period: –		
	Number of study centres: -		
Outcomes	Outcomes listed in the protocol:		

b) Published protocols

	Hb, serum ferritin, serum transferrin receptor and plasma zinc, growth, immune
	function, cognitive function
Identification	Trial identifier: NCT02233764, REF/2014/10/007731, CTRI/2015/11/006376
	Trial terminated early: no
Publication	Language of publication: English
details	Funding: HarvestPlus (2014H8302)
	Publication status: published protocol in peer-reviewed journal
Stated aim for	Quote: "This study aims to investigate the effect of the consumption of foods
study	prepared with iron- and zinc-biofortified pearl millet (FeZn-PM) by children on
	biomarkers of iron and zinc status, growth, and immune function"
Note	
-	

c) Conference abstracts

Study	Hays 2019 (99, 100)
(Covidence	
Identifier)	Study design cluster randomized double blind controlled study
Niethous	Study design: cluster-randomized, double-blind, controlled study
Participants	Inclusion criteria:
	aged 6-18 months
	Exclusion criteria: –
	Setting: La Nkwantanang Municipality of the Greater Accra Region, Ghana
	Age at the start of the intervention (age subgroups): 6-18 months
	Country where trial was performed: Ghana
Interventions	Intervention(s): micronutrient-fortified infant cereal with iron (3.75 mg iron as
	ferrous fumarate / 50 g cereal
	Comparator(s): the same cereal without iron
	Duration of intervention: 6 months
	Duration of follow-up: 8 months
Outcomes	Reported outcomes in the abstract: Hb, weight, height, mid-upper arm
	circumference, usual dietary intake
Identification	Trial identifier: PACTR201906885776793
	Trial terminated early: no
Publication	Language of publication: English
details	Funding: Nestlé Company Limited (Ghana) in collaboration with the University
	of Ghana School of Biological Sciences
	Publication status: conference abstract
Stated aim for	Quote: "to assess the effect of a micronutrient-fortified complementary food
study	on hemoglobin, anemia prevalence, and growth of infants in the La
-	Nkwantanang Municipality of the Greater Accra Region, Ghana."
Note	

Study	Krebs 2011 (101)
(Covidence	(#4299)
identifier)	
Methods	Study design: randomized study

Participants	Inclusion criteria:
	~ 6 mo of ag
	Exclusion criteria: –
	Setting: –
	Age at the start of the intervention (age subgroups): ~ 6 months
	Country where trial was performed: –
Interventions	Intervention(s):
interventions	infant careal with 7n fortification
	Comparator(s):
	infant cereal without 7n fortification
	Duration of intervention: -
	Duration of follow-up: 3-4 months
Outcomes	Reported outcomes in the abstract: Exchangeable zinc (7n) pool (F7P) size. Diet
Outcomes	Zn daily absorbed Zn and plasma Zn
Identification	Trial identifier: –
lucification	Trial terminated early: –
Publication	Language of publication: English
details	Funding: -
	Publication status: conference abstract
Stated aim for	Quote: "Using stable isotope methods, we measured EZP size at 9-10 mo of age
study	in healthy breastfed infants (n=37) who had a wide range of habitual dietary Zn
-	resulting from random assignment at ~ 6 mo of age to 1 of 3 complementary
	feeding groups: infant cereal, with and without Zn fortification, or meats."
Note	

i. Full text not yet available (procurement in progress)

- Araya 1994 (102)Arya 2000 (103)
- Cros 1966 (104)
- OrganizaciónPanamericanadelaSalud 1989 (105)
- Viseshakul 1979 (106)
- Viteri 1981 (107)
- Zhao 2004 (108)
- Zlotkin 2000 (109)

Appendix 5. Characteristics of excludes studies

Study	Reason for exclusion
Dewey 1998 (110)	Wrong comparator
Aakko 2017 (111)	Wrong comparator
Aaron 2011 (112)	Wrong comparator
Aboud 2011 (113)	Wrong intervention (responsive stimilation)
Ackatia-Armah 2012 (114)	Duplicate
Ackatia-Armah 2013 (115)	Wrong comparator
Ackatia-Armah 2015 (116)	Wrong comparator
ACTRN12609000061235 (117)	Wrong comparator
ACTRN12620000026921 (118)	Wrong intervention (prebiotic food)
Agapova 2018 (119)	Wrong intervention (non-fortified food)
Ahmad 2019 (120)	Wrong comparator
Ahmad 2020 (121)	Wrong comparator
Ahmed 2014 (122)	Wrong intervention (non-fortified food)
Ahmed 2017 (123)	Wrong comparator
Akalu 2010 (124)	Wrong intervention (non-fortified food)
Alemán 2008 (125)	Wrong intervention (snack prepared with
	quality protein maize)
Amthor 2009 (126)	Wrong study design
Anorve-Valdez 2018 (127)	Wrong intervention (MNP)
Arcanjo 2019 (128)	Wrong intervention (MNP)
Argaw 2018 (129)	Wrong intervention (n-3 LCPUFA)
Ariff 2013 (130)	Wrong intervention (MNP)
Arsenault 2007 (131)	Wrong intervention (fortified porridge
	combined with liquid multivitamin
	supplement)
Arsenault 2008 (132)	Wrong intervention (fortified porridge
	combined with liquid multivitamin
	supplement)
Arsenault 2016 (133)	Wrong intervention (fortified porridge
------------------------------	--
	combined with liquid multivitamin
	supplement)
Arya 2014 (134)	Wrong intervention (Shashtikashalyadi
	Churna)
As'ad 2003 (135)	Wrong intervention (zinc as supplement)
Asibey-Berko 2007 (136)	Wrong population (aged > 23 months)
Associationforthe 2013 (137)	Wrong comparator
Awasthi 2020 (138)	Wrong comparator
Badau 2016 (139)	Wrong study design
Bagni 2009 (140)	Duplicate
Bajaj 2005 (141)	Wrong intervention (low energy density diet)
Baskaran 1999 (142)	Wrong study design
Bauserman 2015 (143)	Wrong intervention (caterpillar cereal)
Becroft 1965 (144)	Wrong intervention (non-fortified food)
Beinner 2010 (145)	Wrong comparator
Bergmann 1989 (146)	Wrong comparator
Bernal 2013 (147)	Wrong intervention (cereals with different
	carbohydrate profiles)
Bhandari 2016 (148)	Wrong intervention (non-fortified product)
Bhargava 2013 (149)	Wrong study design
Bishop 1996 (150)	Wrong population
Bisimwa 2012 (151)	Wrong comparator
Boateng 2017 (152)	Wrong comparator
Boateng 2018 (153)	Wrong intervention (flour with added moringa
	leaf powder)
Boateng 2019 (154)	Wrong intervention (fortified with moringa
	leaf powder)
Bodwell 1987 (155)	Wrong population
Borg 2017 (156)	Wrong comparator
Borg 2018 (157)	Wrong comparator
Borg 2019 (158)	Wrong comparator
Boston 2008 (159)	Wrong population (aged > 23 months)
Bouhouch 2015 (160)	Wrong population (aged > 23 months)

Brett 2018 (161)	Wrong population (aged > 23 months)
Brnic 2017 (162)	Wrong intervention (cereal porridge with
	phytase)
Brown 2007 (163)	Wrong intervention (fortified porridge
	combined with liquid multivitamin
	supplement)
Campbell 2015 (164)	Wrong comparator
Campbell 2016 (165)	Wrong comparator
Campbell 2016 (166)	Wrong comparator
Campbell 2017 (167)	Wrong study design
Campbell 2018 (168)	Wrong comparator
Campbell 2020 (169)	Wrong comparator
Capozzi 2011 (170)	Wrong intervention (iron fortified formula)
Carol 2019 (171)	Wrong population (children aged > 23 months)
Cercamondi 2013 (172)	Wrong comparator
Chauhan 2019 (173)	Wrong intervention (non-fortified food)
Chavasit 2015 (174)	Wrong comparator
Chilenje Infant Growth 2010 (175)	Wrong comparator
Chisenga 2011 (176)	Wrong study design
Chomba 2015 (177)	Wrong population (aged > 23 months)
Choudhury 2016 (178)	Wrong intervention (MNP)
Christian 2015 (179)	Wrong comparator
Christian 2015 (37)	Wrong comparator
Cliffer 2017 (180)	Wrong comparator
Cliffer 2020 (181)	Wrong comparator
Cook 1997 (182)	Wrong population
Cornell 2010 (183)	Wrong study design
Cornell 2012 (184)	Wrong population (aged > 23 months)
CTRI/2011/12/002259 (185)	Wrong intervention (non-fortified food)
CTRI/2017/08/009260 (186)	Wrong comparator
CTRI/2017/02/007767 2017 (187)	Wrong study design
Cubero 2009 (188)	Wrong intervention (cereal enriched with
	tryptophan)
Cuj 2016 (189)	Wrong study design

Dahl 2019 (190)	Wrong intervention (non-fortified porridge)
Daniels 2016 (191)	Wrong intervention (baby-led approach)
Daniels 2017 (192)	Wrong population (women)
Davidsson 2000 (193)	Wrong comparator
Davidsson 2003 (194)	Wrong population
Davidsson 2009 (24)	Wrong comparator
de Almeida 2003 (195)	Wrong study design
de Almeida 2005 (196)	
de Almeida 2014 (197)	Wrong intervention (fortified water)
Delimont 2017 (198)	Wrong comparator
Delimont 2017 (199)	Wrong comparator
Delimont 2019 (200)	Wrong comparator
DeOliveira 2006 (201)	Wrong intervention (diet with a bran-based
	cereal mixture)
DeOliviera 1996 (202)	Wrong intervention (fortified water)
dePaula 2001 (203)	Wrong comparator
Dewan 2009 (204)	Wrong intervention (leaf protein concentrate)
Dewan 2009 (205)	Wrong intervention (leaf protein concentrate)
Dewey 1998 (206)	Wrong comparator
Dewey 2004 (207)	Wrong intervention (iron supplementation)
Dhingra 2012 (208)	Wrong comparator
Dong 2013 (209)	Wrong intervention (vitamin and mineral
	supplements)
Drks 2014 (210)	Wrong comparator
Dube 2010 (211)	Wrong intervention (low or high meat content)
Duggan 2003 (212)	Wrong comparator
Duizer 2017 (213)	Wrong intervention (home fortifiers)
Dutradeoliveira 1994 (214)	Wrong population (children aged > 23 months)
Ekbote 2011 (215)	Wrong population
Emel 2006 (216)	Wrong study design
Ernst 2013 (217)	Wrong intervention (beef biscuits)
Ernst 2014 (218)	Wrong intervention (non-fortified biscuits)
Faber 2005 (219)	Wrong study design

Fatmah 2018 (220)	Wrong population (aged > 23 months)
Ferreira 2008 (221)	Wrong intervention (bran-based cereal mixture
	as supplement)
Fhi 2018 (222)	Wrong population (aged > 23 months)
Filteau 2011 (223)	Duplicate
Filteau 2011 (224)	Wrong comparator
Fink 2017 (225)	Wrong intervention (growth monitoring)
Finn 2017 (226)	Wrong study design
Fleige 2010 (227)	Wrong study design
Food 2018 (228)	Wrong study design
Friel 2013 (229)	Wrong comparator
Friel 2014 (230)	Wrong comparator
Friel 2015 (231)	Wrong comparator
Friel 2016 (232)	Wrong comparator
Fuchs 1991 (233)	Wrong intervention (milk + fortified cereal or
	formula)
Fuchs 1991 (234)	Wrong intervention (milk + fortified cereal or
	formula)
Fuchs 1993 (235)	formula) Wrong intervention (milk + fortified cereal or
Fuchs 1993 (235)	formula) Wrong intervention (milk + fortified cereal or formula)
Fuchs 1993 (235) Galpin 2007 (236)	formula) Wrong intervention (milk + fortified cereal or formula) Wrong comparator
Fuchs 1993 (235) Galpin 2007 (236) Gannon 2014 (237)	formula) Wrong intervention (milk + fortified cereal or formula) Wrong comparator Wrong population (aged > 23 months)
Fuchs 1993 (235) Galpin 2007 (236) Gannon 2014 (237) Gannon 2014 (238)	formula) Wrong intervention (milk + fortified cereal or formula) Wrong comparator Wrong population (aged > 23 months) Wrong population (aged > 23 months)
Fuchs 1993 (235) Galpin 2007 (236) Gannon 2014 (237) Gannon 2014 (238) GarcĂa-Guerra 2009 (239)	formula) Wrong intervention (milk + fortified cereal or formula) Wrong comparator Wrong population (aged > 23 months) Wrong population (aged > 23 months) Wrong comparator
Fuchs 1993 (235) Galpin 2007 (236) Gannon 2014 (237) Gannon 2014 (238) GarcĂa-Guerra 2009 (239) Gartner 2006 (240)	formula) Wrong intervention (milk + fortified cereal or formula) Wrong comparator Wrong population (aged > 23 months) Wrong population (aged > 23 months) Wrong comparator Wrong study design
Fuchs 1993 (235) Galpin 2007 (236) Gannon 2014 (237) Gannon 2014 (238) GarcĂa-Guerra 2009 (239) Gartner 2006 (240) Geltman 2009 (241)	formula) Wrong intervention (milk + fortified cereal or formula) Wrong comparator Wrong population (aged > 23 months) Wrong population (aged > 23 months) Wrong comparator Wrong study design Wrong intervention (MNP)
Fuchs 1993 (235) Galpin 2007 (236) Gannon 2014 (237) Gannon 2014 (238) GarcĂa-Guerra 2009 (239) Gartner 2006 (240) Geltman 2009 (241) Gershoff 1977 (242)	formula) Wrong intervention (milk + fortified cereal or formula) Wrong comparator Wrong population (aged > 23 months) Wrong population (aged > 23 months) Wrong comparator Wrong study design Wrong intervention (MNP) Wrong study design
Fuchs 1993 (235) Galpin 2007 (236) Gannon 2014 (237) Gannon 2014 (238) GarcĂa-Guerra 2009 (239) Gartner 2006 (240) Geltman 2009 (241) Gershoff 1977 (242) Ghosh 2017 (243)	formula) Wrong intervention (milk + fortified cereal or formula) Wrong comparator Wrong population (aged > 23 months) Wrong population (aged > 23 months) Wrong comparator Wrong study design Wrong intervention (MNP) Wrong study design Wrong intervention (MNP)
Fuchs 1993 (235) Galpin 2007 (236) Gannon 2014 (237) Gannon 2014 (238) GarcĂa-Guerra 2009 (239) Gartner 2006 (240) Geltman 2009 (241) Gershoff 1977 (242) Ghosh 2017 (243) Ghosh 2019 (244)	formula) Wrong intervention (milk + fortified cereal or formula) Wrong comparator Wrong population (aged > 23 months) Wrong population (aged > 23 months) Wrong comparator Wrong study design Wrong intervention (MNP) Wrong study design Wrong intervention (MNP) Wrong intervention (MNP)
Fuchs 1993 (235) Galpin 2007 (236) Gannon 2014 (237) Gannon 2014 (238) GarcĂa-Guerra 2009 (239) Gartner 2006 (240) Geltman 2009 (241) Gershoff 1977 (242) Ghosh 2017 (243) Ghosh 2019 (244) Gibson 2011 (245)	formula) Wrong intervention (milk + fortified cereal or formula) Wrong comparator Wrong population (aged > 23 months) Wrong population (aged > 23 months) Wrong comparator Wrong study design Wrong intervention (MNP) Wrong study design Wrong intervention (MNP) Wrong comparator Wrong comparator Wrong comparator (basal fortified vs. richly
Fuchs 1993 (235) Galpin 2007 (236) Gannon 2014 (237) Gannon 2014 (238) GarcĂa-Guerra 2009 (239) Gartner 2006 (240) Geltman 2009 (241) Gershoff 1977 (242) Ghosh 2017 (243) Ghosh 2019 (244) Gibson 2011 (245)	formula) Wrong intervention (milk + fortified cereal or formula) Wrong comparator Wrong population (aged > 23 months) Wrong population (aged > 23 months) Wrong comparator Wrong study design Wrong intervention (MNP) Wrong study design Wrong intervention (MNP) Wrong comparator Wrong comparator (basal fortified vs. richly fortified porridge)
Fuchs 1993 (235) Galpin 2007 (236) Gannon 2014 (237) Gannon 2014 (238) GarcĂa-Guerra 2009 (239) Gartner 2006 (240) Geltman 2009 (241) Gershoff 1977 (242) Ghosh 2017 (243) Ghosh 2019 (244) Gibson 2011 (245) Glinz 2015 (23)	formula) Wrong intervention (milk + fortified cereal or formula) Wrong comparator Wrong population (aged > 23 months) Wrong population (aged > 23 months) Wrong comparator Wrong study design Wrong intervention (MNP) Wrong study design Wrong intervention (MNP) Wrong comparator Wrong comparator (basal fortified vs. richly fortified porridge) Wrong comparator

Glinz 2017 (247)	Duplicate
GodomarGalindo 1989 (248)	Wrong study design
Gough 2020 (249)	Wrong intervention (improved water,
	sanitation, and hygiene)
Grantham-McGregor 1989 (250)	Wrong intervention (full-cream powdered
	milk)
Granthammcgregor 1993 (251)	Wrong intervention (nutritional
	supplementation)
Gunaratna 2016 (252)	Wrong study design
Gutierrez 1998 (253)	Wrong intervention (received coupons)
Hambidge 1979 (254)	Wrong population (aged > 23 months)
Hambidge 2013 (255)	Wrong comparator
Harrington 2011 (256)	Wrong comparator
Haschke 1988 (257)	Wrong intervention (formula)
HaydomLutheran 2020 (258)	Wrong population (aged > 23 months)
HelenKeller 2011 (259)	Wrong comparator
HeroInstituteforInfant 2017 (260)	Wrong intervention (infant cereal with whole
	grain flour)
Herter-Aeberli 2017 (261)	Wrong population (aged > 23 months)
Herter-Aeberli 2017 (262)	Duplicate
Hertrampf 1990 (263)	Duplicate
Hertrampf 1990 (264)	Wrong intervention (Haemoglobin fortified
	cereal)
Hess 2017 (265)	Wrong intervention (zinc supplementation)
Hi 2020 (266)	Wrong population (aged <6 months)
Hilmers 2002 (267)	Wrong population (aged > 23 months)
Hlaing 2015 (268)	Wrong comparator
Hoffman 2004 (269)	Wrong intervention (fortified with DHA-
	enriched egg yolks)
Hoffman 2014 (270)	Wrong intervention (fortified with DHA-
	enriched egg yolks)
HospitalClinicoUniversitariode 2017 (271)	Wrong intervention (dairy product with
	prebiotic)
Hossain 2005 (272)	Wrong intervention (amylase-rich flour)

Huey 2017 (273)	Duplicate
Huo 2013 (274)	Wrong study design
Hussain 2004 (275)	Wrong intervention (lysine)
Huybregts 2012 (276)	Wrong intervention (non-fortified food)
Isanaka 2008 (277)	Wrong comparator
Isanaka 2019 (278)	Wrong comparator
ISRCTN47598408 (279)	Wrong comparator
ISRCTN30012997 (280)	Wrong comparator
ISRCTN10309022 (281)	Wrong intervention (lactose-free, chickpea
	flour)
luel-Brockdorf 2015 (282)	Wrong intervention (lipid-based nutrient
	supplements, non-fortified corn-soy blended
	flours)
luel-Brockdorf 2016 (283)	Wrong intervention (lipid-based nutrient
	supplements, non-fortified corn-soy blended
	flours)
Jaeggi 2015 (284)	Wrong intervention (home-fortified maize
	porridge)
Jahari 2000 (285)	Wrong intervention (milk plus micronutrients)
Jalla 2002 (286)	Wrong comparator
Javan 2017 (287)	Wrong intervention (multivitamin / mineral
	supplement)
Javaid 1991 (288)	Wrong population (aged <6 months)
Javaid 1991 (289)	Duplicate
Jilcott 2010 (290)	Wrong study design
John 1993 (291)	Wrong intervention (gruels, without
	micronutrient fortification)
Jong-Mee 2005 (292)	micronutrient fortification) Wrong intervention (fortified chewiness)
Jong-Mee 2005 (292) Kaimila 2019 (293)	micronutrient fortification) Wrong intervention (fortified chewiness) Wrong intervention (supplemental legumes)
Jong-Mee 2005 (292) Kaimila 2019 (293) Kajjura 2019 (294)	micronutrient fortification) Wrong intervention (fortified chewiness) Wrong intervention (supplemental legumes) Wrong comparator
Jong-Mee 2005 (292) Kaimila 2019 (293) Kajjura 2019 (294) Kajjura 2020 (295)	micronutrient fortification) Wrong intervention (fortified chewiness) Wrong intervention (supplemental legumes) Wrong comparator Wrong comparator
Jong-Mee 2005 (292) Kaimila 2019 (293) Kajjura 2019 (294) Kajjura 2020 (295) Kalavi 1996 (296)	micronutrient fortification) Wrong intervention (fortified chewiness) Wrong intervention (supplemental legumes) Wrong comparator Wrong comparator Wrong intervention
Jong-Mee 2005 (292) Kaimila 2019 (293) Kajjura 2019 (294) Kajjura 2020 (295) Kalavi 1996 (296) Kalhoff 2020 (297)	micronutrient fortification) Wrong intervention (fortified chewiness) Wrong intervention (supplemental legumes) Wrong comparator Wrong comparator Wrong intervention Wrong intervention

Karakochuk 2012 (299)	Wrong comparator
Kekalih 2019 (300)	Wrong comparator
King 2007 (301)	Wrong intervention (highdiastase malted
	barley)
Kodkany 2013 (302)	Wrong population (aged > 23 months)
Konyole 2013 (303)	Wrong intervention ("Winfood Classic" vs.
	"Winfood Lite" vs. Corn Soy Blend Plus)
Konyole 2017 (304)	Wrong comparator
Konyole 2019 (305)	Wrong comparator
Krebs 2006 (306)	Wrong comparator
Krebs 2012 (307)	Wrong comparator
Krebs 2012 (308)	Wrong comparator
Krebs 2013 (309)	Wrong comparator
Krebs 2013 (310)	Wrong intervention (MNP)
Kuusipalo 2006 (311)	Wrong comparator
Laboratorios 2021 (312)	Wrong intervention (probiotics)
Lachat 2006 (313)	Wrong intervention (processing to improve
	protein digestibility)
LaGrone 2012 (314)	Wrong comparator
Lakkam 2014 (315)	Wrong study design
Langendorf 2014 (316)	Wrong comparator
Langlois 2020 (317)	Wrong comparator
Laylo-NavarroCelestinaRaquel 2011 (318)	Wrong intervention (non-fortified food)
Leroy 2020 (319)	Wrong intervention (micronutrient
	supplements)
Leroy 2021 (320)	Wrong intervention (different timing and
	duration of feeding)
Libuda 2016 (321)	Wrong intervention (food with rapeseed oil or
	oily fish)
Li 2015 (322)	Wrong population (aged > 23 months)
Lin 2008 (323)	Wrong comparator
Lind 2003 (324)	Wrong intervention (phytate-reduced
	products)

Lind 2004 (325)	Wrong intervention (phytate-reduced
	products)
Lind 2019 (326)	Wrong intervention (protein-reduced food)
LitkowskiPe 2016 (327)	Wrong intervention (non-fortified product)
Lo 2011 (328)	Wrong intervention (iron-fortified porridge
	combined with a liquid multivitamin
	supplement)
Long 2012 (329)	Wrong study design
LopezdeRomana 2005 (330)	Wrong population (aged > 23 months)
Ly 2006 (331)	Wrong comparator
Macharia-Mutie 2012 (332)	Wrong intervention (porridge with amaranth
	or MNP)
Macharia-Mutie 2013 (333)	Wrong intervention (porridge with amaranth
	or MNP)
Macharia-Mutie 2015 (334)	Wrong intervention (porridge with amaranth
	or MNP)
Manno 2011 (335)	Wrong comparator
Mahalanabis 1993 (336)	Wrong intervention
Mallard 2014 (337)	Wrong study design
Mamiro 2004 (338)	Wrong intervention (processed
	complementary food)
Manary 2004 (339)	Wrong comparator
Mank 2011 (340)	Wrong intervention (zinc supplement)
Manno 2012 (31)	Wrong comparator (richly fortified vs. basal
	fortified porridge)
Marron 2015 (341)	Wrong comparator
MartinezMartinez 2009 (342)	Wrong study design
Martorell 2020 (343)	Wrong study design
Masuda 2019 (344)	Wrong intervention (spirulina powder)
Masuda 2019 (345)	Wrong intervention (spirulina powder)
Matilsky 2009 (346)	Wrong comparator
Maust 2015 (347)	Wrong intervention (integrated management
	of malnutrition)
McDonald 2019 (348)	Wrong comparator

McGill 2014 (349)	Wrong comparator
McGill 2015 (350)	Wrong population (aged > 23 months)
MedecinsSansFrontieres 2012 (351)	Wrong intervention (MNP)
MeeksGardner 1995 (352)	Wrong intervention (milk-based supplement)
Menon 2007 (353)	Wrong intervention (MNP)
Miles 1987 (354)	Wrong population
Mize 1995 (355)	Wrong intervention (formula)
Moore 2003 (356)	Wrong intervention (fructo-oligosaccharide-
	supplemented infant cereal)
Morales 2008 (357)	Wrong comparator
Moursi 2003 (358)	Wrong intervention (amylase)
Nane 2019 (359)	Wrong comparator
NCT01224535 (360)	Wrong intervention (porridge enriched with
	amaranth)
NCT02162238 (361)	Wrong population (aged > 23 months)
NCT01790048 (362)	Wrong intervention (non-fortified food)
NCT04334538 (363)	Wrong comparator
NCT00998517 (364)	Wrong comparator
NCT01552512 (365)	Wrong intervention (Nutributter)
NCT01785680 (366)	Wrong intervention (integrated protocol)
NCT02053857 (367)	Wrong comparator
NCT02375503 (368)	Wrong population (aged > 23 months)
NCT00822380 (369)	Wrong comparator
NCT01817634 (370)	Wrong intervention (fish oil capsule)
NCT00890695 (371)	Wrong comparator
NCT00631046 (372)	Wrong intervention (fish oil)
NCT01593969 (373)	Wrong intervention (n-3 PUFA enriched food)
NCT01790542 (374)	Wrong population (aged <6 months)
NCT03355222 (375)	Wrong intervention (non-fortified food)
NCT03385590 (376)	Wrong intervention (non-fortified food)
NCT03597061 (377)	Wrong intervention (behavioral)
NCT02221063 (378)	Wrong population (aged > 23 months)

NCT03041103 (379)	Wrong study design
NCT03175003 (380)	Wrong population (aged > 23 months)
NCT02208609 (381)	Wrong intervention (maize tortillas with
	Amaranth)
NCT02142647 (382)	Wrong intervention (non-fortified food)
NCT04137445 (383)	Wrong intervention (non-fortified food)
NCT00653705 (384)	Wrong intervention (probiotic bacteria BB12)
NCT01282788 (385)	Wrong comparator
NCT03355287 (386)	Wrong intervention (iron drops)
NCT01184716 (387)	Wrong population (aged > 23 months)
NCT01097889 (388)	Wrong comparator
NCT01001871 (389)	Wrong intervention (MNP)
NCT01455636 (390)	Wrong intervention (MNP)
NCT02192892 (391)	Wrong comparator
NCT01061307 (392)	Wrong population (aged > 23 months)
NCT01573013 (393)	Wrong population (aged > 23 months)
NCT01321099 (394)	Wrong comparator
NCT01111864 (395)	Wrong intervention (iron and micronutrient
	supplement)
NCT01634945 (396)	Wrong comparator
NCT02176759 (397)	Wrong population (aged > 23 months)
NCT02437955 (398)	Wrong population (aged > 23 months)
NCT02118402 (399)	Wrong intervention (MNP)
NCT03894358 (400)	Wrong intervention (prebiotic mixture)
NCT01423162 (401)	Wrong population (aged > 23 months)
NCT01418898 (402)	Wrong population (aged > 23 months)
NCT00571948 (403)	Wrong population (aged <6 months)
NCT04174846 (404)	Wrong intervention (non-fortified food)
NCT02079961 (405)	Wrong population (aged > 23 months)
NCT04564222 (406)	Wrong population (aged > 23 months)

NCT02847962 (407)	Wrong comparator
NCT01724073 (408)	Wrong comparator
NCT02165956 (409)	Wrong intervention (cereal with prebiotics,
	probiotics, vegetable proteins)
NCT03617575 (410)	Wrong intervention (iron supplement)
NCT02257437 (411)	Wrong comparator
NCT02257762 (412)	Wrong comparator
NCT02078271 (413)	Wrong intervention (food-based dietary
	guidelines)
NCT03474276 (414)	Wrong comparator
NCT01115647 (415)	Wrong comparator
NCT03752762 (416)	Wrong population (aged <6 months)
NCT03399617 (417)	Wrong population (aged <6 months)
NCT00867867 (418)	Wrong intervention (iron supplementation)
NCT04099849 (419)	Wrong population (aged > 23 months)
NCT01553877 (420)	Wrong intervention (non-fortified product)
NCT01634009 (421)	Wrong intervention (non-fortified product)
NCT02185196 (422)	Wrong intervention (vitamin D
	supplementation)
NCT04099849 (423)	Wrong population (aged > 23 months)
NCT03258385 (424)	Wrong population (aged > 23 months)
NCT04015999 (425)	Wrong intervention (non-fortified food)
NCT03084731 (426)	Wrong intervention (non-fortified food)
NCT01562379 (427)	Wrong comparator
NCT01751009 (428)	Wrong intervention (vitamin A supplement)
NCT02073149 (429)	Wrong intervention (point-of-care
	fortification)
NCT02435524 (430)	Wrong population (aged > 23 months)
NCT03038633 (431)	Wrong population (aged > 23 months)
NCT00131222 (432)	Wrong comparator
NCT04250896 (433)	Wrong intervention (behavioral)

combined with a liquid multivitamin supplement)NCT01783067 (435)Wrong population (aged > 23 months)NCT00760890 (436)Wrong comparatorNCT0098202 (438)Wrong population (aged > 23 months)NCT01898871 (439)Wrong comparatorNCT03549156 (440)Wrong comparatorNCT03549156 (440)Wrong population (aged > 23 months)NCT03549156 (440)Wrong comparatorNCT03549156 (441)Wrong population (aged > 23 months)NCT03754543 (422)Wrong comparatorNCT04766346 (444)Wrong population (aged < 23 months)NCT04766346 (444)Wrong study designNCT03111927 (445)Wrong gopulation (aged <6 months)Neufeld 2019 (446)Wrong comparatorNCT0311178 (447)Wrong intervention (MNP)Nicklas 2020 (448)Wrong comparatorNikiema 2014 (449)Wrong comparatorNikiema 2014 (449)Wrong comparatorNikiema 2014 (449)Wrong comparatorNikiema 2014 (451)Wrong comparatorNikiema 2014 (453)Wrong comparatorNikiema 2014 (453)Wrong comparatorNichas 2016 (451)Wrong comparatorNichas 2016 (453)Wrong comparatorNichas 2018 (453)Wrong comparatorNordiz 2020 (456)Wrong comparatorOdida 2020 (456)Wrong comparatorOrdiz 2020 (456)Wrong population (aged > 23 months)Obelofse 2003 (455)Wrong population (aged > 23 months)Ordiz 2020 (456)Wrong population (aged > 23 months)Ordiz 2020 (456)Wrong popula	NCT00944398 (434)	Wrong intervention (iron-fortified porridge
Inclusionsupplement)NCT01783067 (435)Wrong population (aged > 23 months)NCT00760890 (436)Wrong comparatorNCT000841061 (437)Wrong population (aged > 23 months)NCT00098202 (438)Wrong comparatorNCT01898871 (439)Wrong comparatorNCT03549156 (440)Wrong population (aged > 23 months)NCT03549156 (440)Wrong comparatorNct03549156 (441)Wrong population (aged > 23 months)NCT03754543 (442)Wrong comparatorNCT03754543 (442)Wrong population (aged > 23 months)NCT04766346 (444)Wrong study designNCT03111927 (445)Wrong study designNCT03111927 (445)Wrong comparatorNCT0311178 (447)Wrong comparatorNCT0311178 (447)Wrong comparatorNikiama 2014 (449)Wrong comparatorNikiama 2014 (449)Wrong comparatorNikiama 2014 (449)Wrong comparatorNikiama 2014 (451)Wrong comparatorNurth-WestUniversity 2016 (451)Wrong comparatorNurth-San 2018 (453)Wrong comparatorOutal 2003 (454)Wrong comparatorOrdiz 2020 (456)Wrong comparatorOrdiz 2020 (456)Wrong comparatorOrdiz 2020 (458)Wrong comparatorOutal 2030 (455)Wrong comparatorOutal 2030 (454)Wrong comparatorOrdiz 2020 (456)Wrong intervention (legume supplementation)Ordiz 2020 (456)Wrong comparatorOutal 2020 (456)Wrong intervention (micronutrient supplementation)Ordiz 20		combined with a liquid multivitamin
NCT01783067 (435)Wrong population (aged > 23 months)NCT00760890 (436)Wrong comparatorNCT00841061 (437)Wrong comparatorNCT0098202 (438)Wrong population (aged > 23 months)NCT01898871 (439)Wrong comparatorNCT03549156 (440)Wrong comparatorNestel 2004 (441)Wrong comparatorNCT03754543 (442)Wrong comparatorNCT04888453 (443)Wrong intervention (different feeding regimens)NCT04766346 (444)Wrong study designNCT04766346 (444)Wrong study designNCT0311927 (445)Wrong omparatorNCT03111927 (445)Wrong comparatorNCT03181178 (447)Wrong study designNikiema 2014 (449)Wrong comparatorNikiema 2014 (449)Wrong comparatorNikiema 2014 (449)Wrong comparatorNurth-WestUniversity 2016 (451)Wrong comparatorNurhasan 2018 (453)Wrong comparatorNurhasan 2018 (453)Wrong comparatorObatolu 2003 (454)Wrong comparatorOrdiz 2020 (456)Wrong population (aged > 23 months)Ordiz 2020 (455)Wrong comparatorOrdiz 2020 (456)Wrong intervention (legume supplementation)Orsango 2019 (457)Wrong populationOuedraogo 2010 (459)Wrong intervention (micronutrient supplement)Owino 2007 (460)Wrong intervention (alpha-amylase)Owino 2011 (461)Wrong comparator		supplement)
NCT00760890 (436)Wrong comparatorNCT00841061 (437)Wrong comparatorNCT0008202 (438)Wrong population (aged > 23 months)NCT01898871 (439)Wrong comparatorNCT03549156 (440)Wrong comparatorNestel 2004 (441)Wrong comparatorNCT03754543 (442)Wrong comparatorNCT04888453 (443)Wrong intervention (different feeding regimens)NCT04766346 (444)Wrong study designNCT03111927 (445)Wrong study designNCT03111927 (445)Wrong comparatorNCT03181178 (447)Wrong intervention (MNP)Nicklas 2020 (448)Wrong comparatorNikiema 2014 (449)Wrong comparatorNikiema 2014 (449)Wrong comparatorNurhasan 2018 (453)Wrong comparatorNurhasan 2018 (453)Wrong comparatorNurhasan 2018 (453)Wrong comparatorObatolu 2003 (454)Wrong comparatorOrdiz 2020 (456)Wrong population (aged > 23 months)Ordiz 2020 (456)Wrong intervention (legume supplementation)Orsango 2019 (457)Wrong population (aged > 23 months)Ouedraogo 2010 (459)Wrong intervention (legume supplementation)Owino 2007 (460)Wrong intervention (micronutrient supplement)Owino 2007 (460)Wrong intervention (alpha-amylase)Owino 2011 (461)Wrong comparator	NCT01783067 (435)	Wrong population (aged > 23 months)
NCT00841061 (437)Wrong comparatorNCT00098202 (438)Wrong population (aged > 23 months)NCT01898871 (439)Wrong comparatorNCT03549156 (440)Wrong comparatorNestel 2004 (441)Wrong population (aged > 23 months)NCT03754543 (442)Wrong comparatorNCT04483453 (443)Wrong intervention (different feeding regimens)NCT04766346 (444)Wrong study designNCT03111927 (445)Wrong population (aged <6 months)	NCT00760890 (436)	Wrong comparator
NCT00098202 (438)Wrong population (aged > 23 months)NCT01898871 (439)Wrong comparatorNCT03549156 (440)Wrong comparatorNestel 2004 (441)Wrong population (aged > 23 months)NCT03754543 (442)Wrong comparatorNCT04483453 (443)Wrong intervention (different feeding regimens)NCT04766346 (444)Wrong study designNCT03111927 (445)Wrong population (aged <6 months)	NCT00841061 (437)	Wrong comparator
NCT01898871 (439)Wrong comparatorNCT03549156 (440)Wrong population (aged > 23 months)NCT03754543 (442)Wrong comparatorNCT04483453 (443)Wrong intervention (different feeding regimens)NCT04766346 (444)Wrong study designNCT03111927 (445)Wrong population (aged <6 months)	NCT00098202 (438)	Wrong population (aged > 23 months)
NCT03549156 (440)Wrong comparatorNestel 2004 (441)Wrong population (aged > 23 months)NCT03754543 (442)Wrong comparatorNCT04483453 (443)Wrong intervention (different feeding regimens)NCT04766346 (444)Wrong study designNCT03111927 (445)Wrong opulation (aged <6 months)	NCT01898871 (439)	Wrong comparator
Nestel 2004 (441)Wrong population (aged > 23 months)NCT03754543 (442)Wrong comparatorNCT04483453 (443)Wrong intervention (different feeding regimens)NCT04766346 (444)Wrong study designNCT03111927 (445)Wrong population (aged <6 months)	NCT03549156 (440)	Wrong comparator
NCT03754543 (442)Wrong comparatorNCT04483453 (443)Wrong intervention (different feeding regimens)NCT04766346 (444)Wrong study designNCT03111927 (445)Wrong population (aged <6 months)	Nestel 2004 (441)	Wrong population (aged > 23 months)
NCT04483453 (443)Wrong intervention (different feeding regimens)NCT04766346 (444)Wrong study designNCT03111927 (445)Wrong population (aged <6 months)	NCT03754543 (442)	Wrong comparator
regimens)NCT04766346 (444)Wrong study designNCT03111927 (445)Wrong population (aged <6 months)	NCT04483453 (443)	Wrong intervention (different feeding
NCT04766346 (444)Wrong study designNCT03111927 (445)Wrong population (aged <6 months)		regimens)
NCT03111927 (445)Wrong population (aged <6 months)Neufeld 2019 (446)Wrong comparatorNCT03181178 (447)Wrong intervention (MNP)Nicklas 2020 (448)Wrong study designNikiema 2014 (449)Wrong comparatorNikiema 2014 (449)Wrong comparatorNikiema 2021 (450)Wrong intervention (non-fortified food)North-WestUniversity 2016 (451)Wrong comparatorNozari 2015 (452)Wrong population (aged > 23 months)Nurhasan 2018 (453)Wrong comparatorObatolu 2003 (454)Wrong comparatorOrdiz 2020 (456)Wrong intervention (legume supplementation)Orsango 2019 (457)Wrong population (aged > 23 months)Ouedraogo 2010 (459)Wrong intervention (legume supplementation)Ouedraogo 2010 (459)Wrong intervention (legume supplementation)Owino 2007 (460)Wrong intervention (micronutrient supplement)Owino 2011 (461)Wrong comparatorOwino 2013 (462)Wrong comparator	NCT04766346 (444)	Wrong study design
Neufeld 2019 (446)Wrong comparatorNCT03181178 (447)Wrong intervention (MNP)Nicklas 2020 (448)Wrong study designNikiema 2014 (449)Wrong comparatorNikiema 2021 (450)Wrong intervention (non-fortified food)North-WestUniversity 2016 (451)Wrong comparatorNozari 2015 (452)Wrong population (aged > 23 months)Nurhasan 2018 (453)Wrong comparatorObatolu 2003 (454)Wrong comparatorOrdiz 2020 (456)Wrong intervention (legume supplementation)Orsango 2019 (457)Wrong population (aged > 23 months)Ouedraogo 2010 (459)Wrong intervention (legume supplementation)Ovino 2007 (460)Wrong intervention (aged > 23 months)Owino 2011 (461)Wrong intervention (alpha-amylase)Owino 2013 (462)Wrong comparator	NCT03111927 (445)	Wrong population (aged <6 months)
NCT03181178 (447)Wrong intervention (MNP)Nicklas 2020 (448)Wrong study designNikiema 2014 (449)Wrong comparatorNikiema 2021 (450)Wrong intervention (non-fortified food)North-WestUniversity 2016 (451)Wrong comparatorNozari 2015 (452)Wrong population (aged > 23 months)Nurhasan 2018 (453)Wrong comparatorObatolu 2003 (454)Wrong population (aged > 23 months)Oelofse 2003 (455)Wrong comparatorOrdiz 2020 (456)Wrong intervention (legume supplementation)Orsango 2019 (457)Wrong population (aged > 23 months)Ouedraogo 2010 (459)Wrong intervention (legume supplementation)Ouedraogo 2010 (459)Wrong intervention (legume supplementation)Owino 2007 (460)Wrong intervention (micronutrient supplement)Owino 2011 (461)Wrong comparatorOwino 2013 (462)Wrong comparator	Neufeld 2019 (446)	Wrong comparator
Nicklas 2020 (448)Wrong study designNikiema 2014 (449)Wrong comparatorNikiema 2021 (450)Wrong intervention (non-fortified food)North-WestUniversity 2016 (451)Wrong comparatorNozari 2015 (452)Wrong population (aged > 23 months)Nurhasan 2018 (453)Wrong comparatorObatolu 2003 (454)Wrong population (aged > 23 months)Oelofse 2003 (455)Wrong comparatorOrdiz 2020 (456)Wrong comparatorOrdiz 2020 (456)Wrong intervention (legume supplementation)Orsango 2019 (457)Wrong population (aged > 23 months)Ouedraogo 2010 (459)Wrong intervention (alpha-amylase)Owino 2007 (460)Wrong intervention (alpha-amylase)Owino 2011 (461)Wrong comparatorOwino 2013 (462)Wrong comparator	NCT03181178 (447)	Wrong intervention (MNP)
Nikiema 2014 (449)Wrong comparatorNikiema 2021 (450)Wrong intervention (non-fortified food)North-WestUniversity 2016 (451)Wrong comparatorNozari 2015 (452)Wrong population (aged > 23 months)Nurhasan 2018 (453)Wrong comparatorObatolu 2003 (454)Wrong population (aged > 23 months)Oelofse 2003 (455)Wrong comparatorOrdiz 2020 (456)Wrong intervention (legume supplementation)Orsango 2019 (457)Wrong population (aged > 23 months)Osendarp 2002 (458)Wrong population (aged > 23 months)Oudraogo 2010 (459)Wrong intervention (legume supplementation)Owino 2007 (460)Wrong intervention (alpha-amylase)Owino 2011 (461)Wrong comparatorOwino 2013 (462)Wrong comparator	Nicklas 2020 (448)	Wrong study design
Nikiema 2021 (450)Wrong intervention (non-fortified food)North-WestUniversity 2016 (451)Wrong comparatorNozari 2015 (452)Wrong population (aged > 23 months)Nurhasan 2018 (453)Wrong comparatorObatolu 2003 (454)Wrong population (aged > 23 months)Oelofse 2003 (455)Wrong comparatorOrdiz 2020 (456)Wrong intervention (legume supplementation)Orsango 2019 (457)Wrong population (aged > 23 months)Osendarp 2002 (458)Wrong population (aged > 23 months)Ouedraogo 2010 (459)Wrong intervention (legume supplementation)Owino 2007 (460)Wrong intervention (micronutrient supplement)Owino 2011 (461)Wrong comparatorOwino 2013 (462)Wrong comparator	Nikiema 2014 (449)	Wrong comparator
North-WestUniversity 2016 (451)Wrong comparatorNozari 2015 (452)Wrong population (aged > 23 months)Nurhasan 2018 (453)Wrong comparatorObatolu 2003 (454)Wrong population (aged > 23 months)Oelofse 2003 (455)Wrong comparatorOrdiz 2020 (456)Wrong intervention (legume supplementation)Orsango 2019 (457)Wrong population (aged > 23 months)Osendarp 2002 (458)Wrong population (aged > 23 months)Ouedraogo 2010 (459)Wrong intervention (legume supplementation)Owino 2007 (460)Wrong intervention (micronutrient supplement)Owino 2013 (462)Wrong comparator	Nikiema 2021 (450)	Wrong intervention (non-fortified food)
Nozari 2015 (452)Wrong population (aged > 23 months)Nurhasan 2018 (453)Wrong comparatorObatolu 2003 (454)Wrong population (aged > 23 months)Oelofse 2003 (455)Wrong comparatorOrdiz 2020 (456)Wrong intervention (legume supplementation)Orsango 2019 (457)Wrong population (aged > 23 months)Osendarp 2002 (458)Wrong population (aged > 23 months)Ouedraogo 2010 (459)Wrong populationOwino 2007 (460)Wrong intervention (micronutrient supplement)Owino 2011 (461)Wrong comparatorOwino 2013 (462)Wrong comparator	North-WestUniversity 2016 (451)	Wrong comparator
Nurhasan 2018 (453)Wrong comparatorObatolu 2003 (454)Wrong population (aged > 23 months)Oelofse 2003 (455)Wrong comparatorOrdiz 2020 (456)Wrong intervention (legume supplementation)Orsango 2019 (457)Wrong population (aged > 23 months)Osendarp 2002 (458)Wrong populationOuedraogo 2010 (459)Wrong intervention (micronutrient supplement)Owino 2007 (460)Wrong intervention (alpha-amylase)Owino 2011 (461)Wrong comparatorOwino 2013 (462)Wrong comparator	Nozari 2015 (452)	Wrong population (aged > 23 months)
Obatolu 2003 (454)Wrong population (aged > 23 months)Oelofse 2003 (455)Wrong comparatorOrdiz 2020 (456)Wrong intervention (legume supplementation)Orsango 2019 (457)Wrong population (aged > 23 months)Osendarp 2002 (458)Wrong populationOuedraogo 2010 (459)Wrong intervention (micronutrient supplement)Owino 2007 (460)Wrong intervention (alpha-amylase)Owino 2011 (461)Wrong comparatorOwino 2013 (462)Wrong comparator	Nurhasan 2018 (453)	Wrong comparator
Oelofse 2003 (455)Wrong comparatorOrdiz 2020 (456)Wrong intervention (legume supplementation)Orsango 2019 (457)Wrong population (aged > 23 months)Osendarp 2002 (458)Wrong populationOuedraogo 2010 (459)Wrong intervention (micronutrient supplement)Owino 2007 (460)Wrong intervention (alpha-amylase)Owino 2011 (461)Wrong comparatorOwino 2013 (462)Wrong comparator	Obatolu 2003 (454)	Wrong population (aged > 23 months)
Ordiz 2020 (456)Wrong intervention (legume supplementation)Orsango 2019 (457)Wrong population (aged > 23 months)Osendarp 2002 (458)Wrong populationOuedraogo 2010 (459)Wrong intervention (micronutrient supplement)Owino 2007 (460)Wrong intervention (alpha-amylase)Owino 2011 (461)Wrong comparatorOwino 2013 (462)Wrong comparator	Oelofse 2003 (455)	Wrong comparator
Orsango 2019 (457)Wrong population (aged > 23 months)Osendarp 2002 (458)Wrong populationOuedraogo 2010 (459)Wrong intervention (micronutrient supplement)Owino 2007 (460)Wrong intervention (alpha-amylase)Owino 2011 (461)Wrong comparatorOwino 2013 (462)Wrong comparator	Ordiz 2020 (456)	Wrong intervention (legume supplementation)
Osendarp 2002 (458)Wrong populationOuedraogo 2010 (459)Wrong intervention (micronutrient supplement)Owino 2007 (460)Wrong intervention (alpha-amylase)Owino 2011 (461)Wrong comparatorOwino 2013 (462)Wrong comparator	Orsango 2019 (457)	Wrong population (aged > 23 months)
Ouedraogo 2010 (459)Wrong intervention (micronutrient supplement)Owino 2007 (460)Wrong intervention (alpha-amylase)Owino 2011 (461)Wrong comparatorOwino 2013 (462)Wrong comparator	Osendarp 2002 (458)	Wrong population
supplement)Owino 2007 (460)Wrong intervention (alpha-amylase)Owino 2011 (461)Wrong comparatorOwino 2013 (462)Wrong comparator	Ouedraogo 2010 (459)	Wrong intervention (micronutrient
Owino 2007 (460)Wrong intervention (alpha-amylase)Owino 2011 (461)Wrong comparatorOwino 2013 (462)Wrong comparator		supplement)
Owino 2011 (461)Wrong comparatorOwino 2013 (462)Wrong comparator	Owino 2007 (460)	Wrong intervention (alpha-amylase)
Owino 2013 (462) Wrong comparator	Owino 2011 (461)	Wrong comparator
	Owino 2013 (462)	Wrong comparator

Owino 2015 (463)	Wrong comparator
PACTR201604001584278 (464)	Wrong intervention (precooked maize-
	sorghum flour)
PACTR201809662822990 (465)	Wrong comparator
Pactr 2019 (466)	Wrong comparator
Palmer 2018 (467)	Wrong population (aged > 23 months)
Patel 2005 (468)	Wrong comparator
Paul 2007 (469)	Wrong intervention (non-fortified food)
Phu 2010 (28)	Wrong population (aged <6 months)
Phu 2012 (470)	Wrong population (aged <6 months)
Phuka 2008 (471)	Wrong comparator
Phuka 2009 (472)	Wrong intervention (LNS)
Phuka 2009 (473)	Wrong comparator
Picciano 1980 (474)	Wrong intervention (formula)
Pollitt 2002 (475)	Wrong intervention (micronutrient
	supplement)
Purwestri 2012 (476)	Wrong intervention (RUF-Nias biscuits)
Pynaert 2006 (477)	Wrong study design
Qasem 2017 (478)	Wrong comparator
Rahman 1994 (479)	Wrong intervention (amylase)
Rahman 1997 (480)	Wrong intervention (amylase)
Rahman 1997 (481)	Wrong intervention (amylase)
Ramirez 2013 (482)	Wrong study design
Ramirez-Luzuriaga 2016 (483)	Wrong intervention (Powdered fortified milk)
Rao 1992 (484)	Wrong intervention (sweet ready mix with
	amylase)
Rim 2008 (22)	Wrong intervention (point-of-use fortification)
Rivera 1991 (485)	Wrong intervention (Atole, Fresco)
Rivera 2002 (486)	Wrong intervention (Atole, Fresco)
Roberts 2017 (487)	Wrong comparator
Roberts 2020 (488)	Wrong comparator
Roediger 2020 (489)	Wrong intervention (protein quality optimized
	RUSF)

Rosado 2010 (490)	Wrong comparator
Ruel 1997 (491)	Wrong intervention (liquid preparation zinc)
Safaa 2003 (492)	Wrong study design
Sako 2018 (493)	Wrong study design
Salinas-Pielago 1998 (494)	Wrong population (aged > 23 months)
Samadpour 2009 (495)	Wrong intervention (MNP)
Sandjaja 2015 (496)	Wrong study design
Sarojini 1999 (497)	Wrong study design
Sato 2017 (498)	Wrong intervention (MNP)
Sayyad-Neerkorn 2015 (499)	Wrong comparator
Sazawal 2014 (500)	Wrong comparator
Scherbaum 2015 (501)	Wrong comparator
Schlossman 2015 (502)	Wrong intervention (non-fortified food)
Schlossman 2017 (503)	Wrong study design
Schlossman 2018 (504)	Wrong intervention (non-fortified food)
Schroeder 1995 (505)	Wrong intervention (highenergy, high-protein
	beverage)
Schumann 2009 (506)	Wrong intervention (foodLET: chewable,
	flavored multiple-micronutrient vehicle that
	was a hybrid of a food and a tablet)
Schwartz 2009 (507)	Wrong intervention (n-6 linoleic acid)
Seal 2008 (508)	Wrong study design
Shaikh 2020 (509)	Wrong comparator
Shamah-Levy 2008 (510)	Wrong comparator
Shamim 2015 (511)	Wrong comparator
Shen 2017 (512)	Wrong comparator
Shen 2017 (513)	Wrong comparator
Sheng 2019 (514)	Duplicate
Shewade 2013 (515)	Wrong intervention (non-fortified food)
Sigh 2018 (516)	Wrong intervention (non-fortified food)
Simondon 1996 (517)	Wrong population (aged > 23 months)
Simpore 2006 (518)	Wrong intervention (Spirulina, Misola)

Singh 2010 (519)	Wrong intervention (fortified cereal-milk
	supplement)
Skau 2013 (520)	Wrong comparator
Skau 2013 (521)	Wrong comparator
Skau 2015 (522)	Wrong comparator
Stephenson 2017 (523)	Wrong intervention (cowpea or common bean
	flour)
Stobaugh 2016 (524)	Wrong intervention (soy vs. way)
Stobaugh 2017 (525)	Wrong intervention (package of interventions)
Stookey 1967 (526)	Wrong population
Tampere 2006 (527)	Wrong comparator
Tampere 2008 (528)	Wrong comparator
Tano-Debrah 2019 (529)	Wrong study design
Tekale 2015 (530)	Wrong population (aged > 23 months)
Thakur 2016 (531)	Wrong intervention (foods with different
	composition)
Thakwalakwa 2010 (532)	Wrong intervention (corn-soy blend, Lipid-
	based nutrient supplements)
Thakwalakwa 2014 (533)	Wrong comparator
Tharrey 2017 (534)	Wrong intervention (behavioural)
TheMathileInstitutefortheAdvancementofHuma	Wrong comparator
n 2020 (535)	
Tondeur 2004 (536)	Wrong intervention (lipid-based nutrient
	supplement, MNP)
Traore 2005 (537)	Wrong intervention (non-fortified food)
Traore 2013 (538)	Wrong intervention (processed fortified flours
	wih dried milk and without milk, Misola)
Trehan 2015 (539)	Wrong comparator
Tufts 2014 (540)	Wrong comparator
Tufts 2017 (541)	Wrong comparator
Tufts 2017 (542)	Wrong comparator
Tufts 2018 (543)	Wrong comparator
vanderKam 2012 (544)	Wrong comparator

VanderWal 2018 (545)	Wrong intervention (aloe-enriched, whey
	protein drink)
VanHoan 2009 (546)	Wrong intervention (Favina and Favilase
	gruels)
Varea 2011 (547)	Wrong study design
Vega 2016 (548)	Wrong intervention (food supplements:
	Nutrisano, Vitanino)
Verkaik-Kloosterman 2017 (549)	Wrong study design
Verna (550)	Wrong comparator
Villanueva 2016 (551)	Wrong study design
Viseshakul 1979 (552)	Duplicate
Vray 2018 (553)	Wrong intervention (flour with prebiotic)
Vuongle 2002 (554)	Wrong population (aged > 23 months)
Walker 1996 (555)	Wrong intervention (home-fortification)
Wang 2013 (556)	Wrong comparator
Walter 1993 (557)	Wrong population (aged <6 months)
Whitfield 2016 (558)	Wrong population (aged > 23 months)
Whitfield 2017 (559)	Wrong population (aged > 23 months)
Whitfield 2016 (558)	Wrong population (aged > 23 months)
Westcott 2011 (560)	Wrong comparator
Women's 2010 (561)	Wrong comparator
Yeung 2000 (562)	Wrong comparator
Ying 1956 (563)	Wrong population (aged > 23 months)
Yu 2013 (564)	Wrong intervention (education and
	supplementation)
Yuliarti 2017 (565)	Wrong comparator
Zakaria 2019 (566)	Wrong intervention (formulas and Moringa
	Oleifera Leaf Powder)
Zakaria 2020 (567)	Wrong intervention (Moringa Oleifera Leaf
	Powder)
Zavaleta 2011 (568)	Wrong intervention (milk with protein)

Zhang 2016 (569)	Wrong intervention (food supplement+health
	education)
Zhichien 1956 (570)	Wrong intervention (fortification with lysine)
Ziegler 2009 (571)	Wrong comparator
Ziegler 2011 (572)	Wrong study design
Ziegler 2011 (25)	Wrong comparator
Zyba 2019 (573)	Wrong intervention (lipid-based nutrient
	supplement)

Appendix 6. DATA AND ANALYSES

Study or Subgroup	log[Risk Ratio]	SE	Fortified N Total	lon-fortified Total	Weight	Risk Ratio IV, Random, 95% CI		Risk IV, Rando	Ratio m, 95% Cl	
Arcanjo 2012 (C)	-0.6179	0.5253	96	92	11.2%	0.54 [0.19, 1.51]				
Arcanjo 2013 (C)	-1.2068	0.6915	72	70	6.9%	0.30 [0.08, 1.16]			-	
Bagni 2009 (C)	-0.3567	0.3284	180	174	22.9%	0.70 [0.37, 1.33]			-	
Ekoe 2020 (C)	-1.2967	0.5217	82	71	11.3%	0.27 [0.10, 0.76]				
Lartey 2000	-0.0967	0.2756	47	48	28.6%	0.91 [0.53, 1.56]				
Ma 2016 (C)	-0.8398	0.3742	140	133	19.1%	0.43 [0.21, 0.90]				
Total (95% CI)			617	588	100.0%	0.57 [0.39, 0.82]		•		
Heterogeneity: Tau² = Test for overall effect:	0.05; Chi² = 6.57 Z = 2.97 (P = 0.00	, df = 5 (F 03)	° = 0.25); I² =	= 24%			0.01	0.1 Favours fortified	10 Favours non-fort	100 ified

Analysis 1.1 Fortified versus non-fortified complementary food. Outcome: Anaemia

Analysis 1.2 Fortified versus non-fortified complementary food. Outcome: Anaemia by age at the

start of the intervention

			Fortified	Non-fortified		Risk Ratio	Risk Ratio					
Study or Subgroup	log[Risk Ratio]	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI					
1.2.1 6 to 11 months												
Lartey 2000	-0.0967	0.2756	47	48	28.6%	0.91 [0.53, 1.56]						
Ma 2016 (C)	-0.8398	0.3742	140	133	19.1%	0.43 [0.21, 0.90]	- _					
Subtotal (95% CI)			187	181	47.7%	0.65 [0.32, 1.35]						
Heterogeneity: Tau ² = 0.17; Chi ² = 2.56, df = 1 (P = 0.11); i ² = 61%												
Test for overall effect: Z = 1.15 (P = 0.25)												
1.2.2 12 to 23 months	S											
Arcanjo 2012 (C)	-0.6179	0.5253	96	92	11.2%	0.54 [0.19, 1.51]						
Arcanjo 2013 (C)	-1.2068	0.6915	72	70	6.9%	0.30 [0.08, 1.16]						
Subtotal (95% CI)			168	162	18.1%	0.43 [0.19, 0.99]	-					
Heterogeneity: Tau ² =	0.00; Chi ² = 0.46	df = 1 (P	= 0.50);1	²=0%								
Test for overall effect:	Z = 1.99 (P = 0.05	5)										
1.2.3 Mean age >23 r	nonths											
Bagni 2009 (C)	-0.3567	0.3284	180	174	22.9%	0.70 [0.37, 1.33]						
Ekoe 2020 (C)	-1.2967	0.5217	82	71	11.3%	0.27 [0.10, 0.76]						
Subtotal (95% CI)			262	245	34.2%	0.48 [0.19, 1.18]	\bullet					
Heterogeneity: Tau ² =	0.25; Chi ² = 2.33	df = 1 (P	= 0.13);1	²= 57%								
Test for overall effect:	Z = 1.60 (P = 0.11)										
							•					
Total (95% CI)			617	588	100.0%	0.57 [0.39, 0.82]	\bullet					
Heterogeneity: Tau ² =	0.05; Chi ² = 6.57	, df = 5 (P	= 0.25);1	2 =24%								
Test for overall effect:	Z = 2.97 (P = 0.00)3)					Eavours fortified Eavours non-fortified					
Test for subgroup diff	'erences: Chi² = 0	.60, df = 2	? (P = 0.74	4), I² = 0%								

Analysis 1.3 Fortified versus non-fortified complementary food. Outcome: Anaemia by types of

nutrients added through fortification

		F	ortified	Non-fortified		Risk Ratio	Risk Ratio
Study or Subgroup	log[Risk Ratio]	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.3.1 Iron							
Arcanjo 2012 (C)	-0.6179	0.5253	96	92	11.2%	0.54 [0.19, 1.51]	
Arcanjo 2013 (C)	-1.2068	0.6915	72	70	6.9%	0.30 [0.08, 1.16]	
Bagni 2009 (C)	-0.3567	0.3284	180	174	22.9%	0.70 [0.37, 1.33]	
Ekoe 2020 (C)	-1.2967	0.5217	82	71	11.3%	0.27 [0.10, 0.76]	
Subtotal (95% CI)			430	407	52.3%	0.50 [0.32, 0.79]	◆
Heterogeneity: Tau² =	: 0.00; Chi ^z = 2.96	, df = 3 (P	= 0.40); P	²=0%			
Test for overall effect:	Z = 2.97 (P = 0.00)	03)					
1.3.2 Iron, zinc, vitar	nin B12						
Ma 2016 (C)	-0.8398	0.3742	140	133	19.1%	0.43 (0.21, 0.90)	_ _
Subtotal (95% CI)			140	133	19.1%	0.43 [0.21, 0.90]	◆
Heterogeneity: Not as	pplicable						-
Test for overall effect:	Z = 2.24 (P = 0.02	2)					
1.3.3 Multivitamins a	nd minerals						
Lartev 2000	-0.0967	0.2756	47	48	28.6%	0.91 (0.53, 1.56)	
Subtotal (95% CI)			47	48	28.6%	0.91 [0.53, 1.56]	•
Heterogeneity: Not ap	pplicable						
Test for overall effect:	Z = 0.35 (P = 0.73	3)					
		·					
Total (95% CI)			617	588	100.0%	0.57 [0.39, 0.82]	◆
Heterogeneity: Tau ² =	: 0.05; Chi ² = 6.57	, df = 5 (P	= 0.25); P	²= 24%			
Test for overall effect:	Z = 2.97 (P = 0.00)3)					Eavours fortified Eavours non-fortified
Test for subaroup dif	ferences: Chi ² = 3	.61. df = 2	(P = 0.16)	i), ² = 44.7%			r avours foruneu - Favours fformeu

Analysis 1.4 Fortified versus non-fortified complementary food. Outcome: Anaemia by types of

products fortified

		1	ortified	Non-fortified		Risk Ratio	Risk Ratio
Study or Subgroup	log[Risk Ratio]	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.4.1 Wheat							
Ekoe 2020 (C)	-1.2967	0.5217	82	71	11.3%	0.27 [0.10, 0.76]	
Subtotal (95% CI)			82	71	11.3%	0.27 [0.10, 0.76]	
Heterogeneity: Not ap	plicable						
Test for overall effect:	Z = 2.49 (P = 0.01	I)					
1.4.2 Rice							
Arcanjo 2012 (C)	-0.6179	0.5253	96	92	11.2%	0.54 [0.19, 1.51]	
Arcanjo 2013 (C)	-1.2068	0.6915	72	70	6.9%	0.30 [0.08, 1.16]	
Bagni 2009 (C)	-0.3567	0.3284	180	174	22.9%	0.70 [0.37, 1.33]	
Ma 2016 (C)	-0.8398	0.3742	140	133	19.1%	0.43 [0.21, 0.90]	
Subtotal (95% CI)			488	469	60.1%	0.53 [0.35, 0.80]	•
Heterogeneity: Tau² =	: 0.00; Chi² = 1.70	, df = 3 (P	= 0.64); i	²=0%			
Test for overall effect:	Z = 2.99 (P = 0.00)3)					
1.4.3 Cereal-legume	blend						
Lartey 2000	-0.0967	0.2756	47	48	28.6%	0.91 [0.53, 1.56]	
Subtotal (95% CI)			47	48	28.6%	0.91 [0.53, 1.56]	-
Heterogeneity: Not ap	plicable						
Test for overall effect:	Z = 0.35 (P = 0.73	3)					
Total (05% CI)			617	599	100.0%	0 57 [0 30 0 92]	
Iotal (95% Cl)	0.05.052-0.57	-16 - 5 (D	- 0.2617	000 - 040/	100.0%	0.57 [0.59, 0.62]	
Heterogeneity, Tau-=	: 0.05; Chi= 6.57	, ui = 5 (P	= 0.25); (-= 24%			0.01 0.1 i 10 100
Test for overall effect:	Z = 2.97 (P = 0.00	13) 13) - 16 - 2	(D 0.0)				Favours fortified Favours non-fortified
iest for subgroup all	erences: Chi* = 4	.87, dt = 2	(P = 0.0)	9), in = 58.9%			

Analysis 1.5 Fortified versus non-fortified complementary food. Outcome: Anaemia by duration of

intervention

				Fortified	Non-fortified		Risk Ratio		Risk Ratio		
	Study or Subgroup	log[Risk Ratio]	SE	Total	Total	Weight	IV, Random, 95% CI		IV, Random, 95	5% CI	
Î	1.5.1 Less than 6 mo	nths									
	Arcanjo 2012 (C)	-0.6179	0.5253	96	92	11.2%	0.54 [0.19, 1.51]				
	Arcanjo 2013 (C)	-1.2068	0.6915	72	70	6.9%	0.30 [0.08, 1.16]				
	Subtotal (95% CI)			168	162	18.1%	0.43 [0.19, 0.99]				
	Heterogeneity: Tau ² =	0.00; Chi ² = 0.46,	df = 1 (l	P = 0.50); l	²=0%						
	Test for overall effect:	Z = 1.99 (P = 0.05	j)								
	1.5.2 Six months or n	nore									
	Bagni 2009 (C)	-0.3567	0.3284	180	174	22.9%	0.70 [0.37, 1.33]				
	Ekoe 2020 (C)	-1.2967	0.5217	82	71	11.3%	0.27 [0.10, 0.76]				
	Lartey 2000	-0.0967	0.2756	47	48	28.6%	0.91 [0.53, 1.56]				
	Ma 2016 (C)	-0.8398	0.3742	140	133	19.1%	0.43 [0.21, 0.90]				
	Subtotal (95% CI)			449	426	81.9%	0.59 [0.36, 0.94]		•		
	Heterogeneity: Tau ² =	0.10; Chi ² = 5.44,	df = 3 (l	P = 0.14); I	²= 45%						
	Test for overall effect:	Z = 2.21 (P = 0.03	3)								
	Total (95% CI)			617	588	100.0%	0.57 [0.39, 0.82]		•		
	Heterogeneity: Tau ² =	0.05; Chi ² = 6.57,	df = 5 (l	P = 0.25); I	²= 24%						<u> </u>
	Test for overall effect:	Z = 2.97 (P = 0.00)3)	/1				0.01	U.1 1 Fouriers fortified	10	100
	Test for subgroup diff	erences: Chi² = 0.	38. df=	1 (P = 0.54	4), I² = 0%				Favours fortilled Favo	Juis non-torune	u

Analysis 1.6 Fortified versus non-fortified complementary food. Outcome: Anaemia by baseline

anaemia status

			Fortified	Non-fortified		Risk Ratio	Risk Ratio
Study or Subgroup	log[Risk Ratio]	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
1.6.1 Anaemic							
Ekoe 2020 (C)	-1.2967	0.5217	82	71	11.3%	0.27 [0.10, 0.76]	
Subtotal (95% CI)			82	71	11.3%	0.27 [0.10, 0.76]	
Heterogeneity: Not a	oplicable						
Test for overall effect	Z = 2.49 (P = 0.01	1)					
4.0.0.1							
1.6.2 Non-anaemic						Net estimable	
Subtotal (95% CI)			0	0		Not estimable	
Heterogeneity: Not ap	oplicable						
lest for overall effect	Not applicable						
1.6.3 Mixed							
Arcanjo 2012 (C)	-0.6179	0.5253	96	92	11.2%	0.54 [0.19, 1.51]	
Arcanjo 2013 (C)	-1.2068	0.6915	72	70	6.9%	0.30 [0.08, 1.16]	
Bagni 2009 (C)	-0.3567	0.3284	180	174	22.9%	0.70 [0.37, 1.33]	
Lartey 2000	-0.0967	0.2756	47	48	28.6%	0.91 [0.53, 1.56]	
Ma 2016 (C)	-0.8398	0.3742	140	133	19.1%	0.43 [0.21, 0.90]	
Subtotal (95% CI)			535	517	88.7%	0.64 [0.46, 0.90]	•
Heterogeneity: Tau² =	= 0.00; Chi ² = 4.10	, df = 4 (F	? = 0.39); F	²= 2%			
Test for overall effect	Z = 2.56 (P = 0.01	1)					
Total (95% CI)			617	588	100.0%	0.57 [0.39, 0.82]	•
Heterogeneity: Tau ² =	= 0.05; Chi ² = 6.57	, df = 5 (F	e = 0.25); P	²= 24%			
Test for overall effect	Z = 2.97 (P = 0.00	03)					Eavours fortified Eavours non-fortified
Test for subgroup dif	ferences: Chi ^z = 2	.44, df = 1	1 (P = 0.12	:), I² = 59.0%			

Analysis 1.7 Fortified versus non-fortified complementary food. Outcome: Anaemia by country

income classification

Study of Sub-		Fortified	Non-fortified	147-1-1-4	Risk Ratio	Risk Ratio	
Study of Subgroup log(R	ISK Ratioj	SE Total	lotal	weight	IV, Random, 95% CI	IV, Random, 95% CI	_
Subtotal (95% CI)		0	0		Not estimable		
Heterogeneity: Not applicabl	e				not oodindbio		
Test for overall effect: Not ap	plicable						
1.7.2 Upper middle income							
Ekoe 2020 (C)	-1.2967 0.5	217 82	71	11.3%	0.27 [0.10, 0.76]		
Subtotal (95% CI)	-	82	/1	11.3%	0.27 [0.10, 0.76]		
Teet for everall effect: 7 = 2.4	IE IO /D = 0.043						
restior overall ellect. Z = 2.4	is (F = 0.01)						
1.7.3 Lower middle income							
Arcanjo 2012 (C)	-0.6179 0.5	253 96	92	11.2%	0.54 [0.19, 1.51]		
Arcanjo 2013 (C)	-1.2068 0.6	915 72	70	6.9%	0.30 [0.08, 1.16]		
Bagni 2009 (C)	-0.3567 0.3	284 180	174	22.9%	0.70 [0.37, 1.33]		
Lartey 2000	-0.0967 0.2	756 47	48	28.6%	0.91 [0.53, 1.56]		
Ma 2016 (C)	-0.8398 0.3	742 140	133	19.1%	0.43 [0.21, 0.90]		
Subtotal (95% CI)		535	517	88.7%	0.64 [0.46, 0.90]	•	
Heterogeneity: Tau ² = 0.00; (Chi ² = 4.10, df =	= 4 (P = 0.39); I	* = 2%				
Test for overall effect: $Z = 2.5$	66 (P = 0.01)						
1.7.4 Low income							
Subtotal (95% CI)		0	0		Not estimable		
Heterogeneity: Not applicabl	le						
Test for overall effect: Not ap	plicable						
Total (05% CI)		647	500	100.0%	0.57 [0.30, 0.93]		
Hotorogonoity: $Tou^2 = 0.05$		6 /D = 0.25\-1	000 8- 0400	100.0%	0.07 [0.09, 0.02]	▼	
Toet for overall effect: 7 = 2.0	Unit = 0.07, 01= 17 /P = 0.002)	- 5 (F = 0.25); I	- 2470			'0.01 0.1 i 1'0 100'	
Test for subgroup difference	s: Chi ² = 2.44.	2), ² = 59.0%			Favours fortified Favours non-fortified		

Analysis 1.8 Fortified versus non-fortified complementary food. Outcome: Anaemia by study

funding

			Fortified	Non-fortified		Risk Ratio	Risk Ratio
Study or Subgroup	log[Risk Ratio]	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.8.1 Non-commerci	al						
Arcanjo 2012 (C)	-0.6179	0.5253	96	92	11.2%	0.54 [0.19, 1.51]	
Arcanjo 2013 (C)	-1.2068	0.6915	72	70	6.9%	0.30 [0.08, 1.16]	
Bagni 2009 (C)	-0.3567	0.3284	180	174	22.9%	0.70 [0.37, 1.33]	
Ma 2016 (C)	-0.8398	0.3742	140	133	19.1%	0.43 [0.21, 0.90]	
Subtotal (95% CI)			488	469	60.1%	0.53 [0.35, 0.80]	◆
Heterogeneity: Tau ² =	: 0.00; Chi ² = 1.70	, df = 3 (F	2 = 0.64); P	²=0%			
Test for overall effect:	Z = 2.99 (P = 0.00)3)					
1.8.2 Commercial (pa	artly or fully)						
Ekoe 2020 (C)	-1.2967	0.5217	82	71	11.3%	0.27 (0.10, 0.76)	
Lartev 2000	-0.0967	0.2756	47	48	28.6%	0.91 [0.53, 1.56]	_ _ _
Subtotal (95% CI)			129	119	39.9%	0.54 [0.17, 1.73]	
Heterogeneity: Tau ² =	: 0.55; Chi ² = 4.14	. df = 1 (F	P = 0.04); P	²= 76%			
Test for overall effect:	Z = 1.03 (P = 0.30))					
		·					
Total (95% CI)			617	588	100.0%	0.57 [0.39, 0.82]	◆
Heterogeneity: Tau ² =	0.05; Chi ² = 6.57	, df = 5 (F	^e = 0.25); P	²= 24%			
Test for overall effect:	Z = 2.97 (P = 0.00)3)					U.UI U.I I 10 100 Eavours fortified Eavours pop-fortified
Test for subgroup diff	avours formed Favours formed						

1.9 Fortified versus non-fortified complementary food. Outcome: Haemoglobin (g/L)

			Fortified	Non-fortified		Mean Difference	Mean Difference
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
Arcanjo 2012 (C)	3.1	4.9266	96	92	3.9%	3.10 [-6.56, 12.76]	-
Arcanjo 2013 (C)	5.9	5.0181	72	70	3.8%	5.90 [-3.94, 15.74]	
Bagni 2009 (C)	2.4	2.3479	180	174	10.5%	2.40 [-2.20, 7.00]	-+
Ekoe 2020 (C)	3.4	4.6812	82	71	4.2%	3.40 [-5.77, 12.57]	
Faber 2005	9	1.4902	144	142	15.0%	9.00 [6.08, 11.92]	
Lartey 2000	4	4.3191	47	48	4.8%	4.00 [-4.47, 12.47]	
Liu 1993 (C)	2.1	1.6469	77	85	14.1%	2.10 [-1.13, 5.33]	+
Ma 2016 (C)	2.1	1.4917	140	133	14.9%	2.10 [-0.82, 5.02]	+
Nesamvuni 2005	9	7.6844	16	20	1.8%	9.00 [-6.06, 24.06]	
Quintero 2011	0.9	1.0466	195	200	17.5%	0.90 [-1.15, 2.95]	
Schumann 2005	2.48	2.5441	61	30	9.6%	2.48 [-2.51, 7.47]	
Total (95% CI)			1110	1065	100.0%	3.44 [1.33, 5.55]	◆
Heterogeneity: Tau ² =	5.50; Chi ² = 22.00,	df = 10 (F	e = 0.02); I	I ² = 55%			
Test for overall effect:	Z = 3.20 (P = 0.001)					-20 -10 0 10 20 Favours non-fortified Favours fortified

1.10 Fortified versus non-fortified complementary food. Outcome: Haemoglobin by age at the start

of the intervention

		I	ortified	Non-fortified		Mean Difference	Mean Difference				
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI				
1.10.1 6 to 11 months	\$										
Faber 2005	9	1.4902	144	142	15.0%	9.00 [6.08, 11.92]					
Lartey 2000	4	4.3191	47	48	4.8%	4.00 [-4.47, 12.47]					
Liu 1993 (C)	2.1	1.6469	77	85	14.1%	2.10 [-1.13, 5.33]	+				
Ma 2016 (C)	2.1	1.4917	140	133	14.9%	2.10 [-0.82, 5.02]	+				
Subtotal (95% CI)			408	408	48.7%	4.37 [0.39, 8.35]	\bullet				
Heterogeneity: Tau ² = 11.90; Chi ² = 13.84, df = 3 (P = 0.003); i ² = 78%											
Test for overall effect:	Z = 2.15 (P = 0.03)										
1.10.2 12 to 23 month	15										
Arcanjo 2012 (C)	3.1	4.9266	96	92	3.9%	3.10 [-6.56, 12.76]					
Arcanjo 2013 (C)	5.9	5.0181	72	70	3.8%	5.90 [-3.94, 15.74]					
Nesamvuni 2005	9	7.6844	16	20	1.8%	9.00 [-6.06, 24.06]					
Quintero 2011	0.9	1.0466	195	200	17.5%	0.90 [-1.15, 2.95]					
Schumann 2005	2.48	2.5441	61	30	9.6%	2.48 [-2.51, 7.47]					
Subtotal (95% CI)			440	412	36.6%	1.48 [-0.34, 3.29]	•				
Heterogeneity: Tau ² =	0.00; Chi ² = 2.30, d	f=4 (P=	0.68); l² =	:0%							
Test for overall effect:	Z = 1.59 (P = 0.11)										
1.10.3 Mean age > 23	months										
Bagni 2009 (C)	2.4	2 3479	180	174	10.5%	2 40 62 20 7 001					
Ekge 2020 (C)	3.4	4 6812	82	71	4 2%	3 40 [-5 77 12 57]					
Subtotal (95% CI)	0.4	4.0012	262	245	14.7%	2.60 [-1.51, 6.71]	★				
Heterogeneity: Tau ² =	0.00° Chi ² = 0.04 d	f = 1 (P =	0.85): I ? =	: N%			-				
Test for overall effect:	7 = 1.24 (P = 0.22)		0.00/,1	•							
	,										
Total (95% CI)			1110	1065	100.0%	3.44 [1.33, 5.55]	◆				
Heterogeneity: Tau ² =	5.50; Chi ² = 22.00.	df = 10 (P	= 0.02); [P = 55%							
Test for overall effect:	Z = 3.20 (P = 0.001)	//				-20 -10 0 10 20				
Test for subgroup diff	erences: Chi ² = 1.7	6. df = 2. (F	e = 0.42).	I ² = 0%			Favours non-toruned Favours fortified				

1.11 Fortified versus non-fortified complementary food. Outcome: Haemoglobin by types of

nutrients added through fortification

Study or Subgroup Mean Difference SE Total Total Total Total Total Total Nu length Nu len				Fortified I	Non-fortified		Mean Difference	Mean Difference
1.11.1 into Arcanic 2012 (C) 3.1 4.9266 96 92 3.9% 3.10 [6.56, 12.76] Arcanic 2013 (C) 5.9 5.0181 72 70 3.8% 5.90 [5.34, 15.74] Bagni 2003 (C) 2.4 2.4373 180 174 10.5% 2.40 [2.20, 7.00] Exoc 2020 (C) 3.4 4.6812 82 71 4.2% 3.40 [5.77, 12.77] Subtotal (95% C1) 491 437 32.0% 2.89 [0.01, 5.77] Heterogeneity. Nat applicable rest for overall effect Z = 1.80 (P = 0.05) 140 133 14.9% 2.10 [-0.82, 5.02] 1.11.4 iron, zinc, vitamin B12 Ma 2015 (C) 2.1 1.4917 140 133 14.9% 2.10 [-0.82, 5.02] 1.11.4 iron, zinc, vitamin A, niacin, folic acid Ouintero 2011 0.9 1.0.66 195 200 17.5% 0.90 [-1.15, 2.95] Subtotal (95% C1) 0.9 1.0.66 195 200 17.5% 0.90 [-6.06, 24.06] Subtotal (95% C1) 0.8 1.6 20 1.8% 9.00 [-6.06, 24.06] Subtotal (95% C1) 1.4493 1.6 <td>Study or Subgroup</td> <td>Mean Difference</td> <td>SE</td> <td>Total</td> <td>Total</td> <td>Weight</td> <td>IV, Random, 95% Cl</td> <td>IV, Random, 95% Cl</td>	Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Arcano 2012 (C) 3.1 4.9266 96 92 3.9% 3.10 [+0.5b, 12.76] Arcano 2013 (C) 5.9 5.0161 72 70 3.9% 5.90 [:3.44, 15.74] Bagni 2009 (C) 2.4 2.3479 180 174 10.5% 2.40 [:2.07, 70] Ekce 2020 (C) 3.4 4.6812 82 71 4.2% 3.40 [:5.77, 12.57] Subtotal (95% CI) 491 437 32.0% 2.89 [0.01, 5.77] Heterogeneity: Tau ² = 0.00; Chi ² = 0.44, df = 4 (P = 0.98); P = 0% Test for overall effect Z = 1.90 (P = 0.05) 1.11.4 Iron, zinc, vitamin B12 Ma 2016 (C) 2.1 1.4917 140 133 14.9% 2.10 [-0.82, 5.02] Subtotal (95% CI) 10 1046 195 200 17.5% 0.90 [-1.15, 2.95] 1.11.6 Iron, zinc, vitamin A, niacin, folic acid Guintero 2011 0.9 1.0466 195 200 17.5% 0.90 [-1.15, 2.95] 1.11.7 Vitamin A, thiamine, riboflavin, pyridoxine Nesarroul 2005 9 7.6844 16 20 1.8% 9.00 [-6.06, 24.06] Subtotal (95% CI) 1 1490 144 142 15.0% 9.00 [-6.06, 24.06] Subtotal (95% CI) 2 11 1.689 77 85 14.1% 2.10 [-1.15, 5.39] Heterogeneity: Not applicable Test for overall effect Z = 1.17 (P = 0.24) 1.11.8 Multivitamins and minerals Faber 2005 9 1.4902 144 142 15.0% 9.00 [-6.06, 24.06] Subtotal (95% CI) 2 268 275 33.8% 5.26 [-0.07, 10.59] Heterogeneity: Tau ² = 5.50, Chi ² = 9.83, df = 2 (P = 0.007); I ² = 60% Test for overall effect Z = 1.93 (P = 0.05) Total (95% CI) 1 110 1065 100.0% 3.44 [1.33, 5.55] Heterogeneity: Tau ² = 5.50, Chi ² = 22.00, df = 10 (P = 0.02); I ² = 55% Test for overall effect Z = 3.20 (P = 0.001) Total (95% CI) 1110 1065 100.0% 3.44 [1.33, 5.55] Heterogeneity: Tau ² = 5.50, Chi ² = 22.00, df = 10 (P = 0.02); I ² = 55% Test for overall effect Z = 3.20 (P = 0.001) Total (95% CI) 100 1110 1065 100.0% 3.44 [1.33, 5.55] Heterogeneity: Tau ² = 5.50, Chi ² = 22.00, df = 10 (P = 0.02); I ² = 55% Test for overall effect Z = 3.20 (P = 0.001) Test for subrotal effect Z = 3.20 (P = 0.001) Test for subrotal effect Z = 3.20 (P = 0.001) Test for subrotal effect Z = 3.20 (P = 0.001) Test for subrota diffect Chi ² = 3.40, df = 4 (P = 0.44), P = 0%	1.11.1 Iron							
Arcan(2013 (C) 5.9 5.0181 1/2 (70 3.8% 5.90 (3.34, 12.84) Bagn 2005 (C) 2.4 2.3476 180 174 10.5% 2.40 (5.2.0, 7.00) Exoc 2020 (C) 3.4 4.6812 82 71 4.2% 3.40 (5.7.7, 12.5.7) Schurnan 2005 2.48 2.5441 61 30 9.6% 2.44 (J.2.5.1, 7.7) Heterogeneity: Tau ² = 0.00; Ch ² = 0.44, df = 4 (P = 0.98); P = 0% Test for overall effect Z = 1.96 (P = 0.05) 1.11.4 Iron, zinc, vitamin B12 Ma 2016 (C) 2.1 1.4917 140 133 14.9% 2.10 [-0.82, 5.02] Subtotal (95% C) 140 133 14.9% 2.10 [-0.82, 5.02] Heterogeneity: Not applicable Test for overall effect Z = 1.41 (P = 0.16) 1.11.6 Iron, zinc, vitamin A, niacin, folic acid Ouintero 2011 0.9 1.0466 195 200 17.5% 0.90 [-1.15, 2.95] Heterogeneity: Not applicable Test for overall effect Z = 0.86 (P = 0.39) 1.11.7 Vitamin A, thiamine, riboffavin, pyridoxine Nesamvuni 2005 9 7.6844 16 20 1.8% 9.00 [-6.06, 24.06] Subtotal (95% C) 9 7.6844 16 20 1.8% 9.00 [-6.06, 24.06] Heterogeneity: Not applicable Test for overall effect Z = 1.17 (P = 0.24) 1.11.8 Mutivitamins and minerals Faber 2005 9 1.4902 144 142 15.0% 9.00 [-6.06, 24.06] Heterogeneity: Tau ² = 16.28; ChP = 9.83, df = 2 (P = 0.007); P = 60% Test for overall effect Z = 1.93 (P = 0.05) Total (95% C) 15 0 110 268 275 3.8% 5.26 [-0.07, 10.59] Heterogeneity: Tau ² = 15.20; ChP = 2.20, df = 10 (P = 0.02); P = 55% Test for overall effect Z = 1.93 (P = 0.001) Total (95% C) 10 1110 1065 100.0% 3.44 [1.33, 5.55] Heterogeneity: Tau ² = 5.50; ChP = 2.20, df = 10 (P = 0.44), P = 0%	Arcanjo 2012 (C)	3.1	4.9266	96	92	3.9%	3.10 [-6.56, 12.76]	
Begin 2009 (C) 2.4 2.3479 180 174 10.5% 2.40 (F2.0.100) Ekce 2020 (C) 3.4 4.8612 82 71 4.2% 3.40 (F2.7, 12.57) Schumann 2005 2.48 2.5441 61 30 9.6% 2.48 (F2.51, 7.47) Subtota (95% C) 491 437 32.0% 2.89 (0.01, 5.77) Heterogeneity: Tau ² = 0.00; Ch ² = 0.44, df = 4 (P = 0.98); P = 0% Test for overall effect Z = 1.96 (P = 0.05) 1.11.4 Fron, zinc, vitamin B12 Ma 2016 (C) 2.1 1.4917 140 133 14.9% 2.10 [-0.82, 5.02] Heterogeneity: Not applicable Test for overall effect Z = 1.41 (P = 0.16) 1.11.6 Fron, zinc, vitamin A, niacin, folic acid Quintero 2011 0.9 1.0466 195 200 17.5% 0.90 [-1.15, 2.95] Subtota (95% C) 1.9 10.466 195 200 17.5% 0.90 [-1.15, 2.95] Heterogeneity: Not applicable Test for overall effect Z = 0.86 (P = 0.39) 1.11.7 Vitamin A, thiamine, riboflavin, pyridoxine Nesarrwull 2005 9 7.6844 16 20 1.8% 9.00 [6.06, 24.06] Subtota (95% C) 1.11.6469 77 85 14.13% 2.10 [-1.13, 5.33] Subtota (95% C) 2.1 1.6469 77 85 14.13% 2.10 [-1.13, 5.33] Subtota (95% C) 2.1 1.6469 77 85 14.13% 2.10 [-1.13, 5.33] Subtota (95% C) 2.1 1.6469 77 85 14.13% 2.10 [-1.13, 5.33] Subtota (95% C) 1.0 110 1065 100.0% 3.44 [1.33, 5.55] Heterogeneity: Tau ² = 15.28; Chi ² = 9.0.07); P = 60% Test for overall effect Z = 1.93 (P = 0.02); P = 55% Total (95% C) 1.0 110 1065 100.0% 3.44 [1.33, 5.55] Heterogeneity: Tau ² = 5.50; Chi ² = 2.20, df = 10 (P = 0.02); P = 55% Test for overall effect Z = 3.20 (P = 0.001) Total (95% C) 1.0 110 1065 100.0% 3.44 [1.33, 5.55] Heterogeneity: Tau ² = 5.50; Chi ² = 2.20, df = 10 (P = 0.44), P = 0%	Arcanjo 2013 (C) Domi 2000 (O)	5.9	5.0181	12	70	3.8%	5.90 [-3.94, 15.74]	
Extrema 2020 (C) 3.4 + 10012 52 71 + 1.2 x 2.3 + 2.48 [2.51, 7.47] Subtotal (95% C) 2.48 [2.51, 7.47] Subtotal (95% C) 449 4 451 457 32.0% 2.48 [2.51, 7.47] Heterogeneity: Tau" = 0.00; Chi" = 0.44, df = 4 (P = 0.98); P = 0% Test for overall effect. Z = 1.96 (P = 0.05) 1.11.4 iron, zinc, vitamin B12 Ma 2016 (C) 2.1 1.4917 140 133 14.9% 2.10 [-0.82, 5.02] Heterogeneity: Not applicable Test for overall effect. Z = 1.41 (P = 0.16) 1.11.6 iron, zinc, vitamin A, niacin, folic acid Quinter 2011 0.9 1.0466 195 200 17.5% 0.90 [-1.15, 2.95] Subtotal (95% C) 197.6844 16 20 1.8% 9.00 [-6.06, 24.06] Heterogeneity: Not applicable Test for overall effect. Z = 1.07 (P = 0.24) 1.11.8 Multivitamins and minerals Faber 2005 9 1.4902 144 142 15.0% 9.00 [-6.06, 24.06] Heterogeneity: Tau" = 16.29; Chi" = 9.83, df = 2 (P = 0.007); P = 80% Test for overall effect. Z = 1.33 (P = 0.005) Total (95% C) 110 100 1005 100.0% 3.44 [1.33, 5.55] Heterogeneity: Tau" = 16.29; Chi" = 9.23, 0f = 2 (P = 0.007); P = 80% Test for overall effect. Z = 1.33 (P = 0.005) Total (95% C) 101 100 1005 100.0% 3.44 [1.33, 5.55] Heterogeneity: Tau" = 16.29; Chi" = 2.20, 0f = 10 (P = 0.007); P = 56% Test for overall effect. Z = 3.20 (P = 0.007); P = 56% Test for overall effect. Z = 3.20 (P = 0.007); P = 56% Test for overall effect. Z = 3.20 (P = 0.007); P = 56% Test for overall effect. Z = 3.20 (P = 0.007); P = 56% Test for overall effect. Z = 3.20 (P = 0.007); P = 56% Test for overall effect. Z = 3.20 (P = 0.007); P = 56% Test for overall effect. Z = 3.20 (P = 0.007); P = 56% Test for overall effect. Z = 3.20 (P = 0.007); P = 56% Test for overall effect. Z = 3.20 (P = 0.007); P = 56% Test for overall effect. Z = 3.20 (P = 0.007); P = 56% Test for overall effect. Z = 3.20 (P = 0.007); P = 56% Test for overall effect. Z = 3.20 (P = 0.007); P = 56% Test for overall effect. Z = 3.20 (P = 0.007); P = 56% Test for overall effect. Z = 3.20 (P = 0.007); P = 56% Test for overall effect. Z = 3.20 (P = 0.007); P = 56% Test for overall e	Ekoo 2020 (C)	2.4	2.3479	100	174	10.0%	2.40 [-2.20, 7.00]	
$\begin{array}{c} \text{Subtotal (PS% C)} & 2.40 \ 2.44, \text{ dr} = 4 \ (P = 0.98); P = 0\% \\ \text{Testfor overall effect } Z = 1.96 \ (P = 0.05) \\ \hline 1.114 \ \text{Iron, zinc, vitamin B12} \\ \text{Ma 2016 (C)} & 2.1 \ 1.4917 \ 140 \\ \text{133} \ 14.9\% \\ 2.10 \ [-0.82, 5.02] \\ \text{Heterogeneity. Not applicable} \\ \text{Test for overall effect } Z = 1.41 \ (P = 0.16) \\ \hline 1.11.6 \ \text{Iron, zinc, vitamin A, niacin, folic acid} \\ \text{Quintero 2011} & 0.9 \ 1.0466 \ 195 \\ \text{Subtotal (95\% C)} & 195 \ 200 \ 17.5\% \\ \text{Outpot (95\% C)} & 0.90 \ [-1.15, 2.95] \\ \text{Heterogeneity. Not applicable} \\ \text{Test for overall effect } Z = 0.66 \ (P = 0.39) \\ \hline 1.11.7 \ \text{Vitamin A, thiamine, riboflavin, pyridoxine} \\ \text{Nesamvuni 2005} & 9 \ 7.6844 \ 16 \ 20 \ 1.8\% \ 9.00 \ [-6.06, 24.06] \\ \text{Subtotal (95\% C)} & 1.4902 \ 1444 \ 142 \ 15.0\% \ 9.00 \ [-6.06, 24.06] \\ \text{Heterogeneity. Not applicable} \\ \text{Test for overall effect } Z = 1.17 \ (P = 0.24) \\ \hline 1.11.8 \ \text{Multivitamins and minarals} \\ \text{Faber 2005} & 9 \ 1.4902 \ 1444 \ 142 \ 15.0\% \ 9.00 \ [-6.06, 24.06] \\ \text{Subtotal (95\% C)} & 2.11 \ 1.6469 \ 77 \ 85 \ 14.1\% \ 2.10 \ [-1.15, 2.35] \\ \text{Heterogeneity. Tau" = 16.28; ChP = 9.83, df = 2 \ (P = 0.007); P = 80\% \\ \text{Test for overall effect } Z = 1.39 \ (P = 0.005) \\ \hline \text{Total (95\% C)} & 110 \\ \text{Heterogeneity. Tau" = 16.28; ChP = 9.83, df = 2 \ (P = 0.007); P = 55\% \\ \text{Test for overall effect } Z = 3.20 \ (P = 0.007); P = 55\% \\ \text{Test for overall effect } Z = 1.39 \ (P = 0.005) \\ \hline \text{Total (95\% C)} & 110 \\ \text{Heterogeneity. Tau" = 5.50; ChP = 22.00, df = 10 \ (P = 0.02); P = 55\% \\ \text{Test for overall effect } Z = 3.20 \ (P = 0.007); P = 55\% \\ \text{Test for overall effect } Z = 3.20 \ (P = 0.007); P = 55\% \\ \text{Test for overall effect } Z = 3.20 \ (P = 0.007); P = 55\% \\ \text{Test for overall effect } Z = 3.20 \ (P = 0.007); P = 55\% \\ \text{Test for overall effect } Z = 3.20 \ (P = 0.007); P = 55\% \\ \text{Test for overall effect } Z = 3.20 \ (P = 0.007); P = 55\% \\ \text{Test for overall effect } Z = 3.20 \ (P = 0.007); P = 55\% \\ \text{Test for overall effect } Z = 3.33 \ (P = 0.05) \\ \hline Test for $	Schumann 2005	3.4 2.49	2.64.41	61	30	4.270	2 49 [-3.77, 12.37] 2 49 [-2.51, 7.47]	_
Heterogeneity: Tau ² = 0.00; Ch ² = 0.44, df = 4 (P = 0.98); P = 0% Testfor overall effect Z = 1.96 (P = 0.05) 1.11.4 Iron, zinc, vitamin B12 Ma 2016 (C) 2.1 1.4917 140 133 14.9% 2.10 [-0.82, 5.02] Subtotal (95% C) 140 133 14.9% 2.10 [-0.82, 5.02] Heterogeneity: Not applicable Testfor overall effect Z = 1.41 (P = 0.16) 1.11.6 Iron, zinc, vitamin A, niacin, folic acid Quintero 2011 0.9 1.0466 195 200 17.5% 0.90 [-1.15, 2.95] Subtotal (95% C) 195 200 17.5% 0.90 [-1.15, 2.95] Heterogeneity: Not applicable Testfor overall effect Z = 0.86 (P = 0.39) 1.11.7 Vitamin A, thiamine, riboflavin, pyridoxine Nesamvuni 2005 9 7.6844 16 20 1.8% 9.00 [6.66, 24.06] Heterogeneity: Not applicable Testfor overall effect Z = 1.17 (P = 0.24) 1.11.8 Multivitamins and minerals Faber 2005 9 1.4902 144 142 15.0% 9.00 [6.08, 11.92] Laftey 2000 4 4 .3191 47 48 4.8% 4.00 [4.47, 12.47] Lui 1933 (C) 2.1 1.6469 77 85 14.1% 2.10 [-1.13, 5.33] Subtotal (95% C) 1110 165 100.0% 3.44 [1.33, 5.55] Heterogeneity: Tau ² = 5.50; Chi ² = 22.00, df = 10 (P = 0.02); P = 55% Testfor overall effect Z = 1.93 (P = 0.007); P = 80% Testfor overall effect Z = 3.20 (P = 0.007); P = 60% Testfor overall effect Z = 3.20 (P = 0.007); P = 65% Testfor overall effect Z = 3.20 (P = 0.007); P = 65% Testfor overall effect Z = 3.20 (P = 0.007); P = 65% Testfor overall effect Z = 3.20 (P = 0.007); P = 65% Testfor overall effect Z = 3.20 (P = 0.007); P = 65% Testfor overall effect Z = 3.20 (P = 0.007); P = 65% Testfor overall effect Z = 3.20 (P = 0.007); P = 65% Testfor overall effect Z = 3.20 (P = 0.007); P = 65% Testfor overall effect Z = 3.20 (P = 0.007); P = 65% Testfor overall effect Z = 3.20 (P = 0.007); P = 65% Testfor overall effect Z = 3.20 (P = 0.007); P = 65% Testfor overall effect Z = 3.20 (P = 0.007); P = 65% Testfor overall effect Z = 3.20 (P = 0.0017); P = 60%	Subtotal (95% CI)	2.40	2.3441	491	437	32.0%	2.89 [0.01, 5.77]	◆
1.11.4 Iron, zinc, vitamin B12 Ma 2016 (C) 2.1 1.4917 140 133 14.9% 2.10 [-0.82, 5.02] Subtotal (95% CI) 140 133 14.9% 2.10 [-0.82, 5.02] Heterogeneity. Not applicable Test for overall effect Z = 1.41 (P = 0.16) 1.11.6 Iron, zinc, vitamin A, niacin, folic acid 0.90 [-1.15, 2.95] Quintero 2011 0.9 1.0466 195 200 17.5% 0.90 [-1.15, 2.95] Heterogeneity. Not applicable 195 200 17.5% 0.90 [-1.15, 2.95] 144 Test for overall effect Z = 0.86 (P = 0.39) 111.7 Vitamin A, thiamine, riboflavin, pyridoxine 9.00 [-6.06, 24.06] 1.8% 9.00 [-6.06, 24.06] Heterogeneity. Not applicable 16 20 1.8% 9.00 [-6.06, 24.06] 1.41.8 Test for overall effect Z = 1.17 (P = 0.24) 16 20 1.8% 9.00 [-6.06, 24.06] 1.41.8 Heterogeneity. Not applicable 21.1.16469 77 85 14.1% 2.10 [-1.13, 5.33] Subtotal (95% CI) 2.1 1.6469 77 85 14.1% 2.10 [-1.13, 5.33] Heterogeneity. Tau ² = 5.50; Ch ² = 22.00, df = 10 (P = 0.	Heterogeneity: Tau² = Test for overall effect:	: 0.00; Chi ² = 0.44, c Z = 1.96 (P = 0.05)	lf= 4 (P =	= 0.98); I ^z = I	0%			
Ma 2016 (C) 2.1 1.4917 140 133 14.9% 2.10 [-0.82, 5.02] Subtotal (95% CI) 140 133 14.9% 2.10 [-0.82, 5.02] Heterogeneity. Not applicable Test for overall effect $Z = 1.41$ (P = 0.16) 1.11.6 Iron, zinc, vitamin A, niacin, folic acid Quintero 2011 0.9 1.0466 195 200 17.5% 0.90 [-1.15, 2.95] Subtotal (95% CI) 195 200 17.5% 0.90 [-1.15, 2.95] Heterogeneity. Not applicable Test for overall effect $Z = 0.86$ (P = 0.39) 1.11.7 Vitamin A, thiamine, riboflavin, pyridoxine Nesamvuni 2005 9 7.6844 16 20 1.8% 9.00 [-6.06, 24.06] Subtotal (95% CI) 16 20 1.8% 9.00 [-6.06, 24.06] Heterogeneity. Not applicable Test for overall effect $Z = 1.17$ (P = 0.24) 1.11.8 Multivitamins and minerals Faber 2005 9 1.4902 144 142 15.0% 9.00 [6.08, 11.92] Lartey 2000 4 4.3191 47 48 4.8% 4.00 [-4.47, 12.47] Liu 1993 (C) 2.1 1.6469 77 85 14.1% 2.10 [-1.13, 5.33] Subtotal (95% CI) 268 275 33.8% 5.26 [-0.07, 10.59] Heterogeneity. Tau ² = 16.28; Chi ² = 9.83, df = 2 (P = 0.007); P = 50% Test for overall effect $Z = 1.93$ (P = 0.05) Total (95% CI) 10 10 065 100.0% 3.44 [1.33, 5.55] Heterogeneity. Tau ² = 5.50; Chi ² = 2.2.00, df = 10 (P = 0.02); P = 55% Test for overall effect $Z = 1.93$ (P = 0.01) Total (95% CI) 10 20 Total (95% CI) 10 20 Total (95% CI) 10 20 Total (95% CI) 10 20 Total (95% CI) 20 Total (95	1.11.4 Iron, zinc, vita	min B12						
Subtotal (95% Cl) 140 133 14.9% 2.10 [-0.82, 5.02] Heterogeneity: Not applicable Test for overall effect Z = 1.41 (P = 0.16) 133 14.9% 2.10 [-0.82, 5.02] 1.11.6 Iron, zinc, vitamin A, niacin, folic acid Quintero 2011 0.9 1.0466 195 200 17.5% 0.90 [-1.15, 2.95] Subtotal (95% Cl) 0.9 1.95 200 17.5% 0.90 [-6.06, 24.06] Heterogeneity: Not applicable Test for overall effect Z = 0.86 (P = 0.39) 16 20 1.8% 9.00 [-6.06, 24.06] Subtotal (95% Cl) 9 7.6844 16 20 1.8% 9.00 [-6.06, 24.06] Heterogeneity: Not applicable Test for overall effect Z = 1.17 (P = 0.24) 16 20 1.8% 9.00 [-6.06, 24.06] Heterogeneity: Not applicable Test for overall effect Z = 1.17 (P = 0.24) 144 142 15.0% 9.00 [6.08, 11.92] Lartey 2000 4 4.3191 47 48 4.8% 4.00 [-4.47, 12.47] Lui 1993 (C) 2.1 1.6469 77 85 14.1% 2.10 [-1.13, 5.33] 2.20 [-0.07, If = 9.83, df = 2 (P = 0.007); F = 80% 2.46 [-0.07, 10.59]	Ma 2016 (C)	2.1	1.4917	140	133	14.9%	2.10 [-0.82, 5.02]	
Heterogeneity: Not applicable Test for overall effect $Z = 1.41$ (P = 0.16) 1.11.6 Iron, zinc, vitamin A, niacin, folic acid Quintero 2011 0.9 1.0466 195 200 17.5% 0.90 [-1.15, 2.95] Subtotal (95% CI) 195 200 17.5% 0.90 [-1.15, 2.95] Heterogeneity: Not applicable Test for overall effect $Z = 0.86$ (P = 0.39) 1.11.7 Vitamin A, thiamine, riboflavin, pyridoxine Nesamvuni 2005 9 7.6844 16 20 1.8% 9.00 [-6.06, 24.06] Heterogeneity: Not applicable Test for overall effect $Z = 1.17$ (P = 0.24) 1.11.8 Multivitamins and minerals Faber 2005 9 1.4902 144 142 15.0% 9.00 [-6.08, 11.92] Lartey 2000 4 4.3191 47 48 4.8% 4.00 [-4.47, 12.47] Lu 1993 (C) 2.1 1.6469 77 85 14.1% 2.10 [-1.13, 5.33] Subtotal (95% CI) 268 275 33.8% 5.26 [-0.07, 10.59] Heterogeneity: Tau ² = 16.28; Chi ² = 9.83, df = 2 (P = 0.007); P = 80% Test for overall effect $Z = 1.93$ (P = 0.00] Total (95% CI) 1110 1065 100.0% 3.44 [1.33, 555] Heterogeneity: Tau ² = 5.50; Chi ² = 2.20, df = 10 (P = 0.42); P = 55% Test for overall effect $Z = 3.20$ (P = 0.001) Test for suborou differences: Chi ² = 3.74, df = 4 (P = 0.44), P = 0%	Subtotal (95% CI)			140	133	14.9%	2.10 [-0.82, 5.02]	◆
1.11.6 Iron, zinc, vitamin A, niacin, folic acid Quintero 2011 0.9 1.0466 195 200 17.5% 0.90 [-1.15, 2.95] Subtotal (95% CI) 195 200 17.5% 0.90 [-1.15, 2.95] Heterogeneity: Not applicable Test for overall effect $Z = 0.86$ (P = 0.39) 11.17. Vitamin A, thiamine, riboflavin, pyridoxine Nesamvuni 2005 9 7.6844 16 20 1.8% 9.00 [-6.06, 24.06] Subtotal (95% CI) 16 20 1.8% 9.00 [-6.06, 24.06] Heterogeneity: Not applicable 16 20 1.8% 9.00 [-6.06, 24.06] Test for overall effect $Z = 1.17$ (P = 0.24) 142 15.0% 9.00 [6.08, 11.92] Lartey 2000 4 4.3191 47 48 4.8% 4.00 [-4.7, 12.47] Liu 1993 (C) 2.1 1.6469 77 85 14.1% 2.10 [-1.13, 5.3] Subtotal (95% CI) 268 275 33.8% 5.26 [-0.07, 10.59] -20 -10 0 0 20 Heterogeneity: Tau ² = 16.28; Chi ² = 9.83, df = 2 (P = 0.007); I ² = 80% 1065 100.0% 3.44 [1.33, 5.55] -20 -10 0 </td <td>Heterogeneity: Not ap Test for overall effect:</td> <td>oplicable Z = 1.41 (P = 0.16)</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	Heterogeneity: Not ap Test for overall effect:	oplicable Z = 1.41 (P = 0.16)						
Quintero 2011 0.9 1.0466 195 200 17.5% 0.90 [-1.15, 2.95] Subtotal (95% CI) 195 200 17.5% 0.90 [-1.15, 2.95] Heterogeneity: Not applicable Test for overall effect: Z = 0.88 (P = 0.39) 1.11.7 Vitamin A, thiamine, riboflavin, pyridoxine Nesamvuni 2005 9 7.6844 16 20 1.8% 9.00 [-6.06, 24.06] Subtotal (95% CI) 9 7.6844 16 20 1.8% 9.00 [-6.06, 24.06] Heterogeneity: Not applicable 16 20 1.8% 9.00 [-6.06, 24.06] Heterogeneity: Not applicable 16 20 1.8% 9.00 [-6.06, 24.06] Heterogeneity: Not applicable 16 20 1.8% 9.00 [-6.06, 24.06] Lartey 2000 4 4.3191 47 48 4.8% 4.00 [-4.47, 12.47] Lui 1993 (C) 2.1 1.6469 77 85 14.1% 2.10 [-1.13, 5.33] Subtotal (95% CI) 268 275 33.8% 5.26 [-0.07, 10.59] Heterogeneity: Tau ² = 16.28; Chi ² = 9.00; 1110 1065 100.0% 3.44 [1.33, 5.55]	1.11.6 Iron, zinc, vita	min A, niacin, folic a	acid					
Subtotal (95% Cl) 195 200 17.5% 0.90 [-1.15, 2.95] Heterogeneity: Not applicable Test for overall effect: $Z = 0.86$ (P = 0.39) 1.11.7 Vitamin A, thiamine, riboflavin, pyridoxine Nesamvuni 2005 9 7.6844 16 20 1.8% 9.00 [-6.06, 24.06] Subtotal (95% Cl) 16 20 1.8% 9.00 [-6.06, 24.06] Heterogeneity: Not applicable Test for overall effect: $Z = 1.17$ (P = 0.24) 1.11.8 Multivitamins and minerals Faber 2005 9 1.4902 144 142 15.0% 9.00 [6.08, 11.92] Lartey 2000 4 4.3191 47 48 4.8% 4.00 [-4.47, 12.47] Liu 1993 (C) 2.1 1.6469 77 85 14.1% 2.10 [-1.13, 5.33] Subtotal (95% Cl) 268 275 33.8% 5.26 [-0.07, 10.59] Heterogeneity: Tau ² = 16.28; Chi ² = 9.83, df = 2 (P = 0.007); I ² = 80% 3.44 [1.33, 5.55] Total (95% Cl) 1110 1065 100.0% 3.44 [1.33, 5.55] Heterogeneity: Tau ² = 5.50; Chi ² = 22.00, df = 10 (P = 0.02); I ² = 55% -20 -10 0 10 20 -20 -10	Quintero 2011	0.9	1.0466	195	200	17.5%	0.90 [-1.15, 2.95]	
Heterogeneity: Not applicable Test for overall effect: $Z = 0.86$ (P = 0.39) 1.11.7 Vitamin A, thiamine, riboflavin, pyridoxine Nesamvuni 2005 9 7.6844 16 20 1.8% 9.00 [-6.06, 24.06] Subtotal (95% Cl) 16 20 1.8% 9.00 [-6.06, 24.06] Heterogeneity: Not applicable Test for overall effect: $Z = 1.17$ (P = 0.24) 1.11.8 Multivitamins and minerals Faber 2005 9 1.4902 144 142 15.0% 9.00 [6.08, 11.92] Lartey 2000 4 4.3191 47 48 4.8% 4.00 [-4.47, 12.47] Liu 1993 (C) 2.1 1.6469 77 85 14.1% 2.10 [-1.13, 5.33] Subtotal (95% Cl) 268 275 33.8% 5.26 [-0.07, 10.59] Heterogeneity: Tau ² = 16.28; Ch ² = 9.83, df = 2 (P = 0.007); P = 80% Test for overall effect: $Z = 1.93$ (P = 0.05) Total (95% Cl) 1110 1065 100.0% 3.44 [1.33, 5.55] Heterogeneity: Tau ² = 5.50; Ch ² = 22.00, df = 10 (P = 0.02); P = 55% Test for overall effect: $Z = 3.20$ (P = 0.001) Test for subgroup differences: Ch ² = 3.74, df = 4 (P = 0.44), P = 0%	Subtotal (95% CI)			195	200	17.5%	0.90 [-1.15, 2.95]	•
1.11.7 Vitamin A, thiamine, riboflavin, pyridoxine Nesamvuni 2005 9 7.6844 16 20 1.8% 9.00 [-6.06, 24.06] Subtotal (95% Cl) 16 20 1.8% 9.00 [-6.06, 24.06] Heterogeneity: Not applicable Test for overall effect: $Z = 1.17$ (P = 0.24) 1.11.8 Multivitamins and minerals Faber 2005 9 1.4902 144 142 15.0% 9.00 [-6.08, 11.92] Lartey 2000 4 4.3191 47 48 4.8% 4.00 [-4.47, 12.47] Lui 1993 (C) 2.1 1.6469 77 85 14.1% 2.10 [-1.13, 5.33] Subtotal (95% Cl) 268 275 33.8% 5.26 [-0.07, 10.59] Heterogeneity: Tau ² = 16.28; Chi ² = 9.83, df = 2 (P = 0.007); I ² = 80% 3.44 [1.33, 5.55] Total (95% Cl) 110 1065 100.0% 3.44 [1.33, 5.55] Heterogeneity: Tau ² = 5.50; Chi ² = 22.00, df = 10 (P = 0.02); I ² = 55% -20 -10 0 10 20 Favours non-fortified Favours fortified Favours non-fortified Favours fortified	Heterogeneity: Not ap Test for overall effect:	oplicable Z = 0.86 (P = 0.39)						
Nesamvuni 2005 9 7.6844 16 20 1.8% 9.00 [6.06, 24.06] Subtotal (95% Cl) 16 20 1.8% 9.00 [6.06, 24.06] Heterogeneity: Not applicable Test for overall effect: $Z = 1.17$ (P = 0.24) 1.11.8 Multivitamins and minerals Faber 2005 9 1.4902 144 142 15.0% 9.00 [6.08, 11.92] Larley 2000 4 4.3191 47 48 4.8% 4.00 [4.47, 12.47] Liu 1993 (C) 2.1 1.6469 77 85 14.1% 2.10 [-1.13, 5.33] Subtotal (95% Cl) 268 275 33.8% 5.26 [-0.07, 10.59] Heterogeneity: Tau ² = 16.28; Chi ² = 9.83, df = 2 (P = 0.007); i ² = 80% 3.44 [1.33, 5.55] Total (95% Cl) 110 1065 100.0% 3.44 [1.33, 5.55] Heterogeneity: Tau ² = 5.50; Chi ² = 22.00, df = 10 (P = 0.02); i ² = 55% 3.44 [1.33, 5.55] -20 -10 0 10 20 Favours non-fortified Favours fortified Favours fortified Favours fortified	1.11.7 Vitamin A, thia	amine, riboflavin, py	ridoxine	•				
Subtotal (95% Cl) 16 20 1.8% 9.00 [-6.06, 24.06] Heterogeneity: Not applicable Test for overall effect: $Z = 1.17$ (P = 0.24) 1.11.8 Multivitamins and minerals Faber 2005 9 1.4902 144 142 15.0% 9.00 [6.08, 11.92] Lartey 2000 4 4.3191 47 48 4.8% 4.00 [-4.47, 12.47] Lui 1993 (C) 2.1 1.6469 77 85 14.1% 2.10 [-1.13, 5.33] Subtotal (95% Cl) 268 275 33.8% 5.26 [-0.07, 10.59] Heterogeneity: Tau ² = 16.28; Chi ² = 9.83, df = 2 (P = 0.007); I ² = 80% 3.44 [1.33, 5.55] Total (95% Cl) 110 1065 100.0% 3.44 [1.33, 5.55] Heterogeneity: Tau ² = 5.50; Chi ² = 22.00, df = 10 (P = 0.02); I ² = 55% -20 -10 0 10 20 Fest for overall effect: $Z = 3.20$ (P = 0.001) Test for subgroup differences: Chi ² = 3.74, df = 4 (P = 0.44), I ² = 0% -20 -10 0 10 20 Favours non-fortified Favours fortified Favours fortified -20 -10 0 10 20	Nesamvuni 2005	9	7.6844	16	20	1.8%	9.00 [-6.06, 24.06]	
Heterogeneity: Not applicable Test for overall effect: $Z = 1.17$ (P = 0.24) 1.18 Multivitamins and minerals Faber 2005 9 1.4902 144 142 15.0% 9.00 [6.08, 11.92] Lartey 2000 4 4.3191 47 48 4.8% 4.00 [4.47, 12.47] Lui 1993 (C) 2.1 1.6469 77 85 14.1% 2.10 [-1.13, 5.33] Subtotal (95% CI) 268 275 33.8% 5.26 [-0.07, 10.59] Heterogeneity: Tau ² = 16.28; Chi ² = 9.83, df = 2 (P = 0.007); I ² = 80% Total (95% CI) 110 1065 100.0% 3.44 [1.33, 5.55] Heterogeneity: Tau ² = 5.50; Chi ² = 22.00, df = 10 (P = 0.02); I ² = 55% Total (95% CI) 110 1065 100.0% 3.44 [1.33, 5.55] Heterogeneity: Tau ² = 5.50; Chi ² = 22.00, df = 10 (P = 0.02); I ² = 55% Test for subgroup differences: Chi ² = 3.74, df = 4 (P = 0.44), P = 0% Favours non-fortified Favours non-fortified	Subtotal (95% CI)			16	20	1.8%	9.00 [-6.06, 24.06]	
1.11.8 Multivitamins and minerals Faber 2005 9 1.4902 144 142 15.0% 9.00 [6.08, 11.92] Lartey 2000 4 4.3191 47 48 4.8% 4.00 [4.47, 12.47] Liu 1993 (C) 2.1 1.6469 77 85 14.1% 2.10 [-1.13, 5.33] Subtotal (95% CI) 268 275 33.8% 5.26 [-0.07, 10.59] Heterogeneity: Tau ² = 16.28; Chi ² = 9.83, df = 2 (P = 0.007); I ² = 80% 5.26 [-0.07, 10.59] Total (95% CI) 1110 1065 100.0% 3.44 [1.33, 5.55] Heterogeneity: Tau ² = 5.50; Chi ² = 22.00, df = 10 (P = 0.02); I ² = 55% $-20 - 10$ 0 10 20 Test for subgroup differences: Chi ² = 3.74, df = 4 (P = 0.44), I ² = 0% Favours non-fortified Favours fortified	Heterogeneity: Not ap Test for overall effect:	oplicable Z = 1.17 (P = 0.24)						
Faber 2005 9 1.4902 144 142 15.0% 9.00 [6.08, 11.92] Lartey 2000 4 4.3191 47 48 4.8% 4.00 [-4.47, 12.47] Lui 1993 (C) 2.1 1.6469 77 85 14.1% 2.10 [-1.13, 5.33] Subtotal (95% CI) 268 275 33.8% 5.26 [-0.07, 10.59] Heterogeneity: Tau ² = 16.28; Chi ² = 9.83, df = 2 (P = 0.007); I ² = 80% 5.26 [-0.07, 10.59] Total (95% CI) 110 1065 100.0% 3.44 [1.33, 5.55] Heterogeneity: Tau ² = 5.50; Chi ² = 22.00, df = 10 (P = 0.02); I ² = 55% -20 -10 0 10 20 Test for subgroup differences: Chi ² = 3.74, df = 4 (P = 0.44), I ² = 0% -20 -10 0 10 20	1.11.8 Multivitamins	and minerals						
Lartey 2000 4 4.3191 47 48 4.8% $4.00 [4.47, 12.47]$ Liu 1993 (C) 2.1 1.6469 77 85 14.1% 2.10 [-1.13, 5.33] Subtotal (95% CI) 268 275 33.8% 5.26 [-0.07, 10.59] Heterogeneity: Tau ² = 16.28; Chi ² = 9.83, df = 2 (P = 0.007); l ² = 80% Test for overall effect: Z = 1.93 (P = 0.05) Total (95% CI) 110 1065 100.0% 3.44 [1.33, 5.55] Heterogeneity: Tau ² = 5.50; Chi ² = 22.00, df = 10 (P = 0.02); l ² = 55% Test for subgroup differences: Chi ² = 3.74, df = 4 (P = 0.44), l ² = 0%	Faber 2005	9	1.4902	144	142	15.0%	9.00 [6.08, 11.92]	
Liu 1993 (C) 2.1 1.6469 77 85 14.1% 2.10 [-1.13, 5.33] Subtotal (95% Cl) 268 275 33.8% 5.26 [-0.07, 10.59] Heterogeneity: Tau ² = 16.28; Chi ² = 9.83, df = 2 (P = 0.007); I ² = 80% Test for overall effect: Z = 1.93 (P = 0.05) Total (95% Cl) 1110 1065 100.0% 3.44 [1.33, 5.55] Heterogeneity: Tau ² = 5.50; Chi ² = 22.00, df = 10 (P = 0.02); I ² = 55% Test for overall effect: Z = 3.20 (P = 0.001) Test for subgroup differences: Chi ² = 3.74, df = 4 (P = 0.44), I ² = 0%	Lartey 2000	4	4.3191	47	48	4.8%	4.00 [-4.47, 12.47]	
Subtotal (95% Cl) 268 275 33.8% 5.26 [-0.07, 10.59] Heterogeneity: Tau ² = 16.28; Chi ² = 9.83, df = 2 (P = 0.007); l ² = 80% Test for overall effect: Z = 1.93 (P = 0.05) 110 1065 100.0% 3.44 [1.33, 5.55] Total (95% Cl) 1110 1065 100.0% 3.44 [1.33, 5.55] -20 -10 0 10 20 Heterogeneity: Tau ² = 5.50; Chi ² = 22.00, df = 10 (P = 0.02); l ² = 55% Test for overall effect: Z = 3.20 (P = 0.001) -20 -10 0 10 20 Festor overall effect: Z = 3.20 (P = 0.001) Test for subgroup differences: Chi ² = 3.74, df = 4 (P = 0.44), l ² = 0% Favours non-fortified Favours fortified	Liu 1993 (C)	2.1	1.6469	77	85	14.1%	2.10 [-1.13, 5.33]	
Heterogeneity: Tau ² = 16.28; Chi ² = 9.83, df = 2 (P = 0.007); i ² = 80% Test for overall effect: Z = 1.93 (P = 0.05) Total (95% Cl) 1110 1065 100.0% 3.44 [1.33, 5.55] Heterogeneity: Tau ² = 5.50; Chi ² = 22.00, df = 10 (P = 0.02); i ² = 55% Test for overall effect: Z = 3.20 (P = 0.001) Test for subgroup differences: Chi ² = 3.74, df = 4 (P = 0.44), i ² = 0%	Subtotal (95% CI)			268	275	33.8%	5.26 [-0.07, 10.59]	\bullet
Total (95% CI) 1110 1065 100.0% 3.44 [1.33, 5.55] Heterogeneity: Tau ² = 5.50; Chi ² = 22.00, df = 10 (P = 0.02); l ² = 55% -20 -10 0 10 20 Test for overall effect: Z = 3.20 (P = 0.001) Test for subgroup differences: Chi ² = 3.74, df = 4 (P = 0.44), l ² = 0% Favours non-fortified Favours fortified	Heterogeneity: Tau ² = Test for overall effect:	= 16.28; Chi² = 9.83, Z = 1.93 (P = 0.05)	df = 2 (P	= 0.007); I ^z	²= 80%			
Heterogeneity: Tau ² = 5.50; Chi ² = 22.00, df = 10 (P = 0.02); l ² = 55% Test for overall effect: Z = 3.20 (P = 0.001) Test for subgroup differences: Chi ² = 3.74, df = 4 (P = 0.44), l ² = 0%	Total (95% CI)			1110	1065	100.0%	3.44 [1.33, 5.55]	•
Test for overall effect: Z = 3.20 (P = 0.001) -20 -10 0 10 20 Test for subgroup differences: Chi ² = 3.74, df = 4 (P = 0.44), l ² = 0% Favours non-fortified Favours non-fortified	Heterogeneity: Tau ² =	: 5.50° Chi² = 22.00	df = 10.0	P = 0.02); P	'= 55%			
Test for subgroup differences: Chi ² = 3.74, df = 4 (P = 0.44), i ² = 0%	Test for overall effect:	Z = 3.20 (P = 0.001)					-20 -10 0 10 20
	Test for subgroup dif	ferences: Chi ² = 3.7	, 4. df = 4	(P = 0.44), P	²=0%			Favours non-fortified Favours fortified

1.12 Fortified versus non-fortified complementary food. Outcome: Haemoglobin by types of products fortified

			Fortified I	Non-fortified		Mean Difference	Mean Difference
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.12.1 Wheat							
Ekoe 2020 (C)	3.4	4.6812	82	71	4.2%	3.40 [-5.77, 12.57]	
Liu 1993 (C)	2.1	1.6469	77	85	14.1%	2.10 [-1.13, 5.33]	
Subtotal (95% CI)			159	156	18.3%	2.24 [-0.80, 5.29]	◆
Heterogeneity: Tau ² =	: 0.00; Chi ² = 0.07, d	#f = 1 (P =	0.79); l²=1	0%			
Test for overall effect:	Z = 1.44 (P = 0.15)						
1.12.2 Maize/Corn							
Faber 2005	9	1.4902	144	142	15.0%	9.00 [6.08, 11.92]	
Nesamvuni 2005	9	7.6844	16	20	1.8%	9.00 [-6.06, 24.06]	
Quintero 2011	0.9	1.0466	195	200	17.5%	0.90 [-1.15, 2.95]	
Subtotal (95% CI)			355	362	34.2%	5.49 [-1.60, 12.57]	
Heterogeneity: Tau ² =	: 29.05; Chi ² = 20.28	3, df = 2 (i	° < 0.0001)); I² = 90%			
Test for overall effect:	Z = 1.52 (P = 0.13)						
1.12.3 Rice							
Arcanjo 2012 (C)	3.1	4.9266	96	92	3.9%	3.10 [-6.56, 12.76]	
Arcanjo 2013 (C)	5.9	5.0181	72	70	3.8%	5.90 [-3.94, 15.74]	
Bagni 2009 (C)	2.4	2.3479	180	174	10.5%	2.40 [-2.20, 7.00]	
Ma 2016 (C)	2.1	1.4917	140	133	14.9%	2.10 [-0.82, 5.02]	
Subtotal (95% CI)			488	469	33.1%	2.45 [0.12, 4.77]	◆
Heterogeneity: Tau ² =	: 0.00; Chi² = 0.55, d	f = 3 (P =	0.91); l² = l	0%			
Test for overall effect:	Z = 2.06 (P = 0.04)						
1.12.4 Cereal-legume	e blend						
Lartey 2000	4	4.3191	47	48	4.8%	4.00 [-4.47, 12.47]	
Subtotal (95% CI)			47	48	4.8%	4.00 [-4.47, 12.47]	
Heterogeneity: Not ap	plicable						
Test for overall effect:	Z = 0.93 (P = 0.35)						
1.12.5 Legume							
Schumann 2005	2.48	2.5441	61	30	9.6%	2.48 [-2.51, 7.47]	
Subtotal (95% CI)			61	30	9.6%	2.48 [-2.51, 7.47]	
Heterogeneity: Not ap	plicable						
Test for overall effect:	Z = 0.97 (P = 0.33)						
T / 1/05/ 00				1005			
l otal (95% Cl)			1110	1065	100.0%	3.44 [1.33, 5.55]	
Heterogeneity: Tau ² =	5.50; Chi ² = 22.00,	df = 10 (i	° = 0.02); I ²	'= 55%			-20 -10 0 10 20
Test for overall effect:	Z = 3.20 (P = 0.001)					Favours non-fortified Favours fortified
Test for subgroup diff	ferences: Chi² = 0.8	1. df = 4 (P = 0.94), P	²=0%			

1.13 Fortified versus non-fortified complementary food. Outcome: Haemoglobin by duration of

intervention

			Fortified	Non-fortified		Mean Difference	Mean Difference
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.13.1 Less than six	months						
Arcanjo 2012 (C)	3.1	4.9266	96	92	3.9%	3.10 [-6.56, 12.76]	
Arcanjo 2013 (C)	5.9	5.0181	72	70	3.8%	5.90 [-3.94, 15.74]	
Bagni 2009 (C)	2.4	2.3479	180	174	10.5%	2.40 [-2.20, 7.00]	- +-
Liu 1993 (C)	2.1	1.6469	77	85	14.1%	2.10 [-1.13, 5.33]	+
Schumann 2005	2.48	2.5441	61	30	9.6%	2.48 [-2.51, 7.47]	
Subtotal (95% CI)			486	451	41.8%	2.49 [0.28, 4.70]	◆
Heterogeneity: Tau² =	= 0.00; Chi ² = 0.53, d	if = 4 (P =	0.97); l² =	:0%			
Test for overall effect:	Z = 2.21 (P = 0.03)						
1.13.2 Six months or	more						
Ekoe 2020 (C)	3.4	4.6812	82	71	4.2%	3.40 [-5.77, 12.57]	
Faber 2005	9	1.4902	144	142	15.0%	9.00 [6.08, 11.92]	
Lartey 2000	4	4.3191	47	48	4.8%	4.00 [-4.47, 12.47]	
Ma 2016 (C)	2.1	1.4917	140	133	14.9%	2.10 [-0.82, 5.02]	+
Nesamvuni 2005	9	7.6844	16	20	1.8%	9.00 [-6.06, 24.06]	
Quintero 2011	0.9	1.0466	195	200	17.5%	0.90 [-1.15, 2.95]	
Subtotal (95% CI)			624	614	58.2%	4.12 [0.44, 7.80]	◆
Heterogeneity: Tau² =	= 12.55; Chi ² = 21.11	l, df = 5 (l	P = 0.0008	3); I² = 76%			
Test for overall effect:	Z = 2.20 (P = 0.03)						
Total (95% CI)			1110	1065	100.0%	3.44 [1.33, 5.55]	◆
Heterogeneity: Tau ² =	= 5.50; Chi ² = 22.00,	df = 10 (= 0.02);	I² = 55%			
Test for overall effect:	Z = 3.20 (P = 0.001) .					-20 -10 0 10 20
Test for subgroup diff	ferences: Chi ² = 0.5	6, df = 1 (P = 0.46),	I ² = 0%			avours non-toruneu - Favours toruneu

1.14 Fortified versus non-fortified complementary food. Outcome: Haemoglobin by baseline

anaemia status

			Fortified	Non-fortified		Mean Difference	Mean Difference				
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI				
1.14.1 Anaemic											
Ekoe 2020 (C)	3.4	4.6812	82	71	4.2%	3.40 [-5.77, 12.57]					
Schumann 2005	2.48	2.5441	61	30	9.6%	2.48 [-2.51, 7.47]					
Subtotal (95% CI)			143	101	13.9%	2.69 [-1.69, 7.07]	◆				
Heterogeneity: Tau ² = 0.00; Chi ² = 0.03, df = 1 (P = 0.86); i ² = 0%											
Test for overall effect:	Z = 1.20 (P = 0.23)										
1.14.2 Non-anaemic											
Subtotal (95% CI)			0	0		Not estimable					
Heterogeneity: Not ap	plicable										
Test for overall effect:	Not applicable										
1 1/ 3 Mixed/ Unknow	MD.										
Areania 2012 (C)	2.4	4 0 3 6 6	00	00	2.00	04010 EC 40701					
Arcanjo 2012 (C) Arcanio 2012 (C)	3.I 5.0	4.9200	90	92	3.970 3.004	5.10 [-0.30, 12.70] 5.00 [3.04, 15.74]					
Arcariju zuris (C) Dogoj 2000 (C)	0.9	3.0101	100	174	3.070	0.90[-0.94, 10.74]					
Eagril 2009 (C)	2.4	2.3479	100	1/4	16.0%	2.40 [-2.20, 7.00]	·				
Faper 2000	9	1.4902	144	142	10.0%	9.00 [0.00, 11.92] 4.00 [4.47, 40,47]					
Liu 1002 (C)	4	4.5151	47	40	4.070	4.00[-4.47, 12.47]	_ _				
Ma 2016 (C)	2.1	1 /0403	1/0	122	14.170	2.10[1.13, 5.33]					
Maizoro (C) Nacamvuni 2005	2.1	7 6044	140	20	1 0 04	2.10 [0.02, 5.02]					
Ouintere 2011	9 0 0	1.0444	105	20	17.6%	0.00 [-0.00, 24.00]					
Subtotal (95% CI)	0.5	1.0400	967	964	86.1%	3.59 [1.13, 6.06]	•				
Heterogeneity: Tau ² =	7 14: Chi² = 21 94	df = 8 (P)	= 0.005)	I ² = 64%			•				
Test for overall effect:	7 = 2.85 (P = 0.004)	un = 0 (i)	- 0.000),								
reation overall ender.	2 - 2.00 () - 0.004	<i>,</i>									
Total (95% CI)			1110	1065	100.0%	3.44 [1.33, 5.55]	◆				
Heterogeneity: Tau ² =	5.50; Chi ² = 22.00,	df = 10 (l	= 0.02);	I ² = 55%							
Test for overall effect:	Z = 3.20 (P = 0.001))					-20 -10 0 10 20 Eavours pop-fortified Eavours fortified				
Test for subgroup diff	erences: Chi² = 0.1	2. df = 1 (P = 0.73).	I² = 0%							

1.15 Fortified versus non-fortified complementary food. Outcome: Haemoglobin by country

income classification

		F	ortified Nor	-fortified		Mean Difference	Mean Difference
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% CI
1.15.1 High income							
Subtotal (95% CI)			0	0		Not estimable	
Heterogeneity: Not app	olicable						
Test for overall effect: I	Not applicable						
1.15.2 Upper middle ir	ncome						
Arcanio 2012 (C)	31	4 9266	96	92	3.9%	3 10 66 56 12 76	
Arcanio 2013 (C)	5.9	5.0181	72	70	3.8%	5 90 [-3 94 15 74]	
Bagni 2009 (C)	2.4	2 3479	180	174	10.5%	2 40 1-2 20 7 001	_ _
Faber 2005	9	1.4902	144	142	15.0%	9.00 [6.08, 11.92]	
Liu 1993 (C)	2.1	1.6469	77	85	14.1%	2.10 [-1.13, 5.33]	+
Ma 2016 (C)	2.1	1.4917	140	133	14.9%	2.10 [-0.82, 5.02]	+ -
Nesamvuni 2005	9	7.6844	16	20	1.8%	9.00 [-6.06, 24.06]	
Quintero 2011	0.9	1.0466	195	200	17.5%	0.90 [-1.15, 2.95]	
Schumann 2005	2.48	2.5441	61	30	9.6%	2.48 [-2.51, 7.47]	_
Subtotal (95% CI)			981	946	91.0%	3.44 [1.08, 5.79]	◆
Heterogeneity: Tau ² =	6.75; Chi ² = 21.95,	df = 8 (P =	0.005); I ² = 6	4%			
Test for overall effect: 2	Z = 2.86 (P = 0.004)					
1.15.3 Lower middle i	ncome						
Ekoe 2020 (C)	3.4	4.6812	82	71	4.2%	3.40 [-5.77, 12.57]	
Lartey 2000	4	4.3191	47	48	4.8%	4.00 [-4.47, 12.47]	
Subtotal (95% CI)			129	119	9.0%	3.72 [-2.50, 9.95]	-
Heterogeneity: Tau ² =	0.00; Chi² = 0.01, d	if = 1 (P = 0	0.92); I ^z = 0%				
Test for overall effect: 2	Z = 1.17 (P = 0.24)						
1.15.4 LOW INCOME						Not a stimulate	
Subtotal (95% CI)			0	0		Not estimable	
Heterogeneity: Not app	olicable						
Test for overall effect: I	Not applicable						
Total (95% CI)			1110	1065	100.0%	3.44 [1.33, 5,55]	•
Heterogeneity: Tau ² =	5 50° Chi≅ = 22 00	df = 10 (P)	= 0.02); IZ = 6	5%			
Test for overall effect: 3	7 = 3 20 (P = 0 001)	- 0.02/,1 - 0	0.0			-20 -10 0 10 20
Test for subgroup diffe	rences: Chi² = 0.001	/ 1 df=1/P	= 0.93) I ² = I	196			Favours non-fortified Favours fortified

1.16 Fortified versus non-fortified complementary food. Outcome: Haemoglobin by study funding

			Fortified	Non-fortified		Mean Difference	Mean Difference
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.16.1 Non-commerc	ial						
Arcanjo 2012 (C)	3.1	4.9266	96	92	3.9%	3.10 [-6.56, 12.76]	
Arcanjo 2013 (C)	5.9	5.0181	72	70	3.8%	5.90 [-3.94, 15.74]	
Bagni 2009 (C)	2.4	2.3479	180	174	10.5%	2.40 [-2.20, 7.00]	- +
Liu 1993 (C)	2.1	1.6469	77	85	14.1%	2.10 [-1.13, 5.33]	+
Ma 2016 (C)	2.1	1.4917	140	133	14.9%	2.10 [-0.82, 5.02]	+
Subtotal (95% CI)			565	554	47.1%	2.33 [0.44, 4.21]	◆
Heterogeneity: Tau ² =	0.00; Chi ² = 0.57, d	if = 4 (P =	0.97); l² =	:0%			
Test for overall effect:	Z = 2.42 (P = 0.02)						
1.16.2 Commercial (p	artly or fully)						
Ekoe 2020 (C)	3.4	4.6812	82	71	4.2%	3.40 [-5.77, 12.57]	
Faber 2005	9	1.4902	144	142	15.0%	9.00 [6.08, 11.92]	
Lartey 2000	4	4.3191	47	48	4.8%	4.00 [-4.47, 12.47]	
Nesamvuni 2005	0	0	0	0		Not estimable	
Quintero 2011	0.9	1.0466	195	200	17.5%	0.90 [-1.15, 2.95]	
Subtotal (95% CI)			468	461	41.4%	4.44 [-0.99, 9.87]	
Heterogeneity: Tau ² =	22.38; Chi ² = 19.80), df = 3 (i	P = 0.0002	2); I² = 85%			
Test for overall effect:	Z = 1.60 (P = 0.11)						
1.16.3 Unknown							
Nesamvuni 2005	9	7.6844	16	20	1.8%	9.00 [-6.06, 24.06]	
Schumann 2005	2.48	2.5441	61	30	9.6%	2.48 [-2.51, 7.47]	
Subtotal (95% CI)			77	50	11.4%	3.12 [-1.61, 7.86]	
Heterogeneity: Tau ² =	0.00; Chi ² = 0.65, d	if = 1 (P =	0.42); I ^z =	: 0%			
Test for overall effect:	Z = 1.29 (P = 0.20)						
Total (95% CI)			1110	1065	100.0%	3.44 [1.33, 5.55]	•
Heterogeneity: Tau ² =	5.50° Chi ² = 22.00	df = 10.0	P = 0.02) [.]	F = 55%		-	
Test for overall effect:	7 = 3.20 (P = 0.001)		. 0.02),				-20 -10 0 10 20
Test for subaroup diff	erences: Chi ² = 0.5	, 7. df = 2 (P = 0.75).	² = 0%			Favours non-fortified Favours fortified

1.17 Fortified versus non-fortified complementary food. Outcome: Weight-for-age (in z-scores)

			Fortified	Non-fortified		Mean Difference	Mean Difference
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
Ekoe 2020 (C)	0.44	0.3084	82	71	1.3%	0.44 [-0.16, 1.04]	
Faber 2005	-0.04	0.1545	143	145	4.8%	-0.04 [-0.34, 0.26]	
Lartey 2000	-0.01	0.0275	47	50	73.2%	-0.01 [-0.06, 0.04]	
Ma 2016 (C)	-0.13	0.1108	140	133	9.1%	-0.13 [-0.35, 0.09]	
Quintero 2011	0.09	0.0976	195	200	11.5%	0.09 [-0.10, 0.28]	
Total (95% CI)			607	599	100.0%	-0.01 [-0.07, 0.06]	4
Heterogeneity: Tau ² =	0.00; Chi ² = 4.38, d	f= 4 (P =	: 0.36); I ^z =	9%			
Test for overall effect:	Z = 0.15 (P = 0.88)						Favours non-fortified Favours fortified

1.18 Fortified versus non-fortified complementary food. Outcome: Weight-for-age (in z-scores) by

age at the start of the intervention

			Fortified	Non-fortified		Mean Difference	Mean Difference
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.18.1 6 to 11 months	8						
Faber 2005	-0.04	0.1545	143	145	4.8%	-0.04 [-0.34, 0.26]	-
Lartey 2000	-0.01	0.0275	47	50	73.2%	-0.01 [-0.06, 0.04]	
Ma 2016 (C)	-0.13	0.1108	140	133	9.1%	-0.13 [-0.35, 0.09]	
Subtotal (95% CI)			330	328	87.2%	-0.02 [-0.07, 0.03]	•
Heterogeneity: Tau ² =	0.00; Chi ² = 1.13, d	lf = 2 (P =	: 0.57); l² =	:0%			
Test for overall effect:	Z = 0.67 (P = 0.50)						
1.18.2 12 to 23 month	is						
Quintero 2011	0.09	0.0976	195	200	11.5%	0.09 [-0.10, 0.28]	
Subtotal (95% CI)			195	200	11.5%	0.09 [-0.10, 0.28]	◆
Heterogeneity: Not ap	plicable						
Test for overall effect:	Z = 0.92 (P = 0.36)						
1.18.3 Mean age >23	months						
Ekoe 2020 (C)	0.44	0.3084	82	71	1.3%	0.44 [-0.16, 1.04]	
Subtotal (95% CI)			82	71	1.3%	0.44 [-0.16, 1.04]	
Heterogeneity: Not ap	plicable						
Test for overall effect:	Z = 1.43 (P = 0.15)						
Total (95% CI)			607	599	100.0%	-0.01 [-0.07, 0.06]	
Heterogeneity: Tau ² =	0.00; Chi ² = 4.38, d	lf= 4 (P =	: 0.36); I² =	:9%			-2 -1 0 1 2
Test for overall effect:	Z = 0.15 (P = 0.88)						Favours non-fortified Favours fortified
Test for subgroup diff	erences: Chi ² = 3.2	5, df = 2 ((P = 0.20),	I² = 38.5%			

1.19 Fortified versus non-fortified complementary food. Outcome: Weight-for-age (in z-scores) by

types of nutrients added through fortification

			Fortified	Non-fortified		Mean Difference	Mean Difference
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
1.19.1 Iron					-		
Ekoe 2020 (C) Subtotal (95% CI)	0.44	0.3084	82 82	71 71	1.3% 1.3%	0.44 [-0.16, 1.04] 0.44 [-0.16, 1.04]	
Heterogeneity: Not ap	plicable						
Test for overall effect:	Z = 1.43 (P = 0.15)						
1.19.2 Iron, zinc, vita	min B12						
Ma 2016 (C)	-0.13	0.1108	140	133	9.1%	-0.13 [-0.35, 0.09]	
Subtotal (95% CI)			140	133	9.1%	-0.13 [-0.35, 0.09]	•
Heterogeneity: Not ap	plicable						
Test for overall effect:	Z = 1.17 (P = 0.24)						
1.19.4 Iron, zinc, vita	min A, niacin, folic a	acid					
Quintero 2011	0.09	0.0976	195	200	11.5%	0.09 [-0.10, 0.28]	±
Subtotal (95% CI)			195	200	11.5%	0.09 [-0.10, 0.28]	•
Heterogeneity: Not ap	plicable						
lest for overall effect:	Z = 0.92 (P = 0.36)						
1.19.5 Multivitamins	and minerals						
Faber 2005	-0.04	0.1545	143	145	4.8%	-0.04 [-0.34, 0.26]	_
Lartey 2000	-0.01	0.0275	47	50	73.2%	-0.01 [-0.06, 0.04]	#
Subtotal (95% CI)			190	195	78.1%	-0.01 [-0.06, 0.04]	•
Heterogeneity: Tau² =	0.00; Chi ² = 0.04, d	f=1 (P=	0.85); I ^z =	0%			
Test for overall effect:	Z = 0.40 (P = 0.69)						
Total (95% CI)			607	599	100.0%	-0.01 [-0.07, 0.06]	•
Heterogeneity: Tau ² =	0.00; Chi² = 4.38, d	f= 4 (P =	0.36); l² =	9%			
Test for overall effect:	Z = 0.15 (P = 0.88)						Favours non-fortified Eavours fortified
Test for subgroup diff	erences: Chi ² = 4.3	4. df = 3 (P = 0.23), I	²= 30.9%			avoid for formed a doubt formed

1.20 Fortified versus non-fortified complementary food. Outcome: Weight-for-age (in z-scores) by

types of products fortified

			Fortified	Non-fortified		Mean Difference	Mean Difference
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
1.20.1 Wheat							
Ekoe 2020 (C)	0.44	0.3084	82	71	1.3%	0.44 [-0.16, 1.04]	
Subtotal (95% CI)			82	71	1.3%	0.44 [-0.16, 1.04]	
Heterogeneity: Not ap	plicable						
Test for overall effect:	Z = 1.43 (P = 0.15)						
1 20 2 Maize/Corn							
Faher 2005	-0.04	0 1 5 4 5	143	145	4.8%	-0.04 (-0.34, 0.26)	
Quintero 2011	0.04	0.1040	195	200	11 5%	0.04 [0.34, 0.20]	_ _
Subtotal (95% CI)	0.00	0.0010	338	345	16.4%	0.05 [-0.11, 0.21]	•
Heterogeneity: Tau ² =	: 0.00; Chi ² = 0.51, d	f=1 (P=	0.48); I ^z =	: 0%			-
Test for overall effect:	Z = 0.64 (P = 0.52)	`					
1.20.3 Rice							
Ma 2016 (C)	-0.13	0.1108	140	133	9.1%	-0.13 [-0.35, 0.09]	
Subtotal (95% CI)			140	133	9.1%	-0.13 [-0.35, 0.09]	•
Heterogeneity: Not ap	plicable						
Test for overall effect:	Z = 1.17 (P = 0.24)						
1.20.4 Cereal-legume	e blend						
Lartey 2000	-0.01	0.0275	47	50	73.7%	-0.01 60.06 0.041	· · · · · · · · · · · · · · · · · · ·
Subtotal (95% CI)	-0.01	0.0275	47	50	73.2%	-0.01 [-0.06, 0.04]	
Heterogeneity: Not an	nlicable						1
Test for overall effect:	Z = 0.36 (P = 0.72)						
	,						
Total (95% CI)			607	599	100.0%	-0.01 [-0.07, 0.06]	♦
Heterogeneity: Tau ² =	: 0.00; Chi ² = 4.38, d	if = 4 (P =	: 0.36); l ² =	: 9%		-	
Test for overall effect:	Z = 0.15 (P = 0.88)						Eavours non-fortified Eavours fortified
Test for subgroup diff	ferences: Chi² = 3.8	7. df = 3 (P = 0.28),	I² = 22.5%			, arease non totalloa in around totalloa

1.21 Fortified versus non-fortified complementary food. Outcome: Weight-for-age (in z-scores) by

duration of intervention

			Fortified	Non-fortified		Mean Difference	Mean Difference
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.21.1 Less than six	months						
Subtotal (95% CI)			0	0		Not estimable	
Heterogeneity: Not a	pplicable						
Test for overall effect	: Not applicable						
1.21.2 Six months o	r more						
Ekoe 2020 (C)	0.44	0.3084	82	71	1.3%	0.44 [-0.16, 1.04]	
Faber 2005	-0.04	0.1545	143	145	4.8%	-0.04 [-0.34, 0.26]	- _
Lartey 2000	-0.01	0.0275	47	50	73.2%	-0.01 [-0.06, 0.04]	
Ma 2016 (C)	-0.13	0.1108	140	133	9.1%	-0.13 [-0.35, 0.09]	
Quintero 2011	0.09	0.0976	195	200	11.5%	0.09 [-0.10, 0.28]	- -
Subtotal (95% CI)			607	599	100.0%	-0.01 [-0.07, 0.06]	•
Heterogeneity: Tau ² :	= 0.00; Chi ² = 4.38, c	lf = 4 (P :	= 0.36); l ² =	: 9%			
Test for overall effect	t: Z = 0.15 (P = 0.88)						
Total (95% CI)			607	599	100.0%	-0.01 [-0.07, 0.06]	•
Heterogeneity: Tau ² :	= 0.00; Chi ² = 4.38, d	lf = 4 (P :	= 0.36); l ² =	- 9%			
Test for overall effect	: Z = 0.15 (P = 0.88)						-Z -1 U 1 Z
Test for subaroup dir	fferences: Not applic	able					Favours non-toruned Favours toruned

1.22 Fortified versus non-fortified complementary food. Outcome: Weight-for-age (in z-scores) by

baseline anaemia status

			Fortified	Non-fortified		Mean Difference	Mean Difference
Study or Subgroup	Mean Difference	SE	lotal	lotal	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.22.1 Anaemic							
Ekoe 2020 (C)	0.44	0.3084	82	71	1.3%	0.44 [-0.16, 1.04]	
Subtotal (95% CI)			82	71	1.3%	0.44 [-0.16, 1.04]	
Heterogeneity: Not ap	oplicable						
Test for overall effect:	Z = 1.43 (P = 0.15)						
1.22.2 Non-anaemic							
Subtotal (95% CI)			0	0		Not estimable	
Heterogeneity: Not ap	plicable						
Test for overall effect:	Not applicable						
1.22.3 Mixed/ Unknow	wn						
Faber 2005	-0.04	0.1545	143	145	4.8%	-0.04 [-0.34, 0.26]	_
Lartey 2000	-0.01	0.0275	47	50	73.2%	-0.01 [-0.06, 0.04]	
Ma 2016 (C)	-0.13	0.1108	140	133	9.1%	-0.13 [-0.35, 0.09]	
Quintero 2011	0.09	0.0976	195	200	11.5%	0.09 [-0.10, 0.28]	
Subtotal (95% CI)			525	528	98.7%	-0.01 [-0.06, 0.04]	•
Heterogeneity: Tau ² =	: 0.00: Chi ² = 2.26. d	lf = 3 (P =	= 0.52): I ≧ =	0%			
Test for overall effect:	Z = 0.41 (P = 0.68)						
Total (95% CI)			607	599	100.0%	-0.01 [-0.07, 0.06]	•
Heterogeneity: Tau ² =	: 0.00: Chi ² = 4.38. d	lf = 4 (P =	= 0.36); I ² =	9%			
Test for overall effect:	7 = 0.15 (P = 0.88)		0.00//1 =				-2 -1 0 1 2
Test for subgroup diff	ferences: Chi ² = 2.1	7 df = 1	(P = 0.15)	P= 52.8%			Favours non-fortified Favours fortified

1.23 Fortified versus non-fortified complementary food. Outcome: Weight-for-age (in z-scores) by

country income classification

		F	ortified N	Non-fortified		Mean Difference	Mean Difference
Study or Subgroup Mean D	ifference	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.23.1 High income							
Subtotal (95% CI)			0	0		Not estimable	
Heterogeneity: Not applicable							
Test for overall effect: Not appli	cable						
1.23.2 Upper middle income							
Faber 2005	-0.04	0.1545	143	145	4.8%	-0.04 [-0.34, 0.26]	-
Ma 2016 (C)	-0.13	0.1108	140	133	9.1%	-0.13 [-0.35, 0.09]	
Quintero 2011	0.09	0.0976	195	200	11.5%	0.09 [-0.10, 0.28]	
Subtotal (95% CI)			478	478	25.5%	-0.01 [-0.15, 0.12]	•
Heterogeneity: Tau ² = 0.00; Ch	i² = 2.26, d	f= 2 (P = I	0.32); I ž = 1	11%			
Test for overall effect: Z = 0.20	(P = 0.84)						
1.23.3 Lower middle income							
Ekoe 2020 (C)	0.44	0.3084	82	71	1.3%	0.44 [-0.16, 1.04]	
Lartey 2000	-0.01	0.0275	47	50	73.2%	-0.01 [-0.06, 0.04]	
Subtotal (95% CI)			129	121	74.5%	0.11 [-0.28, 0.50]	•
Heterogeneity: Tau ² = 0.05; Ch	i ² = 2.11, d	f=1 (P=)	0.15); I ² = 6	53%			
Test for overall effect: $Z = 0.55$	(P = 0.58)						
1.23.4 Low income							
Subtotal (95% CI)			0	0		Not estimable	
Heterogeneity: Not applicable							
Test for overall effect: Not appli	cable						
Total (95% CI)			607	599	100.0%	-0.01 [-0.07, 0.06]	
Heterogeneity: Tau ² = 0.00; Ch	i² = 4.38. d	f = 4 (P = 1	0.36): I ² = 9	9%			$-\iota$ ι l i l
Test for overall effect: $Z = 0.15$	(P = 0.88)						-2 -1 0 1 2
Test for subaroup differences:	Chi ² = 0.3	5. df = 1 (F	² = 0.56), ²	²= 0%			Favours non-tortified Favours fortified

1.24 Fortified versus non-fortified complementary food. Outcome: Weight-for-age (in z-scores) by

study funding

		1	Fortified	Non-fortified		Mean Difference	Mean Difference
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.24.1 Non-commerce	ial						
Ma 2016 (C)	-0.13	0.1108	140	133	9.1%	-0.13 [-0.35, 0.09]	
Subtotal (95% CI)			140	133	9.1%	-0.13 [-0.35, 0.09]	◆
Heterogeneity: Not ap	plicable						
Test for overall effect:	Z = 1.17 (P = 0.24)						
1.24.2 Commercial (partly or fully)						
Ekoe 2020 (C)	0.44	0.3084	82	71	1.3%	0.44 [-0.16, 1.04]	
Faber 2005	-0.04	0.1545	143	145	4.8%	-0.04 [-0.34, 0.26]	<u>+</u>
Lartey 2000	-0.01	0.0275	47	50	73.2%	-0.01 [-0.06, 0.04]	
Quintero 2011	0.09	0.0976	195	200	11.5%	0.09 [-0.10, 0.28]	- -
Subtotal (95% CI)			467	466	90.9%	0.00 [-0.06, 0.06]	•
Heterogeneity: Tau ² =	: 0.00; Chi² = 3.08, d	f= 3 (P =	0.38); I ² =	: 3%			
Test for overall effect:	Z = 0.08 (P = 0.94)						
Total (95% CI)			607	599	100.0%	-0.01 [-0.07, 0.06]	•
Heterogeneity: Tau ² =	: 0.00; Chi² = 4.38, d	f=4 (P=	0.36); l² =	:9%			
Test for overall effect:	Z = 0.15 (P = 0.88)						Favours non-fortified Favours fortified
The state of the second s		o		17 0.4 7.00			

Test for subgroup differences: $Chi^2 = 1.33$, df = 1 (P = 0.25), I² = 24.7%

1.25 Fortified versus non-fortified complementary food. Outcome: Weight-for-length (in z-scores)

			Fortified	Non-fortified		Mean Difference	Mean Difference
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
Ekoe 2020 (C)	-0.22	0.2367	82	71	8.9%	-0.22 [-0.68, 0.24]	
Faber 2005	-0.17	0.1403	143	145	21.6%	-0.17 [-0.44, 0.10]	
Ma 2016 (C)	-0.09	0.104	140	133	32.9%	-0.09 [-0.29, 0.11]	
Quintero 2011	0.11	0.0956	195	200	36.5%	0.11 [-0.08, 0.30]	
Total (95% CI) Heterogeneity: Tau ² - Test for overall effect	= 0.01; Chi ^z = 4.12, c : Z = 0.61 (P = 0.54)	lf= 3 (P =	560 = 0.25); I ² =	549 = 27%	100.0%	-0.05 [-0.19, 0.10]	-2 -1 0 1 2 Favours non-fortified Favours fortified

1.26 Fortified versus non-fortified complementary food. Outcome: Weight-for-length (in z-scores)

by age at the start of the intervention

			Fortified	Non-fortified		Mean Difference	Mean Difference
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.26.1 6 to 11 month	s						
Faber 2005	-0.17	0.1403	143	145	21.6%	-0.17 [-0.44, 0.10]	
Ma 2016 (C)	-0.09	0.104	140	133	32.9%	-0.09 [-0.29, 0.11]	
Subtotal (95% CI)			283	278	54.5%	-0.12 [-0.28, 0.05]	◆
Heterogeneity: Tau ² =	: 0.00; Chi ² = 0.21, d	lf = 1 (P =	0.65); l² =	:0%			
Test for overall effect:	Z = 1.42 (P = 0.16)						
1.26.2 12 to 23 mont	hs						
Quintero 2011	0.11	0.0956	195	200	36.5%	0.11 [-0.08, 0.30]	-
Subtotal (95% CI)			195	200	36.5%	0.11 [-0.08, 0.30]	◆
Heterogeneity: Not ap	oplicable						
Test for overall effect:	Z = 1.15 (P = 0.25)						
1.26.3 Mean age >23	months						
Ekoe 2020 (C)	-0.22	0.2367	82	71	8.9%	-0.22 [-0.68, 0.24]	
Subtotal (95% CI)			82	/1	8.9%	-0.22 [-0.68, 0.24]	
Heterogeneity: Not ap	oplicable						
Test for overall effect:	Z = 0.93 (P = 0.35)						
T-4-1/05% CIV			500	540	400.0%	0.051040.0401	
Total (95% CI)			000	549	100.0%	-0.05 [-0.19, 0.10]	· · · ·
Heterogeneity: lauf =	= 0.01; Chi* = 4.12, c	It = 3 (P =	0.25); 1*=	: 27%			-2 -1 0 1 2
Test for overall effect:	Z = 0.61 (P = 0.54)						Favours non-fortified Favours fortified
lest for subgroup diff	rerences: Chi*= 3.9	1, at = 2 (i	P = 0.14),	I*= 48.8%			

1.27 Fortified versus non-fortified complementary food. Outcome: Weight-for-length (in z-scores)

by types of nutrients added through fortification

			Fortified	Non-fortified		Mean Difference	Mean Difference
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
1.27.1 Iron							
Ekoe 2020 (C) Subtotal (95% Cl)	-0.22	0.2367	82 82	71 71	8.9% <mark>8.9%</mark>	-0.22 [-0.68, 0.24] - 0.22 [-0.68, 0.24]	-
Heterogeneity: Not appl	licable						
Test for overall effect: Z	= 0.93 (P = 0.35)						
1.27.2 Iron, zinc, vitami	in B12						
Ma 2016 (C)	-0.09	0.104	140	133	32.9%	-0.09 [-0.29, 0.11]	_
Subtotal (95% CI)			140	133	32.9%	-0.09 [-0.29, 0.11]	-
Heterogeneity: Not appl	licable						
l est for overall effect. Z	= 0.87 (P = 0.39)						
1.27.3 Iron, zinc, vitami	in A, niacin, folic a	acid					
Quintero 2011	0.11	0.0956	195	200	36.5%	0.11 [-0.08, 0.30]	T
Subtotal (95% CI)	liaabla		195	200	30.5%	0.11[-0.08, 0.30]	—
Tect for everall effect: 7	- 1 15 (P - 0 25)						
Testion overall ellect. Z	= 1.15 (F = 0.25)						
1.27.4 Multivitamins an	nd minerals						
Faber 2005	-0.17	0.1403	143	145	21.6%	-0.17 [-0.44, 0.10]	
Subtotal (95% CI)			143	145	21.6%	-0.17 [-0.44, 0.10]	-
Heterogeneity: Not appl	licable						
Test for overall effect: Z	= 1.21 (P = 0.23)						
Total (95% CI)			560	549	100.0%	-0.05 [-0.19, 0.10]	+
Heterogeneity: Tau² = 0	.01; Chi² = 4.12, d	f= 3 (P =	= 0.25); l ² =	: 27%			
Test for overall effect: Z	= 0.61 (P = 0.54)						Favours non-fortified Favours fortified
Test for subgroup differ	ences: Chi ² = 4.13	2. df = 3	(P = 0.25),	l² = 27.1%			

1.28 Fortified versus non-fortified complementary food. Outcome: Weight-for-length (in z-scores)

by types of products fortified

			Fortified	Non-fortified		Mean Difference	Mean Difference
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
1.28.1 Wheat							
Ekoe 2020 (C)	-0.22	0.2367	82	71	8.9%	-0.22 [-0.68, 0.24]	
Subtotal (95% CI)			82	71	8.9%	-0.22 [-0.68, 0.24]	
Heterogeneity: Not ap	oplicable						
Test for overall effect:	Z = 0.93 (P = 0.35)						
1.28.2 Maize/Corn							
Faber 2005	-0.17	0.1403	143	145	21.6%	-0.17 [-0.44, 0.10]	-•+
Quintero 2011	0.11	0.0956	195	200	36.5%	0.11 [-0.08, 0.30]	
Subtotal (95% CI)			338	345	58.1%	-0.01 [-0.28, 0.26]	•
Heterogeneity: Tau² =	: 0.02; Chi² = 2.72, d	f=1 (P=	0.10); I ^z =	: 63%			
Test for overall effect:	Z = 0.08 (P = 0.94)						
1.28.3 Rice							
Ma 2016 (C)	-0.09	0.104	140	133	32.9%	-0.09 [-0.29, 0.11]	
Subtotal (95% CI)			140	133	32.9%	-0.09 [-0.29, 0.11]	•
Heterogeneity: Not ap	oplicable						
Test for overall effect:	Z = 0.87 (P = 0.39)						
Total (05% CI)			560	540	400.0%	0.051040.0401	
Total (95% CI)			000	070	100.0%	-0.05 [-0.19, 0.10]	· · · · · ·
Heterogeneity: Taur=	= 0.01; Chi* = 4.12, c	T = 3 (P =	0.25); 1*=	: 27%			-2 -1 0 1 2
Test for overall effect:	Z = 0.61 (P = 0.54)						Favours non-fortified Favours fortified
lest for subgroup diff	terences: Chi² = 0.6	1, df = 2 (P = 0.74),	I* = U%			

1.29 Fortified versus non-fortified complementary food. Outcome: Weight-for-length (in z-scores)

by duration of intervention

			Fortified No	on-fortified		Mean Difference	Mean Difference				
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl				
1.29.1 Less than six	months										
Subtotal (95% CI)			0	0		Not estimable					
Heterogeneity: Not ap	oplicable										
Test for overall effect:	Not applicable										
1.29.2 Six months or	more										
Ekoe 2020 (C)	-0.22	0.2367	82	71	8.9%	-0.22 [-0.68, 0.24]					
Faber 2005	-0.17	0.1403	143	145	21.6%	-0.17 [-0.44, 0.10]					
Ma 2016 (C)	-0.09	0.104	140	133	32.9%	-0.09 [-0.29, 0.11]					
Quintero 2011	0.11	0.0956	195	200	36.5%	0.11 [-0.08, 0.30]					
Subtotal (95% CI)			560	549	100.0%	-0.05 [-0.19, 0.10]	◆				
Heterogeneity: Tau ² =	= 0.01; Chi ² = 4.12, d	lf = 3 (P =	0.25); I ^z = 23	7%							
Test for overall effect:	Z = 0.61 (P = 0.54)										
Total (95% CI)			560	549	100.0%	-0.05 [-0.19, 0.10]					
Heterogeneity: Tau ² =	Heterogeneity: Tau ² = 0.01: Chi ² = 4.12 df = 3 (P = 0.25): P = 27%										
Test for overall effect $Z = 0.61$ (P = 0.54)											
Test for subgroup dif	ferences: Not applic	able					Favours non-toruned Favours foruned				

1.30 Fortified versus non-fortified complementary food. Outcome: Weight-for-length (in z-scores)

by baseline anaemia status

		F	ortified	Non-fortified		Mean Difference	Mean Difference
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.30.1 Anaemic							
Ekoe 2020 (C)	-0.22	0.2367	82	71	8.9%	-0.22 [-0.68, 0.24]	
Subtotal (95% CI)			82	71	8.9%	-0.22 [-0.68, 0.24]	
Heterogeneity: Not ap	plicable						
Test for overall effect:	Z = 0.93 (P = 0.35)						
4 20 2 Non anaomia							
Subtotal (05% CI)			0	0		Not optimable	
Hotorogonoity Not or	nlicoblo		0	0		Notesumable	
Toot for everall offect:	Notapplicable						
restion overall ellect.	Not applicable						
1.30.3 Mixed/ Unknow	wn						
Faber 2005	-0.17	0.1403	143	145	21.6%	-0.17 [-0.44, 0.10]	
Ma 2016 (C)	-0.09	0.104	140	133	32.9%	-0.09 [-0.29, 0.11]	
Quintero 2011	0.11	0.0956	195	200	36.5%	0.11 [-0.08, 0.30]	
Subtotal (95% CI)			478	478	91.1%	-0.03 [-0.20, 0.13]	-
Heterogeneity: Tau² =	: 0.01; Chi² = 3.45, d	f= 2 (P =	0.18); I ² =	42%			
Test for overall effect:	Z = 0.37 (P = 0.71)						
Total (95% CI)			560	549	100.0%	-0.05 [-0.19, 0.10]	•
Heterogeneity: Tau ² =	: 0.01 ⁻ Chi ² = 4.12 .c	f = 3 (P = 1)	0.25); 17 =	27%			-+++
Test for overall effect:	Z = 0.61 (P = 0.54)		/1				-1 -0.5 0 0.5 1
Test for subgroup diff	ferences: Chi ² = 0.5	6. df = 1 (F	^o = 0.45),	I² = 0%			Favours non-toruned Favours fortified

1.31 Fortified versus non-fortified complementary food. Outcome: Weight-for-length (in z-scores)

by country income classification

			Fortified	Non-fortified		Mean Difference	Mean Difference
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
1.31.1 High income							
Subtotal (95% CI)			0	0		Not estimable	
Heterogeneity: Not ap	plicable						
Test for overall effect:	Not applicable						
1 31 2 Upper middle i	income						
Faher 2005	-0.17	0 1 4 0 3	143	145	21.6%	-0.17 [-0.44 0.10]	
Ma 2016 (C)	-0.17	0.1403	140	143	32.9%	-0.09[-0.29_0.11]	-
Quintero 2011	0.03	0.104	195	200	36.5%	0.11 [-0.08_0.30]	
Subtotal (95% CI)	0.11	0.0000	478	478	91.1%	-0.03 [-0.20, 0.13]	
Heterogeneity: Tau ² =	0.01; Chi ² = 3.45, d	lf = 2 (P =	0.18); I ² =	42%			
Test for overall effect:	Z = 0.37 (P = 0.71)						
1.31.3 Lower middle	income						
Ekoe 2020 (C)	-0.22	0.2367	82	71	8.9%	-0.22 [-0.68, 0.24]	
Subtotal (95% CI)			82	71	8.9%	-0.22 [-0.68, 0.24]	-
Heterogeneity: Not ap	plicable						
Test for overall effect:	Z = 0.93 (P = 0.35)						
1.31.4 Low income							
Subtotal (95% CI)			0	0		Not estimable	
Heterogeneity: Not ap	plicable						
Test for overall effect:	Not applicable						
Total (95% CI)			560	549	100.0%	-0.05 [-0.19, 0.10]	
Heterogeneity: Tau² =	0.01; Chi ² = 4.12, d	lf = 3 (P =	0.25); l² =	27%			
Test for overall effect:	Z = 0.61 (P = 0.54)						Favours non-fortified Favours fortified
Test for subgroup diff	erences: Chi ² = 0.5	6, df = 1 (I	P = 0.45),	I² = 0%			

1.32 Fortified versus non-fortified complementary food. Outcome: Weight-for-length (in z-scores)

by study funding

		1	Fortified	Non-fortified		Mean Difference	Mean Difference
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.32.1 Non-commer	cial						
Ma 2016 (C)	-0.09	0.104	140	133	32.9%	-0.09 [-0.29, 0.11]	
Subtotal (95% CI)			140	133	32.9%	-0.09 [-0.29, 0.11]	◆
Heterogeneity: Not a	pplicable						
Test for overall effect	Z = 0.87 (P = 0.39)						
1.32.2 Commercial (partly or fully)						
Ekoe 2020 (C)	-0.22	0.2367	82	71	8.9%	-0.22 [-0.68, 0.24]	
Faber 2005	-0.17	0.1403	143	145	21.6%	-0.17 [-0.44, 0.10]	
Quintero 2011	0.11	0.0956	195	200	36.5%	0.11 [-0.08, 0.30]	
Subtotal (95% CI)			420	416	67.1%	-0.04 [-0.27, 0.18]	•
Heterogeneity: Tau ² =	= 0.02; Chi ² = 3.65, d	lf = 2 (P =	0.16); l ² =	: 45%			
Test for overall effect	: Z = 0.39 (P = 0.70)						
Total (95% CI)			560	549	100.0%	-0.05 [-0.19, 0.10]	•
Heterogeneity: Tau ² =	= 0.01; Chi ² = 4.12, d	lf = 3 (P =	0.25); l ² =	: 27%			
Test for overall effect	Z = 0.61 (P = 0.54)		-Z -1 U 1 Z				
To all fair and supervise all		Favours non-ionnieu Favours lonnieu					

Test for subgroup differences: $Chi^2 = 0.09$, df = 1 (P = 0.76), l² = 0%

1.33 Fortified versus non-fortified complementary food. Outcome: Length-for-age (in z-scores)

Study or Subgroup	Mean Difference	SE	Fortified Total	Non-fortified Total	Weight	Mean Difference IV, Random, 95% Cl	Mean Difference IV, Random, 95% Cl
Ekoe 2020 (C)	0.98	0.4375	82	71	5.0%	0.98 [0.12, 1.84]	
Faber 2005	0.12	0.1297	143	145	25.8%	0.12 [-0.13, 0.37]	
Lartey 2000	-0.11	0.0266	47	50	41.8%	-0.11 [-0.16, -0.06]	•
Ma 2016 (C)	-0.16	0.1203	140	133	27.4%	-0.16 [-0.40, 0.08]	
Total (95% Cl) Heterogeneity: Tau ² =	: 0.03; Chi² = 9.36, d	+ 					
Test for overall effect:	Z = 0.09 (P = 0.93)	Favours non-fortified Favours fortified					

1.34 Fortified versus non-fortified complementary food. Outcome: Length-for-age (in z-scores) by

age at the start of the intervention

			Fortified	Non-fortified		Mean Difference	Mean Difference		
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI		
1.34.1 6 to 11 month	s								
Faber 2005	0.12	0.1297	143	145	25.8%	0.12 [-0.13, 0.37]			
Lartey 2000	-0.11	0.0266	47	50	41.8%	-0.11 [-0.16, -0.06]	•		
Ma 2016 (C)	-0.16	0.1203	140	133	27.4%	-0.16 [-0.40, 0.08]			
Subtotal (95% CI)			330	328	95.0%	-0.08 [-0.20, 0.04]	•		
Heterogeneity: Tau² =	: 0.01; Chi² = 3.25, c	lf = 2 (P =	0.20); l² =	: 38%					
Test for overall effect:	Z = 1.31 (P = 0.19)								
1 34 2 12 to 23 mont	he								
Subtotal (05% CI)	115		0	0		Not estimable			
Jubiotal (95% CI)	nliankla		0	0		notesumable			
Test for succell offect:	upiicapie Noteneliseble								
restior overall ellect.	Nutapplicable								
1.34.3 Mean age >23	months								
Ekoe 2020 (C)	0.98	0.4375	82	71	5.0%	0.98 [0.12, 1.84]			
Subtotal (95% CI)			82	71	5.0%	0.98 [0.12, 1.84]			
Heterogeneity: Not ap	plicable								
Test for overall effect:	Z = 2.24 (P = 0.03)								
Total (95% CI)			412	399	100.0%	-0.01 [-0.21, 0.20]	•		
Heterogeneity: Tau ² = 0.03; Chi ² = 9.36, df = 3 (P = 0.02); l ² = 68%									
Test for overall effect: Z = 0.09 (P = 0.93) Eavours non-fortified Eav									
Test for subgroup differences: Chi ² = 5.76, df = 1 (P = 0.02), l ² = 82.6%									

1.35 Fortified versus non-fortified complementary food. Outcome: Length-for-age (in z-scores) by

types of nutrients added through fortification

			Fortified	Non-fortified		Mean Difference	Mean Difference		
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI		
1.35.1 Iron									
Ekoe 2020 (C)	0.98	0.4375	82	71	5.0%	0.98 [0.12, 1.84]			
Subtotal (95% CI)			82	71	5.0%	0.98 [0.12, 1.84]			
Heterogeneity: Not ap	plicable								
Test for overall effect:	Z = 2.24 (P = 0.03)								
1.35.2 Iron, zinc, vita	min B12								
Ma 2016 (C)	-0.16	0.1203	140	133	27.4%	-0.16 [-0.40, 0.08]			
Subtotal (95% CI)			140	133	27.4%	-0.16 [-0.40, 0.08]	◆		
Heterogeneity: Not ap	plicable								
Test for overall effect:	Z = 1.33 (P = 0.18)								
1.35.3 Multivitamins	and minerals								
Faber 2005	0.12	0.1297	143	145	25.8%	0.12 [-0.13, 0.37]			
Lartey 2000	-0.11	0.0266	47	50	41.8%	-0.11 [-0.16, -0.06]			
Subtotal (95% CI)			190	195	67.6%	-0.03 [-0.24, 0.18]	•		
Heterogeneity: Tau ² = 0.02; Chi ² = 3.02, df = 1 (P = 0.08); l ² = 67%									
Test for overall effect:	Z = 0.27 (P = 0.78)								
Total (95% CI)			412	399	100.0%	-0.01 [-0.21, 0.20]	•		
Heterogeneity: Tau ² = 0.03; Chi ² = 9.36, df = 3 (P = 0.02); i ² = 68%									
Test for overall effect:	Z = 0.09 (P = 0.93)						-Z -1 U 1 Z		
Test for subgroup differences: Chi ² = 6.41, df = 2 (P = 0.04), l ² = 68.8%									

1.36 Fortified versus non-fortified complementary food. Outcome: Length-for-age (in z-scores) by

types of products fortified

			Fortified	Non-fortified		Mean Difference	Mean Difference		
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl		
1.36.1 Wheat									
Ekoe 2020 (C)	0.98	0.4375	82	71	5.0%	0.98 [0.12, 1.84]			
Subtotal (95% CI)			82	71	5.0%	0.98 [0.12, 1.84]			
Heterogeneity: Not ap	plicable								
Test for overall effect:	Z = 2.24 (P = 0.03)								
1 36 2 Maize/Corn									
Faher 2005	0.12	0 1 2 9 7	143	145	25.8%	0 1 2 6 0 1 3 0 371	- -		
Subtotal (95% CI)	0.12	0.1201	143	145	25.8%	0.12 [-0.13, 0.37]	◆		
Heterogeneity: Not ap	plicable						-		
Test for overall effect:	Z = 0.93 (P = 0.35)								
1.36.3 Rice							_		
Ma 2016 (C) Subtotal (05% CI)	-0.16	0.1203	140	133	27.4%	-0.16 [-0.40, 0.08]	—		
Subtotal (95% CI)	ulianhla		140	155	21.470	-0.10 [-0.40, 0.00]	\bullet		
Toot for everall offect:	ipiicapie 7 – 1 22 /D – 0 10)								
restion overall ellect.	Z = 1.33 (F = 0.16)								
1.36.4 Cereal-legume	e blend								
Lartey 2000	-0.11	0.0266	47	50	41.8%	-0.11 [-0.16, -0.06]			
Subtotal (95% CI)			47	50	41.8%	-0.11 [-0.16, -0.06]	•		
Heterogeneity: Not ap	plicable								
Test for overall effect: Z = 4.14 (P < 0.0001)									
Total (95% CI)			412	399	100.0%	-0.01 [-0.21, 0.20]	▲		
Heteronenity: Tau ² = 0.03: Chi ² = 9.36 df = 3 (P = 0.02): P = 68%									
Test for overall effect $7 = 0.00 (P = 0.93)$									
Test for subgroup differences: Chi ² = 9.36, df = 3 (P = 0.02), l ² = 68.0%									
1.37 Fortified versus non-fortified complementary food. Outcome: Length-for-age (in z-scores) by

duration of intervention

Study or Subgroup	Mean Difference	SE	Fortified Total	Non-fortified Total	Weight	Mean Difference IV, Random, 95% Cl	Mean Difference IV, Random, 95% Cl	
1.37.1 Less than six	months							
Subtotal (95% CI)			0	0		Not estimable		
Heterogeneity: Not ap	pplicable							
Test for overall effect	Not applicable							
1.37.2 Six months or	rmore							
Ekoe 2020 (C)	0.98	0.4375	82	71	5.0%	0.98 [0.12, 1.84]		
Faber 2005	0.12	0.1297	143	145	25.8%	0.12 [-0.13, 0.37]		
Lartey 2000	-0.11	0.0266	47	50	41.8%	-0.11 [-0.16, -0.06]		
Ma 2016 (C)	-0.16	0.1203	140	133	27.4%	-0.16 [-0.40, 0.08]		
Subtotal (95% CI)			412	399	100.0%	-0.01 [-0.21, 0.20]	◆	
Heterogeneity: Tau ² =	= 0.03; Chi ² = 9.36, d	lf = 3 (P =	: 0.02); l ² =	: 68%				
Test for overall effect:	Z = 0.09 (P = 0.93)							
Total (95% CI)			412	399	100.0%	-0.01 [-0.21, 0.20]	•	
Heterogeneity: Tau ² =	= 0.03; Chi ² = 9.36, d	lf = 3 (P =	: 0.02); I ² =	: 68%				
Test for overall effect:	Z = 0.09 (P = 0.93)						-2 -1 U 1 2	
Test for subgroup dif	ferences: Not applic	able					Favours non-toruned Favours foruned	

1.38 Fortified versus non-fortified complementary food. Outcome: Length-for-age (in z-scores) by

baseline anaemia status

			Fortified	Non-fortified		Mean Difference	Mean Difference
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
1.38.1 Anaemic							
Ekoe 2020 (C)	0.98	0.4375	82	71	5.0%	0.98 [0.12, 1.84]	
Subtotal (95% CI)			82	71	5.0%	0.98 [0.12, 1.84]	
Heterogeneity: Not ap	oplicable						
Test for overall effect:	Z = 2.24 (P = 0.03)						
1.38.2 Non-anaemic							
Subtotal (95% CI)			0	0		Not estimable	
Heterogeneity: Not ap	plicable						
Test for overall effect:	Not applicable						
1.38.3 Mixed/ Unknow	wn						
Faber 2005	0.12	0.1297	143	145	25.8%	0.12 [-0.13, 0.37]	
Lartey 2000	-0.11	0.0266	47	50	41.8%	-0.11 [-0.16, -0.06]	•
Ma 2016 (C)	-0.16	0.1203	140	133	27.4%	-0.16 [-0.40, 0.08]	
Subtotal (95% CI)			330	328	95.0%	-0.08 [-0.20, 0.04]	•
Heterogeneity: Tau² =	: 0.01; Chi ^z = 3.25, d	f= 2 (P =	: 0.20); l ² =	: 38%			
Test for overall effect:	Z = 1.31 (P = 0.19)						
Total (95% CI)			412	399	100.0%	-0.01 [-0.21, 0.20]	
Heterogeneity: Tau ² =	= 0.03; Chi ² = 9.36, d	f= 3 (P =	0.02); I ² =	: 68%			
Test for overall effect:	Z = 0.09 (P = 0.93)						-2 -1 U I Z
Test for subgroup dif	ferences: Chi² = 5.7	6. df = 1 (P = 0.02),	I² = 82.6%			avours non totalica a avours totalica

1.39 Fortified versus non-fortified complementary food. Outcome: Length-for-age (in z-scores) by

country income classification

		Fortified	Non-fortified		Mean Difference	Mean Difference
Study or Subgroup Mean Dif	fference §	E Tota	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.39.1 High income Subtotal (95% CI) Heterogeneity: Not applicable		0	0		Not estimable	
Test for overall effect: Not applic	able					
1.39.2 Upper middle income						
Faber 2005	0.12 0.129	7 143	145	25.8%	0.12 [-0.13, 0.37]	
Ma 2016 (C) Subtotal (95% CI)	-0.16 0.120	13 140 283	133 278	27.4% 53.2%	-0.16 [-0.40, 0.08] - 0.02 [-0.30, 0.25]	-++
Heterogeneity: Tau ² = 0.02; Chi ² Test for overall effect: Z = 0.17 (F	'= 2.51, df= 1 (l P = 0.86)	° = 0.11); I² =	= 60%			
1.39.3 Lower middle income						
Ekoe 2020 (C)	0.98 0.437	5 82	71	5.0%	0.98 [0.12, 1.84]	
Lartey 2000 Subtotal (95% CI)	-0.11 0.020	i6 47 12 9	50 121	41.8% 46.8%	-0.11 [-0.16, -0.06] 0.35 [-0.71, 1.40]	
Heterogeneity: Tau ^z = 0.50; Chi ^z Test for overall effect: Z = 0.65 (F	^e = 6.18, df= 1 (l ^e = 0.52)	° = 0.01); I² =	= 84%			
1.39.4 Low income						
Subtotal (95% CI)		0	0		Not estimable	
Heterogeneity: Not applicable						
Test for overall effect: Not applic	able					
Total (95% CI)		412	399	100.0%	-0.01 [-0.21, 0.20]	+
Heterogeneity: Tau ² = 0.03; Chi ²	= 9.36, df = 3 (l	° = 0.02); l² =	= 68%			-2 -1 0 1 2
Test for overall effect: Z = 0.09 (F Test for subgroup differences: C	° = 0.93) >hi² = 0.45, df =	1 (P = 0.50),	l² = 0%			Favours non-fortified Favours fortified

1.40 Fortified versus non-fortified complementary food. Outcome: Length-for-age (in z-scores) by

study funding

		F	ortified	Non-fortified		Mean Difference	Mean Difference
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
1.40.1 Non-commerce	ial						
Ma 2016 (C)	-0.16	0.1203	140	133	27.4%	-0.16 [-0.40, 0.08]	
Subtotal (95% CI)			140	133	27.4%	-0.16 [-0.40, 0.08]	◆
Heterogeneity: Not ap	plicable						
Test for overall effect:	Z = 1.33 (P = 0.18)						
1 40 2 Commercial (r	artly or fully)						
T.40.2 Commercial (aruy or runy)	0.4075			5.000		
EK06 2020 (C)	0.98	0.4375	82		5.0%	0.98 [0.12, 1.84]	
Faber 2005	0.12	0.1297	143	145	25.8%	0.12 [-0.13, 0.37]	
Lartey 2000	-0.11	0.0266	47	50	41.8%	-0.11 [-0.16, -0.06]	
Subtotal (95% CI)			272	266	72.6%	0.11 [-0.23, 0.44]	*
Heterogeneity: Tau ^z =	0.06; Chi ² = 9.10, d	f=2 (P=	0.01); I ^z =	: 78%			
Test for overall effect:	Z = 0.62 (P = 0.53)						
Total (95% CI)			412	399	100.0%	-0.01 [-0.21, 0.20]	◆
Heterogeneity: Tau ² =	0.03 [:] Chi ² = 9.36 [.] d	f = 3 (P = 1)	0 02) [,] I ² =	68%			-+ + + + + - + - + + + + + + + + +
Test for overall effect:	7 = 0.09 (P = 0.93)		-2 -1 0 1 2				
Test for subgroup diff	2 = 0.00 (1 = 0.00)	o. d€_ 4./⊓	- 0.200	IZ - 00 CW			Favours non-fortified Favours fortified
rest for subgroup alm	erences. Chi* = 1.6.	s, ui = 1 (F	r = 0.20),	1-= 38.0%			

1.41. Fortified versus non-fortified complementary food. Outcome: Iron status (ferritin

concentrations in µg/L)

			Fortified	Non-fortified		Mean Difference	Mean Difference
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Ekoe 2020 (C)	0.66	0.2078	82	71	16.1%	0.66 [0.25, 1.07]	
Faber 2005	0.89	0.1331	141	138	19.8%	0.89 [0.63, 1.15]	-
Lartey 2000	0.42	0.2222	27	28	15.4%	0.42 [-0.02, 0.86]	
Liu 1993 (C)	0.15	0.0238	56	70	23.5%	0.15 [0.10, 0.20]	•
Ma 2016 (C)	0.2	0.1103	97	104	20.9%	0.20 [-0.02, 0.42]	-
Schumann 2005	0.13	0.6336	61	28	4.4%	0.13 [-1.11, 1.37]	
Total (95% CI)			464	439	100.0%	0.43 [0.14, 0.72]	•
Heterogeneity: Tau ² =	0.09; Chi ² = 36.57,						
Test for overall effect:	Z = 2.92 (P = 0.003	Favours non-fortified Favours fortified					

1.42. Fortified versus non-fortified complementary food. Outcome: Iron status (ferritin) by age at

start of the intervention

			Fortified	Non-fortified		Mean Difference	Mean Difference
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
1.42.1 6 to 11 months	S						
Faber 2005	0.89	0.1331	141	138	19.8%	0.89 [0.63, 1.15]	
Lartey 2000	0.42	0.2222	27	28	15.4%	0.42 [-0.02, 0.86]	
Liu 1993 (C)	0.15	0.0238	56	70	23.5%	0.15 [0.10, 0.20]	•
Ma 2016 (C)	0.2	0.1103	97	104	20.9%	0.20 [-0.02, 0.42]	-
Subtotal (95% CI)			321	340	79.6%	0.40 [0.07, 0.73]	◆
Heterogeneity: Tau ² =	0.09; Chi ² = 31.22,	df = 3 (P	< 0.00001	l); I² = 90%			
Test for overall effect:	Z = 2.39 (P = 0.02)						
1.42.2 12 to 23 month	hs						
Schumann 2005	0.13	0.6336	61	28	4.4%	0.13 [-1.11, 1.37]	
Subtotal (95% CI)			61	28	4.4%	0.13 [-1.11, 1.37]	
Heterogeneity: Not ap	plicable						
Test for overall effect:	Z = 0.21 (P = 0.84)						
1.42.3 Mean age >23	months						
Ekoe 2020 (C)	0.66	0.2078	82	71	16.1%	0.66 [0.25, 1.07]	
Subtotal (95% CI)			82	/1	16.1%	0.66 [0.25, 1.07]	-
Heterogeneity: Not ap	plicable						
Test for overall effect:	Z = 3.18 (P = 0.001))					
Total (05% CI)			464	430	100.0%	0 43 [0 14 0 72]	
Hotorogonoity Tour	0.00-068-08.57	df = 5 /D	+04	-+39	100.070	0.45 [0.14, 0.72]	
Teat for overall offect:	0.09, CHE = 30.57, 7 = 3.03 /0 = 0.003	ui = 5 (P \	< 0.0000	1), 11 = 00%			-'2 -'1 0 1 2
Test for overall effect:	Z = Z.9Z (P = 0.003)) 0.46-0.	(n – 0 cm	17 - 00			Favours non-fortified Favours fortified
rest for subgroup all	erences. Chi* = 1.2	8. ui = 2 i	(F = 0.53),	17 = 0.76			

1.43. Fortified versus non-fortified complementary food. Outcome: Iron status (ferritin) by types of

nutrients added through fortification

Study or Subgroup	Mean Difference	SE I	Fortified	Non-fortified	Weight	Mean Difference	Mean Difference
1.43.1 Iron	mean billerence	JL	Total	Total	reight	iv, rundom, 55% cr	N, Nulldoni, 35% Cl
Ekoe 2020 (C)	0.66	0.2078	82	71	16.1%	0.66 [0.25, 1.07]	_
Schumann 2005 Subtotal (95% Cl)	0.13	0.6336	61 143	28 99	4.4% 20.4%	0.13 [-1.11, 1.37] 0.61 [0.22, 1.00]	•
Heterogeneity: Tau ² = Test for overall effect:	= 0.00; Chi ² = 0.63, c : Z = 3.08 (P = 0.002	lf = 1 (P =)	0.43); I² =	0%			
1.43.3 Iron, zinc, vita	min B12						
Ma 2016 (C) Subtotal (95% CI)	0.2	0.1103	97 97	104 104	20.9% 20.9%	0.20 [-0.02, 0.42] 0.20 [-0.02, 0.42]	•
Heterogeneity: Not ap Test for overall effect:	oplicable : Z = 1.81 (P = 0.07)						
1.43.4 Multivitamins	and minerals						
Faber 2005	0.89	0.1331	141	138	19.8%	0.89 [0.63, 1.15]	
Lartey 2000	0.42	0.2222	27	28	15.4%	0.42 [-0.02, 0.86]	
Liu 1993 (C) Subtotal (95% CI)	0.15	0.0238	56 224	70 236	23.5% 58.7%	0.15 [0.10, 0.20] 0.48 [-0.05, 1.01]	-
Heterogeneity: Tau² = Test for overall effect:	= 0.20; Chi ² = 31.18, : Z = 1.78 (P = 0.07)	df = 2 (P	< 0.00001)); I² = 94%			
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect:	= 0.09; Chi² = 36.57, : Z = 2.92 (P = 0.003	df = 5 (P ·)	464 < 0.00001	439); I² = 86%	100.0%	0.43 [0.14, 0.72]	-2 -1 0 1 2 Favours non-fortified
Test for subgroup dif	ferences: Chi² = 3.6	7. df = 2 (F	P = 0.16), I	l² = 45.5%			

1.44. Fortified versus non-fortified complementary food. Outcome: Iron status (ferritin) by types of

products fortified

			Fortified	Non-fortified		Mean Difference	Mean Difference
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.44.1 Wheat							
Ekoe 2020 (C)	0.66	0.2078	82	71	16.1%	0.66 [0.25, 1.07]	→
Liu 1993 (C)	0.15	0.0238	56	70	23.5%	0.15 [0.10, 0.20]	•
Subtotal (95% CI)			138	141	39.6%	0.36 [-0.13, 0.86]	-
Heterogeneity: Tau ² =	0.11; Chi ² = 5.95, d 7 = 1.44 (P = 0.15)	f=1 (P=	0.01); I² =	83%			
restion overall enect.	2 - 1.44 (1 - 0.13)						
1.44.2 Maize/Corn							
Faber 2005	0.89	0.1331	141	138	19.8%	0.89 [0.63, 1.15]	
Subtotal (95% CI)			141	138	19.8%	0.89 [0.63, 1.15]	•
Heterogeneity: Not ap	plicable						
Test for overall effect:	Z = 6.69 (P < 0.000	01)					
1.44.3 Rice							
Ma 2016 (C)	0.2	0.1103	97	104	20.9%	0.201-0.02_0.421	- - -
Subtotal (95% CI)			97	104	20.9%	0.20 [-0.02, 0.42]	◆
Heterogeneity: Not ap	plicable						
Test for overall effect:	Z = 1.81 (P = 0.07)						
1.44.4 Cereal-legume	e blend						
Lartey 2000	0.42	0.2222	27	28	15.4%	0.42 [-0.02, 0.86]	
Subtotal (95% CI)			27	28	15.4%	0.42 [-0.02, 0.86]	
Heterogeneity: Not ap	plicable						
Test for overall effect:	Z = 1.89 (P = 0.06)						
1.44.5 Legume							
Schumann 2005	0.13	0.6336	61	28	4.4%	0.13 [-1.11.1.37]	
Subtotal (95% CI)			61	28	4.4%	0.13 [-1.11, 1.37]	
Heterogeneity: Not ap	plicable						
Test for overall effect:	Z = 0.21 (P = 0.84)						
T-4-1 (05% OB			10.1		400.05	0.40 00.44.0 707	
Total (95% CI)			464	439	100.0%	0.43 [0.14, 0.72]	
Heterogeneity: Tau ² =	0.09; Chi ² = 36.57,	df = 5 (P	< 0.00001); I* = 86%		-	-2 -1 0 1 2
lest for overall effect:	Z = 2.92 (P = 0.003)					Favours non-fortified Favours fortified
lest for subgroup diff	erences: Chi ² = 16.	44. df = 4	(P = 0.002)	2), I≝ = 75.7%			

1.45. Fortified versus non-fortified complementary food. Outcome: Iron status (ferritin) by

duration of intervention

			Fortified	Non-fortified		Mean Difference	Mean Difference
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.45.1 Less than six	months						
Liu 1993 (C)	0.15	0.0238	56	70	23.5%	0.15 [0.10, 0.20]	-
Schumann 2005	0.13	0.6336	61	28	4.4%	0.13 [-1.11, 1.37]	
Subtotal (95% CI)			117	98	27.9%	0.15 [0.10, 0.20]	•
Heterogeneity: Tau ² =	= 0.00; Chi ² = 0.00, d	f=1 (P=	= 0.97); l ² =	:0%			
Test for overall effect:	Z = 6.31 (P < 0.000)	01)					
1.45.2 Six months or	more						
Ekoe 2020 (C)	0.66	0.2078	82	71	16.1%	0.66 [0.25, 1.07]	
Faber 2005	0.89	0.1331	141	138	19.8%	0.89 [0.63, 1.15]	
Lartey 2000	0.42	0.2222	27	28	15.4%	0.42 [-0.02, 0.86]	
Ma 2016 (C)	0.2	0.1103	97	104	20.9%	0.20 [-0.02, 0.42]	
Subtotal (95% CI)			347	341	72.1%	0.54 [0.17, 0.91]	◆
Heterogeneity: Tau ² =	= 0.11; Chi ² = 16.70,	df = 3 (P	= 0.0008)	; I² = 82%			
Test for overall effect:	Z = 2.87 (P = 0.004))					
Total (95% CI)			464	439	100.0%	0.43 [0.14, 0.72]	◆
Heterogeneity: Tau ² =	= 0.09; Chi ² = 36.57,	df = 5 (P	< 0.00001); I² = 86%		-	
Test for overall effect:	Z = 2.92 (P = 0.003)		-2 -1 U 1 2				
Test for subaroup diff	ferences: Chi ² = 4.24	4. df = 1 i	(P = 0.04).	I² = 76.4%			Favours non-formed Favours formed

1.46. Fortified versus non-fortified complementary food. Outcome: Iron status (ferritin) by baseline

anaemia status

	Fortified	Non-fortified		Mean Difference	Mean Difference
Study or Subgroup Mean Difference	SE Tota	l Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.46.1 Anaemic					
Ekoe 2020 (C) 0.66	0.2078 8	2 71	16.1%	0.66 [0.25, 1.07]	_
Schumann 2005 0.13	0.6336 6	1 28	4.4%	0.13 [-1.11, 1.37]	
Subtotal (95% CI)	14	3 99	20.4%	0.61 [0.22, 1.00]	-
Heterogeneity: Tau ² = 0.00; Chi ² = 0.63,	df = 1 (P = 0.43); I ²	= 0%			
Test for overall effect: Z = 3.08 (P = 0.002	2)				
1 46 3 Non anacmia					
1.40.2 NOR-anatemic Subtotal (05% CI)				Not optimable	
Listeregeneitir bist ennliseble		0		Notesumable	
Test for everall effect: Not applicable					
restion overall ellect. Not applicable					
1.46.3 Mixed/Unknown					
Faber 2005 0.89	0.1331 14	1 138	19.8%	0.89 [0.63, 1.15]	
Lartey 2000 0.42	0.2222 2	7 28	15.4%	0.42 [-0.02, 0.86]	
Liu 1993 (C) 0.15	0.0238 5	6 70	23.5%	0.15 [0.10, 0.20]	•
Ma 2016 (C) 0.2	0.1103 9	7 104	20.9%	0.20 [-0.02, 0.42]	
Subtotal (95% CI)	32	1 340	79.6%	0.40 [0.07, 0.73]	◆
Heterogeneity: Tau ² = 0.09; Chi ² = 31.22	, df = 3 (P ≺ 0.0000	1); I² = 90%			
Test for overall effect: Z = 2.39 (P = 0.02)					
Total (95% CI)	46	4 439	100.0%	0.43 [0.14, 0.72]	•
Heterogeneity: $Tau^2 = 0.09$: $Chi^2 = 36.57$	df = 5 (P < 0.0000	1)· I≅ = 86%			
Test for overall effect: $7 = 2.92$ (P = 0.00)	ui = 0 (i = 0.0000 })	17,1 = 30.0			-2 -1 0 1 2
Test for subgroup differences: Chi ² = 0.8	-/)5. df = 1 (P = 0.42)	. I ² = 0%			Favours non-fortified Favours fortified

1.47. Fortified versus non-fortified complementary food. Outcome: Iron status (ferritin) by country

income classification

	Fortified	Non-fortified		Mean Difference	Mean Difference
Study or Subgroup Mean Difference	SE Tota	l Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
1.47.1 High income					
Subtotal (95% CI)	() 0		Not estimable	
Heterogeneity: Not applicable					
Test for overall effect: Not applicable					
1.47.2 Upper middle income					
Faber 2005 0.89 0.13	31 141	138	19.8%	0.89 [0.63, 1.15]	
Liu 1993 (C) 0.15 0.02	38 56	6 70	23.5%	0.15 [0.10, 0.20]	•
Ma 2016 (C) 0.2 0.11	3 93	' 104	20.9%	0.20 [-0.02, 0.42]	
Schumann 2005 0.13 0.63	36 6 [.]	28	4.4%	0.13 [-1.11, 1.37]	
Subtotal (95% CI)	35	5 340	68.6%	0.38 [0.01, 0.74]	\bullet
Heterogeneity: Tau ² = 0.10; Chi ² = 30.02, df = 3	(P < 0.0000	1); I² = 90%			
Test for overall effect: Z = 2.04 (P = 0.04)					
1.47.3 Lower middle income					
Ekoe 2020 (C) 0.66 0.20	'8 8:	2 71	16.1%	0.66 [0.25, 1.07]	
Lartey 2000 0.42 0.22:	2 2	' 28	15.4%	0.42 [-0.02, 0.86]	
Subtotal (95% CI)	109) 99	31.4%	0.55 [0.25, 0.85]	◆
Heterogeneity: Tau ² = 0.00; Chi ² = 0.62, df = 1 (° = 0.43); I²	= 0%			
Test for overall effect: Z = 3.61 (P = 0.0003)					
1.47.4 Low income					
Subtotal (95% CI)	() 0		Not estimable	
Heterogeneity: Not applicable					
Test for overall effect: Not applicable					
Total (95% CI)	464	439	100.0%	0.43 [0.14, 0.72]	•
Heterogeneity: Tau ² = 0.09: Chi ² = 36.57 df = 5	(P < 0.0000	1); ² = 86%			
Test for overall effect: $Z = 2.92$ (P = 0.003)	. 0.0000	.,,			-2 -1 0 1 2
Test for subgroup differences: Chi ² = 0.50, df =	1 (P = 0.48)	. I² = 0%			Favours non-tortified Favours fortified

1.48. Fortified versus non-fortified complementary food. Outcome: Iron status (ferritin) by study

funding

			Fortified	Non-fortified		Mean Difference	Mean Difference				
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI				
1.48.1 Non-commerce	ial										
Liu 1993 (C)	0.15	0.0238	56	70	23.5%	0.15 [0.10, 0.20]	•				
Ma 2016 (C)	0.2	0.1103	97	104	20.9%	0.20 [-0.02, 0.42]					
Subtotal (95% CI)			153	174	44.4%	0.15 [0.11, 0.20]	•				
Heterogeneity: Tau ² = 0.00; Chi ² = 0.20, df = 1 (P = 0.66); l ² = 0%											
Test for overall effect:	Z = 6.54 (P < 0.000	01)									
1.48.2 Commercial (partly or fully)										
Ekoe 2020 (C)	0.66	0.2078	82	71	16.1%	0.66 [0.25, 1.07]					
Faber 2005	0.89	0.1331	141	138	19.8%	0.89 [0.63, 1.15]					
Lartey 2000	0.42	0.2222	27	28	15.4%	0.42 [-0.02, 0.86]					
Subtotal (95% CI)			250	237	51.2%	0.70 [0.43, 0.98]	•				
Heterogeneity: Tau ² =	0.03; Chi ² = 3.49, d	if = 2 (P =	= 0.17); l ² =	: 43%							
Test for overall effect:	Z = 5.01 (P < 0.000	01)									
1.48.3 Unknown											
Schumann 2005	0.13	0.6336	61	28	4.4%	0.13 [-1.11, 1.37]					
Subtotal (95% CI)			61	28	4.4%	0.13 [-1.11, 1.37]					
Heterogeneity: Not ap	plicable										
Test for overall effect:	Z = 0.21 (P = 0.84)										
Total (95% CI)			464	439	100.0%	0.43 [0.14, 0.72]	◆				
Heterogeneity: Tau ² =	0.09; Chi ² = 36.57,	df = 5 (P	< 0.00001	l); I² = 86%							
Test for overall effect:	Z = 2.92 (P = 0.003)					Favours non-fortified Eavours fortified				
Test for subgroup diff	erences: Chi ² = 14.	99, df = 2	2 (P = 0.00	06), I ² = 86.7%			r avoirs non totalloa - r avoirs totalloa				

1.49. Fortified versus non-fortified complementary food. Outcome: Iron status (body iron in

mg/kg)

Study or Subgroup	Std. Mean Difference	SE	Favours non-fortified Total	Non-fortified Total	Weight	Std. Mean Difference IV, Random, 95% Cl	Std. Mean Difference IV, Random, 95% Cl
Ma 2016 (C)	1.47	0.4309	97	104	100.0%	1.47 [0.63, 2.31]	
Total (95% CI) Heterogeneity: Not ap Test for overall effect:	plicable Z = 3.41 (P = 0.0006)		97	104	100.0%	1.47 [0.63, 2.31]	-10 -5 0 5 10 Favours non-fortified Favours fortified

1.50. Fortified versus non-fortified complementary food. Outcome: Iron status (free erythrocyte

porphyrin in µg/L)

			Fortified	Non-fortified		Mean Difference		Me	an Dif	ference		
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI		IV, R	andor	n, 95% Cl		
Liu 1993 (C)	30	30.231	69	78	100.0%	30.00 [-29.25, 89.25]		_				
Total (95% CI)			69	78	100.0%	30.00 [-29.25, 89.25]						_
Heterogeneity: Not ap Test for overall effect:	oplicable Z = 0.99 (P = 0.32)						-100 Fav	-50 ours non-for	0 tified	Favours fo	50 rtified	100

1.51. Fortified versus non-fortified complementary food. Outcome: Serum retinol ($\mu mol/L$)

Study or Subgroup	Mean Difference	SE	Fortified Total	Non-fortified Total	Weight	Mean Difference IV, Random, 95% Cl	Mean Difference IV, Random, 95% Cl	
Faber 2005	0.11	0.0557	68	69	19.3%	0.11 [0.00, 0.22]		
Lartey 2000	0.05	0.0862	29	37	8.1%	0.05 [-0.12, 0.22]	-	
Liu 1993 (C)	0	0.0358	60	66	46.8%	0.00 [-0.07, 0.07]	-	
Nesamvuni 2005	-0.01	0.1368	16	20	3.2%	-0.01 [-0.28, 0.26]		
Palmer 2021	0.02	0.0515	52	58	22.6%	0.02 [-0.08, 0.12]		
Total (95% CI)			225	250	100.0%	0.03 [-0.02, 0.08]	•	
Heterogeneity: Tau ² = 0.00; Chi ² = 2.94, df = 4 (P = 0.57); l ² = 0%								
Test for overall effect:	Z = 1.20 (P = 0.23)						Favours non-fortified Favours fortified	

1.52. Serum zinc concentration

	Fo	rtifie	d	Non-	fortifi	ed	Mean Difference			Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% Cl
Lartey 2000	14.4	3.4	30	15.5	4.3	31	11.7%	-1.10 [-3.04, 0.84]	2000	-
Faber 2005	10.6	2.1	140	10.6	1.8	132	88.3%	0.00 [-0.46, 0.46]	2005	
Total (95% CI)			170			163	100.0%	-0.13 [-0.82, 0.56]		
Heterogeneity: Tau² = Test for overall effect:	0.09; C Z = 0.38	hi² = 6 (P =	1.17, df 0.72)	f=1(P=	= 0.28); I ^z = 1	4%			-10 -5 0 5 10 Favours pon-fortified Favours fortified

1.53. Fortified versus non-fortified complementary food. Outcome: Morbidity



1.54. Fortified versus non-fortified complementary food. Outcome: Mental skill development

Study or Subgroup	Mean Difference	SE	Fortified Total	Non-fortified Total	Weight	Mean Difference IV, Random, 95% Cl	Mean IV, Ran	Difference dom, 95% C	1	
Ma 2016 (C)	0.8	0.3894	55	58	78.6%	0.80 [0.04, 1.56]				
Quintero 2011	0.8	0.7473	195	200	21.4%	0.80 [-0.66, 2.26]	-		_	
Total (95% CI)			250	258	100.0%	0.80 [0.12, 1.48]		•		
Heterogeneity: Tau ² = Test for overall effect:	: 0.00; Chi ² = 0.00, c Z = 2.32 (P = 0.02)	lf = 1 (P =	= 1.00); I² =	= 0%			-4 -2 Favours non-fortifie	0 2 ed Favours	2 4 fortified	

1.55. Fortified versus non-fortified complementary food. Outcome: Motor skill development

			Fortified	Non-fortified		Mean Difference	Mean Difference
Study or Subgroup	Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.55.1 Fine motor sc	ore (BSID III)						
Ma 2016 (C) Subtotal (95% CI)	0	0.205	55 55	58 58	100.0%	0.00 [-0.40, 0.40]	.
Heterogeneity: Not ar	nlicable			50	100.070	0.00 [-0.10, 0.10]	Ť
Test for overall effect:	7 = 0.00 (P = 1.00)						
	,						
1.55.2 Gross motor s	score (BSID III)						
Ma 2016 (C)	-0.2	0.2142	55	58	100.0%	-0.20 [-0.62, 0.22]	
Subtotal (95% CI)			55	58	100.0%	-0.20 [-0.62, 0.22]	
Heterogeneity: Not ap	oplicable						
Test for overall effect:	Z = 0.93 (P = 0.35)						
1.55.3 Motor skill (Ba	aley)						_
Faber 2005	1.1	0.4735	128	138	69.8%	1.10 [0.17, 2.03]	
Quintero 2011	1.2	0.7205	195	200	30.2%	1.20 [-0.21, 2.61]	
Subtotal (95% CI)			323	338	100.0%	1.13 [0.35, 1.91]	-
Heterogeneity: Tau² =	: 0.00; Chi² = 0.01, d	lf = 1 (P =	: 0.91); I ² =	:0%			
Test for overall effect:	Z = 2.86 (P = 0.004))					
							-4 -2 0 2 4
Ta at fan andernander die		7 46 0	(D. 0.04)	17 77 600			Favours non-fortified Favours fortified

Test for subgroup differences: Chi² = 8.87, df = 2 (P = 0.01), l² = 77.5%

1.56. Fortified versus non-fortified complementary food. Outcome: Iron deficiency

Study or Subgroup	log[Risk Ratio]	SE	Fortified Total	Non-fortified Total	Weight	Risk Ratio IV, Random, 95% Cl		Risk I IV, Rando	Ratio m, 95% Cl		
Ekoe 2020 (C) Lartey 2000 Ma 2016 (C)	-1.1202 -1.6328 -0.5558	0.511 0.5694 0.1948	106 28 140	133 31 133	25.1% 21.8% 53.1%	0.33 [0.12, 0.89] 0.20 [0.06, 0.60] 0.57 [0.39, 0.84]					
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect:	: 0.16; Chi² = 3.89 Z = 2.86 (P = 0.00	, df= 2 (1 04)	274 P = 0.14); I ²	297 = 49%	100.0%	0.39 [0.21, 0.75]	H 0.01	0.1 1 Favours fortified	Favours non) -fortifie	100 d

1.57. Fortified versus non-fortified complementary food. Outcome: Vitamin A deficiency

	Fortified Non-fortified			Risk Ratio	Risk Ratio	
Study or Subgroup	Events T	fotal Eve	ents Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Lartey 2000	3	29	10 31	36.5%	0.32 [0.10, 1.05]	
Nesamvuni 2005	7	16	0 20	16.5%	18.53 [1.14, 301.79]	
Palmer 2021	29	103	20 58	47.0%	0.82 [0.51, 1.31]	
Total (95% CI)		148	109	100.0%	0.97 [0.24, 3.90]	
Total events	39		30			
Heterogeneity: Tau² = Test for overall effect:	1.01; Chi² = Z = 0.04 (P	= 7.61, df = 0.97)	⁷ = 2 (P = 0.02); I² = 74%		0.1 0.2 0.5 1 2 5 10 Favours fortified Favours non-fortified

1.58. Fortified versus non-fortified complementary food. Outcome: Zinc deficiency

	Fortifi	ed	Non-fortified			Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl		M-H, Rand	om, 95% Cl	
Lartey 2000	3	30	1	31		3.10 [0.34, 28.17]				
							0.01	0.1	+ + 1 11	0 100
							0.01	Favours fortified	Favours non	-fortified

Appendix 7. Information about malaria in the area of the trial

Study	Country	Malaria presence in	Children	Malaria
		the region	with	endemic
		mentioned in the	malaria	country *
		manuscript	included	
Palmer 2021	Zambia	yes	yes	yes
Lartey 2000	Ghana	yes	yes	yes
Ma 2016	China	no	-	no
Arcanjo 2012	Brazil	no	-	yes
Schumann 2005	Guatemala	yes	yes	yes
Huey 2018	India	no	-	yes
Faber 2005	South Africa	no	-	yes
Liu 1993	China	no	-	no
Nesamvuni 2005	South Africa	no	-	yes
Bovell-Benjamin 1999	USA	no	-	no
Gershoff 1977	Thailand	no	-	yes
Gannon 2019	India	yes	no	yes
Arcanjo 2013	Brazil	no	-	yes
Bagni 2009	Brazil	no	-	yes
Ekoe 2020	(East) Cameroon	yes	yes**	yes
Quintero 2011	Mexico	no	-	yes

*based on: Word Malaria Report, 10 years of Global Progress & Challenges, 2020

**severe malaria cases were excluded

Appendix 8. GRADE Assessment

Certainty assessment						№ of patients		Effect				
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Fortified complementary food	Non-fortified complementary food	Relative (95% Cl)	Absolute (95% Cl)	Certainty	Importance

Anaemia (follow-up: 3 to 12 months)

6 ^{1,2,3,4,5,6} randomised serious ^a not serious not serious not serious	erious ^b none 51/617 (8.3%)	90/588 (15.3%) RR 0.57 (0.39 to 0.82) 66 fewer per 1 000 (from 93 fewer to 28 fewer)	⊕⊕⊕⊖ CRITICAL Moderate
--	--	---	---------------------------

Haemoglobin (follow-up: 3 to 12 months; assessed with: g/L)

nigner)

Weight-for-age (follow-up: 6 to 12 months; assessed with: z-scores)

		(Certainty assess	ment			№ of patients Effec			ct		
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Fortified complementary food	Non-fortified complementary food	Relative (95% Cl)	Absolute (95% Cl)	Certainty	Importance
51,4,8,11,12	randomised trials	serious ^f	not serious	not serious	not serious ^e	none	607	599	-	MD 0.01 z-score lower (0.07 lower to 0.06 higher)	⊕⊕⊕⊖ Moderate	CRITICAL

Weight-for-length (follow-up: 6 to 12 months; assessed with: z-scores)

4 1.4.8,12	randomised serious ⁹ trials	s ^g not serious r	not serious	not serious ^e	none	560	549	-	MD 0.05 z-score lower (0.19 lower to 0.1 higher)	⊕⊕⊕⊖ Moderate	CRITICAL
-------------------	---	------------------------------	-------------	--------------------------	------	-----	-----	---	--	------------------	----------

Length-for-age (follow-up: 6 to 12 months; assessed with: z-scores)

41,4,5,12	randomised	serious ^g	serious ^h	not serious	not serious ^e	none	412	399	-	MD 0.01	$\oplus \oplus \bigcirc \bigcirc$	CRITICAL
	triais									z-score	LOW	l
										lower		l
										(0.21		l
										lower to		l
										0.2		l
										higher)		l
										. ,		ĺ

Iron status (follow-up: 3 to 12 months; assessed with: ferritin concentrations in ug/L)

		(Certainty assess	ment			Nº of patients Effect			ect		
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Fortified complementary food	Non-fortified complementary food	Relative (95% Cl)	Absolute (95% Cl)	Certainty	Importance
61,4,5,7,10,12	randomised trials	serious ⁱ	serious ⁱ	not serious	not serious ^e	none	464	439	-	MD 0.43 ug/L higher (0.14 higher to 0.72 higher)	⊕⊕⊖⊖ Low	CRITICAL

Iron status (follow-up: 12 months; assessed with: body iron in mg/kg)

1 ⁴	randomised trials	serious ^k	not serious ^ı	not serious	serious ^m	none	97	104	-	MD 1.47 mg/kg	⊕⊕⊖⊖ Low	CRITICAL
										higher		
										higher to		
										2.31 higher)		

Iron status (follow-up: 3 months; assessed with: free erythrocythe porphyrin in µg/L)

110	randomised trials	very serious ⁿ	not serious ⁱ	not serious	serious ^m	none	69	78	-	MD 30 higher (26.06 lower to 86.06 higher)	⊕⊖⊖⊖ Very low	CRITICAL

Serum retinol (follow-up: 3 to 12 months; assessed with: µmol/L)

		(Certainty assess	ment			№ of p	atients	Effe	ect		
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Fortified complementary food	Non-fortified complementary food	Relative (95% Cl)	Absolute (95% Cl)	Certainty	Importance
55,9,10,12,13	randomised trials	serious⁰	not serious	not serious	not serious ^e	none	225	250	-	MD 0.03 umol/L higher (0.02 lower to 0.08 higher)	⊕⊕⊕⊖ Moderate	CRITICAL

Serum zinc (follow-up: 6 months; assessed with: g/dL)

25,12	randomised se trials	serious ^p	not serious	not serious	serious ^m	none	170	163	-	MD 0.13 lower (0.82 lower to 0.56 higher)	⊕⊕⊖⊖ Low	CRITICAL
-------	-------------------------	----------------------	-------------	-------------	----------------------	------	-----	-----	---	--	-------------	----------

Diarrhoea (follow-up: 6 months; assessed with: number of new episoded/ 100 days at risk)

15	randomised trials	serious ^k	not serious ⁱ	not serious	very serious ^q	none	47	50	-	MD 0.6 higher (2.16 lower to 3.36 higher)	⊕⊖⊖⊖ Very low	IMPORTANT
										- ,		

Acute respiratory tract diseases (follow-up: 6 months; assessed with: number of new episoded/ 100 days at risk)

		(Certainty assess	ment			№ of p	atients	Effe	ect		
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Fortified complementary food	Non-fortified complementary food	Relative (95% Cl)	Absolute (95% Cl)	Certainty	Importance
15	randomised trials	serious ^k	not serious ⁱ	not serious	very serious ^q	none	47	50	-	MD 0.3 higher (0.38 lower to 0.98 higher)	⊕OOO Very low	IMPORTANT

Fever diseases (follow-up: 6 months; assessed with: number of new episoded/ 100 days at risk)

15	randomised trials	serious ^k	not serious ⁱ	not serious	very serious ^q	none	47	50	-	MD 0.1 higher (1.21 lower to 1.41 higher)	⊕⊖⊖⊖ Very low	IMPORTANT

Mental skill development (follow-up: 10 to 12 months; assessed with: BSID I-III)

2 ^{4,8}	randomised trials	serious ^r	not serious	not serious	not serious ^e	none	250	258	_	MD 0.8 higher (0.12 higher to 1.48 higher)	⊕⊕⊕⊖ Moderate	IMPORTANT
------------------	----------------------	----------------------	-------------	-------------	--------------------------	------	-----	-----	---	--	------------------	-----------

Fine motor score (follow-up: 12 months; assessed with: BSID III)

		(Certainty assess			№ of p	atients	Effe	ect			
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Fortified complementary food	Non-fortified complementary food	Relative (95% Cl)	Absolute (95% Cl)	Certainty	Importance
14	randomised trials	serious ^k	not serious ⁱ	not serious	serious ^m	none	55	58	-	MD 0 (0.4 lower to 0.4 higher)	⊕⊕⊖⊖ Low	IMPORTANT

Gross motor score (follow-up: 12 months; assessed with: BSID III)

14	randomised s trials	serious ^k	not serious ⁱ	not serious	serious ^m	none	55	58	-	MD 0.2 lower (0.62 lower to 0.22 higher)	⊕⊕⊖⊖ Low	IMPORTANT
----	------------------------	----------------------	--------------------------	-------------	----------------------	------	----	----	---	---	-------------	-----------

Psychomotor development (follow-up: 6 to 10 months; assessed with: BSID I-III)

28,12	randomised trials	serious ^p	not serious	not serious	not serious ^e	none	323	338	-	MD 1.13 higher (0.35 higher to 1.91 higher)	⊕⊕⊕⊖ Moderate	IMPORTANT

Acceptability (follow-up: 3 days; assessed with: 9-point hedonic scale)

	Certainty assessment							№ of patients		ect		
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Fortified complementary food	Non-fortified complementary food	Relative (95% Cl)	Absolute (95% Cl)	Certainty	Importance
314,15,16	randomised + non- randomised trials	very serious ^s	not serious	not serious	serious ^m	none	Acceptability of fo complementary fo with a total of 215 significant differer allocated to the tw	rtified as compared ood was measured i children. All descri nces between the ra vo groups	to unfortified n three acute bed that there atings of childr	studies were no en	⊕⊖⊖⊖ Very low	IMPORTANT

Iron deficiency (follow-up: 6 to 12 months)

31.4,5	randomised trials	serious ^t	not serious	not serious	not serious ^u	none	48/274 (17.5%)	120/297 (40.4%)	RR 0.39 (0.21 to 0.75)	246 fewer per 1 000 (from 319 fewer to 101 fewer)	⊕⊕⊕⊖ Moderate	CRITICAL
--------	----------------------	----------------------	-------------	-------------	--------------------------	------	----------------	--------------------	-------------------------------------	--	------------------	----------

Vitamin A deficiency (follow-up: 3 to 12 months)

35,9,13	randomised trials	very serious ^v	serious ^w	not serious	serious ^x	none	39/148 (26.4%)	30/109 (27.5%)	RR 0.97 (0.24 to 3.90)	8 fewer per 1 000 (from 209 fewer to 798 more)	⊕⊖⊖⊖ Very low	CRITICAL
										more)		

Zinc deficiency (follow-up: 6 months)

	Certainty assessment							№ of patients		ect		
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Fortified complementary food	Non-fortified complementary food	Relative (95% Cl)	Absolute (95% Cl)	Certainty	Importance
15	randomised trials	serious ^y	not serious ⁱ	not serious	very serious ^z	none	3/30 (10.0%)	1/31 (3.2%)	RR 3.10 (0.34 to 28.17)	68 more per 1 000 (from 21 fewer to 876 more)	⊕⊖⊖⊖ Very low	CRITICAL

CI: confidence interval; MD: mean difference; RR: risk ratio

Explanations

a. Downgraded by one level for risk of bias (RoB) since 1 out of 6 studies was rated with a high RoB, and none of the included studies was rated with a low RoB.

b. Not downgraded for imprecision. Although the number of events was low (<400), the outcome was a common event (occurred >1/100), and there were 6 studies with a median sample size of 170 children included. The 95% confidence interval (CI) for the pooled estimate is narrow and is consistent with benefit.

c. Downgraded by one level for RoB since 5 out of 11 studies were rated with a high RoB, and none of the included studies was rated with a low RoB.

d. Not downgraded for inconsistency although l² was 55% (driven by the study of Faber et al. 2005), since 95% CI overlaps mainly between studies. In all sub-group analyses heterogeneity was present only in those sub-groups which contained the study Faber et al. 2005, while no heterogeneity was observed in other sub-groups.

e. Not downgraded for imprecision since number of participants was >400.

f. Downgraded by one level for RoB since 1 out of 5 studies were rated with a high RoB, and none of the included studies was rated with a low RoB.

g. Downgraded by one level for RoB since 1 out of 4 studies were rated with a high RoB, and none was rated as low RoB.

h. Downgraded by one level for inconsistency since I² was 68%, p-value for heterogeneity was 0.02, point estimates and 95% CI did not overlap between studies. Sub-group analyses did not fully explain heterogeneity.

i. Downgraded by one level for RoB since 3 out of 6 studies were rated with a high RoB, and none was rated as low RoB.

j. Downgraded by one level for inconsistency since I² was 86%, p-value for heterogeneity was <0.001, point estimates and 95% CI did not overlap between studies. Sub-group analyses did not fully explain heterogeneity.

k. Downgraded by one level for RoB since the included study was rated with some concerns of RoB.

I. This is a single study so inconsistency cannot be judged.

m. Downgraded by one level for imprecision since total sample size was low (<400).

n. Downgraded by two levels for RoB since the included study was rated with a high RoB.

o. Downgraded by one level for RoB since 3 out of 5 studies were rated with a high RoB, and 1 study was rated as low RoB.

p. Downgraded by one level since 1 out of 2 included studies was rated with a high RoB, and none of the included studies was rated with a low RoB.

q. Downgraded by two levels for imprecision since sample size was very low (<100).

r. Downgraded by one level for RoB since both included studies were rated with some concerns for RoB.

s. Downgraded by two levels for RoB since 2 out of 3 included studies was rated with high RoB, and none of the included studies was rated with a low RoB.

t. Downgraded by one level for RoB since all included studies were rated with some concerns for RoB.

u. Not downgraded for imprecision. Although the number of included studies is low (n=3), studies had an intermediate sample size with a median of 239 participants, and the outcome was a common event (occurred >1/100).

v. Downgraded by two levels for RoB, as for this outcome 1 out of the 3 included studies was rated with high RoB, and none of the included studies was rated with a low RoB. There were large baseline between-group differences in the number of vitamin A deficient participants in two studies (Nesamvuni 2005: 7 out of 16 in the experimental and 0 out of 20 in the control group; Palmer 2021: 10 out of 51 in the biofortified, 11 out 52 in the fortified and 18 out of 58 in the control group)

w. Downgraded by one level for inconsistency as point estimates did vary widely, 95% CI did not overlap between studies, the direction of effect was not consistent. and the magnitude of heterogeneity was high (I² was 74%, p-value for heterogeneity was 0.02). Due to the low number of studies subgroup analyses were not possible.

x. Downgraded by one level for imprecision since total sample size was low (<400).

y. Downgraded by one level for RoB since the included study was rated with some concerns of RoB.

z. Downgraded by two levels for imprecision since results are derived from one study, where total sample size was very low (n<100).

References

1. Ekoe, T., Bianpambe, O. I., Nguefack, F., Pondi, D. M., Kana-Sop, M. M., Hays, N. P., Medoua, G., Koki, P. N. Efficacy of an iron-fortified infant cereal to reduce the risk of iron deficiency anemia in young children in East Cameroon. Food sci; 2020.

2.Nogueira Arcanjo, F. P., Roberto Santos, P., Madeiro Leite, A. J., Bastos Mota, F. S., Duarte Segall, S. Rice fortified with iron given weekly increases hemoglobin levels and reduces anemia in infants: a community intervention trial. Int J Vitam Nutr Res; 2013.

3. Nogueira Arcanjo, F. P., Santos, P. R., Arcanjo, C. P., Amancio, O. M., Braga, J. A. Use of iron-fortified rice reduces anemia in infants. J Trop Pediatr; 2012.

4.Ma, J., Sun, Q., Liu, J., Hu, Y., Liu, S., Zhang, J., Sheng, X., Hambidge, K. M. The Effect of Iron Fortification on Iron (Fe) Status and Inflammation: A Randomized Controlled Trial. PLoS ONE; 2016.

5.Lartey, A., Manu, A., Brown, K. H., Peerson, J. M., Dewey, K. G. A randomized, community-based trial of the effects of improved, centrally processed complementary foods on growth and micronutrients status of Ghanaian infants from 6 to 12 mo of age Weanimix, a cereal-legume blend. American Journal of Clinical Nutrition; 1999.

6.Bagni, U. V., Baiao, M. R., Santos, M. M., Luiz, R. R., Veiga, G. V. [Effect of weekly rice fortification with iron on anemia prevalence and hemoglobin concentration among children attending public daycare centers in Rio de Janeiro, Brazil]. Cad Saude Publica; 2009. 7.Schumann, K., Romero-Abal, M. E., Maurer, A., Luck, T., Beard, J., Murray-Kolb, L., Bulux, J., Mena, I., Solomons, N. W. Haematological response to haem iron or ferrous sulphate mixed with refried black beans in moderately anaemic Guatemalan pre-school children. Public Health Nutr; 2005.

8. Quintero, M. D. C., Hernandez, L. O., Villasana, A. C., Amaro, J. A. R., Soto, N. G., Arenas, J. A., Solano, J. A. L. IMPACT OF CONSUMPTION FO CORN FLOUR WITH LOW LEVEL ENRICHMENT IN CHILDREN OF RURAL ZONES. Nutr. Hosp.; 2011.

9.Nesamvuni, A. E., Vorster, H. H., Margetts, B. M., Kruger, A., Nesamvuni, Alufheli E., Vorster, Hester H., Margetts, Barrie M., Kruger, Annamarie. Fortification of maize meal improved the nutritional status of 1-3-year-old African children. Public Health Nutrition; 2005.

10.Liu, D. S., Bates, C. J., Yin, T. A., Wang, X. B., Lu, C. Q. Nutritional efficacy of a fortified weaning rusk in a rural area near Beijing. Am J Clin Nutr; 1993.

11.Lartey, A., Manu, A., Brown, K. H., Dewey, K. G. Predictors of micronutrient status among six- to twelve-month-old breast-fed Ghanaian infants. J Nutr; 2000.

12.Faber, M., Kvalsvig, J. D., Lombard, C. J., Benade, A. J. Effect of a fortified maize-meal porridge on anemia, micronutrient status, and motor development of infants. Am J Clin Nutr; 2005.

13.Palmer, A. C., Jobarteh, M. L., Chipili, M., Greene, M. D., Oxley, A., Lietz, G., Mwanza, R., Haskell, M. J. Biofortified and fortified maize consumption reduces prevalence of low milk retinol, but does not increase vitamin A stores of breastfeeding Zambian infants with adequate reserves: a randomized controlled trial. Am J Clin Nutr; 2021.

14.Huey, S. L., Venkatramanan, S., Udipi, S. A., Finkelstein, J. L., Ghugre, P., Haas, J. D., Thakker, V., Thorat, A., Salvi, A., Kurpad, A. V., Mehta, S. Acceptability of Iron- and Zinc-Biofortified Pearl Millet (ICTP-8203)-Based Complementary Foods among Children in an Urban Slum of Mumbai, India (vol 4, 39, 2017). Front. Nutr.; 2018.

15.Gannon, B. M., Thakker, V., Bonam, V. S., Haas, J. D., Bonam, W., Finkelstein, J. L., Udipi, S. A., Mehta, S. A Randomized Crossover Study to Evaluate Recipe Acceptability in Breastfeeding Mothers and Young Children in India Targeted for a Multiple Biofortified Food Crop Intervention. Food Nutr Bull; 2019.

16.Bovell-Benjamin, A. C., Allen, L. H., Guinard, J. X. Toddlers' acceptance of whole maize meal porridge fortified with Ferrous Bisglycinate. Food. Qual. Prefer.; 1999.

REFERENCES

1. Guideline: counselling of women to improve breastfeeding practices: World Health Organization; 2018 [Available from: <u>https://www.who.int/publications/i/item/9789241550468</u>.

2. Nutrition ECo, Agostoni C, Braegger C, Decsi T, Kolacek S, Koletzko B, et al. Breast-feeding: A commentary by the ESPGHAN Committee on Nutrition. Journal of pediatric gastroenterology and nutrition. 2009;49(1):112-25.

3. Section on B. Breastfeeding and the use of human milk. Pediatrics. 2012;129(3):e827-41.

4. Fewtrell M, Bronsky J, Campoy C, Domellof M, Embleton N, Fidler Mis N, et al. Complementary Feeding: A Position Paper by the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Committee on Nutrition. Journal of pediatric gastroenterology and nutrition. 2017;64(1):119-32.

5. Global Nutrition Targets 2025: Stunting policy brief: World Health Organization; [Available from: <u>https://www.who.int/nutrition/publications/globaltargets2025_policybrief_stunting/en/</u>.

6. Guiding principles for complementary feeding of the breastfed child: WHO, PAHO; 2003 [Available from: <u>https://www.who.int/publications/i/item/9275124604</u>.

7. Beal T, White JM, Arsenault JE, Okronipa H, Hinnouho GM, Murira Z, et al. Micronutrient gaps during the complementary feeding period in South Asia: A Comprehensive Nutrient Gap Assessment. Nutr Rev. 2021;79(Suppl 1):26-34.

8. Harika R, Faber M, Samuel F, Mulugeta A, Kimiywe J, Eilander A. Are Low Intakes and Deficiencies in Iron, Vitamin A, Zinc, and Iodine of Public Health Concern in Ethiopian, Kenyan, Nigerian, and South African Children and Adolescents? Food and nutrition bulletin. 2017;38(3):405-27.

9. White JM, Beal T, Arsenault JE, Okronipa H, Hinnouho GM, Chimanya K, et al. Micronutrient gaps during the complementary feeding period in 6 countries in Eastern and Southern Africa: a Comprehensive Nutrient Gap Assessment. Nutr Rev. 2021;79(Suppl 1):16-25.

10. Mallard SR, Houghton LA, Filteau S, Chisenga M, Siame J, Kasonka L, et al. Micronutrient Adequacy and Dietary Diversity Exert Positive and Distinct Effects on Linear Growth in Urban Zambian Infants. J Nutr. 2016;146(10):2093-101.

11. Dewey KG. Increasing iron intake of children through complementary foods. Food and nutrition bulletin. 2007;28(4 Suppl):S595-609.

12. The global prevalence of anaemia in 2011: World Health Organization; 2015 [Available from: <u>https://www.who.int/publications/i/item/9789241564960</u>.

13. Lozoff B. Iron deficiency and child development. Food and nutrition bulletin. 2007;28(4 Suppl):S560-71.

14. Stephensen CB. Vitamin A, infection, and immune function. Annual review of nutrition. 2001;21:167-92.

15. Vijayaraghavan K. National control programme against nutritional blindness due to vitamin A deficiency: Current status & future strategy. The Indian journal of medical research. 2018;148(5):496-502.

16. Wirth JP, Petry N, Tanumihardjo SA, Rogers LM, McLean E, Greig A, et al. Vitamin A Supplementation Programs and Country-Level Evidence of Vitamin A Deficiency. Nutrients. 2017;9(3).

17. Chasapis CT, Loutsidou AC, Spiliopoulou CA, Stefanidou ME. Zinc and human health: an update. Archives of toxicology. 2012;86(4):521-34.

18. Black RE. Zinc deficiency, infectious disease and mortality in the developing world. J Nutr. 2003;133(5 Suppl 1):1485S-9S.

19. Feeding the non-breastfed child 6–24 months of age: World Health Organization; 2004 [Available from: <u>https://www.who.int/publications/i/item/WHO-FCH-CAH-04.13</u>.

20. Allen L, de Benoist B, Dary O, Hurrell R. Guidelines on food fortification with micronutrients: World Health Organization; 2006 [Available from:

https://www.who.int/publications/i/item/9241594012.

21. Dewey KG, Adu-Afarwuah S. Systematic review of the efficacy and effectiveness of complementary feeding interventions in developing countries. Maternal & child nutrition. 2008;4 Suppl 1(Suppl 1):24-85.

22. Rim H, Kim S, Sim B, Gang H, Kim H, Kim Y, et al. Effect of iron fortification of nursery complementary food on iron status of infants in the DPRKorea. Asia Pacific journal of clinical nutrition. 2008;17(2):264-9.

23. Glinz D, Hurrell RF, Ouattara M, Zimmermann MB, Brittenham GM, Adiossan LG, et al. The effect of iron-fortified complementary food and intermittent preventive treatment of malaria on anaemia in 12- to 36-month-old children: a cluster-randomised controlled trial. Malaria journal. 2015;14:347.

24. Davidsson L, Sarker SA, Jamil KA, Sultana S, Hurrell R. Regular consumption of a complementary food fortified with ascorbic acid and ferrous fumarate or ferric pyrophosphate is as useful as ferrous sulfate in maintaining hemoglobin concentrations >105 g/L in young Bangladeshi children. Am J Clin Nutr. 2009;89(6):1815-20.

25. Ziegler EE, Fomon SJ, Nelson SE, Jeter JM, Theuer RC. Dry cereals fortified with electrolytic iron or ferrous fumarate are equally effective in breast-fed infants. J Nutr. 2011;141(2):243-8.

26. Glinz D, Wegmuller R, Ouattara M, Diakite VG, Aaron GJ, Hofer L, et al. Iron Fortified Complementary Foods Containing a Mixture of Sodium Iron EDTA with Either Ferrous Fumarate or Ferric Pyrophosphate Reduce Iron Deficiency Anemia in 12- to 36-Month-Old Children in a Malaria Endemic Setting: A Secondary Analysis of a Cluster-Randomized Controlled Trial. Nutrients. 2017;9(7).

27. Liu DS, Bates CJ, Yin TA, Wang XB, Lu CQ. Nutritional efficacy of a fortified weaning rusk in a rural area near Beijing. Am J Clin Nutr. 1993;57(4):506-11.

28. Phu PV, Hoan NV, Salvignol B, Treche S, Wieringa FT, Khan NC, et al. Complementary foods fortified with micronutrients prevent iron deficiency and anemia in Vietnamese infants. J Nutr. 2010;140(12):2241-7.

29. Awasthi S, Reddy NU, Mitra M, Singh S, Ganguly S, Jankovic I, et al. Micronutrient-fortified infant cereal improves Hb status and reduces iron-deficiency anaemia in Indian infants: an effectiveness study. The British journal of nutrition. 2020;123(7):780-91.

30. Faber M, Kvalsvig JD, Lombard CJ, Benadé AJ. Effect of a fortified maize-meal porridge on anemia, micronutrient status, and motor development of infants. Am J Clin Nutr. 2005;82(5):1032-9.

31. Manno D, Kowa PK, Bwalya HK, Siame J, Grantham-McGregor S, Baisley K, et al. Rich micronutrient fortification of locally produced infant food does not improve mental and motor development of Zambian infants: a randomised controlled trial. The British journal of nutrition. 2012;107(4):556-66.

32. Oelofse A, Van Raaij JM, Benade AJ, Dhansay MA, Tolboom JJ, Hautvast JG. The effect of a micronutrient-fortified complementary food on micronutrient status, growth and development of 6-to 12-month-old disadvantaged urban South African infants. International journal of food sciences and nutrition. 2003;54(5):399-407.

33. Field MS, Mithra P, Pena-Rosas JP. Wheat flour fortification with iron and other micronutrients for reducing anaemia and improving iron status in populations. The Cochrane database of systematic reviews. 2021;1:CD011302.

34. Garcia-Casal MN, Pena-Rosas JP, De-Regil LM, Gwirtz JA, Pasricha SR. Fortification of maize flour with iron for controlling anaemia and iron deficiency in populations. The Cochrane database of systematic reviews. 2018;12:CD010187.

35. Pena-Rosas JP, Mithra P, Unnikrishnan B, Kumar N, De-Regil LM, Nair NS, et al. Fortification of rice with vitamins and minerals for addressing micronutrient malnutrition. The Cochrane database of systematic reviews. 2019;2019(10).

36. Tam E, Keats EC, Rind F, Das JK, Bhutta AZA. Micronutrient Supplementation and Fortification Interventions on Health and Development Outcomes among Children Under-Five in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis. Nutrients. 2020;12(2).

37. Christian P, Shaikh S, Shamim AA, Mehra S, Wu L, Mitra M, et al. Effect of fortified complementary food supplementation on child growth in rural Bangladesh: a cluster-randomized trial. International journal of epidemiology. 2015;44(6):1862-76.

38. Pham VP, Nguyen VH, Salvignol B, Treche S, Wieringa FT, Dijkhuizen MA, et al. A six-month intervention with two different types of micronutrient-fortified complementary foods had distinct short- and long-term effects on linear and ponderal growth of Vietnamese infants. J Nutr. 2012;142(9):1735-40.

39. Lazzerini M, Wanzira H. Oral zinc for treating diarrhoea in children. The Cochrane database of systematic reviews. 2016;12:CD005436.

40. Mayo-Wilson E, Junior JA, Imdad A, Dean S, Chan XH, Chan ES, et al. Zinc supplementation for preventing mortality, morbidity, and growth failure in children aged 6 months to 12 years of age. The Cochrane database of systematic reviews. 2014(5):CD009384.

41. Liu E, Pimpin L, Shulkin M, Kranz S, Duggan CP, Mozaffarian D, et al. Effect of Zinc Supplementation on Growth Outcomes in Children under 5 Years of Age. Nutrients. 2018;10(3).

42. Gera T, Shah D, Sachdev HS. Zinc Supplementation for Promoting Growth in Children Under 5 years of age in Low- and Middle-income Countries: A Systematic Review. Indian pediatrics. 2019;56(5):391-406.

43. Govender L, Pillay K, Siwela M, Modi AT, Mabhaudhi T. Improving the Dietary Vitamin A Content of Rural Communities in South Africa by Replacing Non-Biofortified white Maize and Sweet Potato with Biofortified Maize and Sweet Potato in Traditional Dishes. Nutrients. 2019;11(6).

44. Govender L, Pillay K, Siwela M, Modi AT, Mabhaudhi T. Consumer Perceptions and Acceptability of Traditional Dishes Prepared with Provitamin A-Biofortified Maize and Sweet Potato. Nutrients. 2019;11(7).

45. Lartey A, Manu A, Brown KH, Peerson JM, Dewey KG. A randomized, community-based trial of the effects of improved, centrally processed complementary foods on growth and micronutrient status of Ghanaian infants from 6 to 12 mo of age. Am J Clin Nutr. 1999;70(3):391-404.

46. Keats EC, Neufeld LM, Garrett GS, Mbuya MNN, Bhutta ZA. Improved micronutrient status and health outcomes in low- and middle-income countries following large-scale fortification: evidence from a systematic review and meta-analysis. Am J Clin Nutr. 2019;109(6):1696-708.

47. Obbagy JE, English LK, Psota TL, Wong YP, Butte NF, Dewey KG, et al. Complementary feeding and micronutrient status: a systematic review. Am J Clin Nutr. 2019;109(Suppl_7):852S-71S.

48. De-Regil LM, Jefferds MED, Pena-Rosas JP. Point-of-use fortification of foods with micronutrient powders containing iron in children of preschool and school-age. The Cochrane database of systematic reviews. 2017;11:CD009666.

49. Suchdev PS, Jefferds MED, Ota E, da Silva Lopes K, De-Regil LM. Home fortification of foods with multiple micronutrient powders for health and nutrition in children under two years of age. The Cochrane database of systematic reviews. 2020;2:CD008959.

50. Das JK, Salam RA, Mahmood SB, Moin A, Kumar R, Mukhtar K, et al. Food fortification with multiple micronutrients: impact on health outcomes in general population. The Cochrane database of systematic reviews. 2019;12:CD011400.

51. Das JK, Salam RA, Hadi YB, Sadiq Sheikh S, Bhutta AZ, Weise Prinzo Z, et al. Preventive lipidbased nutrient supplements given with complementary foods to infants and young children 6 to 23 months of age for health, nutrition, and developmental outcomes. The Cochrane database of systematic reviews. 2019;5:CD012611.

52. Masuda K, Chitundu M. Multiple Micronutrient Supplementation Using Spirulina platensis during the First 1000 Days is Positively Associated with Development in Children under Five Years: A Follow up of A Randomized Trial in Zambia. Nutrients. 2019;11(4).

53. Cliffer IR, Nikiema L, Langlois BK, Zeba AN, Shen Y, Lanou HB, et al. Cost-Effectiveness of 4 Specialized Nutritious Foods in the Prevention of Stunting and Wasting in Children Aged 6-23 Months in Burkina Faso: A Geographically Randomized Trial. Current developments in nutrition. 2020;4(2):nzaa006.

54. WHO. World Malaria Report 2020. Geneva: WHO, 2020. Available at:

https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2020/.

55. Veritas Health Innovation Covidence. Version v2614 0610d3cf. Melbourne, Australia: Veritas Health Innovation. Available at covidence.org.

56. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clinical research ed). 2009;339:b2700.

57. Scherer RW, Meerpohl JJ, Pfeifer N, Schmucker C, Schwarzer G, von Elm E. Full publication of results initially presented in abstracts. The Cochrane database of systematic reviews. 2018;11(11):Mr000005.

58. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Annals of internal medicine. 2010;152(11):726-32.

59. Higgins JPT SJ, Page MJ, Elbers RG, Sterne JAC. Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from <u>www.training.cochrane.org/handbook</u>.

60. Higgins JPT ES, Li T (editors). Chapter 23: Including variants on randomized trials. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.

61. Leyrat C, Caille A, Eldridge S, Kerry S, Dechartres A, Giraudeau B. Intervention effect estimates in cluster randomized versus individually randomized trials: a meta-epidemiological study. International journal of epidemiology. 2019;48(2):609-19.

62. Campbell MK, Fayers PM, Grimshaw JM. Determinants of the intracluster correlation coefficient in cluster randomized trials: the case of implementation research. Clinical trials (London, England). 2005;2(2):99-107.

63. Higgins JPT, Eldridge S, Li T (editors). Chapter 23: Including variants on randomized trials. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from <u>www.training.cochrane.org/handbook</u>.

64. Deeks JJ, Higgins JP, . Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.

65. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in medicine. 2002;21(11):1539-58.

66. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed). 2003;327(7414):557-60.

67. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed). 1997;315(7109):629-34.

68. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ. What is "quality of evidence" and why is it important to clinicians? BMJ (Clinical research ed). 2008;336(7651):995-8.
69. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines:

3. Rating the quality of evidence. Journal of clinical epidemiology. 2011;64(4):401-6.

70. Brown KH DK, Allen LH. Complementary feeding of young children in developing countries: a review of current scientific knowledge. Geneva: World Health Organization, 1998. (WHO/NUT/98.1.).

71. Department of Health. Dietary reference values for food energy and nutrients for the United Kingdom. London: Her Majesty's Stationery Office, 1991.

72. Eichler K, Wieser S, Ruthemann I, Brugger U. Effects of micronutrient fortified milk and cereal food for infants and children: a systematic review. BMC Public Health. 2012;12:506.

73. Eichler K, Hess S, Twerenbold C, Sabatier M, Meier F, Wieser S. Health effects of micronutrient fortified dairy products and cereal food for children and adolescents: A systematic review. PloS one. 2019;14(1):e0210899.

74. Palmer AC, Jobarteh ML, Chipili M, Greene MD, Oxley A, Lietz G, et al. Biofortified and fortified maize consumption reduces prevalence of low milk retinol, but does not increase vitamin A stores of breastfeeding Zambian infants with adequate reserves: a randomized controlled trial. Am J Clin Nutr. 2021.

75. Johns Hopkins Bloomberg School of Public H, University of California D, Newcastle U, HarvestPlus. Efficacy of Biofortified Maize to Improve Maternal and Infant Vitamin A Status. 2017.

76. Ekoe T, Bianpambe OI, Nguefack F, Pondi DM, Kana-Sop MM, Hays NP, et al. Efficacy of an iron-fortified infant cereal to reduce the risk of iron deficiency anemia in young children in East Cameroon. Food sci. 2020;8(7):3566-77.

77. Pactr. Efficacy of an iron fortified wheat flour for the correction and the prevention of iron deficiency anaemia of children in Salapoumbe.

http://www.hoint/trialsearch/Trial2aspx?TrialID=PACTR201802003069111. 2018.

78. Gannon BM, Thakker V, Bonam VS, Haas JD, Bonam W, Finkelstein JL, et al. A Randomized Crossover Study to Evaluate Recipe Acceptability in Breastfeeding Mothers and Young Children in India Targeted for a Multiple Biofortified Food Crop Intervention. Food Nutr Bull. 2019;40(4):460-70.

79. Huey SL, Venkatramanan S, Udipi SA, Finkelstein JL, Ghugre P, Haas JD, et al. Acceptability of Iron- and Zinc-Biofortified Pearl Millet (ICTP-8203)-Based Complementary Foods among Children in an Urban Slum of Mumbai, India (vol 4, 39, 2017). Front Nutr. 2018;5:2.

80. Ma J, Sun Q, Liu J, Hu Y, Liu S, Zhang J, et al. The Effect of Iron Fortification on Iron (Fe) Status and Inflammation: A Randomized Controlled Trial. PLoS ONE. 2016;11(12):e0167458.

81. Sheng XY, Wang JL, Li F, Ouyang FX, Ma JQ. Effects of dietary intervention on vitamin B-12 status and cognitive level of 18-month-old toddlers in high-poverty areas: a cluster-randomized controlled trial. BMC Pediatr. 2019;19(1):9.

82. Krebs NF, Sheng XY, Westcott JE, Hu YQ, Liu SS, Hambidge KM. Higher cognitive and gross motor scores in Chinese toddlers randomized to meat compared to either micro-nutrient fortified or unfortified infant cereal as first complementary food. Faseb J. 2013;27:1.

83. University of Colorado D, Shanghai Jiao Tong University School of M, Xi-Chou W, Children's H. Development and Health of Rural Chinese Children Fed Meat as a Daily Complementary Food From 6-18 Mos of Age. 2012.

84. Nogueira Arcanjo FP, Santos PR, Arcanjo CP, Amancio OM, Braga JA. Use of iron-fortified rice reduces anemia in infants. J Trop Pediatr. 2012;58(6):475-80.

85. Nogueira Arcanjo FP, Roberto Santos P, Madeiro Leite AJ, Bastos Mota FS, Duarte Segall S. Rice fortified with iron given weekly increases hemoglobin levels and reduces anemia in infants: a community intervention trial. Int J Vitam Nutr Res. 2013;83(1):59-66.

86. Quintero MDC, Hernandez LO, Villasana AC, Amaro JAR, Soto NG, Arenas JA, et al. IMPACT OF CONSUMPTION FO CORN FLOUR WITH LOW LEVEL ENRICHMENT IN CHILDREN OF RURAL ZONES. Nutr Hosp. 2011;26(5):1097-104.

87. Bagni UV, Baiao MR, Santos MM, Luiz RR, Veiga GV. [Effect of weekly rice fortification with iron on anemia prevalence and hemoglobin concentration among children attending public daycare centers in Rio de Janeiro, Brazil]. Cad Saude Publica. 2009;25(2):291-302.

88. Universidade Federal do Rio de J. Effect of Rice Fortification With Iron on Anemia Among Children.

89. Nesamvuni AE, Vorster HH, Margetts BM, Kruger A, Nesamvuni AE, Vorster HH, et al. Fortification of maize meal improved the nutritional status of 1-3-year-old African children. Public Health Nutrition. 2005;8(5):461-7.

90. Schumann K, Romero-Abal ME, Maurer A, Luck T, Beard J, Murray-Kolb L, et al. Haematological response to haem iron or ferrous sulphate mixed with refried black beans in moderately anaemic Guatemalan pre-school children. Public Health Nutr. 2005;8(6):572-81. 91. Lartey A, Manu A, Brown KH, Dewey KG. Predictors of micronutrient status among six- to twelve-month-old breast-fed Ghanaian infants. J Nutr. 2000;130(2):199-207.

92. Lartey A, Manu A, Brown KH, Peerson JM, Dewey KG. A randomized, community-based trial of the effects of improved, centrally processed complementary foods on growth and micronutrients status of Ghanaian infants from 6 to 12 mo of age Weanimix, a cereal-legume blend. American Journal of Clinical Nutrition.70(3):391-404.

93. Bovell-Benjamin AC, Allen LH, Guinard JX. Toddlers' acceptance of whole maize meal porridge fortified with Ferrous Bisglycinate. Food Qual Prefer. 1999;10(2):123-8.

94. Gershoff SN, McGandy RB, Suttapreyasri D, Promkutkao C, Nondasuta A, Pisolyabutra U, et al. Nutrition studied in Thailand. II. Effects of fortification of rice with lysine, threonine, thiamin, riboflavin, vitamin A, and iron on preschool children. Am J Clin Nutr. 1977;30(7):1185-95.

95. Gershoff SN, McGandy RB, Suttapreyasri D, Nondasuta A, Pisolyabutra U, Tantiwongse P. Amino acid fortification of rice studies in Thailand. I. Background and baseline data. The American journal of clinical nutrition. 1975;28(2):170-82.

96. Mehta S, Finkelstein JL, Venkatramanan S, Huey SL, Udipi SA, Ghugre P, et al. Effect of iron and zinc-biofortified pearl millet consumption on growth and immune competence in children aged 12-18 months in India: study protocol for a randomised controlled trial. BMJ Open. 2017;7(11):e017631.

97. Stanford U, Government of Tamil N, Global Innovation F, National ARI, King P. Reducing Anemia Through Food Fortification at Scale. 2020.

98. Food SRCf, Nutrition, Nestlé F, Indonesia U, Institut Pertanian B, London School of H, et al. Nutrient-Dense Complementary Foods on Catch-up Growth and Nutritional Status of Stunting Children. 2016.

99. Hays N, Vuvor F, Paul S, Ansong R, Baah RO, Annor DA, et al. Effect of an Iron-Fortified Complementary Food on Anemia and Nutritional Status of Infants Aged 6-18 Months in Ghana. Nutrition 2019. 2019.

100. Pactr. Efficacy of an iron fortified complementary food in improving the nutritional status of children aged 6-18 months in the La Nkwantanang Municipality of the Greater Accra Region. http://www.hoint/trialsearch/Trial2aspx?TrialID=PACTR201906885776793. 2019.

101. Krebs NF, Westcott JE, Culbertson D, Miller LV, Lei S, Hambidge KM. Exchangeable zinc (Zn) pool (EZP) size, but not plasma Zn, reflects absorbed Zn in breastfed infants on different complementary foods. FASEB journal. 2011;25.

102. Araya L H. Importancia de la fortificación de alimentos en la salud de la población chilena. Rev chil nutr. 1994;22(3):137-43.

103. Arya V. Calcium and the treatment of nutritional rickets. 2000.

104. Cros J, Schartner J. [Trial food supplementation for children of Diack canton (Senegal)]. Bull Soc Med Afr Noire Lang Fr. 1966;11(2):193-7.

105. Organización Panamericana de la Salud. Programa de Alimentación y N, Chile. Instituto de Nutrición y Tecnología de los A. Estudio sobre intervenciónes alimentario-nutricionales para poblaciones de bajos ingresos en Latinoamerica y el Caribe: Resumen del proyecto colaborativo OPS/INTA. 1989. p. 139-.

106. Viseshakul D, Premwatana P, Kewsiri D. A field trial of supplementary feeding in hilltribe children (1-4 years old): one year follow-up study. J Med Assoc Thai. 1979;62(4):190-200.

107. Viteri FE, Alvarez E, Bulux J, Gonzalez H, Pineda O, Mejia LA, et al. Iron fortification in developing countries. Prog Clin Biol Res. 1981;77:345-54.

108. Zhao X, Lu Q, Wang S, Yin S. [Efficiency of NaFeEDTA fortified soy sauce on anemia prevention]. Wei Sheng Yen Chiu. 2004;33(2):202-4.

109. Zlotkin SH, Yeung GS, Colleta F, Schauer CS. Fractional zinc absorption from Zn-fortified cereals in infants and young children. Pediatric research. 2000;47(4):237A.

110. Dewey KG, Cohen RJ, Rivera LL, Brown KH. Effects of age of introduction of complementary foods on iron status of breast-fed infants in Honduras including commentary by Garza C and Frongillo EA Jr. American Journal of Clinical Nutrition.67(5):878-16.

111. Aakko J, Grzeskowiak L, Asukas T, Paivansade E, Lehto KM, Fan YM, et al. Lipid-based Nutrient Supplements Do Not Affect Gut Bifidobacterium Microbiota in Malawian Infants: A Randomized Trial. J Pediatr Gastroenterol Nutr. 2017;64(4):610-5.

112. Aaron GJ, Lo NB, Hess SY, Guiro AT, Wade S, Ndiaye NF, et al. Acceptability of Complementary Foods and Breads Prepared from Zinc-Fortified Cereal Flours among Young Children and Adults in Senegal. J Food Sci. 2011;76(1):S56-S62.

113. Aboud FE, Akhter S. A cluster-randomized evaluation of a responsive stimulation and feeding intervention in bangladesh. Pediatrics. 2011;127(5):e1191-7.

114. Ackatia-Armah RS, McDonald C, Doumbia S, Brown KH. Effect of selected dietary regimens on recovery from moderate acute malnutrition in young Malian children. FASEB journal. 2012;26.

115. Ackatia-Armah RS, Mc Donald CM, Doumbia S, Earhardt J, Peerson J, Brown KH. Effect of selected dietary supplements on micronutrient status during recovery from moderate acute malnutrition in young malian children. Annals of nutrition & metabolism. 2013;63:842.

116. Ackatia-Armah RS, McDonald CM, Doumbia S, Erhardt JG, Hamer DH, Brown KH. Malian children with moderate acute malnutrition who are treated with lipid-based dietary supplements have greater weight gains and recovery rates than those treated with locally produced cereal-legume products: a community-based, cluster-randomized trial. Am J Clin Nutr. 2015;101(3):632-45.

117. Actrn. Evaluation of the efficacy of different strategies to treat anemia in Mexican children. <u>http://www.hoint/trialsearch/Trial2aspx?TrialID=ACTRN12609000061235</u>. 2009.

118. Actrn. Seeding throUgh FeediNg: nourishing the infant microbiome to support immune health. <u>http://www.hoint/trialsearch/Trial2aspx?TrialID=ACTRN12620000026921</u>. 2020.

119. Agapova SE, Stephenson KB, Divala O, Kaimila Y, Maleta KM, Thakwalakwa C, et al. Additional Common Bean in the Diet of Malawian Children Does Not Affect Linear Growth, but Reduces Intestinal Permeability. J Nutr. 2018;148(2):267-74.

120. Ahmad A, Madanijah S, Dwiriani CM, Kolopaking R. Nutrition education using food monitoring card and multi-nutrient biscuit interventions improving nutritional and iron status in undernourished children aged 6-23 months: A cluster randomized control trial in Aceh, Indonesia. Annals of Nutrition and Metabolism. 2019;75(3):316.

121. Ahmad A, Madanijah S, Dwiriani CM, Kolopaking R. Effect of Nutrition Education and Multi-Nutrient Biscuit Interventions on Nutritional and Iron Status: A Cluster Randomized Control Trial on Undernourished Children Aged 6-23 Months in Aceh, Indonesia. J Nutr Sci Vitaminol (Tokyo). 2020;66(Supplement):S380-S90.

122. Ahmed T, Choudhury N, Hossain MI, Tangsuphoom N, Islam MM, de Pee S, et al. Development and acceptability testing of ready-to-use supplementary food made from locally available food ingredients in Bangladesh. BMC Pediatr. 2014;14:164.

123. Ahmed T, Islam M, Choudhury N, Hossain I, Huq S, Mahfuz M, et al. Results with
Complementary Food Using Local Food Ingredients. Nestle Nutr Inst Workshop Ser. 2017;87:103-13.
124. Akalu G, Taffesse S, Gunaratna NS, De Groote H, Akalu G, Taffesse S, et al. The effectiveness of quality protein maize in improving the nutritional status of young children in the Ethiopian highlands. Food & Nutrition Bulletin. 2010;31(3):418-30.

125. Ortega Alemán EdC, Coulson Romero AJ, Ordóñez Argueta LI, Pachón H. Efectos de la ingesta de maíz de alta calidad de proteína (QPM) versus maíz convencional en el crecimiento y la morbilidad de niños nicaragüenses desnutridos de 1 a 5 años de edad. Arch latinoam nutr. 2008;58(4):377-85.

126. Amthor RE, Cole SM, Manary MJ. The use of home-based therapy with ready-to-use therapeutic food to treat malnutrition in a rural area during a food crisis. Journal of the American Dietetic Association. 2009;109(3):464-7.

127. Anorve-Valdez G, Quezada-Sanchez AD, Mejia-Rodriguez F, Garcia-Guerra A, Neufeld LM. Fortified food supplementation in children with reduced dietary energy and micronutrients intake in Southern Mexico. Nutr J. 2018;17(1):76.

128. Arcanjo FPN, da Costa Rocha TC, Arcanjo CPC, Santos PR. Micronutrient Fortification at Child-Care Centers Reduces Anemia in Young Children. J Diet Suppl. 2019;16(6):689-98. 129. Argaw A, Wondafrash M, Bouckaert KP, Kolsteren P, Lachat C, Belachew T, et al. Effects of n-3 long-chain PUFA supplementation to lactating mothers and their breastfed children on child growth and morbidity: A 2 x 2 factorial randomized controlled trial in rural Ethiopia. American journal of clinical nutrition. 2018;107(3):454-64.

130. Ariff SS, Soofi SSB, Krebs NN, Westcott JJ, Bhatti ZZ, Bhutta ZZA. Exchangeable zn pool size and zn absorption from sprinkles and traditional foods in pakistani infants/toddlers. Annals of Nutrition and Metabolism. 2013;63:257-8.

131. Arsenault JE, Havel PJ, Lopez de Romana D, Penny ME, Van Loan MD, Brown KH. Longitudinal measures of circulating leptin and ghrelin concentrations are associated with the growth of young Peruvian children but are not affected by zinc supplementation. Am J Clin Nutr. 2007;86(4):1111-9.

132. Arsenault JE, Lopez de Romana D, Penny ME, Van Loan MD, Brown KH. Additional zinc delivered in a liquid supplement, but not in a fortified porridge, increased fat-free mass accrual among young Peruvian children with mild-to-moderate stunting. J Nutr. 2008;138(1):108-14.

133. Arsenault JE, De Romaña DL, Penny M, Brown KH. Dietary pattern with high dairy intake is associated with linear growth in Peruvian infants. FASEB Journal. 2016;30.

134. Arya TU. Assessment of growth and development in infants with Shashtikshalyadi Churna as weaning food: A clinical study. International Journal of Research in Ayurveda and Pharmacy. 2014;5(4):439-43.

135. As'ad S, Yusuf I. The effects of zinc supplementation on the TNF- α profile and diarrhea in severely malnourished children of low income family. 2003.

136. Asibey-Berko E, Zlotkin SH, Yeung GS, Nti-Nimako W, Ahunu B, Kyei-Faried S, et al. Dual fortification of salt with iron and iodine in women and children in rural Ghana. East Afr Med J. 2007;84(10):473-80.

137. Association for the S, Prevention of HA. Comparison of the Effect of Two Treatments on the Nutritional and Micronutrient Status of Malnourished Children. 2013.

138. Awasthi S, Reddy NU, Mitra M, Singh S, Ganguly S, Jankovic I, et al. Micronutrient-fortified infant cereal improves Hb status and reduces iron-deficiency anaemia in Indian infants: an effectiveness study. Br J Nutr. 2020;123(7):780-91.

139. Badau MH, Bristone C, Igwebuike JU, Danbaba N. Production, viscosity, microbiological quality and sensory properties of complementary food blends of improved rice cultivars, soybean and sorghum malt. Pakistan Journal of Nutrition. 2016;15(9):849-56.

140. Bagni UV, Baião MR, Santos MMAdS, Luiz RR, Veiga GVd. Efeito da fortificação semanal do arroz com ferro quelato sobre a freqüência de anemia e concentração de hemoglobina em crianças de creches municipais do Rio de Janeiro, Brasil. Cad saúde pública. 2009;25(2):291-302.

141. Bajaj M, Dubey AP, Nagpal J, Singh PK, Sachdev HP. Short-term effect of oil supplementation of complementary food on total ad libitum consumption in 6- to 10-month-old breastfed Indian infants. J Pediatr Gastroenterol Nutr. 2005;41(1):61-5.

142. Baskaran V, Mahadevamma, Malleshi NG, Shankara R, Lokesh BR. Acceptability of supplementary foods based on popped cereals and legumes suitable for rural mothers and children. Plant Food Hum Nutr. 1999;53(3):237-47.

Bauserman M, Lokangaka A, Gado J, Close K, Wallace D, Kodondi KK, et al. A clusterrandomized trial determining the efficacy of caterpillar cereal as a locally available and sustainable complementary food to prevent stunting and anaemia. Public Health Nutr. 2015;18(10):1785-92.
Becroft T, Bailey KV. Supplementary feeding trial in New Guinea Highland infants. J Trop Pediatr Afr Child Health. 1965;11(2):28-34.

145. Beinner MA, Velasquez-Melendez G, Pessoa MC, Greiner T. Iron-fortified rice is as efficacious as supplemental iron drops in infants and young children. J Nutr. 2010;140(1):49-53.

146. Bergmann R, Bergler H, Moshoudis E, Bergmann E, Lachmann E, Bergmann KE. [Preventing iron deficiency in breast-fed infants by suitable supplementary food. A prospective, controlled study]. Monatsschr Kinderheilkd. 1989;137(12):775-9.

147. Bernal MJ, Periago MJ, Martinez R, Ortuno I, Sanchez-Solis M, Ros G, et al. Effects of infant cereals with different carbohydrate profiles on colonic function--randomised and double-blind

clinical trial in infants aged between 6 and 12 months--pilot study. Eur J Pediatr. 2013;172(11):1535-42.

148. Bhandari N, Mohan SB, Bose A, Iyengar SD, Taneja S, Mazumder S, et al. Efficacy of three feeding regimens for home-based management of children with uncomplicated severe acute malnutrition: a randomised trial in India. BMJ glob. 2016;1(4):e000144.

149. Bhargava A. Iron status, malaria parasite loads and food policies: evidence from sub-Saharan Africa. Econ Hum Biol. 2013;11(1):108-12.

150. Bishop WB, Laubscher I, Labadarios D, Rehder P, Louw ME, Fellingham SA. Effect of vitaminenriched bread on the vitamin status of an isolated rural community--a controlled clinical trial. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde. 1996;86(4 Suppl):458-62.

151. Bisimwa G, Owino VO, Bahwere P, Dramaix M, Donnen P, Dibari F, et al. Randomized controlled trial of the effectiveness of a soybean-maize-sorghum-based ready-to-use complementary food paste on infant growth in South Kivu, Democratic Republic of Congo. Am J Clin Nutr. 2012;95(5):1157-64.

152. Boateng L OAAMS-AM. Measuring blood retinol concentrations of infants fed with complementary foods fortified with Moringa Oleifera leaf powder-a pilot study. Annals of nutrition & metabolism. 2017;71:655.

153. Boateng L, Ashley I, Ohemeng A, Asante M, Steiner-Asiedu M. Improving Blood Retinol Concentrations with Complementary Foods Fortified with Moringa oleifera Leaf Powder - A Pilot Study. Yale J Biol Med. 2018;91(2):83-94.

154. Boateng L, Quarpong W, Ohemeng A, Asante M, Steiner-Asiedu M. Effect of complementary foods fortified with Moringa oleifera leaf powder on hemoglobin concentration and growth of infants in the Eastern Region of Ghana. Food sci. 2019;7(1):302-11.

155. Bodwell CE, Miles CW, Morris E, Prather ES, Mertz W, Canary JJ. Long-term consumption of beef extended with soy protein by men, women and children: II. Effects on iron status. Plant Foods Hum Nutr. 1987;37(4):361-76.

156. Borg B SDMSGMCCLABJWF. Efficacy of a locally-produced multiple micronutrient-fortified ready-to-use supplementary food (RUSF) for children under two years in Cambodia. Annals of nutrition & metabolism. 2017;71:329.

157. Borg B, Mihrshahi S, Griffin M, Sok D, Chhoun C, Laillou A, et al. Randomised controlled trial to test the effectiveness of a locally-produced ready-to-use supplementary food (RUSF) in preventing growth faltering and improving micronutrient status for children under two years in Cambodia: a study protocol. Nutr J. 2018;17(1):39.

158. Borg B, Mihrshahi S, Griffin M, Sok D, Chhoun C, Laillou A, et al. Acceptability of locallyproduced Ready-to-Use Supplementary Food (RUSF) for children under two years in Cambodia: A cluster randomised trial. Matern Child Nutr. 2019;15(3):e12780.

159. Boston U. A Randomized Controlled Trial Testing The Effect Of A Multi-Nutrient Fortified Juice. 2008.

160. Bouhouch RR, Fadeli SE, Sedki A, Chabaa L, Aboussad A, Andersson M, et al. Reducing Lead Burden and Improving Iron Status with Iron Fortification Using NaFeEDTA: A Double- Blind, Bandomized Blaceba, Controlled Intervention Trial (BCT) in Lead expected Moreoscan Children, 2015

Randomized, Placebo- Controlled Intervention Trial (RCT) in Lead-exposed Moroccan Children. 2015.
161. Brett NR, Lavery P, Agellon S, Vanstone CA, Goruk S, Field CJ, et al. Vitamin D Status and Immune Health Outcomes in a Cross-Sectional Study and a Randomized Trial of Healthy Young Children. Nutrients. 2018;10(6):27.

162. Brnić M, Hurrell RF, Songré-Ouattara LT, Diawara B, Kalmogho-Zan A, Tapsoba C, et al. Effect of phytase on zinc absorption from a millet-based porridge fed to young Burkinabe children. European Journal of Clinical Nutrition. 2017;71(1):137-41.

163. Brown KH, Lopez de Romana D, Arsenault JE, Peerson JM, Penny ME. Comparison of the effects of zinc delivered in a fortified food or a liquid supplement on the growth, morbidity, and plasma zinc concentrations of young Peruvian children. Am J Clin Nutr. 2007;85(2):538-47.

164. Campbell R, Hurley K, Shamim AA, Shaikh S, Chowdhury Z, Mehra S, et al. Children receiving complementary food supplements (CFS) have higher nutrient intakes from home foods in jivita-4 trial Rural Bangladesh. FASEB journal. 2015;29(1 Meeting Abstracts).

165. Campbell R SKSSAHMSWLCP. An enteropathy score predicts subsequent length better than lactulose mannitol (L:M) ratio alone in children enrolled in a community-based randomized trial of complementary food supplements in rural Bangladesh. FASEB journal. 2016;30.

166. Campbell RK, Hurley KM, Shamim AA, Shaikh S, Chowdhury ZT, Mehra S, et al. Effect of complementary food supplementation on breastfeeding and home diet in rural Bangladeshi children. Am J Clin Nutr. 2016;104(5):1450-8.

167. Campbell RK, Schulze KJ, Shaikh S, Mehra S, Ali H, Wu L, et al. Biomarkers of Environmental Enteric Dysfunction Among Children in Rural Bangladesh. J Pediatr Gastroenterol Nutr. 2017;65(1):40-6.

168. Campbell RK, Hurley KM, Shamim AA, Shaikh S, Chowdhury ZT, Mehra S, et al. Complementary Food Supplements Increase Dietary Nutrient Adequacy and Do Not Replace Home Food Consumption in Children 6-18 Months Old in a Randomized Controlled Trial in Rural Bangladesh. J Nutr. 2018;148(9):1484-92.

169. Campbell RK, Shaikh S, Schulze K, Arguello M, Ali H, Wu L, et al. Micronutrient and Inflammation Status Following One Year of Complementary Food Supplementation in 18-Month-Old Rural Bangladeshi Children: A Randomized Controlled Trial. Nutrients. 2020;12(5):18.

170. Capozzi L, Russo R, Bertocco F, Ferrara D, Ferrara M. Effect on haematological and anthropometric parameters of iron supplementation in the first 2 years of life. Risks and benefits. Hematol. 2011;16(5):261-4.

171. Carol H, Brac, Marywood U, Nutrition I, University of S. Iron-fortified Lentils to Improve Iron (Fe) Status in Bangladesh. 2019.

172. Cercamondi CI, Egli IM, Mitchikpe E, Tossou F, Hessou J, Zeder C, et al. Iron bioavailability from a lipid-based complementary food fortificant mixed with millet porridge can be optimized by adding phytase and ascorbic acid but not by using a mixture of ferrous sulfate and sodium iron EDTA. J Nutr. 2013;143(8):1233-9.

173. Chauhan HH, Javadekar BB, Jayswal AV, Thakkar PA, Parmar NT. Non-milk based local therapeutic feed plus home-based diet as compared to home-based diet alone for nutritional rehabilitation of severe acute malnutrition following discharge: A randomised clinical trial. Journal of Clinical and Diagnostic Research. 2019;13(2):SC05-SC8.

174. Chavasit V, Porasuphatana S, Suthutvoravut U, Zeder C, Hurrell R. Iron bioavailability in 8-24month-old Thai children from a micronutrient-fortified quick-cooking rice containing ferric ammonium citrate or a mixture of ferrous sulphate and ferric sodium ethylenediaminetetraacetic acid. Matern Child Nutr. 2015;11:179-87.

175. Chilenje Infant Growth N, Infection Study T. Micronutrient fortification to improve growth and health of maternally HIV-unexposed and exposed Zambian infants: a randomised controlled trial. PLoS ONE. 2010;5(6):e11165.

176. Chisenga M SJBKKLFS. Determinants of infant feeding choices by Zambian mothers: A mixed quantitative and qualitative study. Maternal & child nutrition. 2011;7(2):148-59.

177. Chomba E, Westcott CM, Westcott JE, Mpabalwani EM, Krebs NF, Patinkin ZW, et al. Zinc absorption from biofortified maize meets the requirements of young rural Zambian children. J Nutr. 2015;145(3):514-9.

178. Choudhury N, Bromage S, Alam MA, Shamsir Ahmed AM, Munirul Islam M, Iqbal Hossain M, et al. Intervention study shows suboptimal growth among children receiving a food supplement for five months in a slum in Bangladesh. Acta Paediatr. 2016;105(10):e464-73.

179. Christian P, Shaikh S, Shamim AA, Mehra S, Wu L, Merrill RD, et al. Effect of Fortified Complementary Food Supplementation on Child Growth in Rural Bangladesh - a Cluster-Randomized Trial. Faseb J. 2015;29:1. 180. Cliffer I, Langlois B, Suri D, Walton S, Ouedraogo L, Zeba A, et al. Design and baseline characteristics of a study comparing four supplementary foods in the prevention of stunting and wasting among children 6-23 months in Burkina Faso. FASEB Journal. 2017;31(1).

181. Cliffer IR, Nikiema L, Langlois BK, Zeba AN, Shen Y, Lanou HB, et al. Cost-Effectiveness of 4 Specialized Nutritious Foods in the Prevention of Stunting and Wasting in Children Aged 6-23 Months in Burkina Faso: A Geographically Randomized Trial. Curr. 2020;4(2):nzaa006.

182. Cook JD, Reddy MB, Burri J, Juillerat MA, Hurrell RF. The influence of different cereal grains on iron absorption from infant cereal foods. American Journal of Clinical Nutrition. 1997;65(4):964-9.

183. Cornell U, Haitian Group for the Study of Kaposi's S, Opportunistic, Weill Medical College of Cornell U, University of V. Evaluation of an Infant Feeding Intervention for HIV-exposed Haitian Infants. 2010.

184. Cornell U, University SWs. Feeding Trial of Bio-fortified Pearl Millet. 2012.

185. Ctri. Study to see how good Ready to use therapeutic food is in treating uncomplicated severe acute malnourished under-five children in community settings.

http://www.hoint/trialsearch/Trial2aspx?TrialID=CTRI/2011/12/002259. 2011.

186. Ctri. To check how intake of iron rich baby food can help in increasing the level of iron in blood and reduce the risk of iron deficiency. 2017.

187. Ctri. Dharavi Nutrition Project.

http://www.hoint/trialsearch/Trial2aspx?TrialID=CTRI/2017/08/009260. 2017.

188. Cubero J, Chanclon B, Sanchez S, Rivero M, Rodriguez AB, Barriga C. Improving the quality of infant sleep through the inclusion at supper of cereals enriched with tryptophan, adenosine-5'-phosphate, and uridine-5'-phosphate. Nutr Neurosci. 2009;12(6):272-80.

189. Cuj M, Mazariegos M, Fischer E, Román AV. Aceptabilidad y uso en el hogar de un alimento complementario listo para consumir en el área rural de Guatemala. Rev cient (Guatem). 2016;26(1):[60]-[70].

190. Dahl W, Lungu E. P145 Feasibility and Acceptability of a Soy-Fiber-Maize Blend Complementary Food for Children Aged 6-36 Months in Malawi...Society for Nutrition Education and Behavior, 52nd Annual Conference, Nutrition Education: Rooted in Food, July 27-30, 2019, Orlando. Journal of nutrition education and behavior. 2019;51:S97.

191. Daniels L TRWWSMFLAWBJTBJHJJSSHA. Impact of a baby-led approach to complementary feeding on iron intake and status at 12 months of age: A randomised controlled trial. European journal of pediatrics. 2016;175(11):1542.

192. Daniels L TRWGRSSSHJJWSMWBJTBJHA. Impact of a baby-led approach to complementary feeding on iron status at 12 months of age: A randomised controlled trial. Nutrients. 2017;9(3).

193. Davidsson L, Kastenmayer P, Szajewska H, Hurrell RF, Barclay D. Iron bioavailability in infants from an infant cereal fortified with ferric pyrophosphate or ferrous fumarate. Am J Clin Nutr. 2000;71(6):1597-602.

194. Davidsson L, Adou P, Zeder C, Walczyk T, Hurrell R. The effect of retinyl palmitate added to iron-fortified maize porridge on erythrocyte incorporation of iron in African children with vitamin A deficiency. British Journal of Nutrition. 2003;90(2):337-43.

195. de Almeida CAN, Crott GCl, Ricco RG, Del Ciampo LA, Dutra-de-Oliveira JE, Cantolini A. Control of iron-deficiency anaemia in Brazilian preschool children using iron-fortified orange juice. Nutrition Research. 2003;23(1):27-33.

196. de Almeida CA, Dutra-De-Oliveira JE, Crott GC, Cantolini A, Ricco RG, Del Ciampo LA, et al. Effect of fortification of drinking water with iron plus ascorbic acid or with ascorbic acid alone on hemoglobin values and anthropometric indicators in preschool children in day-care centers in Southeast Brazil. Food Nutr Bull. 2005;26(3):259-65.

197. de Almeida CA, De Mello ED, Ramos AP, Joao CA, Joao CR, Dutra-de-Oliveira JE. Assessment of drinking water fortification with iron plus ascorbic Acid or ascorbic Acid alone in daycare centers as a strategy to control iron-deficiency anemia and iron deficiency: a randomized blind clinical study. J Trop Pediatr. 2014;60(1):40-6. 198. Delimont NM, Alavi S, Lindshield B. New formulations for fortified-blended foods: The mffapp Tanzania efficacy trial. FASEB Journal. 2017;31(1).

199. Delimont NM, Chanadang S, Joseph MV, Rockler BE, Guo Q, Regier GK, et al. The MFFAPP Tanzania Efficacy Study Protocol: Newly Formulated, Extruded, Fortified Blended Foods for Food Aid. Curr. 2017;1(5):e000315.

200. Delimont NM, Vahl CI, Kayanda R, Msuya W, Mulford M, Alberghine P, et al. Complementary Feeding of Sorghum-Based and Corn-Based Fortified Blended Foods Results in Similar Iron, Vitamin A, and Anthropometric Outcomes in the MFFAPP Tanzania Efficacy Study. Current Developments in Nutrition. 2019;3(6).

201. De Oliveira SMS, Costa M, Rivera MAA, Santos LMP, Ribeiro M, Soares G, et al. [Impact of a dietary supplement on the nutritional status of preschool children enrolled in day care centers]. Revista de Nutricao. 2006;19(2):169-76.

202. de Oliveira JE, Scheid MM, Desai ID, Marchini S. Iron fortification of domestic drinking water to prevent anemia among low socioeconomic families in Brazil. Int J Food Sci Nutr. 1996;47(3):213-9.
203. de Paula RA, Fisberg M. The use of sugar fortified with iron tris-glycinate chelate in the prevention of iron deficiency anemia in preschool children. Arch Latinoam Nutr. 2001;51(1 Suppl 1):54-9.

204. Dewan P, Kaur IR, Faridi MM, Agarwal KN. Cytokine response to dietary rehabilitation with curd (Indian dahi) & leaf protein concentrate in malnourished children. The Indian journal of medical research. 2009;130(1):31-6.

205. Dewan P, Kaur IR, Faridi MMA, Agarwal KN. Cytokine response to dietary rehabilitation with curd (Indian dahi) & amp; leaf protein concentrate in malnourished children. 2009.

206. Dewey KG, Cohen RJ, Rivera LL, Brown KH. Effects of age of introduction of complementary foods on iron status of breast-fed infants in Honduras. Am J Clin Nutr. 1998;67(5):878-84.

207. Dewey KG, Cohen RJ, Brown KH. Exclusive breast-feeding for 6 months, with iron supplementation, maintains adequate micronutrient status among term, low-birthweight, breast-fed infants in Honduras. J Nutr. 2004;134(5):1091-8.

208. Dhingra U, Pradhan A, Menon VP, Dutta A, Dhingra P, Black R, et al. Evaluating mode of delivery of iron or iron and zinc on iron status and iron stress markers. Archives of disease in childhood. 2012;97:A299.

209. Dong C, Ge P, Ren X, Wang J, Fan H, Yan X, et al. Prospective study on the effectiveness of complementary food supplements on improving status of elder infants and young children in the areas affected by Wenchuan earthquake. PLoS ONE. 2013;8(9):e72711.

210. Drks. Effectiveness of Locally Produced Peanut/Milk spread and Newly Developed Ready-to-Use Foods (RUF) for Malnourished Children in Nias Island, Indonesia?

http://www.hoint/trialsearch/Trial2aspx?TrialID=DRKS00006174. 2014.

211. Dube K, Schwartz J, Mueller MJ, Kalhoff H, Kersting M. Complementary food with low (8%) or high (12%) meat content as source of dietary iron: a double-blinded randomized controlled trial. Eur J Nutr. 2010;49(1):11-8.

212. Duggan C, Penny ME, Hibberd P, Gil A, Huapaya A, Cooper A, et al. Oligofructosesupplemented infant cereal: 2 randomized, blinded, community-based trials in Peruvian infants. Am J Clin Nutr. 2003;77(4):937-42.

213. Duizer LM, Diana A, Rathomi HS, Luftimas DE, Rahmannia S, Santi W, et al. An Acceptability Trial of Desiccated Beef Liver and Meat Powder as Potential Fortifiers of Complementary Diets of Young Children in Indonesia. J Food Sci. 2017;82(9):2206-12.

214. Dutradeoliveira JE, Ferreira JB, Vasconcellos VP, Marchini JS. DRINKING-WATER AS AN IRON CARRIER TO CONTROL ANEMIA IN PRESCHOOL-CHILDREN IN A DAY-CARE-CENTER. J Am Coll Nutr. 1994;13(2):198-202.

215. Ekbote VH, Khadilkar AV, Chiplonkar SA, Hanumante NM, Khadilkar VV, Mughal MZ. A pilot randomized controlled trial of oral calcium and vitamin D supplementation using fortified laddoos in underprivileged Indian toddlers. Eur J Clin Nutr. 2011;65(4):440-6.

216. Emel K, Sm. Ziauddin H, Melody C T, Shabina R, Noor Ahmad K, Stanley H Z. Home fortification with sprinkles [TM] to reduce childhood anaemia: lessons learned in North West Frontier Province Pakistan. 2006. p. 35-40.

217. Ernst J, Ettyang G, Neumann C. High nutrition biscuits as a supplement to increase animal protein in diets of HIV-infected kenyan women and their children. Annals of Nutrition and Metabolism. 2013;63:144.

218. Ernst J, Ettyang G, Neumann CG. High-nutrition biscuits to increase animal protein in diets of HIV-infected Kenyan women and their children: a study in progress. Food Nutr Bull. 2014;35(4 Suppl):S198-204.

219. Faber M. Complementary foods consumed by 6-12-month-old rural infants in South Africa are inadequate in micronutrients. Public Health Nutrition. 2005;8(4):373-81.

220. Fatmah. MOCAF TEMPEH DATES BISCUIT FOR THE IMPROVEMENT NUTRITIONAL STATUS OF UNDERWEIGHT CHILDREN. Int J GEOMATE. 2018;15(49):155-61.

221. Ferreira HdS, Cavalcante SdA, Cabral Júnior CR, Paffer ATd. Efeitos do consumo da multimistura sobre o estado nutricional: ensaio comunitário envolvendo crianças de uma favela da periferia de Maceió, Alagoas, Brasil. Rev bras saúde matern infant. 2008;8(3):309-18.

222. Fhi, International Food Policy Research I, Project Concern International I. Evaluation of Integrating MIYCN Interventions in Existing CGPP of PCI. 2018.

223. Filteau S, Baisley K, Chisenga M, Kasonka L, Gibson RS. Provision of micronutrient-fortified food from 6 months of age does not permit HIV-exposed, uninfected Zambian children to catch up in growth to HIV-unexposed children: a randomised controlled trial. Journal of acquired immune deficiency syndromes (1999). 2011;56(2):166-75.

224. Filteau S, Baisley K, Chisenga M, Kasonka L, Gibson RS, Team CS. Provision of micronutrientfortified food from 6 months of age does not permit HIV-exposed uninfected Zambian children to catch up in growth to HIV-unexposed children: a randomized controlled trial. J Acquir Immune Defic Syndr. 2011;56(2):166-75.

225. Fink G, Levenson R, Tembo S, Rockers PC. Home- and community-based growth monitoring to reduce early life growth faltering: an open-label, cluster-randomized controlled trial. Am J Clin Nutr. 2017;106(4):1070-7.

226. Finn K, Callen C, Bhatia J, Reidy K, Bechard LJ, Carvalho R. Importance of Dietary Sources of Iron in Infants and Toddlers: Lessons from the FITS Study. Nutrients. 2017;9(7):9.

227. Fleige LE, Sahyoun NR, Murphy SP. A New Simulation Model Estimates Micronutrient Levels to Include in Fortified Blended Foods Used in Food Aid Programs. J Nutr. 2010;140(2):355-65.

228. Food U, Nutrition S, Westat, University of California LA, University of California B. Feeding My Baby - A National WIC Study. 2018.

229. Friel JK, Qasem W, Cai C, Hossain Z, Jorgensen S, Zackert B, et al. Iron and complementary feeding of breast-fed infants. Free radical biology & medicine. 2013;65:S108-S9.

230. Friel J, Qasem W, Hossain Z, Jorgensen S. Iron and complementary feeding of breast-fed infants. FASEB Journal. 2014;28(1).

231. Friel J, Azad E, Azad M, Qasem W, Cai C, Kafipour E. Iron and complementary feeding of breastfed infants: Impact on gut inflammation and microbiota. FASEB journal. 2015;29(1 Meeting Abstracts).

232. Friel J. Effect of iron rich foods on gut oxidative status and microbiota of the newborn. Free radical biology & medicine. 2016;100:S191.

233. Fuchs GJ, DeWier M, Hutchinson SW, Farris RP, Doucet H, Schwartz S, et al. Impact of whole cow's milk with iron-fortified cereal or formula on dietary intake and iron status of infants 6-12 months of age. American journal of clinical nutrition. 1991;53(5):P-18.

234. Fuchs George J, DeWier M, Hutchinson S, Doucet H, Suskind Robert M. Iron intake, occult blood loss, and iron status in infants 6-12 months fed formula or WCM + Fe-fortified cereal [abstract]. Pediatric research. 1991;29 Suppl:119A.

235. Fuchs GJ, Farris RP, DeWier M, Hutchinson SW, Warrier R, Doucet H, et al. Iron status and intake of older infants fed formula vs cow milk with cereal. Am J Clin Nutr. 1993;58(3):343-8.

236. Galpin L, Thakwalakwa C, Phuka J, Ashorn P, Maleta K, Wong WW, et al. Breast milk intake is not reduced more by the introduction of energy dense complementary food than by typical infant porridge. J Nutr. 2007;137(7):1828-33.

237. Gannon B, Kaliwile C, Arscott S, Schmaelzle S, Masi C, Chileshe J, et al. Biofortified orange maize is as efficacious as a vitamin A supplement in Zambian children even on the background of high liver reserves of vitamin A. FASEB journal. 2014;28(1 SUPPL. 1).

238. Gannon B, Kaliwile C, Arscott SA, Schmaelzle S, Chileshe J, Kalungwana N, et al. Biofortified orange maize is as efficacious as a vitamin A supplement in Zambian children even in the presence of high liver reserves of vitamin A: a community-based, randomized placebo-controlled trial. Am J Clin Nutr. 2014;100(6):1541-50.

239. García-Guerra A, Rivera-Dommarco J, Neufeld L, Domínguez-Islas CP. Effect of three supplements with equal micronutrient content on serum zinc concentrations in Mexican children. The FASEB Journal. 2009;23(S1).

240. Gartner A, Maire B, Traissac P, Kameli Y, Delpeuch F. Determinants of nutrition improvement in a large-scale urban project: a follow-up study of children participating in the Senegal Community Nutrition Project. Public Health Nutr. 2006;9(8):982-90.

241. Geltman PL, Hironaka LK, Mehta SD, Padilla P, Rodrigues P, Meyers AF, et al. Iron supplementation of low-income infants: a randomized clinical trial of adherence with ferrous fumarate sprinkles versus ferrous sulfate drops. J Pediatr. 2009;154(5):738-43.

242. Gershoff SN, McGandy RB, Suttapreyasri D, et al. Nutrition studies in Thailand. II. Effects of fortification of rice with lysine, threonine, thiamin, riboflavin, vitamin A, and iron on preschool children. AMJCLINNUTR. 1977;30(7):1185-95.

243. Ghosh S, Strutt N, Otoo GE, Suri DJ, Ankrah J, Johnson T, et al. Effect of the provision of a macro- and micro-nutrient fortified complementary food supplement on nutritional status of Ghanaian infants. FASEB Journal. 2017;31(1).

244. Ghosh SA, Strutt NR, Otoo GE, Suri DJ, Ankrah J, Johnson T, et al. A macro- and micronutrientfortified complementary food supplement reduced acute infection, improved haemoglobin and showed a dose-response effect in improving linear growth: a 12-month cluster randomised trial. J. 2019;8:e22.

245. Gibson RS, Kafwembe E, Mwanza S, Gosset L, Bailey KB, Mullen A, et al. A micronutrientfortified food enhances iron and selenium status of Zambian infants but has limited efficacy on zinc. Journal of Nutrition. 2011;141(5):935-43.

246. Glinz D, Wegmuller R, Ouattara M, Diakite VG, Aaron GJ, Hofer L, et al. Iron Fortified Complementary Foods Containing a Mixture of Sodium Iron EDTA with Either Ferrous Fumarate or Ferric Pyrophosphate Reduce Iron Deficiency Anemia in 12-to 36-Month-Old Children in a Malaria Endemic Setting: A Secondary Analysis of a Cluster-R. Nutrients. 2017;9(7):15.

247. Glinz D, Wegmüller R, Ouattara M, Diakité VG, Aaron GJ, Hofer L, et al. Iron Fortified Complementary Foods Containing a Mixture of Sodium Iron EDTA with Either Ferrous Fumarate or Ferric Pyrophosphate Reduce Iron Deficiency Anemia in 12- to 36-Month-Old Children in a Malaria Endemic Setting: A Secondary Analysis of a Cluster. Nutrients. 2017;9(7):759.

248. Godomar Galindo R. Mejoramiento de la olla familiar para alimentar a los niños en edad de lactancia. Rev chil nutr. 1989;17(1,supl):77-82.

249. Gough EK, Moulton LH, Mutasa K, Ntozini R, Stoltzfus RJ, Majo FD, et al. Effects of improved water, sanitation, and hygiene and improved complementary feeding on environmental enteric dysfunction in children in rural Zimbabwe: A cluster-randomized controlled trial. PLoS Negl Trop Dis. 2020;14(2):e0007963.

250. Grantham-McGregor S, Powell C, Walker S. Nutritional supplements, stunting, and child development. Lancet. 1989;2(8666):809-10.

251. Granthammcgregor SM, Walker SP, Himes JH, Powell CA. THE EFFECT OF NUTRITIONAL SUPPLEMENTATION AND STUNTING ON MORBIDITY IN YOUNG-CHILDREN - THE JAMAICAN STUDY. Trans Roy Soc Trop Med Hyg. 1993;87(1):109-13.

252. Gunaratna NS, Bosha T, Belayneh D, Fekadu T, De Groote H. Women's and children's acceptance of biofortified quality protein maize for complementary feeding in rural Ethiopia. J Sci Food Agric. 2016;96(10):3439-45.

253. Gutierrez MR, Bettiol H, Barbieri MA. Avaliação de um programa de suplementação alimentar. Rev panam salud pública. 1998;4(1):32-9.

254. Hambidge KM, Chavez MN, Brown RM, Walravens PA. Zinc nutritional status of young middle-income children and effects of consuming zinc-fortified breakfast cereals. Am J Clin Nutr. 1979;32(12):2532-9.

255. Hambidge KM, Sheng X, Westcott J, Sun QQ, Hu YQ, Liu JR, et al. Growth of poor rural Chinese children fed meat as a daily complementary food from 6-18 months of age. FASEB journal. 2013;27.

256. Harrington M, Hotz C, Zeder C, Polvo GO, Villalpando S, Zimmermann MB, et al. A comparison of the bioavailability of ferrous fumarate and ferrous sulfate in non-anemic Mexican women and children consuming a sweetened maize and milk drink. Eur J Clin Nutr. 2011;65(1):20-5.

257. Haschke F, Pietschnig B, Vanura H, Heil M, Steffan I, Hobiger G, et al. Iron intake and iron nutritional status of infants fed iron-fortified beikost with meat. Am J Clin Nutr. 1988;47(1):108-12.
258. Haydom Lutheran H, University of T, Tanzania F, Drugs A. Quadruple Fortified Salt Clinical Trial. 2020.

259. Helen Keller I, University of B, University of California D, Unicef, United Nations World Food P. Management of Children With Moderate Acute Malnutrition in Mali. 2011.

260. Hero Institute for Infant N, Universidad de M, Hospital Universitario Virgen de la A, Quantum E. Acceptability, Tolerance, Satiety and Prebiotic Effect of a New Infant Cereal. 2017.

261. Herter-Aeberli I, Eliancy K, Rathon Y, Loechl CU, Marhone Pierre J, Zimmermann MB. In Haitian women and preschool children, iron absorption from wheat flour-based meals fortified with sodium iron EDTA is higher than that from meals fortified with ferrous fumarate, and is not affected by Helicobacter pylori infection in children. Br J Nutr. 2017;118(4):273-9.

262. Herter-Aeberli I EKRYLCMJZMB. In Haitian women and children, iron absorption from wheat flour fortified with NaFeEDTA is higher than from flour fortified with ferrous fumarate and is not affected by H. pylori infection. Annals of nutrition & metabolism. 2017;71:1075.

263. Hertrampf E, Olivares M, Pizarro F, Walter T, Cayazzo M, Heresi G, et al. HEMOGLOBIN FORTIFIED CEREAL - A SOURCE OF AVAILABLE IRON TO BREAST-FED INFANTS. Eur J Clin Nutr. 1990;44(11):793-8.

264. Hertrampf E, Olivares M, Pizarro F, Walter T, Cayazzo M, Heresi G, et al. Haemoglobin fortified cereal: a source of available iron to breast-fed infants. Eur J Clin Nutr. 1990;44(11):793-8.
265. Hess SY, Peerson JM, Becquey E, Abbeddou S, Ouedraogo CT, Some JW, et al. Differing growth responses to nutritional supplements in neighboring health districts of Burkina Faso are likely due to benefits of small-quantity lipid-based nutrient supplements (LNS). PLoS ONE. 2017;12(8):e0181770.

266. Hi PPG, Co. Vertrieb KG, Biofortis Mérieux N. The Combiotic-Study. 2020.

267. Hilmers DC, Mushi A, Griffin IJ, Allen LH, Hicks PD, Abrams SA. A trial of a multi-nutrient fortified beverage in Botswana children. Pediatr Res. 2002;51(4):210A-A.

268. Hlaing LM, Fahmida U, Htet MK, Firmansyah A, Utomo B, Gibson RS. Iron Supplementation with or without Optimized Complementary Feeding Recommendations: Effect on Micronutrient Status and Growth of 1-2 Year Old Myanmar Children. 2015.

269. Hoffman DR, Theuer RC, Castaneda YS, Wheaton DH, Bosworth RG, O'Connor AR, et al. Maturation of visual acuity is accelerated in breast-fed term infants fed baby food containing DHAenriched egg yolk. J Nutr. 2004;134(9):2307-13.

270. Hoffman DR, Garfield S, Morale SE, Bosworth RG, Castaneda YS, Wheaton DKH, et al. Visual and neural development of breast-fed infants receiving docosahexaenoic acid (DHA)-enriched baby food: A randomized clinical trial. Invest Ophthalmol Vis Sci. 2004;45:U158-U.

271. Hospital Clinico Universitario de S, Centre for the Development of Industrial T. Effect of a Kefir Beverage on Immunity and Lipid Profile. 2017.

272. Hossain MI, Wahed MA, Ahmed S. Increased food intake after the addition of amylase-rich flour to supplementary food for malnourished children in rural communities of Bangladesh. Food Nutr Bull. 2005;26(4):323-9.

273. Huey SL, Venkatramanan S, Udipi SA, Finkelstein JL, Ghugre P, Haas JD, et al. Acceptability of Iron- and Zinc-Biofortified Pearl Millet (ICTP-8203)-Based Complementary Foods among Children in an Urban Slum of Mumbai, India. Front Nutr. 2017;4:10.

274. Huo J, Sun J, Chen J. Iron-fortified soy sauce in China-an assessment of 10 years of policy and business development. Annals of Nutrition and Metabolism. 2013;63:91.

275. Hussain T, Abbas S, Khan MA, Scrimshaw NS. Lysine fortification of wheat flour improves selected indices of the nutritional status of predominantly cereal-eating families in Pakistan. Food Nutr Bull. 2004;25(2):114-22.

276. Huybregts L, Houngbe F, Salpeteur C, Brown R, Roberfroid D, Ait-Aissa M, et al. The effect of adding ready-to-use supplementary food to a general food distribution on child nutritional status and morbidity: a cluster-randomized controlled trial. PLoS Med. 2012;9(9):e1001313.

277. Isanaka S, Nombella N, Djibo A, Poupard M, Van Beckhoven D, Gaboulaud V, et al. EFFECT OF READY-TO-USE-THERAPEUTIC FOOD SUPPLEMENTATION ON THE NUTRITIONAL STATUS, MORTALITY AND MORBIDITY OF CHILDREN 6 TO 60 MONTHS IN NIGER: A CLUSTER RANDOMIZED TRIAL. Am J Trop Med Hyg. 2008;79(6):359-.

278. Isanaka S, Barnhart DA, McDonald CM, Ackatia-Armah RS, Kupka R, Doumbia S, et al. Costeffectiveness of community-based screening and treatment of moderate acute malnutrition in Mali. BMJ Glob Health. 2019;4(2):10.

279. Isrctn. A comparison of diets to treat moderate childhood malnutrition.

http://www.hoint/trialsearch/Trial2aspx?TrialID=ISRCTN47598408. 2008.

280. Isrctn. The WinFood Intervention Study: the effect of improved complementary foods on nutrition and health among infants in Western Kenya.

http://www.hoint/trialsearch/Trial2aspx?TrialID=ISRCTN30012997. 2012.

281. Isrctn. Evaluating the effectiveness of a legume-enriched nutritional intervention, in treatment of severe undernutrition in children.

http://www.hoint/trialsearch/Trial2aspx?TrialID=ISRCTN10309022. 2018.

282. Iuel-Brockdorf AS, Dræbel TA, Fabiansen C, Cichon B, Christensen VB, Yameogo C, et al. Acceptability of new formulations of corn-soy blends and lipid-based nutrient supplements in Province du Passoré, Burkina Faso. Appetite. 2015;91:278-86.

283. Iuel-Brockdorf AS, Draebel TA, Ritz C, Fabiansen C, Cichon B, Brix Christensen V, et al. Evaluation of the acceptability of improved supplementary foods for the treatment of moderate acute malnutrition in Burkina Faso using a mixed method approach. Appetite. 2016;99:34-45.

284. Jaeggi T, Kortman GA, Moretti D, Chassard C, Holding P, Dostal A, et al. Iron fortification adversely affects the gut microbiome, increases pathogen abundance and induces intestinal inflammation in Kenyan infants. Gut. 2015;64(5):731-42.

285. Jahari AB, Haas J, Husaini MA, Pollitt E. Effects of an energy and micronutrient supplement on skeletal maturation in undernourished children in Indonesia. European journal of clinical nutrition. 2000;54 Suppl 2:S74-9.

286. Jalla S, Westcott J, Steirn M, Miller LV, Bell M, Krebs NF. Zinc absorption and exchangeable zinc pool sizes in breast-fed infants fed meat or cereal as first complementary food. J Pediatr Gastroenterol Nutr. 2002;34(1):35-41.

287. Javan R, Kooshki A, Afzalaghaee M, Aldaghi M, Yousefi M. Effectiveness of supplementary blended flour based on chickpea and cereals for the treatment of infants with moderate acute malnutrition in Iran: A randomized clinical trial. Electron Physician. 2017;9(12):6078-86.

288. Javaid N, Haschke F, Pietschnig B, Schuster E, Huemer C, Shebaz A, et al. Interactions between infections, malnutrition and iron nutritional status in Pakistani infants. A longitudinal study. Acta Paediatr Scand Suppl. 1991;374:141-50.
289. Javaid N HFPBSEHCSAGPSIHRSMC. Interactions between infections, malnutrition and ironnutritional status in Pakistani infants. Acta Paediatrica Scandinavica, Supplement. 1991;80(374):141-50.

290. Jilcott SB, Ickes SB, Ammerman AS, Myhre JA. Iterative design, implementation and evaluation of a supplemental feeding program for underweight children ages 6-59 months in Western Uganda. Maternal and child health journal. 2010;14(2):299-306.

John C, Gopaldas T. Evaluation of the impact on growth of a controlled 6-month feeding trial on children (6-24 months) fed a complementary feed of a high energy-low bulk gruel versus a high energy-high bulk gruel in addition to their habitual home diet. J Trop Pediatr. 1993;39(1):16-22.
Jong-Mee LEE, Hea-Jin P. Effects of Supplementary Diet on Iron Status and Development in

Infants. The Korean Journal of Nutrition. 2005:226-31.

293. Kaimila Y, Pitman RT, Divala O, Hendrixson DT, Stephenson KB, Agapova S, et al. Development of Acute Malnutrition Despite Nutritional Supplementation in Malawi. J Pediatr Gastroenterol Nutr. 2019;68(5):734-7.

294. Kajjura RB, Veldman FJ, Kassier SM. Effect of a novel supplementary porridge on the nutritional status of infants and young children diagnosed with moderate acute malnutrition in Uganda: a cluster randomised control trial. J Hum Nutr Diet. 2019;32(3):295-302.

295. Kajjura RB, Veldman FJ, Kassier SM. Maternal perceptions and barriers experienced during the management of moderately malnourished children in northern Uganda. Maternal and Child Nutrition. 2020.

296. Kalavi FN, Muroki NM, Omwega AM, Mwadime RK. Effect of tempe-yellow maize porridge and milk-yellow maize porridge on growth rate, diarrhoea and duration of rehabilitation of malnourished children. East Afr Med J. 1996;73(7):427-31.

297. Kalhoff H, Mesch CM, Stimming M, Israel A, Spitzer C, Beganovic L, et al. Effects of LC-PUFA supply via complementary food on infant development-a food based intervention (RCT) embedded in a total diet concept. Eur J Clin Nutr. 2020;74(5):682-90.

298. Kampstra NA, Hoan NV, Koenders D, Schoop R, Broersen BC, Mouquet-Rivier C, et al. Energy and nutrient intake increased by 47-67% when amylase was added to fortified blended foodsa study among 12-to 35-month-old Burkinabe children. Matern Child Nutr. 2018;14(1):12.

299. Karakochuk C, van den Briel T, Stephens D, Zlotkin S. Treatment of moderate acute malnutrition with ready-to-use supplementary food results in higher overall recovery rates compared with a corn-soya blend in children in southern Ethiopia: an operations research trial. Am J Clin Nutr. 2012;96(4):911-6.

300. Kekalih A, Anak Agung Sagung IO, Fahmida U, Ermayani E, Mansyur M. A multicentre randomized controlled trial of food supplement intervention for wasting children in Indonesia-study protocol. BMC Public Health. 2019;19(1):305.

301. King S PADUJOGT. The impact of high diastase malted barley flour on weight and height of malnourished children in Panama. Journal of hunger & environmental nutrition. 2007;1(4):23-35. 302. Kodkany BS, Bellad RM, Mahantshetti NS, Westcott JE, Krebs NF, Kemp JF, et al.

Biofortification of pearl millet with iron and zinc in a randomized controlled trial increases absorption of these minerals above physiologic requirements in young children. J Nutr. 2013;143(9):1489-93.

303. Konyole S, Kinyuru J, Owuor B, Roos N, Friis H, Aagaard J, et al. Acceptability of complementary foods with indigenous animal source foods and corn soy blend plus among young children/mothers in Kenya. Annals of Nutrition and Metabolism. 2013;63:1729.

304. Konyole S ASKJOBEBWJMKFFHRNOV. Effect on lean mass, linear growth and iron status of improved animal source foods and micronutrients fortified complementary foods among kenyan young children: A randomized controlled trial. Annals of nutrition & metabolism. 2017;71:496-7. 305. Konyole SO, Omollo SA, Kinyuru JN, Skau JKH, Owuor BO, Estambale BB, et al. Effect of locally produced complementary foods on fat-free mass, linear growth, and iron status among Kenyan infants: A randomized controlled trial. Matern Child Nutr. 2019;15(4):e12836.

306. Krebs NF, Westcott JE, Butler N, Robinson C, Bell M, Hambidge KM. Meat as a first complementary food for breastfed infants: feasibility and impact on zinc intake and status. J Pediatr Gastroenterol Nutr. 2006;42(2):207-14.

307. Krebs NF, Sherlock L, Robertson CE, Westcott J, Culbertson D, Feazel L, et al. Enteric Microbiome (EMB) of breastfed infants (BFI) on complementary feeding (CF) regimens with different iron (Fe) exposure. FASEB journal. 2012;26.

308. Krebs NF, Westcott JE, Culbertson DL, Sian L, Miller LV, Hambidge KM. Comparison of complementary feeding strategies to meet zinc requirements of older breastfed infants. Am J Clin Nutr. 2012;96(1):30-5.

309. Krebs NF, Sherlock LG, Westcott J, Culbertson D, Hambidge KM, Feazel LM, et al. Effects of different complementary feeding regimens on iron status and enteric microbiota in breastfed infants. J Pediatr. 2013;163(2):416-23.

310. Krebs NF, Hambidge KM, Ikemeri JE, Westcott JE, Kemp J, Lei S, et al. Zinc (Zn) absorption from SprinklesTM is not affected by iron (Fe) in Kenyan infants in malaria endemic area. FASEB journal. 2013;27.

311. Kuusipalo H, Maleta K, Briend A, Manary M, Ashorn P. Growth and change in blood haemoglobin concentration among underweight Malawian infants receiving fortified spreads for 12 weeks: a preliminary trial. J Pediatr Gastroenterol Nutr. 2006;43(4):525-32.

312. Laboratorios O, Ministerio de Ciencia e Innovación S. Whole Grain, Gluten-containing Cereal and PROBIOtics to Evaluate Digestive TOLERAance and Immuno-inflammatory Response. 2021.

313. Lachat CK, Van Camp JH, Mamiro PS, Wayua FO, Opsomer AS, Roberfroid DA, et al. Processing of complementary food does not increase hair zinc levels and growth of infants in Kilosa district, rural Tanzania. Br J Nutr. 2006;95(1):174-80.

314. LaGrone LN, Trehan I, Meuli GJ, Wang RJ, Thakwalakwa C, Maleta K, et al. A novel fortified blended flour, corn-soy blend "plus-plus," is not inferior to lipid-based ready-to-use supplementary foods for the treatment of moderate acute malnutrition in Malawian children. Am J Clin Nutr. 2012;95(1):212-9.

315. Lakkam M, Wager S, Wise PH, Wein LM. Quantifying and exploiting the age dependence in the effect of supplementary food for child undernutrition. PLoS ONE. 2014;9(6):e99632.

316. Langendorf C, Roederer T, de Pee S, Brown D, Doyon S, Mamaty AA, et al. Preventing acute malnutrition among young children in crises: a prospective intervention study in Niger. PLoS medicine. 2014;11(9):e1001714.

317. Langlois BK, Cliffer IR, Nikiema L, Suri DJ, Garanet F, Shen Y, et al. Factors that May Influence the Effectiveness of 4 Specialized Nutritious Foods in the Prevention of Stunting and Wasting in Children Aged 6-23 Months in Burkina Faso. Curr Dev Nutr. 2020;4(2):11.

318. Laylo-Navarro Celestina Raquel B, Limos Elizabeth M, Martinez Elizabeth G. A randomized controlled trial on the efficacy and safety of a modified ready to use therapeutic food among malnourished children. Acta Medica Philippina. 2011:29-33.

319. Leroy JL, D KO, Bliznashka L, Ruel M. Tubaramure, a Food-Assisted Maternal and Child Health and Nutrition Program in Burundi, Increased Household Food Security and Energy and Micronutrient Consumption, and Maternal and Child Dietary Diversity: A Cluster-Randomized Controlled Trial. J Nutr. 2020;150(4):945-57.

320. Leroy JL, Olney DK, Nduwabike N, Ruel MT. Tubaramure, a Food-Assisted Integrated Health and Nutrition Program, Reduces Child Wasting in Burundi: A Cluster-Randomized Controlled Intervention Trial. J Nutr. 2021;151(1):197-205.

321. Libuda L, Mesch CM, Stimming M, Demmelmair H, Koletzko B, Warschburger P, et al. Fatty acid supply with complementary foods and LC-PUFA status in healthy infants: results of a randomised controlled trial. Eur J Nutr. 2016;55(4):1633-44.

322. Li M, Wu J, Ren T, Wang R, Li W, Piao J, et al. Effect of NaFeEDTA-fortified soy sauce on zinc absorption in children. Food Funct. 2015;6(3):788-92.

323. Lin CA, Manary MJ, Maleta K, Briend A, Ashorn P. An energy-dense complementary food is associated with a modest increase in weight gain when compared with a fortified porridge in Malawian children aged 6-18 months. J Nutr. 2008;138(3):593-8.

324. Lind T, Lonnerdal B, Persson LA, Stenlund H, Tennefors C, Hernell O. Effects of weaning cereals with different phytate contents on hemoglobin, iron stores, and serum zinc: a randomized intervention in infants from 6 to 12 mo of age. Am J Clin Nutr. 2003;78(1):168-75.

325. Lind T, Hernell O, Lonnerdal B, Stenlund H, Domellof M, Persson LA. Dietary iron intake is positively associated with hemoglobin concentration during infancy but not during the second year of life. J Nutr. 2004;134(5):1064-70.

326. Lind T, Johansson U, Ohlund I, Lindberg L, Lonnerdal B, Tennefors C, et al. Study protocol: optimized complementary feeding study (OTIS): a randomized controlled trial of the impact of a protein-reduced complementary diet based on Nordic foods. BMC Public Health. 2019;19(1):134.

327. Litkowski Pe SHCTIMMJ. The addition of whey permeate to ready-to use supplementary food improves recovery from moderate acute malnutrition. Annals of global health. 2016;82(3):393.
328. Lo NB, Aaron GJ, Hess SY, Dossou NI, Guiro AT, Wade S, et al. Plasma zinc concentration responds to short-term zinc supplementation, but not zinc fortification, in young children in

Senegal1,2. Am J Clin Nutr. 2011;93(6):1348-55.

329. Long SE, Murphy KE, Davis WC, Wood LJ. Methods and reference materials for measuring iodine status. Planta Medica. 2012;78(5).

330. Lopez de Romana D, Salazar M, Hambidge KM, Penny ME, Peerson JM, Krebs NF, et al. Longitudinal measurements of zinc absorption in Peruvian children consuming wheat products fortified with iron only or iron and 1 of 2 amounts of zinc. Am J Clin Nutr. 2005;81(3):637-47.

331. Ly CT, Diallo A, Simondon F, Simondon KB. Early short-term infant food supplementation, maternal weight loss and duration of breast-feeding: a randomised controlled trial in rural Senegal. Eur J Clin Nutr. 2006;60(2):265-71.

332. Macharia-Mutie CW, Moretti D, Van den Briel N, Omusundi AM, Mwangi AM, Kok FJ, et al. Maize porridge enriched with a micronutrient powder containing low-dose iron as NaFeEDTA but not amaranth grain flour reduces anemia and iron deficiency in Kenyan preschool children. J Nutr. 2012;142(9):1756-63.

333. Macharia-Mutie CW, Omusundi AM, Mwai JM, Mwangi AM, Brouwer ID. Simulation of the effect of maize porridge fortified with grain amaranth or micronutrient powder containing NaFeEDTA on iron intake and status in Kenyan children. Public Health Nutr. 2013;16(9):1605-13.

334. Macharia-Mutie C, Mwangi A, Brouwer I. Efficacy of Amaranth Grain Flour or Multimicronutrient Fortified Maize Porridge on Iron of Kenyan Pre-school Children: A Randomized, Controlled Intervention. 2015.

335. Manno D, Siame J, Larke N, Baisley K, Kasonka L, Filteau S. Effect of multiple micronutrientfortified food on mild morbidity and clinical symptoms in Zambian infants: results from a randomised controlled trial. Eur J Clin Nutr. 2011;65(10):1163-6.

336. Mahalanabis D, Faruque AS, Wahed MA. Energy dense porridge liquified by amylase of germinated wheat: use in infants with diarrhoea. Acta Paediatr. 1993;82(6-7):603-4.

337. Mallard SR, Houghton LA, Filteau S, Mullen A, Nieuwelink J, Chisenga M, et al. Dietary diversity at 6 months of age is associated with subsequent growth and mediates the effect of maternal education on infant growth in urban Zambia. J Nutr. 2014;144(11):1818-25.

338. Mamiro PS, Kolsteren PW, van Camp JH, Roberfroid DA, Tatala S, Opsomer AS. Processed complementary food does not improve growth or hemoglobin status of rural tanzanian infants from 6-12 months of age in Kilosa district, Tanzania. J Nutr. 2004;134(5):1084-90.

339. Manary MJ, Ndkeha MJ, Ashorn P, Maleta K, Briend A. Home based therapy for severe malnutrition with ready-to-use food. Arch Dis Child. 2004;89(6):557-61.

340. Mank T, Veenemans J, Olomi R, Wielders J, Savelkoul H, Verhoef H. Protection against diarrhoea associated with asymptomatic giardiasis is lost with multi-nutrient supplementation: A prospective study among rural Tanzanian children. Tropical Medicine and International Health. 2011;16:256.

341. Marron B, Green J, Jayson L, Suri D, Marcus S, Boiteau J, et al. Comparison of four different supplementary foods in the treatment of moderate acute malnutrition (MAM) in children under five in sierra leone. FASEB journal. 2015;29(1 Meeting Abstracts).

342. Martínez Martínez ÓA. Complementos nutricionales y capitalhumano: un análisis desde los beneficiarios al nutrisano y nutrivida del programa oportunidades de México. Rev gerenc políticas salud. 2009;8(17):140-54.

343. Martorell R. Complementary Food Supplementation Helps Build Fat-Free Mass, a Little Anyway. Journal of Nutrition. 2020;150(7):1676-7.

344. Masuda K, Chitundu M. Multiple micronutrient supplementation using spirulina platensis and infant growth, morbidity, and motor development: Evidence from a randomized trial in Zambia. PLoS ONE. 2019;14(2):e0211693.

345. Masuda K, Chitundu M. Multiple Micronutrient Supplementation Using Spirulina platensis during the First 1000 Days is Positively Associated with Development in Children under Five Years: A Follow up of A Randomized Trial in Zambia. Nutrients. 2019;11(4):29.

346. Matilsky DK, Maleta K, Castleman T, Manary MJ. Supplementary feeding with fortified spreads results in higher recovery rates than with a corn/soy blend in moderately wasted children. J Nutr. 2009;139(4):773-8.

347. Maust A, Koroma AS, Abla C, Molokwu N, Ryan KN, Singh L, et al. Severe and Moderate Acute Malnutrition Can Be Successfully Managed with an Integrated Protocol in Sierra Leone. J Nutr. 2015;145(11):2604-9.

348. McDonald CM, Ackatia-Armah RS, Doumbia S, Kupka R, Duggan CP, Brown KH. Percent Fat Mass Increases with Recovery, But Does Not Vary According to Dietary Therapy in Young Malian Children Treated for Moderate Acute Malnutrition. J Nutr. 2019;149(6):1089-96.

349. McGill U, Micronutrient I, Ethiopian H, Nutrition Research I. The Effects of Iodized Salt on Cognitive Development in Ethiopia. 2014.

350. McGill U. Fortified Cheese and Yogurt Products and Vitamin D Status in Young Children? Phase 2. 2015.

351. Medecins Sans Frontieres S. Effectiveness of Nutritional Supplementation in Preventing Malnutrition in Children With Infection in Karamoja, Uganda. 2012.

352. Meeks Gardner J, Grantham-McGregor SM, Chang SM, Himes JH, Powell CA. Activity and behavioral development in stunted and nonstunted children and response to nutritional supplementation. Child Dev. 1995;66(6):1785-97.

353. Menon P, Ruel MT, Loechl CU, Arimond M, Habicht JP, Pelto G, et al. Micronutrient Sprinkles reduce anemia among 9- to 24-mo-old children when delivered through an integrated health and nutrition program in rural Haiti. J Nutr. 2007;137(4):1023-30.

354. Miles CW, Bodwell CE, Morris E, Ziyad JA, Prather ES, Mertz W, et al. Long-term consumption of beef extended with soy protein by men, women and children: I. Study design, nutrient intakes, and serum zinc levels. Plant Foods Hum Nutr. 1987;37(4):341-59.

355. Mize CE, Uauy R, Kramer R, Benser M, Allen S, Grundy SM. Lipoprotein-cholesterol responses in healthy infants fed defined diets from ages 1 to 12 months: comparison of diets predominant in oleic acid versus linoleic acid, with parallel observations in infants fed a human milk-based diet. J Lipid Res. 1995;36(6):1178-87.

356. Moore N, Chao C, Yang L, Storm H, Oliva-Hemker M, Saavedra JM. Effects of fructooligosaccharide-supplemented infant cereal: a double-blind, randomized trial. British Journal of Nutrition. 2003;90(3):581-7.

357. Morales J, Vargas F, Cassis L, Sanchez E, Villalpando S. Sensorial evaluation of nutritional supplements (PROGRESA) enriched with 3 different forms of iron in a rural Mexican community. J Food Sci. 2008;73(1):S1-5.

358. Moursi M, Mbemba M, Trèche S, Mbemba F. Does the consumption of amylase-containing gruels impact on the energy intake and growth of Congolese infants? Public Health Nutrition. 2003;6(3):249-57.

359. Nane D, Hatloy A, Tadesse E, Lindtjorn B. Research protocol local ingredients-based supplementary food as an alternative to corn-soya blends plus for treating moderate acute malnutrition among children aged 6 to 59 months: a randomized controlled non-inferiority trial in Wolaita. BMC Public Health. 2019;19(1):1689.

360. Wageningen U, University of N, Nestlé F, Nevin Scrimshaw International Nutrition F. Improving Iron Status of Children: Potential of Amaranth. 2011.

361. Wageningen U, Zurich ETH, Maseno U. Assessment of Zinc Intake From Enriched Water and Other Dietary Sources in Kisumu, Kenya. 2014.

362. Washington University School of M. Whey Permeate Study. 2015.

363. Washington University School of M, Project Peanut Butter SL, Ministry of H, Sanitation GoSL.Effect of an Alternative RUTF on Intestinal Permeability in Children With Severe Acute Malnutrition.2021.

364. Washington University School of M. Effectiveness Comparison of Three Supplementary Foods in the Treatment of Moderate Acute Malnutrition. 2011.

365. Washington University School of M, University of California D, World B, United Nations World Food P. Nutributter Programming to Prevent Undernutrition: an Evaluation. 2013.

366. Washington University School of M. Moderate Acute Malnutrition (MAM) and Severe Acute Malnutrition (SAM) in Sierra Leone. 2013.

367. Washington University School of M, University of M. Pilot Study of PUFA-optimized RUTF for Severe Acute Malnutrition. 2014.

368. United States Army Research Institute of Environmental M, United States Department of D. Efficacy of a Once Daily Calcium and Vitamin D Fortified Food Product to Improve Bone Microarchitecture. 2015.

369. Universidad Autonoma de Q, Procter, Gamble. Evaluation of the Efficacy of Different Strategies to Treat Anemia in Mexican Children. 2003.

370. University G, Jimma U, Programme VIUC, Nutrition Tiers M, Nutricia Research F. ω3 LCPUFAs
for Healthy Growth and Development of Infants and Young Children in Southwest Ethiopia. 2016.
371. University of O. Effectiveness of Supplementary Feeding During Infection Among Moderately

Malnourished Children. 2009.

372. University of C, Axellus. Essential Fatty Acids During Complementary Feeding. 2009.

373. University of O, Program KE-WTCR. A Trial of n-3 PUFA-Enriched Ready to Use Therapeutic Food for Childhood Severe Malnutrition. 2013.

374. University of M. Assessment of Complementary Feeding of Canadian Infants. 2014.

375. University of S, Hawassa U. Using Eggshell Calcium to Mitigate Fluorosis in Ethiopia. 2018.

376. University of F, Michigan State U. Feasibility and Acceptability of a Soy-fiber-maize Complementary Food in Malawi. 2018.

377. University of C, Children's Hospital Medical Center C. Healthy Start to Feeding Intervention.2020.

378. University of British C, Helen Keller I, Grand Challenges C, International Development Research Centre C, Canadian Institutes of Health R. Thiamin Fortified Fish Sauce as a Means of Combating Infantile Beriberi in Rural Cambodia. 2015.

379. University of California D. Acceptability and Tolerance of a Protein and Micronutrient Fortified Food. 2017.

380. University of California D. Assessment of a New Food Product in Metabolically at Risk Children. 2018.

381. University of Colorado D, International Atomic Energy A, Universidad Francisco M. Zinc Bioavailability From Amaranth-enriched Maize Tortillas. 2015.

382. University of Colorado D, Colorado C, Translational Sciences I, National Cattlemen's Beef A, National Institute of D, Digestive, et al. Effect of Protein From Complementary Foods on Infant Growth, Body Composition and Gut Health. 2018.

383. University of Colorado D. The Effects of Early Complementary Feeding on Growth, Neurodevelopment, Sleep and Gut Health. 2022.

384. University of North Carolina CH, General M. The Effect of Yogurt Containing BB12 on Children's Health and Child Care Absenteeism. 2008.

385. University of North Carolina CH, Kinshasa School of Public H, University of California D, Bill, Melinda Gates F, Thrasher Research F. Efficacy of Caterpillar Cereal for Complementary Feeding in the Democratic Republic of Congo. 2012.

386. Swiss Federal Institute of T, Addis Ababa U, HarvestPlus. Iron Status in Infants in Ethiopia.2019.

387. Technical University of D. The Effect of Vitamin D Fortification of Bread and Milk in Danish Families. 2011.

388. The Hospital for Sick C. Evaluating the Relative Effectiveness of Two Feeding Interventions for the Treatment of Moderate Acute Malnutrition. 2009.

389. The Hospital for Sick C. Treatment of Iron Deficiency Anemia in Malaria Endemic Ghana.2010.

390. The Hospital for Sick C. Preventing Linear Growth Faltering Among Low Birth Weight Infants in Bangladesh. 2011.

391. Specialties DSMF, United Nations World Food P. Acceptability Among Children and Caregivers of Amylase Porridges. 2014.

392. Swiss Federal Institute of T, Mahidol U. An Efficacy Trial of Iron, Zinc and Vitamin A Fortified Rice in Children in Satun, Thailand. 2010.

393. Swiss Federal Institute of T. Iron Fortification Trail Using NaFeEDTA in Iron Deficient Leadexposed Children. 2012.

394. Swiss Federal Institute of T, Université dA-C. Iron Absorption From Complementary Food Fortificants (CFFs) and Acceptability of CFFs by Beninese Children. 2012.

395. Swiss Federal Institute of T, University of K, University of N. Changes in Microbiota and Iron Status After Iron Fortification of Complementary Foods. 2012.

396. Swiss Federal Institute of T, Swiss T, Public Health I, Swiss National Science F. Efficacy of Iron Fortified Complementary Food and IPT of Malaria in Young Children in Côte d'Ivoire. 2013.

397. Swiss Federal Institute of T. Iron Absorption From Rice Fortified With Ferric Pyrophosphate.2014.

398. Swiss Federal Institute of T, Cheikh Anta Diop University S. Fe Absorption in Mother and Child Pairs From Wheat Fortified With Iron With and Without Phenolic Containing Beverages. 2015.

399. Swiss Federal Institute of T, Dsm Nutritional Products I. Iron and Prebiotics Fortification in Kenyan Infants. 2015.

400. Swiss Federal Institute of T, Danone Nutricia R. Iron Absorption From a Wheat-based Instant Cereal:Gut and Stable Isotope Studies in Kenyan Infants. 2020.

401. PepsiCo Global R, Food, Nutrition Research Institute P. Iron Bioavailability of Fortified Oat Drink. 2011.

402. PepsiCo Global R, PepsiCo P. Nutrient Fortified Oat Drink. 2011.

403. Research Institute of Child Nutrition D. Modification in Complementary Food Composition to Improve the Status of Iron and Fatty Acids in Infants. 2007.

404. Aga Khan U, United Nations World Food P, People's Primary Healthcare Initiative S. Comparison of Treatment of SAM in Children 6-59 Months With RUTF and RUSF in Umerkot, Sindh, Pakistan. 2021.

405. Agnes L, Gret, Cellule de Lutte contre la M, Universite Gaston B, International Food Policy Research I. Distribution of Fortified Yoghurt in Senegal to Decrease Children's Anemia and Improve Milk Supply. 2014.

406. Food SRCf, Nutrition, Universitas P, University of O, Usda WHNRC, VitMin L, et al. Sustainable Intervention of Supplementation to Improve Kid's Growth Study. 2023.

407. Kansas State U, Project Concern International T, National Institute for Medical Research T, United States Department of Agriculture Foreign Agricultural S. Newly Formulated, Extruded Fortified-blended Foods for Food Aid: the MFFAPP Tanzania Efficacy Study. 2016. 408. Institut de Recherche pour le D, Faso IDB, Hopital Yalgado Ouedraogo Burkina F. Regular Consumption of Leafy Vegetable Sauces and Micro-nutrient Status of Young Children in Burkina Faso. 2013.

409. Laboratorios O. Effect of a New Infant Cereal on Weight Gain. 2012.

410. Swiss Federal Institute of T. The Effect of Lactoferrin and Dosing Regimen on Iron Absorption From a Maize-based Porridge in Kenyan Infants. 2019.

411. Institut de Recherche pour le Developpement C, Unicef, Department of Fisheries Post-harvest T, Quality C. Acceptability of a Multiple Micronutrient-Fortified Lipid-Based Nutrient Supplement for Children Under Two in Cambodia. 2015.

412. Institut de Recherche pour le Developpement C, Unicef, Department of Fisheries Post-harvest T, Quality C. Efficacy of a Multiple Micronutrient-Fortified Lipid-Based Nutrient Supplement for Children Under Two in Cambodia. 2016.

413. Indonesia U, Nestlé F. Food-Based Intervention and Psychosocial Stimulation to Improve Growth & Development of < 24 Month Indonesian Children. 2011.

414. Institut P, Action Contre la F, Centre de Recherches Médicales et Sanitaires CN, Institut Pasteur de M, Institut Pasteur de B, Institut Pasteur de D. Comparing Several Strategies to Manage Moderate Acute Malnutrition Among Children From 6 to 24 Months Old. 2018.

415. Institute of Tropical Medicine B, Institut de Recherche en Sciences de la Sante BF, Ministry of Health BF, University G. Treating Moderate Malnutrition in 6-24 Months Old Children. 2011.

416. Inter-American Development B, Hospital Infantil de Mexico Federico G, Servicios de Salud de N, The PepsiCo F. SPOON:Sustained Program for Improving Nutrition - Mexico. 2020.

417. Inter-American Development B, The PepsiCo F, Program J-JPR, Fundazúcar. SPOON: Sustained Program for Improving Nutrition - Guatemala. 2021.

418. International Centre for Diarrhoeal Disease Research B, Nutrition Third World B, Nestlé F.
Ferrous Fumarate and Ferric Pyrophosphate as Food Fortificants in Developing Countries. 2008.
419. International Centre for Diarrhoeal Disease Research B. Zinc Absorption From Zinc
Biofortified Rice in Bangladeshi Children. 2020.

420. International Centre for Diarrhoeal Disease Research B. Development and Acceptability
Testing of Ready-to-use-complementary Food Supplement (RUCFS) for Children in Bangladesh. 2012.
421. International Centre for Diarrhoeal Disease Research B. Soy-Ready to Use Therapeutic Food (RUTF) in Severely Malnourished Children. 2016.

422. International Centre for Diarrhoeal Disease Research B, Centers for Disease C, Prevention. Vitamin-D Supplementation: Impact on Severe Pneumonia Among Under-five Children. 2017.

423. International Centre for Diarrhoeal Disease Research B, HarvestPlus, International Atomic Energy A. Zinc Absorption From Zinc Biofortified Rice. 2011.

424. International Centre for Diarrhoeal Disease Research B, University of California D. Vitamin B12 Supplementation to Improve B12 Status and Child Development. 2020.

425. International Centre for Diarrhoeal Disease Research B, Washington University School of M. Community-based Clinical Trial With Microbiota-directed Complementary Foods (MDCFs) Made of Locally Available Food Ingredients for the Management of Children With Primary Moderate Acute Malnutrition. 2021.

426. International Centre for Diarrhoeal Disease Research B, Washington University School of M. 'Pre-Proof of Concept (Pre-POC)' Clinical Trials to Optimize Lead Microbiota-directed Complementary Food (MDCF) Prototypes for Their Ability to Repair Microbiota Immaturity and Establish Their Organoleptic Acceptability. 2021.

427. Johns Hopkins Bloomberg School of Public H, International Centre for Diarrhoeal Disease Research B, United Nations World Food P, Ltd DSM. Complementary Food Supplements for Reducing Childhood Undernutrition. 2014.

428. Kintampo Health Research Centre G, University of Wisconsin M. Effects of Fortified Complementary Foods on Vitamin A Status and Body Pool Size in Ghanaian Infants. 2010.

429. London School of H, Tropical M, Maseno University MK. Safe and Efficacious Iron for Children in Kenya. 2014.

430. London School of H, Tropical M, Fhi, Centre M, Africsanté. Alive & Thrive Evaluation in Burkina Faso. 2017.

431. Milton SHMC. A Trial to Evaluate the Safety and Tolerability of a Novel Medical Food for Management of Iron Deficiency Anemia. 2015.

432. Tampere U, Academy of F, Foundation for Paediatric Research F. Trial to Alleviate Malnutrition With Fortified Spread Given as a Food Supplement to Underweight Infants.

433. Mexican National Institute of Public H, Unicef. mHealth for Prevention of Childhood Obesity in Mexico. 2020.

434. University of California D, Helen Keller I, Cheikh Anta Diop University S, Global Alliance for Improved N. Impact of Targeted Zinc Fortification Programs on Plasma Zinc Concentration. 2009.

435. University of Colorado D, Jawaharlal Nehru Medical C, HarvestPlus, International Atomic Energy A. Zinc and Iron Bioavailability From Biofortified Pearl Millet. 2012.

436. National Institutes of H, Eunice Kennedy Shriver National Institute of Child H, Human D. Iron and the Breast-Fed Infant: Iron Status and Two Regimens of Iron Supplementation. 2005.

437. National Institutes of H, Eunice Kennedy Shriver National Institute of Child H, Human D. Cereals as a Source of Iron for Breastfed Infants. 2006.

438. Nct. Randomized Placebo-Controlled Trial (RPCT) of Maize/Zinc in Guatemala. <u>https://clinicaltrialsgov/show/NCT00098202</u>. 2004.

439. Nct. Effectiveness of Nutritional Products to Treat Moderate Acute Malnutrition. https://clinicaltrialsgov/show/NCT01898871. 2013.

440. Nct. Comparison of a Two Ready-to-use Supplementary Foods of Differing Protein Quality for the Treatment of MAM. <u>https://clinicaltrialsgov/show/NCT03549156</u>. 2018.

441. Nestel P, Nalubola R, Sivakaneshan R, Wickramasinghe AR, Atukorala S, Wickramanayake T. The use of iron-fortified wheat flour to reduce anemia among the estate population in Sri Lanka. Int J Vitam Nutr Res. 2004;74(1):35-51.

442. Nestlé, Swiss Federal Institute of T, University of Malawi College of M. Baby Iron Bioavailability Study. 2019.

443. Nestlé. Effect of Nutritional Intervention on Metabolic Response in Infants. 2021.

444. Nestlé. Nutritional Supplementation in Children Aged 1-3 Years Experiencing Growth Concerns. 2021.

445. Nestlé. Infant Nutrition and Brain Development. 2022.

446. Neufeld LM, Garcia-Guerra A, Quezada AD, Theodore F, Bonvecchio Arenas A, Islas CD, et al. A Fortified Food Can Be Replaced by Micronutrient Supplements for Distribution in a Mexican Social Protection Program Based on Results of a Cluster-Randomized Trial and Costing Analysis. J Nutr. 2019;149(Suppl 1):2302S-9S.

447. Nevin Scrimshaw International Nutrition F, University of G, University of Cape C, Ajinomoto Usa INC, Ghana Health S. Effect of a Complementary Food Supplement on Growth and Morbidity of Ghanaian Infants. 2015.

448. Nicklas TA, O'Neil CE, Fulgoni VL. Nutrient intake, introduction of baby cereals and other complementary foods in the diets of infants and toddlers from birth to 23 months of age. AIMS Public Health. 2020;7(1):123-47.

449. Nikiema L, Huybregts L, Kolsteren P, Lanou H, Tiendrebeogo S, Bouckaert K, et al. Treating moderate acute malnutrition in first-line health services: an effectiveness cluster-randomized trial in Burkina Faso. Am J Clin Nutr. 2014;100(1):241-9.

450. Nikiema V, Kangas ST, Salpeteur C, Ouedraogo A, Lachat C, Bassole NHI, et al. Adequacy of Nutrient Intakes of Severely and Acutely Malnourished Children Treated with Different Doses of Ready-To-Use Therapeutic Food in Burkina Faso. J Nutr. 2021;11:11.

451. North-West University SA, Global Alliance for Improved N, Ltd DSM, Unilever R. Randomized Controlled Trial in South Africa Comparing the Efficacy of Complementary Food Products on Child Growth. 2016.

452. Nozari A, Motamedifar M, Seifi N, Hatamizargaran Z, Ranjbar MA. The Effect of Iranian Customary Used Probiotic Yogurt on the Children's Salivary Cariogenic Microflora. J Dent (Shiraz). 2015;16(2):81-6.

453. Nurhasan M, Roos N, Skau JK, Wieringa FT, Friis H, Michaelsen KF, et al. Effect of complementary food with small amounts of freshwater fish on whole blood n-3 fatty acids in Cambodian infants age 6-15 months. Prostaglandins Leukot Essent Fatty Acids. 2018;135:92-101.
454. Obatolu VA. Growth pattern of infants fed with a mixture of extruded malted maize and cowpea. Nutrition. 2003;19(2):174-8.

455. Oelofse A, Van Raaij JMA, Benade AJS, Dhansay MA, Tolboom JJM, Hautvast J. The effect of a micronutrient-fortified complementary food on micronutrient status, growth and development of 6-to 12-month-old disadvantaged urban South African infants. Int J Food Sci Nutr. 2003;54(5):399-407.

456. Ordiz MI, Janssen S, Humphrey G, Ackermann G, Stephenson K, Agapova S, et al. The effect of legume supplementation on the gut microbiota in rural Malawian infants aged 6 to 12 months. Am J Clin Nutr. 2020;111(4):884-92.

457. Orsango AZ, Loha E, Lindtjorn B, Engebretsen IMS. The efficacy of processed amaranth on anemia prevalence and hemoglobin level in preschool children in South Ethiopia: A randomised controlled trial. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2019;113:S213-S4.

458. Osendarp SJ, Santosham M, Black RE, Wahed MA, van Raaij JM, Fuchs GJ. Effect of zinc supplementation between 1 and 6 mo of life on growth and morbidity of Bangladeshi infants in urban slums. The American journal of clinical nutrition. 2002;76(6):1401-8.

459. Ouedraogo HZ, Traore T, Zeba AN, Dramaix-Wilmet M, Hennart P, Donnen P. Effect of an improved local ingredient-based complementary food fortified or not with iron and selected multiple micronutrients on Hb concentration. Public Health Nutr. 2010;13(11):1923-30.

460. Owino VO, Kasonka LM, Sinkala MM, Wells JK, Eaton S, Darch T, et al. Fortified complementary foods with or without alpha-amylase treatment increase hemoglobin but do not reduce breast milk intake of 9-mo-old Zambian infants. Am J Clin Nutr. 2007;86(4):1094-103.

461. Owino VO, Bahwere P, Bisimwa G, Mwangi CM, Collins S. Breast-milk intake of 9-10-mo-old rural infants given a ready-to-use complementary food in South Kivu, Democratic Republic of Congo. Am J Clin Nutr. 2011;93(6):1300-4.

462. Owino V, Kasonka L, Wells J, Eaton S, Sinkala M, Tomkins A, et al. Breast milk intake of 9month old zambian infants given fortified complementary foods. Annals of nutrition & metabolism. 2013;63:554.

463. Owino VO, Skau J, Omollo S, Konyole S, Kinyuru J, Estambale B, et al. WinFood data from Kenya and Cambodia: constraints on field procedures. Food Nutr Bull. 2015;36(1 Suppl):S41-6.

464. Pactr. DEVELOPMENT AND UTILIZATION OF AMARANTH-SORGHUM GRAINS PRODUCT TO ENHANCE THE NUTRITIONAL STATUS OF MODERATELY MALNOURISHED CHILDREN IN THIKA DISTRICT. <u>http://www.hoint/trialsearch/Trial2aspx?TrialID=PACTR201604001584278</u>. 2016.

465. Pactr. Moderate acute malnutrition treatment.

http://www.hoint/trialsearch/Trial2aspx?TrialID=PACTR201809662822990. 2018.

466. Pactr. Efficacy of a strategy combining the promotion of responsive feeding with the daily consumption of a fortified cereal-based blend to reduce anemia, micronutrient deficiencies and stunting in infants from Amparafaravola District, Madagascar.

http://www.hoint/trialsearch/Trial2aspx?TrialID=PACTR201906819960554. 2019.

467. Palmer AC, Craft NE, Schulze KJ, Barffour M, Chileshe J, Siamusantu W, et al. Impact of biofortified maize consumption on serum carotenoid concentrations in Zambian children. Eur J Clin Nutr. 2018;72(2):301-3.

468. Patel MP, Sandige HL, Ndekha MJ, Briend A, Ashorn P, Manary MJ. Supplemental feeding with ready-to-use therapeutic food in Malawian children at risk of malnutrition. J Health Popul Nutr. 2005;23(4):351-7.

469. Paul KH, Dickin KL, Ali NS, Stoltzfus RJ. Acceptability by mothers and children of two fortified, processed complementary foods for use in an upcoming efficacy trial in Tanzania. Faseb J. 2007;21(5):A677-A.

470. Phu PV, Hoan NV, Salvignol B, Treche S, Wieringa FT, Dijkhuizen MA, et al. A six-month intervention with two different types of micronutrient-fortified complementary foods had distinct short- and long-term effects on linear and ponderal growth of vietnamese infants. Journal of nutrition. 2012;142(9):1735-40.

471. Phuka JC, Maleta K, Thakwalakwa C, Cheung YB, Briend A, Manary MJ, et al. Complementary feeding with fortified spread and incidence of severe stunting in 6- to 18-month-old rural Malawians. Arch Pediatr Adolesc Med. 2008;162(7):619-26.

472. Phuka JC, Maleta K, Thakwalakwa C, Cheung YB, Briend A, Manary MJ, et al. Postintervention growth of Malawian children who received 12-mo dietary complementation with a lipid-based nutrient supplement or maize-soy flour. Am J Clin Nutr. 2009;89(1):382-90.

473. Phuka J, Thakwalakwa C, Maleta K, Cheung YB, Briend A, Manary M, et al. Supplementary feeding with fortified spread among moderately underweight 6-18-month-old rural Malawian children. Matern Child Nutr. 2009;5(2):159-70.

474. Picciano MF, Deering RH. The influence of feeding regimens on iron status during infancy. Am J Clin Nutr. 1980;33(4):746-53.

475. Pollitt E, Jahari A, Husaini M, Kariger P, Saco-Pollitt C. Developmental trajectories of poorly nourished toddlers that received a micronutrient supplement with and without energy. J Nutr. 2002;132(9):2617-25.

476. Purwestri RC, Scherbaum V, Inayati DA, Wirawan NN, Suryantan J, Bloem MA, et al. Supplementary feeding with locally-produced Ready-to-Use Food (RUF) for mildly wasted children on Nias Island, Indonesia: comparison of daily and weekly program outcomes. Asia Pac J Clin Nutr. 2012;21(3):374-9.

477. Pynaert I, Armah C, Fairweather-Tait S, Kolsteren P, van Camp J, De Henauw S. Iron solubility compared with in vitro digestion-Caco-2 cell culture method for the assessment of iron bioavailability in a processed and unprocessed complementary food for Tanzanian infants (6-12 months). Br J Nutr. 2006;95(4):721-6.

478. Qasem W, Azad MB, Hossain Z, Azad E, Jorgensen S, Castillo San Juan S, et al. Assessment of complementary feeding of Canadian infants: effects on microbiome & oxidative stress, a randomized controlled trial. BMC Pediatr. 2017;17(1):54.

479. Rahman MM, Islam MA, Mahalanabis D, Biswas E, Majid N, Wahed MA. Intake from an energy-dense porridge liquefied by amylase of germinated wheat: a controlled trial in severely malnourished children during convalescence from diarrhoea. Eur J Clin Nutr. 1994;48(1):46-53.

480. Rahman MM, Mahalanabis D, Ali M, Mazumder RN, Wahed MA, Fuchs GJ. Absorption of macronutrients and nitrogen balance in children with dysentery fed an amylase-treated energydense porridge. Acta Paediatr. 1997;86(12):1312-6.

481. Rahman MM, Mitra AK, Mahalanabis D, Wahed MA, Khatun M, Majid N. Absorption of nutrients from an energy-dense diet liquefied with amylase from germinated wheat in infants with acute diarrhea. Journal of pediatric gastroenterology and nutrition. 1997;24(2):119-23.

482. Ramirez MJ, Gonzalez De Cossio T, Rodriguez S, Unar M, Rivera J. Impact evaluation of the nutritional support program (pal by its spanish acronym) on food diversity and consumption of iron-rich or iron-fortified foods in 6-23 month-old children. Annals of Nutrition and Metabolism. 2013;63:1028.

483. Ramirez-Luzuriaga MJ, Unar-Munguia M, Rodriguez-Ramirez S, Rivera JA, Gonzalez de Cosio T. A Food Transfer Program without a Formal Education Component Modifies Complementary Feeding Practices in Poor Rural Mexican Communities. J Nutr. 2016;146(1):107-13.

484. Rao DH, Sarma KV, Kumar S, Reddy CG, Roa NP. Acceptability trials with ready to eat foods in a rural area. Indian Pediatr. 1992.

485. Rivera JA, Habicht JP, Robson DS. Effect of supplementary feeding on recovery from mild to moderate wasting in preschool children. Am J Clin Nutr. 1991;54(1):62-8.

486. Rivera JA, Habicht JP. Effect of supplementary feeding on the prevention of mild-to-moderate wasting in conditions of endemic malnutrition in Guatemala. Bull World Health Organ. 2002;80(12):926-32.

487. Roberts SB, Franceschini MA, Krauss A, Lin PY, de Sa AB, Co R, et al. A Pilot Randomized Controlled Trial of a New Supplementary Food Designed to Enhance Cognitive Performance during Prevention and Treatment of Malnutrition in Childhood. Curr. 2017;1(11).

488. Roberts SB, Franceschini MA, Silver RE, Taylor SF, de Sa AB, Co R, et al. Effects of food supplementation on cognitive function, cerebral blood flow, and nutritional status in young children at risk of undernutrition: randomized controlled trial. Bmj. 2020;370:m2397.

489. Roediger R, Callaghan-Gillespie M, Blackman JK, Kohlmann K, Maleta KM, Manary M. COMPARISON OF TWO READY-TO-USESUPPLEMENTARY FOODS (RUSF) OF DIFFERING PROTEIN QUALITY FOR THE TREATMENT OF MODERATE ACUTE MALNUTRITION (MAM) IN MALAWI: A RANDOMISED, DOUBLE-BLINDED, CLINICAL EFFECTIVENESS TRIAL. Gastroenterology. 2020;158(6):S-993.

490. Rosado JL, Gonzalez KE, Caamano Mdel C, Garcia OP, Preciado R, Odio M. Efficacy of different strategies to treat anemia in children: a randomized clinical trial. Nutr J. 2010;9:40.

491. Ruel MT, Rivera JA, Santizo MC, Lonnerdal B, Brown KH. Impact of zinc supplementation on morbidity from diarrhea and respiratory infections among rural Guatemalan children. Pediatrics. 1997;99(6):808-13.

492. Safaa T Z, Salwa M ES, Fawzi A ES. Role of iron zinc supplementation in the growth retardation and iron deficiency anaemia in Egyptian children. 2003. p. 183-7.

493. Sako B, Leerlooijer JN, Lelisa A, Hailemariam A, Brouwer ID, Brown AT, et al. Exploring barriers and enablers for scaling up a community-based grain bank intervention for improved infant and young child feeding in Ethiopia: A qualitative process evaluation. Matern Child Nutr. 2018;14(2):11.

494. Salinas-Pielago JE, Vega-Dienstmaier JM, Rojas-Oblitas M. [Effect of biscuits fortified with haem iron on the intellectual status of pre-school children]. Rev Neurol. 1998;27(157):400-4.
495. Samadpour K, Marks GC, Mohammad R, Long K. RANDOMIZED COMPARISON OF TWO TYPES OF MULTIPLE MICRONUTRIENT SUPPLEMENTS (Sprinkles, Foodlets) WITH RECOMMENDED SUPPLEMENT (Drops) IN IRANIAN INFANTS. Ann Nutr Metab. 2009;55:168-.

496. Sandjaja S, Jus, at I, Jahari AB, Tilden R, Ernawati F, et al. Fortifying Cooking Oil with Vitamin A in Two Rural Districts of Indonesia: Impact on Vitamin A Status of Mothers and Children. 2015.

497. Sarojini G, Nirmala G, Geetha R. Introduction of red palm oil into the 'ready to eat' used supplementary feeding programme through ICDS. Indian J Public Health. 1999;43(4):125-31.
498. Sato W FCMHSDOGT-DKGS. A macro and micronutrient fortified complementary food

supplement enhances plasma branched-chain amino acid levels in Ghanaian infants. Annals of nutrition & metabolism. 2017;71:481.

499. Sayyad-Neerkorn J LCRTDSMAAW-MLMMLHSDPSGRF. Preventive effects of long-term supplementation with 2 nutritious food supplements in young children in Niger. Journal of nutrition. 2015;145(11):2596-603.

500. Sazawal S, Dhingra P, Dhingra U, Gupta S, Iyengar V, Menon VP, et al. Compliance with homebased fortification strategies for delivery of iron and zinc: its effect on haematological and growth markers among 6-24 months old children in north India. J Health Popul Nutr. 2014;32(2):217-26.

501. Scherbaum V, Purwestri RC, Stuetz W, Inayati DA, Suryantan J, Bloem MA, et al. Locally produced cereal/nut/legume-based biscuits versus peanut/milk-based spread for treatment of moderately to mildly wasted children in daily programmes on Nias Island, Indonesia: an issue of acceptance and compliance? Asia Pac J Clin Nutr. 2015;24(1):152-61.

502. Schlossman N, Batra P, Balan E, Pruzensky W, Shae K, Schleicher M, et al. The effectiveness of two ready to use supplementary foods (RUSFs) differing in dairy protein content on growth and nutritional status of young children: A pilot study in preschools in guinea-bissau. FASEB Journal. 2015;29(1).

503. Schlossman N, Brown C, Batra P, de Sa AB, Balan I, Balan A, et al. A Randomized Controlled Trial of Two Ready-to-Use Supplementary Foods Demonstrates Benefit of the Higher Dairy Supplement for Reduced Wasting in Mothers, and Differential Impact in Infants and Children Associated With Maternal Supplement Response. Food Nutr Bull. 2017;38(3):275-90.

504. Schlossman N. Higher Levels of Dairy Result in Improved Physical Outcomes: A Synthesis of 3 Randomized Controlled Trials in Guinea-Bissau Comparing Supplements with Different Levels of Dairy Ingredients Among Children 6 to 59 Months, 5 to 19 Year Olds, and Mothers in P. Food Nutr Bull. 2018;39(2_suppl):S35-S44.

505. Schroeder DG, Martorell R, Rivera JA, Ruel MT, Habicht JP. Age differences in the impact of nutritional supplementation on growth. J Nutr. 1995;125(4 Suppl):1051S-9S.

506. Schumann K, Longfils P, Monchy D, von Xylander S, Weinheimer H, Solomons NW. Efficacy and safety of twice-weekly administration of three RDAs of iron and folic acid with and without complement of 14 essential micronutrients at one or two RDAs: a placebo-controlled intervention trial in anemic Cambodian infants 6 to 24 months of ag. Eur J Clin Nutr. 2009;63(3):355-68.

507. Schwartz J, Dube K, Sichert-Hellert W, Kannenberg F, Kunz C, Kalhoff H, et al. Modification of dietary polyunsaturated fatty acids via complementary food enhances n-3 long-chain polyunsaturated fatty acid synthesis in healthy infants: a double blinded randomised controlled trial. Arch Dis Child. 2009;94(11):876-82.

508. Seal A, Kafwembe E, Kassim IAR, Hong M, Wesley A, Wood J, et al. Maize meal fortification is associated with improved vitamin a and iron status in adolescents and reduced childhood anaemia in a food aid-dependent refugee population. Public health nutrition. 2008;11(7):720-8.

509. Shaikh S, Campbell RK, Mehra S, Kabir A, Schulze KJ, Wu L, et al. Supplementation with Fortified Lipid-Based and Blended Complementary Foods has Variable Impact on Body Composition Among Rural Bangladeshi Children: A Cluster-Randomized Controlled Trial. J Nutr. 2020;150(7):1924-32.

510. Shamah-Levy T, Villalpando S, Rivera-Dommarco JA, Mundo-Rosas V, Cuevas-Nasu L, Jimenez-Aguilar A. Ferrous gluconate and ferrous sulfate added to a complementary food distributed by the Mexican nutrition program Oportunidades have a comparable efficacy to reduce iron deficiency in toddlers. J Pediatr Gastroenterol Nutr. 2008;47(5):660-6.

511. Shamim A, Hanif AAM, Merrill RD, Campbell RK, Kumkum MA, Shaikh S, et al. Preferred Delivery Method and Acceptability of Wheat-Soy Blend (WSB++) as a Daily Complementary Food Supplement in Northwest Bangladesh. Ecol Food Nutr. 2015;54(1):74-92.

512. Shen Y CISDVSWPRB. Research methods used to determine cost-effectiveness of a supplementary feeding trial to prevent child undernutrition in Burkina Faso. Annals of nutrition & metabolism. 2017;71:455-6.

513. Shen YK, Griswold S, Suri D, Vosti SA, Rogers B. Costing methods for a cluster-randomized cost-effectiveness trial comparing the performance of four supplementary foods in treating Sierra Leonean children with moderate acute malnutrition (MAM). FASEB Journal. 2017;31(1).

514. Sheng X, Wang J, Li F, Ouyang F, Ma J. Effects of dietary intervention on vitamin B₁₂ status and cognitive level of 18-month-old toddlers in high-poverty areas: a cluster-randomized controlled trial. BMC Pediatr. 2019;19(1):334.

515. Shewade HD, Patro BK, Bharti B, Soundappan K, Kaur A, Taneja N. Effectiveness of indigenous ready-to-use therapeutic food in community-based management of uncomplicated severe acute malnutrition: a randomized controlled trial from India. J Trop Pediatr. 2013;59(5):393-8.

516. Sigh S, Roos N, Sok D, Borg B, Chamnan C, Laillou A, et al. Development and Acceptability of Locally Made Fish-Based, Ready-to-Use Products for the Prevention and Treatment of Malnutrition in Cambodia. Food Nutr Bull. 2018;39(3):420-34.

517. Simondon KB, Gartner A, Berger J, Cornu A, Massamba JP, San Miguel JL, et al. Effect of early, short-term supplementation on weight and linear growth of 4-7-mo-old infants in developing countries: a four-country randomized trial. Am J Clin Nutr. 1996;64(4):537-45.

518. Simpore J, Kabore F, Zongo F, Dansou D, Bere A, Pignatelli S, et al. Nutrition rehabilitation of undernourished children utilizing Spiruline and Misola. Nutr J. 2006;5:3.

519. Singh AS, Kang G, Ramachandran A, Sarkar R, Peter P, Bose A. Locally made ready to use therapeutic food for treatment of malnutrition a randomized controlled trial. Indian Pediatr. 2010;47(8):679-86.

520. Skau JKH, Bunthang T, Chamnan C, Mary C, Unni US, Filteau S, et al. Effects of animal-source foods and micronutrientfortification complementary foods on body composition, linear growth, iron status-the WinFood project in Cambodia. Tropical medicine & international health. 2013;18:87.

521. Skau JKH, Chamnan C, Touch B, Chea M, Unni U, Filteau S, et al. Effect of animal-source foods and micronutrient-fortification complementary foods on body composition, linear growth, iron status-the winfood project in cambodia. Annals of nutrition & metabolism. 2013;63:163-4.

522. Skau JK, Touch B, Chhoun C, Chea M, Unni US, Makurat J, et al. Effects of animal source food and micronutrient fortification in complementary food products on body composition, iron status, and linear growth: a randomized trial in Cambodia. Am J Clin Nutr. 2015;101(4):742-51.

523. Stephenson KB, Agapova SE, Divala O, Kaimila Y, Maleta KM, Thakwalakwa C, et al. Complementary feeding with cowpea reduces growth faltering in rural Malawian infants: a blind, randomized controlled clinical trial. Am J Clin Nutr. 2017;106(6):1500-7.

524. Stobaugh HC, Ryan KN, Kennedy JA, Grise JB, Crocker AH, Thakwalakwa C, et al. Including whey protein and whey permeate in ready-to-use supplementary food improves recovery rates in children with moderate acute malnutrition: a randomized, double-blind clinical trial. Am J Clin Nutr. 2016;103(3):926-33.

525. Stobaugh HC, Bollinger LB, Adams SE, Crocker AH, Grise JB, Kennedy JA, et al. Effect of a package of health and nutrition services on sustained recovery in children after moderate acute malnutrition and factors related to sustaining recovery: a cluster-randomized trial. Am J Clin Nutr. 2017;106(2):657-66.

526. Stookey GK, Carroll RA, Muhler JC. The clinical effectiveness of phosphate-enriched breakfast cereals on the incidence of dental caries in children: results after 2 years. J Am Dent Assoc. 1967;74(4):752-8.

527. Tampere U, Academy of F, Foundation for Paediatric Research F. Trial to Test the Growth-Promoting Effect of Fortified Spreads When Used as Complementary Food for Infants. 2006.

528. Tampere U. Effectiveness Trial on Alleviation of Infant Malnutrition With Fortified Spread or Maize-Soy Flour Food Supplements. 2008.

529. Tano-Debrah K, Saalia FK, Ghosh S, Hara M. Development and Sensory Shelf-Life Testing of KOKO Plus: A Food Supplement for Improving the Nutritional Profiles of Traditional Complementary Foods. Food and nutrition bulletin. 2019;40(3):340-56.

530. Tekale N, Kulkarni S. Designing of Nutritional Snacks to Address Micronutrient Deficiency among the Malnourished Tribal Children below Age Five in Western Part of India. 2015.

531. Thakur HS, Gottapu GS, Kadali SP, Kulkarni B, Mamidi RS. Effect of Nutrition Supplementation in Children Living with HIV at ART Centre. Indian J Pediatr. 2016;83(3):232-7.

532. Thakwalakwa C, Ashorn P, Phuka J, Cheung YB, Briend A, Puumalainen T, et al. A lipid-based nutrient supplement but not corn-soy blend modestly increases weight gain among 6- to 18-month-old moderately underweight children in rural Malawi. J Nutr. 2010;140(11):2008-13.

533. Thakwalakwa C, Phiri A, Rollins N, Heikens GT, Barnell EK, Manary M. Growth and HIV-free survival of HIV-exposed infants in Malawi: a randomized trial of two complementary feeding interventions in the context of maternal antiretroviral therapy. J Acquir Immune Defic Syndr. 2014;66(2):181-7.

534. Tharrey M, Olaya GA, Fewtrell M, Ferguson E. Adaptation of New Colombian Food-based Complementary Feeding Recommendations Using Linear Programming. J Pediatr Gastroenterol Nutr. 2017;65(6):667-72.

535. The Mathile Institute for the Advancement of Human N, Fundación Salvadoreña para la Salud y el Desarrollo H, Humanitas Global D, Ministry of Health ES. Comparison of Two Nutrition Interventions in Young Children in El Salvador. 2020.

536. Tondeur MC, Schauer CS, Christofides AL, Asante KP, Newton S, Serfass RE, et al. Determination of iron absorption from intrinsically labeled microencapsulated ferrous fumarate

(sprinkles) in infants with different iron and hematologic status by using a dual-stable-isotope method. Am J Clin Nutr. 2004;80(5):1436-44.

537. Traore T, Vieu MC, Alfred TS, Serge T. Effects of the duration of the habituation period on energy intakes from low and high energy density gruels by Burkinabe infants living in free conditions. Appetite. 2005;45(3):279-86.

538. Traore T, Mouquet-Rivier C, Kabore C, Bruyeron O. Efficacy of different fortified gruels on the recovery from moderate acute malnutrition in burkinabe 6-23-month-old children. Annals of nutrition & metabolism. 2013;63:1024-5.

539. Trehan I, Banerjee S, Murray E, Ryan KN, Thakwalakwa C, Maleta KM, et al. Extending supplementary feeding for children younger than 5 years with moderate acute malnutrition leads to lower relapse rates. J Pediatr Gastroenterol Nutr. 2015;60(4):544-9.

540. Tufts U, Washington University School of M, Project Peanut B, United Nations World Food P, United States Agency for International D. Comparison of Four Different Supplementary Foods in the Treatment of Moderate Acute Malnutrition (MAM) in Children in Sierra Leone: a Cluster-randomised, Controlled Clinical Effectiveness Trial. 2014.

541. Tufts U, Massachusetts General H, Global F, Nutrition I. Locally Prepared Supplement to Support Growth and Brain Health. 2017.

542. Tufts U, United States Agency for International D, Acdi/Voca, Save the C, Institut de Recherche en Sciences de la Sante BF. Effectiveness and Cost-Effectiveness of Four Formulations of Food Supplements for the Prevention of Wasting and Stunting in Burkina Faso. 2017.

543. Tufts U, Washington University School of M, Project Peanut B, Caritas B, Ministry of H, Sanitation SL, et al. Comparison of Four Different Supplementary Foods in the Treatment of Moderate Acute Malnutrition. 2018.

544. van der Kam S, Swarthout T, Niragira O, Froud A, Sompwe EM, Mills C, et al. Ready-to-use therapeutic food for catch-up growth in children after an episode of Plasmodium falciparum malaria: an open randomised controlled trial. PLoS ONE. 2012;7(4):e35006.

545. Vander Wal MC. Evaluation of Antihelminth Treatment and an Aloe Enriched Whey Protein Drink on Measures of HIV Enteropathy and Immune Activation in HIV+ Children in Addis Ababa. Dissertation/ Thesis. 2018:1-.

546. Van Hoan N, Van Phu P, Salvignol B, Berger J, Treche S. Effect of the consumption of high energy dense and fortified gruels on energy and nutrient intakes of 6-10-month-old Vietnamese infants. Appetite. 2009;53(2):233-40.

547. Varea A, Malpeli A, Etchegoyen G, Vojkovic M, Disalvo L, Apezteguia M, et al. Short-term evaluation of the impact of a food program on the micronutrient nutritional status of Argentinean children under the age of six. Biological trace element research. 2011;143(3):1337-48.

548. Vega NIV, Levy TS, Pineda EBG, Nasu LC, Gomez-Humaran IM. Adherence to the consumption of food supplements of PROSPERA program, in the decrease of the prevalence of anemia in children under three years old in the state of San Luis Potosi, Mexico. Nutr Hosp. 2016;33(4):782-9.

549. Verkaik-Kloosterman J, Beukers MH, Jansen-van der Vliet M, Ocké MC. Vitamin D intake of Dutch infants from the combination of (fortified) foods, infant formula, and dietary supplements. European Journal of Nutrition. 2017;56(2):581-90.

550. Verna M, Corradi M, Fantoni S, Proietti I, Savina F, Del Rio D, et al. Parma pap project: A ready to use therapeutic food for moderately malnourished children in sierra leone. Archives of disease in childhood. 2012;97:A301.

551. Villanueva LM, Norton SA, Palacios AM, Reinhart GA. Acceptability of a fortified atole among guatemalan children who attend six casa Del niño day care centers, and the effects on linear growth and hemoglobin status. FASEB Journal. 2016;30.

552. Viseshakul D, Premwatana P, Kewsiri D. FIELD TRIAL OF SUPPLEMENTARY FEEDING IN HILL-TRIBE CHILDREN (1-4 YEARS OLD) - ONE YEAR FOLLOW-UP-STUDY. Journal of the Medical Association of Thailand. 1979;62(4):190-9.

553. Vray M, Hedible BG, Adam P, Tondeur L, Manirazika A, Randremanana R, et al. A multicenter, randomized controlled comparison of three renutrition strategies for the management of moderate

acute malnutrition among children aged from 6 to 24 months (the MALINEA project). Trials. 2018;19(1):666.

554. Vuong le T, Dueker SR, Murphy SP. Plasma beta-carotene and retinol concentrations of children increase after a 30-d supplementation with the fruit Momordica cochinchinensis (gac). Am J Clin Nutr. 2002;75(5):872-9.

555. Walker SP, Grantham-McGregor SM, Himes JH, Powell CA, Chang SM. Early childhood supplementation does not benefit the long-term growth of stunted children in Jamaica. J Nutr. 1996;126(12):3017-24.

556. Wang RJ, Trehan I, LaGrone LN, Weisz AJ, Thakwalakwa CM, Maleta KM, et al. Investigation of food acceptability and feeding practices for lipid nutrient supplements and blended flours used to treat moderate malnutrition. J Nutr Educ Behav. 2013;45(3):258-63.

557. Walter TD, P. R.; Pizarro, F.; Velozo, L.; Pena, G.; Bartholmey, S. J.; Hertrampf, E.; Olivares, M.; Letelier, A.; Arredondo, M. Effectiveness of iron-fortified infant cereal in prevention of iron deficiency anemia. Pediatrics. 1993;91(5):976-82.

558. Whitfield KC, Karakochuk CD, Kroeun H, Chan B, Borath M, Lynd LD, et al. Consumption of novel thiamin-fortified fish sauce improves the thiamin status of rural cambodian women of childbearing age and their children <5 years. FASEB Journal Conference: Experimental Biology 2016, EB San Diego, CA United States Conference Start: 20160402 Conference End: 20160406 Conference Publication: (varpagings). 2016;30(no pagination).

559. Whitfield KC, Karakochuk CD, Kroeun H, Sokhoing L, Chan BB, Borath M, et al. Household Consumption of Thiamin-Fortified Fish Sauce Increases Erythrocyte Thiamin Concentrations among Rural Cambodian Women and Their Children Younger Than 5 Years of Age: A Randomized Controlled Efficacy Trial. J Pediatr. 2017;181:242-7.e2.

560. Westcott JE, Culbertson D, Lei S, Hambidge KM, Post K, Krebs NF. Complementary food (CF) choices are critical to meet physiologic requirements for zinc (Zn). FASEB journal. 2011;25.

561. Women's NGNf, Children's H, Kinshasa School of Public H, University of Z, Incap CG, Aga Khan U, et al. First Bites: Complementary Feeding - A Global Network Cluster Randomized Controlled Trial.2010.

562. Yeung GS, Zlotkin SH. Efficacy of meat and iron-fortified commercial cereal to prevent iron depletion in cow milk-fed infants 6 to 12 months of age: a randomized controlled trial. Can J Public Health. 2000;91(4):263-7.

563. Ying C, Dongsheng LIU, Jiguo BAI, Wenguang W, Jianhua DAI, Taian YIN, et al. THE RELATIONSHIP BETWEEN THE DIET AND THE GROWTH OF INFANTS DURING THE WEANING PERIOD (6-18 MONTHS). Acta Nutrimenta Sinica. 1956(6).

564. Yu D, Ma G, Joop V, Wanda B, Fang Z, Zhao L. The effects on children's growth, hemoglobin concentration, and anemia in 3 nutrition interventions in poor rural, China. Annals of nutrition & metabolism. 2013;63:611.

565. Yuliarti K, Honoris E, Sjarif D. Chicken liver compared to fortified rice cereal as a first complementary food for breastfed infants: Effectivity on zinc intake and status. Journal of Pediatric Gastroenterology and Nutrition. 2017;64:809.

566. Zakaria, Rauf S, Salim A. Development of instant powder formula with addition of moringa oleifera as a complementary food for infants aged 6-12 months. Annals of Nutrition and Metabolism. 2019;75(3):172.

567. Zakaria, Rauf S, Salim A, Rahman N, Bohari. Development of instant powder with the addition of Moringa oleifera leaf powder as complementary food for infants 6-12 months old. Systematic Reviews in Pharmacy. 2020;11(7):61-4.

568. Zavaleta N, Kvistgaard AS, Graverholt G, Respicio G, Guija H, Valencia N, et al. Efficacy of an MFGM-enriched complementary food in diarrhea, anemia, and micronutrient status in infants. J Pediatr Gastroenterol Nutr. 2011;53(5):561-8.

569. Zhang Y, Wu Q, Wang W, van Velthoven MH, Chang S, Han H, et al. Effectiveness of complementary food supplements and dietary counselling on anaemia and stunting in children aged

6-23 months in poor areas of Qinghai Province, China: a controlled interventional study. BMJ Open. 2016;6(10):e011234.

570. Zhichien HE. THE INFLUENCE OF WEANING FOOD ON THE GROWTH OF INFANTS WHILE BREAST-FEEDING. Acta Nutrimenta Sinica. 1956(6).

571. Ziegler EE, Nelson SE, Jeter JM. Iron status of breastfed infants is improved equally by medicinal iron and iron-fortified cereal. Am J Clin Nutr. 2009;90(1):76-87.

572. Ziegler EE, Nelson SE, Jeter JM. Iron supplementation of breastfed infants. Nutr Rev. 2011;69:S71-S7.

573. Zyba SJ, Wegmuller R, Woodhouse LR, Ceesay K, Prentice AM, Brown KH, et al. Effect of exogenous phytase added to small-quantity lipid-based nutrient supplements (SQ-LNS) on the fractional and total absorption of zinc from a millet-based porridge consumed with SQ-LNS in young Gambian children: a randomized controlled trial. Am J Clin Nutr. 2019;110(6):1465-75.